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Background: Ageing is a major risk factor for chronic diseases of the nervous, cardiovascular 
and musculoskeletal systems.  Since ion channels are key regulatory proteins in all body 
systems, I investigated whether there were tissue independent changes in ion channel gene 
expression with age. I hypothesised that the expression of a common set of ion channel genes 
would change in different tissues with age. 
Methods:  One theory of ageing states that ageing is associated with a chronic low-grade 
inflammatory status (”inflammageing”) and, in line with this, cytokines levels are typically 
increased by 2-3-fold in the elderly.   I thus used two models to test my hypothesis (i) real 
ageing of Wistar Kyoto rats and (ii) cytokine treatment of cells in vitro. For the real ageing 
models; fibroblast-like synoviocytes (FLS) from joints, aortae, and paraventricular nuclei 
(PVN) from the hypothalamus were dissected from young and old rats and subjected to deep 
RNA-sequencing (Next Generation Sequencing, NGS). For the inflammatory model, I used FLS, 
chondrocytes, and aortic vascular smooth muscle cells (VSMC) from young rats and exposed 
them to 10ng/ml Interleukin-1β+Tumor Necrosis Factor α (IL-1β+TNFα) for 72hrs before NGS 
RNA-sequencing. Where possible I followed this with patch-clamp electrophysiology to 
establish functional changes in channel expression.  
Results:  Our gene expression data from our in vitro inflammatory model of ageing showed 
some similarities with naturally aged (old) rat tissue, in particular, Gene Ontology (GO) 
clusters were enriched for proteins involved in the extracellular matrix. In general, ion 
channel gene changes were different between the models and between tissues.  An 
exception to this was the differential expression of Gja1, the gene encoding gap junction 
protein connexin 43.  Statistically significant changes in Gja1 were detected in VSMCs and 
aged aorta. 
Conclusions: Our study suggests that the expression of a common set of ion channel proteins 
is not linked with age.   However, the finding of common patterns of Gja1 expression is 
interesting particularly in light of recent evidence that knockdown of gap junctions extends 
lifespan in worms. This family of communicating junctions warrants additional investigation 
in terms of its contribution to the ageing process.  All our data will be publicly shared and 
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1.1 Ageing Theories  
There is a growing interest in the field of ageing biology; what exactly is ageing, how 
and why does it happen (Gavrilov and Gavrilova, 2002)? There have been several proposed 
theories to explain what is happening in the ageing process, and the underlying mechanisms 
(Medvedev, 1990, Weinert and Timiras, 2003). With more important discoveries at the 
molecular and cellular levels, new families of ageing theories have been proposed although 
most of them have old origins. Ageing is more complex than just a single factor cause (i.e. a 
single gene mutation or a decline of a key body system) (Weinert and Timiras, 2003). Among 
the factors that make it difficult to study ageing in humans are (a) inadequate models, (b) the 
long periods involved, and (c) the cost. Also, longevity studies are controversial and the 
inability to differentiate cause from effects adds to the difficulty. Therefore, no consensus 
exists over the causes of ageing, the rate of ageing or what changes that occur, leading to the 
well-established increased chances of death between age 30-70 (Reddy and Kar, 2019).  
When talking about evolutionary theories of ageing, it is quite interesting to mention 
that the scientists thought about the idea that the force of selection declines with ageing. 
This means that the selection shadow (also known as evolutionary shadow) cannot see the 
harmful mutations that appear late in life and have negative effects on the organism. Also, 
these negative effects have been passed to the offspring of the individual who has it. 
Therefore, the selection is unable to remove such mutations from the population. Although, 
as mentioned above, there are several evolutionary theories of ageing, I will discuss the major 
three ones; (i) the theory of programmed death (by August Weismann), (ii) the mutation 
accumulation theory of ageing (by peter Medawar), and (iii) the antagonistic pleiotropy 
theory of ageing (by George Williams) (Gavrilov and Gavrilova, 2002).  
20 
 
The theory of programmed death 
The theory of programmed death was developed by August Weismann as described here 
(Gavrilov and Gavrilova, 2002, Moskalev et al., 2014). It states that a specific-death 
mechanism created by natural selection to remove old members of the population (worn-
out) (Gavrilov and Gavrilova, 2002). This occurs to clean up the living space and save 
resources for the younger generations (Gavrilov and Gavrilova, 2002). Ironically, when he got 
old he corrected his version of the theory “that ageing is not an adaptive trait but rather 
simply a neutral trait” which did not receive much attention as his early version of the 
programmed death theory (Gavrilov and Gavrilova, 2002). One of the ways to test his 
programmed death theory is to compare two groups of animals. One in the wild (natural) and 
the other one in a protective environment (i.e. laboratory). It is expected that both will have 
the same age and there is not much difference. However, the results showed the opposite 
where the group in the protective environment lived longer (Shock, 1964) compared to those 
in the wild (Gavrilov and Gavrilova, 2002).  
The mutation accumulation theory  
The theory of mutation accumulation was suggested by Peter Medawar as described 
here (Weinert and Timiras, 2003). Briefly, he considered ageing as a by-product of natural 
selection. This means that ageing is a nonadaptive trait simply because natural selection 
ignores any events that happen in long-lived animals that offer a slight contribution to 
offspring numbers. In other words, mutations that are harmful and only-act late in life may 
accumulate in populations resulting in diseases and senescence (Weinert and Timiras, 2003).  
Reproduction depends on an age where it is zero at birth, peaks at young adults and 
decreases as we age due to increased link to death. The reasons for death can be internal 
(within the body, i.e. senescence) or external (i.e. accidents, illness, etc). Therefore, harmful 
mutations expressed at a young age are strongly selected against because of their negative 
effects on reproduction while harmful mutations expressed later in life are considered 
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neutral to selection because the one who has it has already passed his/her genes to the 
offspring (Gavrilov and Gavrilova, 2002). Therefore, according to this theory, the chances that 
a person can reproduce are really small if he/she were loaded with deleterious mutations 
that are expressed early in life. For example, a person with deleterious mutations affecting 
reproduction that appear early in life will not be passed on since the individual cannot 
reproduce (Ahmed et al., 2017) while the harmful mutations that appear later in the life of a 
person will not affect reproduction because the person has already passed his genes to the 
offspring (Gavrilov and Gavrilova, 2002). This theory has survived so far compared to others, 
but it is still pending further validation.  
The antagonistic pleiotropy theory of ageing   
The theory of antagonistic pleiotropy of ageing was proposed by George Williams as an 
evolutionary explanation for senescence. It was built on two assumptions; (i) a gene can 
influence multiple traits (pleiotropic) of an organism rather than just one trait, and (ii) these 
pleiotropic effects can affect the individual’s fitness in opposite (antagonistic) ways. In other 
words, this theory applies when one gene control for more than one trait where at least one 
trait is beneficial, and one is harmful (detrimental) to the organism’s fitness.  
The disposable soma theory can be considered a special case of the antagonistic 
pleiotropy theory of ageing that was developed by Tom Kirkwood and Robin Holliday 
(Kirkwood, 1977, Kirkwood and Holliday, 1979). It was an effort of renaming the antagonistic 
pleiotropy theory proposed by Kirkwood et al (described here (Gavrilov and Gavrilova, 2002, 
Ackermann et al., 2007)) to explain how the same gene can have both effects (positive and 
negative). Simply, a special class of gene mutations would end up with saving energy for 
reproduction (positive effect) by reducing error regulation in somatic cells (negative effect). 
In other words, reduced investment of resources in the somatic cells for development and 
reproduction. Eventually, deterioration and death are inevitable (Kirkwood and Holliday, 
1979).   
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It is noteworthy mentioning that Kirkwood’s disposable soma theory (above) was 
primarily proposed to prove the Orgel’s theory of error catastrophe that considered ageing 
as a product of a breakdown in the accuracy of protein synthesis in the somatic cells (Gavrilov 
and Gavrilova, 2002). Although error catastrophe theory failed, the disposable soma theory 
remains a narrow definition of the antagonistic pleiotropy theory of ageing and the authors 
of this disposable soma theory themselves admitted it (Gavrilov and Gavrilova, 2002, 
Kirkwood and Holliday, 1979).  
There are several examples of the antagonistic pleiotropy theory including cytokines 
such as IL-6 which can play two opposite roles; pro- and anti-inflammatory cytokine (Scheller 
et al., 2011). The balance between the cytokines (pro-inflammatory and anti-inflammatory) 
is tightly regulated. When this balance is disturbed, the pro-inflammatory cytokine levels 
increase leading to several diseases or conditions such as “Inflammageing”.  
Inflammageing  
The word “inflammageing” is composed of two parts; inflammation and ageing relating 
the perceived association between chronic low-grade inflammation and the ageing process 
(Franceschi et al., 2007a, Day, 2010). Inflammation is caused by pro-inflammatory cytokines. 
This process has to be resolved as soon as the threat is cleared. However, with ageing, the 
level of pro-inflammatory cytokines that initiated the immune defence stays high leading to 
a state of chronic low-grade systemic inflammation which is also known as the pro-
inflammatory phenotype or “inflammageing”. There is no clear understanding of the causes 
of inflammageing that is behind the major age-related diseases such as diabetes, CVD, 
neurodegenerative diseases, and musculoskeletal diseases although it can affect almost all 
tissues of the body.  
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1.2 Tissues  
Although all our body tissues can be the target of inflammageing, tissues of the major 
age-related diseases will be discussed here.  
Musculoskeletal system (FLS) 
Three systems known to be dysfunctional with age were chosen to be examined in 
this thesis. As an example of musculoskeletal tissue, synoviocytes that are involved with the 
development of osteoarthritis were chosen.  Fibroblast-like synoviocytes (FLS) are one of the 
key cells in particular joints. It forms a lining layer in the articular joint.  
Structure and functions 
The intimal lining layer of the synovium produces lubricious synovial fluid and is 
composed of two cell types in relatively equal proportions: Type A or macrophage-like 
synovial cells and Type B or FLS. The synovium is the major barrier between the joint and the 
systemic circulation (Berenbaum, 2013, Sutton et al., 2009).  
It plays a role in maintaining healthy cartilage of the articular joint (Berenbaum, 2013, 
Sutton et al., 2009). FLS cells contribute to the protection and maintaining (Hui et al., 2012) 
the structural integrity of the joints by controlling the composition of the (a) synovial fluid 
and extracellular matrix (ECM) of the joint (Burmester et al., 1983, Iwanaga et al., 2000). The 
synovial fluid is produced using the FLS cellular components and the two main important 
molecules secreted by the intimal lining layer of the FLS cells in the fluid are lubricins and 
hyaluronic acid (HA) that can lubricate the articular surfaces (Hui et al., 2012, Scanzello and 
Goldring, 2012). Lubricin and HA are high molecular weight molecules that are not permeable 
through the synovium unlike other molecules such as cytokines. This is vital to maintain the 
viscosity of the synovial fluid by maintaining the average concentration and molecular weight 
of these main components. Also, the synovium prevents depositing of other high molecular 
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weight proteins or plasma components in the articular joint which will eventually reduce 
viscosity and causes damage to the joint tissues (Scanzello and Goldring, 2012).  
FLS can also provide nutrients for chondrocytes within the avascular cartilage. It has 
also been suggested that catabolic enzymes such as matrix metalloproteinase (MMPs) are 
produced by synovial cells and diffuse into the cartilage (Sutton et al., 2009). Thus, 
modulating the activities of the chondrocytes (Hui et al., 2012). Synovium must remain 
healthy as increased production of MMPs can lead to degradation of the articular matrix 
(Scanzello and Goldring, 2012).  
FLS in diseases and age  
The synovial environment changes physically, chemically and physiologically with 
injury or the onset of disease and is thought to be a mediator in arthritis pain (Grubb, 2004, 
Kumahashi et al., 2011, Sellam and Berenbaum, 2010). In diseases like inflammation, 
hyperplasia or arthritis, the permeability of the synovium is changed leading to higher 
concentrations of hyaluronic acid (HA) detected in the blood (Scanzello and Goldring, 2012). 
Also, FLS cells have been implicated in arthritis as they exhibit a transformed phenotype with 
increased invasiveness and production of various pro-inflammatory mediators that 
perpetuate inflammation and proteases that contribute to cartilage destruction as seen with 
ageing (Bartok and Firestein, 2010, Noss and Brenner, 2008). 
Ion channels in FLS 
Like many other cells, FLS cells have several different ion channels that play roles in 
a multitude of cell regulating processes by modulating the membrane potential and cellular 
function (Abdul Kadir et al., 2018). Examples of such channels include aquaporins (i.e. AQP0-
AQP12), K+ channels (i.e. Ca2+ activated potassium channels Kca1.1, also known as BK 
channels), acid-sensing ion channels (i.e. ASIC3), and TRP channels ((TRPC1 & TRPC5), TRPV1, 
TRPV2 & TRPV4), TRPM-Melastatin or -7 & TRPM8) and TRPA1) (Ji and Hong, 2019).  
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Aquaporins are channels that transport water or small molecules across cell 
membranes of different cell types. The BK channel is a member of the Ca2+-activated 
potassium channel family and a very important channel in the FLS plasma membrane (Ji and 
Hong, 2019).  Experimental pieces of evidence including but not limited to wound healing 
and proliferation assays have shown that BK drives invasiveness of the synoviocyte and 
progression of arthritis on many species by increasing production of inflammatory mediators 
and catabolic enzymes (Friebel et al., 2015, Hu et al., 2012b, Tanner et al., 2015a). Acid-
sensing channels control tissue acidosis via pH changes. They are associated with 
inflammatory pain (i.e. musculoskeletal pain). They are also known as voltage-insensitive 
ligand-gated cation channels with protons (Ji and Hong, 2019). TRP channels have been 
known as non-selective cation channels and play roles in inflammatory mediated arthritis (Ji 
and Hong, 2019).  
Understanding the biology and regulation of FLS may provide insight into the 
pathogenesis of inflammatory arthritis. FLS cells could potentially be targeted, 
pharmacologically, to produce increased volumes of synovial fluid as an alternative to intra-
articular hyaluronan (Anon, 2000) or synthetic fluid injection (Dane and Grinstaff, 2012) 
therapies. They are also a plausible analgesic target because they may interact with sensory 
neurons (von Banchet et al., 2007) and have been described as “amplifiers” of neuropeptide 
mediated inflammation and pain (Niissalo et al., 2002).  
Cardiovascular system 
The second system in this thesis to address is the vasculature which is well known to 
dysfunction with age (Laina et al., 2018).  This project will cover the aorta and vascular 
smooth muscle cells (VSMC) harvested from the aorta.  Smooth muscle cells are part of many 
hollow organs including but not limited to blood vessels, gastrointestinal tract, airways, 
reproductive tract (including the uterus), bladder, and urethra. The main and significant roles 
of smooth muscle cells are (i) to shape and alter the shape of organs and (ii) to resist the force 
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of internal load that the organ is facing (Cowled and Fitridge, 2011). One example of this is 
vascular smooth muscle cells which are found in blood vessels, especially thick in arteries.  
Structure and functions of VSMC in the artery 
The wall of the aorta is composed of three layers: i) Tunica intima which is the 
innermost layer, ii) Tunica media which is the thick middle layer), and iii) Tunica adventitia 
which is the outermost layer (Karimi and Milewicz, 2016). Also, the aortic wall contains elastic 
fibres which are elastin surrounded by microfibrils (Karimi and Milewicz, 2016). 
Figure 1 shows the structure of the aortic wall. The tunica intima which is a single layer 
of endothelial cells is supported by the internal elastic lamina while the tunica media consists 
of 50 alternating layers of VSMCs and elastic fibres. Microfibrils of the elastic fibres are linked 
to focal adhesions (on the VSMC surface) which are linked to the contractile units inside the 
VSMCs.  
 
Figure 1: Structure of the aortic wall.  
The three layers of the aortic wall are shown above which are (1) Tunica intima, (2) Tunica media and (3) Tunica 
externa. Also, internal and external elastic membranes that surround the thick middle layer (tunica media) are 
shown as well. Source: https://healthjade.com/blood-vessels/  
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Finally, tunica adventitia which is the outermost layer of the aortic wall is composed 
of collagen and vasa vasorum (which are small arteries that supply the middle layer with 
nutrients) and autonomic nerves.  
This project will focus on the VSMC which are classified as fusiform cells with 200 
microns long and 5 microns in diameter and large central nucleus surrounded by an abundant 
array of ER and Golgi apparatus. Their cytosol and plasma membrane are decreasing toward 
the poles (Cowled and Fitridge, 2011).  
It is thought that aorta has a unique role in blood flow as about 50% of the left 
ventricular stroke volume during systole is stored there (and with some other proximal large 
vessels). With the help of the aortic elastic wall forces, this as well as other blood in the left 
ventricle is pushed forward and circulated to the peripheral circulation which assures 
continuous blood flow to the peripheral circulation. Interestingly enough, this unique role of 
the aorta is known as elastic buffering chamber and termed the Windkessel function and it is 
due to elastin in the aortic wall not the contraction of the VSMC as the elastic recoil of the 
aorta does not change if the VSMC’s contraction is pharmacologically inhibited (Karimi and 
Milewicz, 2016). 
Roles of important ion channels in regulating VSMC function   
Ionic balance and VSMC membrane potential are important in regulating VSMC 
function and electrogenic ion channels are among the best-known ones as well as other 
potassium channels. 
Regulation of cellular Ca2+ 
Several ion channels play roles in regulating cellular Ca2+ including 3Na+/2K+ ATPase 
and voltage-gated L-Type Ca2+ channels (Martinsen et al., 2014). Different ion channels have 
different roles in regulating cellular Ca2+. For examples, (a) Na+/Ca2+ exchangers (Lytton, 
2007)and plasma membrane Ca2+ ATPases (PMCA)) play roles in removing Ca2+ from cytosol 
to the extracellular space, (b) Sarcoplasmic Reticulum (SR) Ca2+ ATPases (SERCA) channels 
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have been shown to remove Ca2+ from the cytosol to the SR, (c) Stromal Interacting Molecule 
1 (STIM1); translocates Ca2+ from extracellular space to the SR once SR’s Ca2+ depletion is 
sensed by Ca2+ sensor proteins in the SR and once Ca2+ in the cytosol another channels (Orai1) 
are activated to facilitate the entry to SR, (d) non-selective cation channels of the 
transmembrane receptor potential canonical (TRPC) family are thought to regulate Na+ and 
Ca2+ entry and (e) a series of potassium channels are involved in re- or hyperpolarization of 
the VSMC membrane. The latter can be therapeutically targeted to limit Ca2+ entry and 
thereby limiting vasoconstriction (Cowled and Fitridge, 2011). An example of a calcium ion 
channel that changes with ageing is the voltage-gated L-Type Ca2+ channels (Albarwani et al., 
2016).  
In the cytosol, the Ca2+ level is maintained by either Ca2+ entry from extracellular 
space or by release from intracellular Ca2+ stores (Zhu et al., 2019b)(Endoplasmic Reticulum 
(ER) or Sarcoplasmic Reticulum (SR) in muscle cells).  Also, in muscle cell agents that activate 
the ryanodine receptor such as caffeine or phospholipase C (PLC) which releases IP3 that 
binds to IP3 receptors on the SR resulting in Ca2+ release into the cytosol. Ca2+ entry into the 
cytosol of the muscle cell from extracellular space occurs through non-selective cation 
channels or selective Ca2+ channels which could be voltage-gated or non-voltage gated. 
Additionally, membrane depolarization or stretch/pressure-dependent route of Ca2+ entry 
into the cell has been recognized (Cowled and Fitridge, 2011). 
The most important Ca2+ entry into VSMC is mediated by the voltage-dependant Ca2+ 
Channels (VDCC) especially the L-type or Cav1.2. Another VDCC is the T-type Ca2+ channels 
which are known as the Cav3 family which is thought to mediate Ca2+ entry into 
microvasculature (reviewed here (Catterall, 2011)). Depolarization of the plasma membrane 
activates VDCC which increases the open probability as well as overall Ca2+ conductance into 
the cell. Other ways of Ca2+ entry into the VSMC are non-selective cation channels that can 
allow a variety of ions such as Ca2+ and Na+ to enter the cell (Cowled and Fitridge, 2011).  
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Given the importance of the Ca2+ channels, they change with age and an example of that is 
provided by Mansour et al (Mansour et al., 2016). 
Potassium channels  
Like many other cells, VSMC expresses potassium channels. Different types of K+ 
channels have different roles. For example, the insulin-dependent electrogenic 3N+/2K+ 
ATPase is crucial in establishing the resting membrane potential (EM) of the VSMC (Mansour 
et al., 2016). Depolarization (contraction) and hyperpolarization (relaxation/vasodilation) of 
VSMC are more than just a single ion channel that can exert such effects. Also, when the 
VSMC gets hyperpolarized the inward rectifier KIR channels get activated resulting in the 
transportation of more K+ from extracellular space into the cell to neutralise or offset the 
hyperpolarization stimulus. Additionally, KIR channels play roles in the equilibrium potential 
for potassium (Cowled and Fitridge, 2011). In rare conditions where membrane potential (ME) 
is more negative than equilibrium potential for potassium (EK), KIR conducts small outward 
rectifying K+ current that regulates VSMC tone by combinational effects of KIR and 3Na+/2K+ 
ATPase channels (Cowled and Fitridge, 2011).  
On the other hand, the Kv family are activated by depolarization, and can, therefore, 
be targeted to hyperpolarize the VSMC to counterbalance any neural or hormonal-mediated 
depolarization (Cowled and Fitridge, 2011). Also, Kv channels in coronary arteries can be 
blocked using histamine which acts through H1 receptor while other blocking options (such 
as venom peptides, antibodies and small molecules) can be used, as well (reviewed here 
(Wulff et al., 2009, Cowled and Fitridge, 2011).   
Physiologically, many K+ channels (i.e. KATP, BK, GPCRs) have been shown to play 
different roles in VSMC functions. KATP channels are activated or inhibited by different ways. 
For example, many agents or K+ openers such as adenosine, calcitonin gene regulated peptide 
(CGRP), vasoactive intestinal peptide (VIP), pinacidil, minoxidil can activate KATP channels. 
Activation of KATP results in hyperpolarization and vasodilation. Mechanism of activation of 
30 
 
KATP involves activation of adenylyl cyclase that activates cAMP that activates protein kinase 
A (PKA). Also, the PCK-dependant pathway activation of KATP has been recognized. Another 
different way of KATP regulation involves high cytosolic ATP: ADP (control the open and close 
states of the channels) ratio as found in ischemic tissues resulting in attempts to throw K+ to 
hyperpolarize the membrane to create vasodilation. Some drugs that are used to treat 
certain conditions can affect KATP channels activity. For example, sulfonylurea which is used 
to treat type II diabetes can inhibit KATP channels resulting in membrane depolarization and 
consequently activation of Voltage operated Ca2+ Channels (VOCC) in pancreatic cells 
resulting in insulin release. Overuse of sulfonylurea can result in vasoconstriction as it will 
interfere with the effectiveness of the vascular K+ openers (Nichols et al., 2013, Cowled and 
Fitridge, 2011).   
BK channels are among the most studied channels. BK stands for big or large-
conductance Ca2+ activated potassium (BK) channels. Although BK is mainly activated by Ca2+ 
they are also voltage sensitive, unlike the small conductance smKCa channels. As the name 
suggests, these types of K+ channels are activated by increased cytosolic Ca2+ (reviewed here 
(Yang et al., 2015)).  
Potassium channels and especially BK are very important channels in the normal 
function of the VSMC. Age-related changes in these channels are expected to have serious 
consequences. Abnormal expression and function of the BK have been observed in animals 
which indicate that these channels may play significant roles in the abnormalities of aged 
blood vessels (reviewed here (Carvalho-de-Souza et al., 2013)).  
Regulation of VSMC relaxation by endothelial cells  
Nitric oxide (NO) is a very potent vasodilator. It is produced within the endothelial 
cells and has a variety of effects on the blood vessels structure and function including platelet 
aggregation and adhesion, and acts as a vasoconstrictor. In the endothelial cells, NO can 
activate both guanylyl cyclase (GC) and cyclooxygenase (CO). Once GC is activated, it can form 
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cyclic GMP (cGMP) which activates protein kinase G (PKG) leading to activation of K+ channels 
affecting removal of intracellular K+  which leads to membrane hyperpolarization, inactivation 
of VDCC that leads to low intracellular Ca2+ level resulting in vasorelaxation. Additionally, the 
activation of CO leads to vasoconstriction (Cowled and Fitridge, 2011, Pecanha et al., 2010). 
VSMC also changes with age that affects its normal contraction relaxation functions. The 
effects of ageing on VSMC behaviour is reviewed here (Monk and George, 2015). 
Brain (PVN) 
The paraventricular nucleus (PVN) of the hypothalamus is one of the most important 
hypothalamic autonomic control centres (Ferguson et al., 2008, Coote, 2005).  
Structure and functions of PVN  
The PVN has a complicated structure. Briefly, the PVN is composed of magnocellular 
and parvocellular neurons that can be seen with their subdivisions in (Figure 2-Error! 
Reference source not found.A). The PVN can be simply or ‘loosely’ separated (as seen in 
Figure 2Error! Reference source not found.B and C) into the posterior magnocellular lateral 
area, parvocellular area and intermediocellular region (dorsal and caudal PVN). Most of the 
pre-autonomic neurons are abundant in the intermediocellular (Me) area (Feetham et al., 
2018).  
‘Spinally-projecting PVN neurons project from the parvocellular PVN to the 
intermediolateral cell column of the thoracolumbar spinal cord (IML) and can control 
cardiovascular function such as blood pressure and heart rate. There is an additional role for 
the PVN, often called a “premotor nucleus”, where sympathetic premotor neurons play a role 
in body fluid homeostasis (Shih et al., 2003). Direct projections arise from PVN and innervate 
the pressor region of the rostral ventrolateral medulla (RVLM) which enables the PVN to 
control cardiovascular function via sympathetic tone (Shih et al., 2003, Sawchenko and 
Swanson, 1982).  
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With the projections mentioned above, the PVN can influence sympathetic nerve 
activity directly (via PVN–IML connections), indirectly (via PVN–RVLM connections) or by both 
mechanisms (via neurons with collaterals to the IML and RVLM). It is suggested that with 
these connections, the PVN can affect the reflex changes in the sympathetic nerve activity 
involved in the blood volume regulation (Shih et al., 2003).  
The PVN has additional physiological roles. Among these are its vital neuroendocrine 
roles in controlling (Ferguson et al., 2008) (a) the hypothalamo-pituitary-adrenal (HPA) axis 
(corticotropin-releasing hormone (CRH) neurons projecting to the median eminence), (b) the 
thyroid axis (thyrotropin-releasing hormone (TRH) neurons projecting to the median 
eminence), (c) the reproductive axis (dopamine and oxytocin neurons projecting to the 
median eminence or posterior pituitary), (d) the regulation of body fluid balance (vasopressin 
and oxytocin neurosecretory cells projecting to the posterior pituitary), (e) cardiovascular 
function through traditional autonomic outputs (neurons projecting to caudal medullary and 
spinal autonomic control centres), (f) growth and development (somatostatin neurons 





Figure 2:Hypothalamic PVN structure.  
The subdivisions of PVN are close to the third ventricle (3V). (A) The major parts of the PVN are the parvocellular 
and magnocellular. These can be further subdivided into the following: medial parvocellular (PaMP), medial 
ventral parvocellular (PaVP), lateral parvocellular (PaLP), periventricular subnucleus (PaPV), lateral magnocellular 
(PaLM), medial magnocellular (PaMM), and dorsal cap (PaDC). (B, C) the PVN can be divided into major areas; 
parvocellular (Pa), posterior magnocellular lateral (Ma), and the intermediocellular regions (Me) (Feetham et al., 
2018).  
PVN in diseases and ageing  
Dysfunction of sympathetic pre-autonomic neurons (usually hyperactivity) has been 
linked to several serious diseases such as hypertension and heart failure (Patel et al., 2000, Li 
and Patel, 2002, Li et al., 2003). Additionally, there is some evidence that direct ion channel 
dysfunction in the PVN is responsible for diseases. Examples include hormonal changes 
associated with depression, hypertension (i.e. decreased small Ca2+ sensitive potassium 
channels (SK)), heart failure (i.e. inhibition of GABA-ergic neurotransmission), and diabetes 
(i.e. increased TRPC) (Feetham et al., 2018).  
Also importantly, in regards to ageing, the PVN can influence the sympathetic 
nervous system, control of cardiovascular function (i.e. regulation of blood volume, circadian 
regulation of blood pressure, cardiovascular response to stress), regulatory functions for 
hepatic glucose control (liver-related PVN neurons express corticotrophin-releasing hormone 
and oxytocin), circadian pacemaker in mammals, role in osmoregulation and 
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thermoregulation (Feetham et al., 2018, Nunn et al., 2011). Not only this but also ageing 
affects the arginine vasopressin that is synthesized in the magnocellular neurons of the 
supraoptic nucleus and PVN of the hypothalamus (Greenwood et al., 2018).  
Ion channels in the PVN 
Due to its multiple and diverse functions, ion channels in PVN are also abundant and 
variable (Feetham et al., 2018). These channels include the major ones such as amino acid 
receptor channels, transient receptor potential channels (TRP), potassium channels, sodium 
channels, voltage-gated Ca2+ channels, and other channels like purinergic membrane 
receptor family, acid-sensing channels (ASICs), and proton-gated voltage insensitive cation 
channels (Feetham et al., 2018). 
Electrophysiologically, in PVN the main difference between neurones types depends 
on the nature of the principle voltage-gated (voltage-gated potassium and calcium) ion 
channels expressed.  (i) Type I neurosecretory magnocellular neurons that express a rapidly 
inactivated or “A-type” potassium conductance, and (ii) Type II parvocellular neurons 
expressing a slowly inactivating delayed rectifier potassium conductance (Feetham et al., 
2018).  
Role of PVN in the cardiovascular regulation  
PVN has a powerful influence on the cardiovascular system (Coote, 2007). GABAergic 
inhibitory synapses tonically inhibit the PVN’s cardiovascular activity (Martin et al., 1991, 
Martin and Haywood, 1993). PVN has projections to ILM and RVLM that act on the 
sympathetic neural outflow (Feetham et al., 2018, Nunn et al., 2011). With the decreased 
activity of the GABAergic inhibitory synapsis and increased excitatory signals to the PVN (as 
in chronic heart failure), the sympathetic neuronal activity increases and its outflow into the 
blood increases as well (Li et al., 2003, Li and Patel, 2003, Li et al., 2006b, Li et al., 2006a). 
This will influence the cardiovascular regulation, kidney and splanchnic beds as seen in 
35 
 
hypertensive models. Therefore, GABAergic influence on the PVN can be considered as a 
limiting step in the creation of sympathetic overactivity and its consequences.  
Catecholamines are other factors affecting the PVN’s activity. PVN neurons express 
α- and β-adrenergic receptors that can be activated by noradrenaline (NE) coming from the 
brainstem (Flak et al., 2009, Flak et al., 2014). The shift in the sympathetic basal tone that is 
observed in heart failure could be attributed to NE effects on the PVN. Therefore, Modulation 
of the activity of the PVN neurons through GABAergic and adrenergic mechanisms can 
control cardiac function (i.e. blood pressure and heart rate) (Mendonca et al., 2018).  
With ageing, dysregulation of the GABAergic system is associated with an imbalance 
in autonomic nervous activities. Not only this but also the resting blood pressure and heart 
rate are altered (Li et al., 2017).  
Role of PVN in plasma volume control 
Data indicates that parvocellular spinal projections are responsible for plasma 
volume regulation as lesioning of the PVN and destroying a substantial portion of the PVN-
spinal neurons leads to a decrease in the renal response to plasma volume expansion (Lovick 
and Coote, 1988, Lovick and Coote, 1989, Lovick et al., 1993). Many factors can activate or 
inhibit the PVN-spinal neurons including stimulation of cardiac afferents, arterial 
baroreceptors or the circulating atrial natriuretic factor. Also, the PVN-spinal neurons can be 
excited by injection of hyperosmotic solutions into the blood or through brain supply via the 
internal carotid artery. Not only this but also stimulation of the volume receptors via 
distending the right atrial-caval junction with a balloon catheter or expanding the plasma 
volume will activate the c-Fos in the parvocellular neurone of the PVN (Coote, 2007).  
Plasma volume is changed with ageing due to several factors including the 
inappropriate release of arginine vasopressin; which is released by the PVN, affecting the 
body’s water and salt contents which may lead to serious diseases such as hypertension 
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(Greenwood et al., 2018). Due to its important roles in several body functions and has been 
associated with age-related diseases, it is interesting to study ion channel changes in PVN 
with inflammageing.  
 Inflammageing is one of the events that take place in the body which affect the 
overall function of different tissues. Inflammaging is largely related to the increased 
abundance of cytokines.  
Cytokines  
It is thought that increased levels of cytokines is the key aspect of inflammageing 
(Ferrucci and Fabbri, 2018). Cytokines are small proteins of less than 80kDa. They are 
signalling proteins as they regulate a wide range of cellular functions including immune 
response (innate and acquired), inflammation and repair, haematopoiesis, and proliferation. 
Several different cells can secrete cytokines at local high concentrations. Cytokines are also 
involved in cell-to-cell communications. They can apply their effects through autocrine, 
paracrine or endocrine (systemic) fashions. Individual cytokine cannot exert its effect without 
activating other cytokines and proteins (Chung, 2009). With ageing, Cytokine levels increase 
by 2-3 folds (Pedersen, 2006b).  
Cytokines are produced and secreted dynamically. Therefore, the immune response 
must be tightly regulated as lifestyles and some external (i.e. environment) factors can 
change the cytokine concentrations that initiate inflammatory defence response by fighting 
infections (i.e. bacterial or viral) through the pro-inflammatory pathway/cytokines (Rea et al., 
2018). The initiation of this pathway must be regulated and turned off as soon as the 
pathogen is cleared. There are two types of inflammatory cytokines/pathways; pro- and anti-
inflammatory (Rea et al., 2018).   
Rather than just clinical signs and symptoms, more biomarkers and biochemical 
indices are used in medicine to improve diagnosis and treatment of diseases. For example, a 
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biomarker for inflammation that circulates in the blood called C-reactive protein. Modest 
elevation in its level has been associated with large numbers of age-related conditions. Such 
conditions represent minor metabolic stressors. Different cytokines are also used in the 
clinical diagnosis of diseases. More investigations are carried to find out their roles in terms 
of molecular processes and pathways leading to inflammation at all ages in general and in 
ageing specifically (Rea et al., 2018). Inflammageing is a common finding in ageing and age-
related diseases. Pro-inflammatory cytokines play an important role in immune system 
remodelling with age as shown in Figure 3.  
 
 
Figure 3: Dysregulation of cytokines and NF-kB signalling in ageing and age-related diseases. 
A reshaping of cytokines expression with a tendency towards increased pro-inflammatory and decreased anti-
inflammatory cytokines. This tendency called pro-inflammatory phenotype or “Inflammageing”. In this figure, IL-
1β binds its receptor IL-1R which activates signalling cascades that are mediated through MyD88 and TRAF6 which 
activates NF-kB. The later is inhibited by IKK. Activated IL-1β-IL-1R leads to phosphorylation of IKK and labels it for 
proteasomal degradation. Activated NF-kB then translocates into the nucleus and activates gene transcription 
including the production of cytokines and other enzymes that induce inflammation. Additionally, TNFα binds its 
receptor TNFR1. Then, a complex is formed containing TRADD, TRAF2 and RIP which activates NF-kB by 
phosphorylation of IKK. Phosphorylated IKK is degraded by proteasomes. Activated NF-kB is translocated into the 
nucleus and activates genes involved in inflammation. Inflammation can cause different diseases including 
arthritis, rheumatoid arthritis, atherosclerosis, heart failure, Alzheimer’s disease and Parkinson’s diseases. 
Abbreviations; IL-1β: Interleukin-1 beta, IL-1R: Interleukin-1 Receptor, IL-10: interleukin 10, IL-37: interleukin 37, 
TGF-β: Tumor growth factor-beta, MyD88, myeloid differentiation factor 88, TRAF6: TNFR-associated factor 6 
(TRAF6), NF-κB: nuclear factor κB, IKK: IκB kinase, RIP: Receptor-interacting serine/threonine-protein kinase, TNFα: 
Tumor necrosis factor-alpha, TNFR1: Tumor necrosis factor receptor 1,  TRADD: Tumor necrosis factor receptor 




Mechanism of action of cytokines  
Cytokines bind to their receptors (soluble or membrane-bound), induce 
conformational changes, activate proteins that start downstream signalling cascade through 
second messengers (Figure 4). This may end up with activation of gene transcription and 
protein synthesis that activate other proteins or cytokines. There can variable final effects 
including cell survival, activation of other cells, gene activation, apoptosis or cytoskeletal 
changes. 
 
Figure 4: Schematic diagram of how cytokines work in general.  
Cytokines usually bind to their cell surface receptor although some cytokines bind to their intracellular receptor. In 
this schematic diagram, I show a general mechanism of action of cytokines. Normally, a ligand (cytokine) binds to 
its receptor activating second messengers (adaptors) which work on effectors leading to a cellular function 
(effects). The second messenger behaviour of each cytokine is complex and can be quite different. As an example, 
I show here Tumor necrosis factor-alpha (TNFα) cytokine. Once the TNFα binds its receptor TNFR1, a protein 
complex containing TRADD protein, TRAF2 and RIP are recruited. TRADD, TRAF2 and RIP and the inhibitor of kB 
(IKK) can function together to activate NF-kB which activates gene transcription leading to cell survival. Gene 
activation can also occur through the MAP kinase pathway. Apoptosis (cell death) can occur through the 
interaction of TRADD with FADD protein and caspase-8 leading to activation of caspase-3 and apoptosis. Besides, 
TNF-mediated recruitment of TRAF2 can activate JNK which in turn activates Jun leading to apoptosis as well. 
Cytoskeletal changes occur through activation of Rho family GTPases. TRADD: Tumor necrosis factor receptor type 
1-associated DEATH domain protein, TRAF2: TNF receptor-associated factors, RIP: Receptor-interacting 
serine/threonine-protein kinase, MAP: mitogen-activated protein, JNK: c-Jun N-terminal kinase, Jun: Jun Proto-
Oncogene, AP-1 Transcription Factor Subunit, FADD: Fas-associated protein with death domain.  
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Pro-inflammatory cytokines in ageing and age-related diseases  
Pro-inflammatory cytokines are produced and secreted mainly by activated 
macrophages (Zhang and An, 2007).  The major pro-inflammatory cytokines that contribute 
significantly to the phenomenon of inflammageing, as well as many other age-related 
diseases in healthy elderly people, are IL-6, TNF α, and IL-1α. To achieve healthy ageing, the 
balance between pro- and anti-inflammatory cytokines must be retained. This means the 
ability to respond to immune messengers and integrated return to inflammation resolution 
and finally restore immune homeostasis (Rea et al., 2018). Next, examples of the important 
pro-inflammatory cytokines (IL-1β and TNFα) that were used in this study will be covered.  
Interleukin-1 (IL-1)  
IL-1 is the central mediator of the innate immunity and inflammation in the body. IL-
1 binds its receptor and initiate signalling cascades leading to inflammation that can cause 
several diseases as shown in (Figure 3). Both IL-1 and IL-18 initiate stress-induced 
inflammatory cascade (Sims and Smith, 2010). Such association has also been linked to 
ageing. A study involved young, elderly and Centenarians included three different 
polymorphisms of IL-1α to evaluate whether IL-1 cluster alleles could be differently 
characterized in people selected for longevity, no significant differences detected in the 
genotype and allele frequency distribution. However, an increase in the IL-1Ra (antagonist) 
level was detected while IL-1β showed no age-related trend. The increase in IL-1Ra seemed 
not to be related to the genotype but to the age-related increased inflammation and as a 
protection measure (Cavallone et al., 2003). Another study showed an association between 
increased serum level of IL-1β and congestive heart failure, angina and dyslipidaemia without 
any associations with age [8]. IL-1β could be related to the cardiomyocyte function alterations 
rather than ageing itself or age-related diseases (Di Iorio et al., 2003). Only IL-1Ra showed a 
significant predictor of mortality and a powerful prognostic marker in elderly people (Jylha 
et al., 2007).  
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A polymorphism (- 889C > T) IL-1α was found to be strongly associated with increased 
risk of Alzheimer’s disease (Mun et al., 2016). Since inflammation is thought to play a 
significant role in cognitive decline and dementia with ageing, Trompet et al (Trompet et al., 
2008) found that certain IL-1 haplotype in elderly people produced lower levels of IL-1β-
converting enzyme that decreased IL-1β levels resulting in improved memory function 
compared to the other polymorphisms. Therefore, lower levels of IL-1β at old age can be 
considered as a defensive mechanism against memory loss and learning deficit. 
Tumour Necrosis Factor-α (TNF-α)  
TNF-α is a pro-inflammatory cytokine and is one of the major players in the immune 
system. Once this cytokine binds its receptor, the complex initiates signalling cascades that 
change cellular functions (Figure 3 and Figure 4). It has been reported to increase with ageing 
and age-related diseases (Ferrucci et al., 2005). A study reported increased levels in ageing in 
elder people (octogenarians and centenarians) with atherosclerosis and associated with 
mortality (McNerlan et al., 2002, O'Mahony et al., 1998, Armstrong et al., 2001, Bruunsgaard 
et al., 2000, Bruunsgaard et al., 2003b, Bruunsgaard et al., 2003a). It has been associated with 
an increased risk of recurrent cardiac events in post-MI as its levels increased. Additionally, 
renal patients with TNF-α receptors predicted cardiovascular disease (Ridker et al., 2000, 
Nilsson et al., 2013, Bae et al., 2017). It is more beneficial when it acts locally and harmful 
systematically. TNF-α has also been reported to be associated with risk for MI and 
Alzheimer’s diseases. It can affect cellular metabolism, increased in type II diabetes, lower 
muscle mass and strength in older people (Zhang et al., 2017, Wang, 2015, McCusker et al., 
2001, Collins et al., 2000, Zheng et al., 2016). The available TNF-α inhibitors may have possible 
prophylactic or ameliorating roles in cardiovascular and Alzheimer’s disease in animal models 
(Ruparelia et al., 2017, Shamim and Laskowski, 2017). 
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There are also other pro-inflammatory cytokines including IL-6, IL-18, IL-2, IL-7, IL-8, 
IL-12 and IL-17. To ensure the balanced response of the pro-inflammatory cytokines, an anti-
inflammatory mechanism must be effective and respond appropriately.  
  
Anti-inflammatory cytokines in ageing and age-related diseases 
Anti-inflammatory cytokines play a role in balancing the immune response initiated 
by the pro-inflammatory cytokines. This role is very important to avoid the transition of the 
immune response into chronic resulting in a disease-inducing state or even pro-inflammatory 
phenotype “inflammageing”. Anti-inflammatory cytokines act on the pro-inflammatory 
cytokines such as IL-1α, TNF, and other major pro-inflammatory cytokines to block or 
modulate their levels to restore immune homeostasis (Rea et al., 2018). There are specific 
receptors for cytokines such as IL-1, TNFα, IL-18, soluble receptor antagonists/blocker, 
chemokines, siRNAs and/or microRNA can all play roles as inhibitors of the pro-inflammatory 
cytokines. The anti-inflammatory cytokines along with soluble receptor antagonists work in 
a complex network to achieve or restore immune homeostasis. Therefore, enhanced anti-
inflammatory phenotype rather than pro-inflammatory phenotype can be a significant 
contributor to longevity which is highly affected by the pro-inflammatory phenotype 
(Franceschi et al., 2007b, Franceschi and Campisi, 2014, Westendorp et al., 1997).  
The major anti-inflammatory cytokines players are IL-10, IL-37 and TGF-β (Rea et al., 2018).     
1.3  Ion channels  
A key objective of this project was to identify any common changes in ion channel genes 
(channelome) across different models of ageing.  Ion channels are transmembrane proteins 
that are located on membranes of all cells and some subcellular organelles. They provide ion 
fluxes (gating; opening “activation” or closing “deactivation or inactivation” of the ion 
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channels) following electrochemical ingredients of different ions including K+, Na+, Ca2+ and 
Cl-. The electrochemical ingredients mean that there are different concentrations of these 
ions across the membrane. Not only this but also different charges as well. When changes in 
the membrane potential take place, the cell tends to restore its equilibrium potential. To do 
this, the open channels allow their specific ions to pass through and this moves the 
membrane potential towards the ion’s specific equilibrium potential. Since there are many 
ions, the final equilibrium potential will be somewhere closer to the major contributor to the 
membrane potential of the cell. Mostly, the membrane potential is closer to the K+ 
equilibrium potential which is around -70mV.  
The activity of ion channels depends on several factors such as changes in membrane 
voltage, binding of ligands (i.e. neurotransmitter and hormone), second messengers, 
temperature, chemical and/or physical stimuli. Ion channel-dependent cellular functions 
such as cell excitability, neurotransmitter and hormone release, gene expression, 
contraction, ion and water/fluid homeostasis are all dependent on ion channel isoforms as 
well as their tissue-type and age-dependent expression. Ion channels are extensively 
distributed among all cells in all tissues. They exist in open, inactivated closed, and closed 





Figure 5: Ion channels states.  
Ion channels exist in three forms; resting closed, open or inactivated closed.  Cited from(Kim, 2014).   
Structurally, a single protein can form an ion channel, but also ion channels often exist in 
a more complicated form composing of several subunits with each subunit encoded by a 
different gene (heteromultimers)  (Bruunsgaard, 2002, Kang et al., 2009). There are more 
than 400 genes that encode for ion channels (Bruunsgaard, 2002, Kang et al., 2009). 
Ion channels implicated in inflammageing  
As described above, there are several ion channels and related porin genes. Many of 
these could be involved with inflammageing. The best known are described below.  
K+ channels  
Potassium cation channels are a diverse family of membrane proteins in excitable 
and non-excitable cells. In human, there are more than 90 genes coding for α-subunits 
potassium channels. These channels have been studied for more than 20 years for their 
structures, gating mechanism, diseases and therapeutic drugs (Tian et al., 2014). Recently, 
the focus on these channels has increased that led to a deep understanding of their molecular 
mechanisms including ion selectivity, conduction/gating and related functional domains 
contributing to gating (Weingarth et al., 2013). 
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They are often made up of two main subunits; an α-subunit or principal subunit that 
determines the structure of the channel and a β- or auxiliary subunits that modify the 
properties of that channel. The α-subunits express in heterologous expression systems as 
functional homo-multimeric channel complexes and can co-assemble with β-subunits to form 
functional channels. According to structural and functional similarities, it is predicted that 
these principal subunits are at least eight families (Wei et al., 1996). Three of them (a) Kv, (b) 
ether-a-go-go-related gene (EAG), and (c) KQT, share a common motif of six transmembrane 
domains (TM) and are voltage-gated. Another two families (d) CNG (gated by cyclic 
nucleotide) and (e) SK/IK (gated by calcium) and the last three families of these α-subunits of 
the potassium channels are (f)  Slo family (BK) channels with seven TM domains and gated by 
voltage and calcium or pH (Meera et al., 1997, Schreiber, 1998), (g) Kir channels contain two 
TM domains, and the last functionally diverse family is (h) K2p channels with two tandem 
repeats of the inward-rectifier motif (Tian et al., 2014).  
The above-mentioned families are used to categorize potassium channels into three 
groups as (i) voltage-gated 6 TM potassium channels (Kv channels), (ii) calcium-activated 6/7 
TM potassium channels (Kca channels) and (iii) 2 TM potassium channels.  
One example of the K channels is the Big-conductance K channels (BK). It belongs to 
the calcium-activated 6/7 TM potassium channels (Kca channels) group with the ability to get 
activated by both Ca2+ and voltage (Meera et al., 1997). A unique feature of the BK structure 
is that it has a unique TM helix known as S0 (segment 0) at the N-terminus which is absent in 
other potassium channels (Figure 6). Through this S0, the N-terminus of the BK channel ends 
up in the outside region of the cell. The pore region of K+ ion pass through the channel is 
located between S5 and S6 (Tian et al., 2014). The voltage sensors of the BK are like the other 
potassium channels in which they are comprised of S1-S4 membrane-spanning segments 
with 4 positively charged arginine residues in the S4 helix (Long et al., 2005a, Long et al., 
2005b). The C-terminus of the BK is located inside the cell with two regulators of K+ 
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conductance (RCK) domains (RCK1 and RCK2) with a binding site for Ca2+ ions (referred to as 




Figure 6: A schematic representation of the topology of the BK channel.  
(A) The big conductance K channel (BK) subunits are composed of seven TM segments. The pore region is formed 
by S5 and S6 segments while the two regulators of the BK channels; RCK 1&2 with the Ca2+ bowl are shown in the 
intracellular (cytoplasmic) side of the cell. Also, the S0 segment that is unique to the BK channel is shown as well 
as the N-terminus of the channel in the extracellular side. (B) Structure of the tetrameric assembly of the BK 
channel. Cited here (Tian et al., 2014).  
When a mutation(s) in genes coding potassium channels occurs, this can lead to 
dysfunction of the potassium channels and results in diseases in systems where these 
channels are broadly distributed (i.e. neuronal or cardiac) or other systems including nervous, 
musculoskeletal, and circulatory systems (Tian et al., 2014). Table 1 shows examples of 




Table 1: Diseases with their related potassium channels. 
Diseases Systems  Organs  Potassium 
channels  
References  





et al., 1993, 
Angulo et al., 
2004, Boda et 
al., 2012, 
Maezawa et al., 
2012) 
Parkinson’s disease Nervous system  Brain  KCNJ2, KCNJ4, 
KCNJ12, 
KCNJ14 
(Gui et al., 2011, 
Deutch and 
Winder, 2006, 
Wang et al., 
2005, Wu et al., 
2010, Sander et 
al., 2012) 
Short QT syndrome  Cardiovascular 
system  
Heart  KCNH2, 
KCNQ1, 
KCNJ2 
(Bellocq et al., 
2004) 




KCa1.1 (Beeton, 2017, 
Okamoto et al., 
2010, He et al., 
2011, Okamoto 
et al., 2012) 
 
As more data has become available about potassium channels, researchers have 
started to test some modulators of these channels to obtain more and deep understanding 
of the structure, function and possible therapeutic targets. These modulators can be divided 
into peptide toxins and small molecules (Moczydlowski et al., 1988, Robertson and Steinberg, 
1990). Peptide toxins can affect potassium channels from the extracellular side by either (i) 
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binding to the outer vestibule of potassium channels and mostly they insert a lysine side chain 
into the channel pore and block it (MacKinnon and Miller, 1989, MacKinnon et al., 1990) or 
by (ii) interaction with the voltage sensor domain of the potassium channels and keep them 
stably closed (Swartz and Mackinnon, 1997, Swartz, 2007). On the other hand, the small 
molecules bind to the inner side of the pore, the gating hinge, or the interface between the 
channels’ subunits (α- and β-). These small molecules can be categorized into blockers and 
openers or specific vs multitarget (Robertson and Steinberg, 1990, MacKinnon and Miller, 
1989, MacKinnon et al., 1990, Swartz and Mackinnon, 1997, Swartz, 2007).  
BK channels have been reported to change with ageing in different cells including but 
not limited to VSMC and suprachiasmatic nucleus (Carvalho-de-Souza et al., 2013, Farajnia et 
al., 2015). The later is important for normal sleep and rest in the night as it is one of the 
circadian related genes. Additionally, other potassium channels such as voltage-gated K+ 
channels are altered with ageing, as well. Such alterations can occur through oxidation of the 
potassium channels leading to age-related diseases such as neurodegeneration (Sesti, 2016).  
Ca2+ channels   
There are multiple types of calcium channels, physiologically distinguishable based 
on their sensitivities to voltage; they can be categorized into high and low voltage-activated 
Ca2+ channels.  
Ca2+ ion channels are critical channels and they carry out important functions at the 
cellular and tissue levels including the activation of calcium-dependent enzymes, muscle 
contraction, secretion of neurotransmitters and hormones, and gene transcription (Zamponi, 
2016, Simms and Zamponi, 2014, Zamponi et al., 2015).  
Ca2+ channels have distinct functions depending on the tissue they are expressed in. 
For example, Cav2.2 channels are expressed in neurons and trigger the release of 
neurotransmitters  (Zamponi et al., 2015).  Additionally, Cav1.1 channels; the sole Ca2+  
channels expressed in skeletal muscles, are very important in muscle contraction, triggering 
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excitation-contraction coupling.  Skeletal muscle is one of the best-studied tissues in the 
context of ageing since skeletal muscle loss; sarcopenia is one of the major causes of frailty 
in the elderly (Vasilaki et al., 2010, Walston, 2012).  
Usually, the behaviour of Ca2+ channels is regulated by a wide range of second 
messenger pathway with accessory proteins such as calmodulin. This depends on the isoform 
of the channel offering cell specificity in fine-tuning cell signalling through these calcium 
channels (Simms and Zamponi, 2014).  
Mutations in genes coding for Ca2+ channels subunits can have serious consequences. 
For example, mutations in different Cav-α1 subunits have been reported in patients with 
congenital stationary blindness (Cav1.4) and in patients with familial hemiplegic migraine 
(Cav2.1) (Zamponi et al., 2015, Zamponi, 2016).  
Other factors that can lead to dysregulation of calcium channels are abnormal 
channel expression and function (Zamponi, 2016). There are many examples for this including 
dysregulation of L-type channels that are involved in the age-related conditions, Parkinson’s 
disease and drug addiction, and upregulation of N- and T-type calcium channels during 
different age-related conditions, chronic pain (Zamponi, 2016).   
Many therapeutic Ca2+ channel modulators are available and so these could 
potentially help to treat age-related conditions involving Ca2+ channels. For example, 
isradipine (for Parkinson’s disease), N-type channel blocker (for chronic pain), T-type channel 
blocker (for absence epilepsy), and dihydropyridine (DHPs, for hypertension) (Zamponi et al., 
2015, Zamponi, 2016).  
However, the side effects or less efficiency of the above mentioned Ca2+ channel 
modulators have been reported which can be attributed to the lack of specificity because 
there are different isoforms of the Ca2+ channels. (Zamponi, 2017, Zamponi et al., 2015).  .   
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Na+ channels  
Sodium channels largely occur in two families; (a) voltage-gated sodium channels 
(VGSC) family which are distributed in various cell types throughout the body and (b) the 
epithelial sodium channels (ESC) that is expressed primarily in the skin and kidneys 
(Hernandez and Richards, 2019).  
 Voltage-gated sodium channels are transmembrane proteins. They are made up of 
two subunits. The first subunit is the one-pore forming α-subunit that allows the ions to pass 
through. This α-subunit consists of four transmembrane domains with six segments per 
domain and has the voltage sensor on the fourth segment of each domain (Yu and Catterall, 
2003). The second subunit of the VGSC is the one to two β-subunits that regulate cells’ 
excitability through modulating localization, gating and kinetics of the pore formed by the 
adjacent α-subunit (Hernandez and Richards, 2019). Because of their large and extracellular 
V-set immunoglobulin domain of the β-subunits, they are part of the Ig superfamily of cell 
adhesion molecules. The β-subunits are encoded by SCN1B-SCN4B genes (Yu et al., 2005, 
O'Malley and Isom, 2015).  
These channels open when the membrane potential in their surrounding area 
become depolarized. This allows the flow of sodium ions following their concentration 
gradients. Once the membrane potential altered, these sodium channels are the first to open 
which leads to the accumulation of positively charged sodium ions inside the cell (Grider and 
Glaubensklee, 2019). The ability of excitable cells (neurons or muscle cells) to depolarize is 
vital as it results in the generation of an action potential leading to a formation of cellular 
response/function such as contraction (Grider and Glaubensklee, 2019). There is two gates 
for voltage-gated sodium channels; (a) activation gate that allows the flow of sodium ions 
into the cell and depolarization and (b) inactivation gate that stops the flow of sodium ions 
regardless of the status of the activation gate. These together maintain the membrane 
depolarization in balance. This also means that once the activation gate opens, they will 
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remain like this for a few milliseconds before they close and will never open again unless cell 
repolarization takes place to a certain voltage threshold even if there is a continuous 
stimulus. This mechanism is important to prevent cells from prolonged or continuous 
depolarization (Wang et al., 2017). To achieve such balances, voltage-gated sodium channels 
must be targeted to specific cellular domains and interact with several proteins (extracellular 
matrix, membrane and cytoskeletal proteins) to form a multiprotein complex (Wang et al., 
2017).  
Sodium channels are important clinically in ageing because any impairment or 
dysfunction can lead to some neurological (i.e. epilepsy) or cardiac (i.e. myopathies or cardiac 
arrhythmias) diseases. Dysfunction can be genetic or acquired. Many pharmacological 
compounds target sodium channels such as lidocaine (anaesthetics), phenytoin and 
lamotrigine (antiepileptics), and flecainide and mexiletine as antiarrhythmics (Kotipoyina and 
Warrington, 2019, Hernandez and Richards, 2019, Iorga and Horowitz, 2019). With sodium 
channel blockers, care must be taken as inappropriate use may have negative consequences 
such as seizures and arrhythmias (Torp and Simon, 2019).   
Cl- channels  
Chloride channels are expressed in every cell types with different cellular functions 
(Jentsch et al., 2002, Jentsch and Gunther, 1997).  These channels are involved in the control 
of transepithelial transport, membrane excitability, the regulation of cell volume, and 
repolarization after contraction (Jentsch et al., 2002, Planells-Cases and Jentsch, 2009, 
Vaishali and Satya, 2016). They are also involved in the regulation of the intracellular and 
intraorganelle pH. The major chloride channels that are involved in these functions are 
voltage-gated, the cystic fibrosis transmembrane conductance regulator (CFTR) and its 
related channels, and the ligand-gated chloride channels that are activated by gamma-
aminobutyric acid (GABA) and glycine (Planells-Cases and Jentsch, 2009, Vaishali and Satya, 
2016).   
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The importance of chloride channels appears more in cases where there are 
mutations in the genes encoding these channels resulting in diseases such as osteoporosis, 
inherited kidney stone disease, some forms of myotonia, epilepsy diseases (GABA and glycine 
receptor), and the most popular one is the cystic fibrosis (Planells-Cases and Jentsch, 2009).  
Although Chloride channels have been targeted for medications ((Tang and Chen, 
2011)), they have been less extensively studied at the molecular levels as other channels 
which resulted in a relative lack of information of their structure, function leading to less 
utilization of these channels as treatment targets (Martinez and Mohiuddin, 2019).  
TRP channels  
Transient Receptor Potential Channels (TRPs) are one of the largest families of ion 
channels. They are involved in the detection of chemical, thermal, mechanical stimuli as well 
as the transduction of pain in the form of inward current (Wang and Woolf, 2005).  
There are many types of TRP channels. Six subfamilies have been identified in 
mammals. Also, an additional subfamily found in invertebrates and nonmammalian 
vertebrate animals. TRP channels are members of the voltage-gated ion channels (Rosasco 
and Gordon, 2017) and they are predominantly non-selective cation channels. They play roles 
in several physiological functions such as store-operated Ca2+ entry, axonal guidance, Mg2+ 
uptake, and thermal/mechano/chemical-sensation (Song and Yuan, 2010, Ramsey et al., 
2006, Levine and Alessandri-Haber, 2007). Although heterotetramers of TRP channel 
subunits have been identified (Cheng et al., 2010), they form tetramers of identical subunits.  
Structurally, as other voltage-gated superfamilies, each subunit of the TRP channels 
consists of six membrane-spanning helices with a re-entrant pole loop between the 5th and 
6th transmembrane helices. Also, TRP channels have their amino- and carboxy-terminal in the 
intracellular compartment. The voltage-sensing or voltage-sensing-like domains are the first 
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four segments while the ion-conducting pore is formed by the remaining two segments and 
the re-entrant pole loop (Rosasco and Gordon, 2017).  
There are seven subfamilies of TRP channels that are (a) TRPA, (b) TRPC, (c) TRPM, 
(d) TRPML, (e) TRPN, (f) TRPP, and (g) TRPV. The individual subunits of all subfamilies’ 
members are thought to contain six transmembrane segments assembling in tetrameters to 
form a functional TRP channel (Rosasco and Gordon, 2017). These subfamilies are not 
distributed equally in all tissues, species and even their functions are not the same (Rosasco 
and Gordon, 2017). TRP channels also change with ageing. For example, TRPV4 has been 
reported to change in terms of its distribution with ageing (Lee and Choe, 2014). Additionally, 
decreased RyR expression in atrial cells could be attributed to the age-related reduction in 
the intrinsic heart rate (reviewed here (Rao, 2016).  
General roles and functions of ion channels  
Resting membrane potential (RMP)  
One of the clearest general roles of ion channels is the control of RMP.   RMP of a 
given cell is the electrical potential (voltage) difference across the cell membrane when it is 
at a non-excitable state. Typically, cells have their RMP in the range of -70 to -80 mV. This 
means that the potential inside the cell is 70 to 80mV lower than that of the outside when 
the cell is at rest (Morth et al., 2007, Wright, 2004).  
Although many ions contribute to the RMP, the most common candidates are the K+ 
channels. Additionally, there are other intracellularly negative proteins and organic 
phosphates that cannot cross the cell membrane and contribute to the RMP (Morth et al., 
2007). Furthermore, Lewis et al (Lewis et al., 2011a) showed that in chondrocytes TRPV5 
channels have partially participated in the control of RMP in chondrocytes that eventually 
controlled cell volume. Different cell types in the body have different and characteristic RMP. 
The most important ones are those of the nervous and muscular (smooth, skeletal and 
cardiac cells) systems (Chrysafides and Sharma, 2019).  
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The importance of RMP is that it allows cells to perform a specific role via a rapid 
change in the membrane potential when gets excited. For example, in neurons the change in 
RMP allows the cell to communicate with other cells by releasing neurotransmitters while in 
muscle cells such changes of RMP can lead to muscle contraction (Chrysafides and Sharma, 
2019).  
Physiologically, ions that contribute to RMP rarely reach equilibrium potential 
because they cannot freely move across the cell membrane which is not permeable to most 
ions. This is because most key K+ ion channels are closed at rest. One exception here is the K+ 
ions that has a “leak” channel that allows it to diffuse out of the cell down its electrochemical 
gradient which means that the K+ is close to its equilibrium potential and the cell membrane 
potential is close to the equilibrium potential of the K+ ions that is approximately around -
90mV (Chrysafides and Sharma, 2019, Wright, 2004).  
The ionic distribution necessary to maintain the RMP is created by the ATP-driven 
pump (Na/K-ATPase). Although both ions do not completely reach their equilibrium 
potentials, small amounts of Na+ ions can find their way into the cell and some K+ ion leaves 
it through the leak channels. Therefore, Na/K-ATPase removes three Na+ ions from the 
intracellular space to outside and brings two K+ ions into the cell in exchange (Enyedi and 
Czirjak, 2010).  
Clinically, it is vital to maintain the RMP because any abnormal changes in it can affect 
the normal functions of the cells. In this thesis, there will be a particular focus on any changes 
of ion channels that might change with age and affect the RMP.  An example, clinically where 
RMP does change is, for example, hypokalaemia (lower concentration of K+ ions in the blood). 
This triggers the flux of K+ ions out of the cell leading to hyperpolarization of the cell. This 
means that a higher trigger is required to achieve an action potential leading to a more 
negative potential in the cardiac muscle from the more complete recovery of Na+ channel 
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inactivation. Consequently, hypokalaemia leads to delayed ventricular repolarization leading 
to re-entrant arrhythmias (Castro and Sharma, 2019) and other physiological dysfunctions. 
On the other hand, hyperkalaemia results in depolarization of the cell membrane that 
inactivates Na+ channels leading to major arrhythmias (Simon et al., 2019). In short, due to 
the fundamental importance of the RMP, any major electrolyte abnormalities with age would 
have serious consequences.  
Action potential  
An action potential is defined as the fast sequence of voltage changes across a 
membrane that transmits information along a neuron or muscle fibre. Although action 
potential is mainly discussed in the context of neurons, it also occurs in all excitable cells such 
as cardiac muscle and some cells of the endocrine system (Wei and Richards, 2019, Stojilkovic 
et al., 2010). This membrane voltage or potential is determined by the relative ratio of ions 
(extracellular to intracellular) and the membrane’s permeability of each ion (i.e. Ca2+, Na2+, 
K+, Cl-, etc). the initial rapid rise in potential (from the RMP to less negative levels) of cells; is 
known as depolarization, and mediated by the opening of voltage-gated sodium channels in 
the cell membrane. This is an all or none event. Once channels open, they would tend to go 
back to their normal state and in this case, the repolarization is triggered by the opening of 
potassium ion channels. In turn, the normal resting state, the RMP, as described above is 
then maintained by the Na/K-ATPase. This pump ensuring that appropriate amounts of these 
ions are maintained in each side of the membrane (Grider and Glaubensklee, 2019).  
There are three main stages of each action potential; depolarization, repolarization 
and hyperpolarization (Ulbricht, 2005). Depolarization is determined by a cell’s threshold 
voltage at which voltage-gated sodium channels (Nav) open allowing an influx of the 
positively charged Na ions into the cell leading to further depolarization of the membrane 
and opening more Na channels. This process lasts up to 1ms. After that, Nav becomes 
inactivated and can no longer be able to flux ions (Ulbricht, 2005). As a cellular response to 
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restore its resting state, voltage-gated potassium (Kv) channels open starting the 
repolarization state. The kinetics of these channels are slower than Nav although both have 
nearly the same threshold voltage. So, after 1 ms the slow Kv opens while the faster Nav gets 
inactivated leading to the move of K+ ions out of the cell and decreasing the membrane 
potential towards the cell’s resting voltage. Once the membrane potential falls below the 
threshold (repolarization), Nav channels close and the slow Kv starts to close but it remains 
longer in order to return the cell to resting membrane voltage (Ulbricht, 2005, Grider et al., 
2019).  
In neurons, action potentials spread a signal along the length of an axon differently 
in myelinated versus unmyelinated axons based on the lipid contents that acts as an insulator 
of ion flow (Grider et al., 2019). Therefore, even if ion channels themselves turn-out not to 
change with age, changes in the control of myelin production could have similar effects.  
Deficits in action potentials can be determined by conduction velocity tests especially 
in the peripheral nerves, but this requires identification of specific mechanism(s) that block 
the conduction or decrease its velocity (Burke et al., 2001). Some conditions that can affect 
the conduction velocity by decreasing or even blocking the speed of electrical signal 
conduction include injured axons and nerve construction as seen in carpal tunnel syndrome 
while diseases that decrease the conduction velocity involve diabetic neuropathy, and 
multiple sclerosis (Grider et al., 2019, Burke et al., 2001, Nguyen and Taylor, 2019, Bodman 
and Varacallo, 2019). Additionally, some genetic disorders that lead to channelopathies can 
also decrease the conduction velocity in the peripheral nervous system. Examples of such 
channelopathies include neuromyotonia, epileptic seizures or migraines (Grider and 
Glaubensklee, 2019).  
Clinically, it is important to know how action potential work. For example, local 
anaesthetics usually work via blocking voltage-gated sodium channels that prevent signal 
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transmission in pain. This occurs when the anaesthetics pass through the cell membrane and 
block the open Na channels (Scholz, 2002). To summarize, the action potential is very 
important to normal cellular functions and any age-related abnormal changes would have 
global serious consequences on the cell or tissue functions.  
Cell volume  
The RMP, and thus ion channels, are crucial to cell volume control. A cell needs to 
maintain its volume for survival (Abdul Kadir et al., 2018). When changes occur in the 
environment around the cell such as constantly changing osmolality and compressive loads, 
the cell volume changes (i.e. shrinkage) as well (Abdul Kadir et al., 2018). This requires the 
cell’s response that can either regulate this change or go through the apoptotic pathway 
(Wibberley et al., 2015). Such changes are called (i) regulatory volume increase (RVI), which 
is involved in adaptation to hypertonic media and cell survival, and (ii) apoptotic volume 
decrease (AVD) mechanism which is mainly involved in cell death (Orlov et al., 2013, Lang 
and Hoffmann, 2013).  
Naturally, the osmolarity of the blood must be maintained precisely to allow cell 
volume to be maintained.  At the systemic level, osmolality is affected by several 
periventricular osmosensing structures in the brain. The response usually involves neurons 
that act in a way like that of the cell (Wibberley et al., 2015, Feetham et al., 2018).  
At the cellular level, one of the key regulators of maintaining cell volume is the 
membrane potential and has been shown in a few cells such as cardiomyocyte, chondrocyte 
and retinal Muller cells (Abdul Kadir et al., 2018). Membrane potentials contribute to cell 
volume control by changes in ion fluxes. For example, ion channels selective for KC behave 
like osmolyte channels rather than just maintaining the RMP (Abdul Kadir et al., 2018). 
Additionally, Lewis et al, have shown that TRP channels are significant players of the RMP in 
chondrocytes (Lewis et al., 2011a) and suggested that these channels may facilitate the 
control of cell volume (Lewis et al., 2011b).  Also, TRPV4 have been suggested as central to 
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the regulatory volume decrease and that chondrocytes decrease in number but increase in 
cellular volume with age (Lewis et al., 2011b). 
Channelopathies  
Diseases resulting from deficits of ion channels are termed channelopathies. To date, 
there are few channelopathies specifically linked to ageing, but this may be because they 
have not yet been discovered.  Channelopathies can be (a) acquired (i.e by acquired 
disorders, toxins, drugs, etc) or (b) inherited through genetic mutations in genes encoding 
ion channels or its associated/accessory proteins (inherited ion channelopathies) (Imbrici et 
al., 2016).  Mutations may include small deletions/insertions, frame-shifts, stop codons, 
missense, splice-site mutations and deletions or duplications of exons. Consequently, ion 
channel biophysical properties are altered which include voltage-dependent gating, single-
channel conductance, kinetics, ion selectivity and change of signalling pathways. Also, ion 
channel expression may be decreased. Hyperexcitability disorders may result from mutations 
that lead to loss-of-function in K+ or Cl- channels and gain-of-function mutations in Na+ and 
Ca2+ channels.  An example of this can be seen in epilepsy or myotonia. Oppositely, the 
excitability of inhibitory neurons can lead to epilepsy through loss-of-function mutation in 
Na+ channels and gain-of-function mutations in neuronal K+ channels. Therefore, the 
phenotype or the final effect of a mutation in ion channel gene depends on the functional 
role of the ion channel itself, and the specific expression pattern (Imbrici et al., 2016, Kim, 
2014). 
Channelopathies can be life-threatening diseases such as sudden cardiac death 
(Fernandez-Falgueras et al., 2017) and cause rare diseases (Imbrici et al., 2016). Also, the 
involvement of ion channel dysfunction in some diseases with abnormal movement, epilepsy, 
and migraine and/or ataxia as seen in Paroxysmal Dyskinesias in which mutations in genes 
encoding for calcium-activated potassium channel subunit alpha-1 (KCNMA1) and voltage-
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gated sodium channel type 8 (SCN8A) affecting ion channel function and neuronal excitability 
are detected (Erro et al., 2017). 
Channelopathies can be detected in any organ. However, some tissues/organs may show 
symptoms of channelopathies while the same ion channel expressed in other tissues do not. 
For example, AQP4 (Aquaporin4) is involved in NMO (an autoimmune disease called 
neuromyelitis optica) with symptoms such as blindness, sensory defects and paralysis but 
does not manifest any pathological phenotypes when expressed in kidneys. Another example 
is TRPC6 (Transient Receptor Potential canonical 6) which is expressed in the kidneys. It is 
involved in Focal and segmental glomerulosclerosis (FSGS type 2) disease with symptoms 
such as proteinuria and rapid renal function decline but has not been associated with any 
pathological phenotypes in smooth muscle (Kim, 2014).  
Since the major age-related diseases are musculoskeletal, cardiovascular, and brain, 
disorders, examples of ion channelopathies in these tissues will be covered.  
Channelopathies in the Musculoskeletal system 
In this section, examples of channelopathies in the musculoskeletal system will be 
covered. Also, a link to a common age-related disease such as OA will be made.  
Genetic mutations of genes coding for musculoskeletal ion channels result in gain/loss 
of function that can affect muscle relaxation. Generally, most mutations occur in the chloride 
channel (ClC-1), calcium channel (CaV1.1), sodium channel (Nav1.4) and several potassium 
channels (Kir2.1, Kir2.6, and Kir3.4) (Cannon, 2015). There are several examples of musculoskeletal 
ion channelopathies including but not limited to myotonia and periodic paralysis. Myotonia 
is characterized by impaired muscle relaxation after contraction and periodic paralysis (PP) is 
characterized by transient loss of muscle excitation. Several diseases are belonging to the 
same group of Non-dystrophic myotonias such as (a) myotonia congenital (MC) which is 
caused by loss-of-function mutations in the CLCN1 gene coding for the skeletal muscle 
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chloride channel ClC-1 while (b) paramyotonia congenital (PMC) and (c) sodium channel 
myotonia (SCM) are caused by missense mutations in the SCN4A gene coding for voltage-
gated sodium channel NAv1.4 in the skeletal muscle. On the other hand, periodic paralysis is 
characterized by transient loss of muscle excitability that leads to flabby paralysis with 
weakness (Imbrici et al., 2016). PP can be classified into: 
a) Hyperkalemic PP caused by gain of function mutations in Nav1.4 that show 
impaired inactivation leading to continuous Na influx and cell depolarization that inactivates 
the Nav1.4 channel. The depolarization increases K+ efflux from the muscle to the serum in 
which its level increases up to 6 mEq/L leading to paralysis (Imbrici et al., 2016). Hyperkalemia 
is also observed in elderly people due to several factors including age-related physiological 
changes and has been associated with increased morbidity and mortality (Turgutalp et al., 
2016).  
b) Hypokalemic PP is caused by SCN4A (20%) and CACNA1S (60%) mutations of 
positively charged residues in the voltage sensors of the channel. This produces an abnormal 
infusion pathway for Na+ and H+ ions leading to depolarizing cation leak currents which are 
known as gating pore currents (Igp) (Imbrici et al., 2016). Such fibre depolarization results 
from the unbalance between the depolarizing Igp and repolarizing Kir and sarcoplasmic KATP 
channel currents. Marked serum hypokalemia that decreases gene expression of the Kir 
channels is produced by activation of 3Na+/2K+-ATPase upon administration of 
insulin/glucose (as a treatment) (Imbrici et al., 2016). Together, these factors contribute to 
the fibre depolarization which inactivates ion channels; Nav1.4 and Cav1.1 that are 
associated with paralysis (Imbrici et al., 2016). Hypokalemia has also been reported in elderly 
people (Bardak et al., 2017). The third classification of the PP is:  
c) Andersen-Tawil Syndrome (ATS) which is a multi-organ syndrome. It is 
associated with PP, cardiac arrhythmias, and dysmorphic features (skeletal malformation). 
Can occur with both hyper- or hypo-kalemia that is associated with paralysis as well as various 
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heart manifestations including long QT syndrome. So far, the KCNJ2 gene on chromosome 17 
has been found to play a significant role in ATS. About two-thirds of the ATS patients have 
mutations in this gene. Such mutations can have several consequences including but not 
limited to (a) suppressing Kir2.1 currents and/or enhancing the inward currents because of the 
dominant-negative effects, (b) decreasing the PIP2 sensitivity, (c) exaggerating the inhibitory 
effects of intracellular Mg2+ or H+. Patients with ATS, the Kir2.1 channel in their heart and 
skeletal muscle is influenced by the dominant-negative effects exerted by KCNJ5 (Imbrici et 
al., 2016, Statland et al., 2014).  
Osteoarthritis is one of the age-related diseases of the musculoskeletal system. 
Skeletal muscle wasting has been linked to OA as such muscle waste affects the stability of a 
joint leading to the development and/or progression of OA (Shorter et al., 2019). Several 
membrane proteins, ion channels and receptors change in OA models and/or A patients 
(Lewis and Barrett-Jolley, 2015). Ion channels have been used/suggested as biomarkers for 
several diseases (Lewis and Barrett-Jolley, 2015, Daniil et al., 2016, Javier Camacho et al., 
2016). In Osteoarthritis (OA), Lewis et al (Lewis and Barrett-Jolley, 2015) showed that several 





Figure 7: Key membrane ion channels and receptors differentially expressed in OA.  
Genes/proteins labelled in red are overexpressed, in green downregulated and in black not changed although 
linked to OA. The written format is as following: common names/alternative names (human gene or equivalent). 
Cited from (Lewis and Barrett-Jolley, 2015).  
Although there are several drugs targeting ion channels such as Nav channels 
blockers (which has been successfully employed as anticonvulsants and antiarrhythmics), still 
several other drugs that target ion channels such as ion channel modulators are not able to 
distinguish different isoforms of specific ion channels which expose patients to the side 
effects of the drug that can be very serious (Imbrici et al., 2016).  The second example of 
channelopathies in this thesis will be on the cardiovascular system.  
Channelopathies in the Cardiovascular system 
Balanced ionic currents generate cardiac action potential which contributes to 
normal cardiac function (Amin et al., 2010). When such balance is disturbed due to ion 
channel dysfunction, cardiac arrhythmias may occur which can be life-threatening (Kim, 
2014). About 50% of sudden arrhythmic death syndrome (Behr et al., 2008) and around 20% 
of sudden infant death syndrome (Wilders, 2012) are caused by cardiac ion channel 
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dysfunction (cardiac channelopathies). Cardiac arrhythmic disorders occur due to mutations 
in genes encoding for Ca2+, Na+, K+ and TRP (Transient Receptor Potential) genes. For example, 
ATP-sensitive K+ channel in mitochondria (mitoKATP) of the cardiomyocyte plays a significant 
role in cardiomyocyte protection and this channel is altered with aging. However, the reasons 
for this age-related dysfunction of the mitoKATP are not known and could be due to; (a) change 
of channel density, (b) responsiveness to stress stimuli, or (c) defective communication to 
respiratory electron transport chain (Pi et al., 2007). Regarding endothelial and vascular 
smooth muscle cells, several ion channels are expressed including but not limited to chloride, 
calcium (voltage-gated and store-operated), and stretch-activated cation channels. All those 
channels can be involved in vascular tone regulation. For instance, BK opening leads to efflux 
of K+ that results in membrane hyperpolarization followed by the closure of a Ca2+ channel 
(voltage-dependent) and decreased Ca+ entry to cell leading to vasodilation. Also, 
vasodilation can occur through nitric oxide which is regulated by BK as well (Carvalho-de-
Souza et al., 2013). With ageing, this channel has its expression, structure and function 
changed (Carvalho-de-Souza et al., 2013).  Since increases in blood pressure (Pinto, 2007) are 
one of the most common conditions associated with age, and this is dependent, in part, on 
vascular tone, it will be particularly interesting to discover whether these ion channels 
involved with vascular tone are altered in age. Next, ion channel dysfunction in the nervous 
system is also an interesting topic to look at and will be covered in the following section.  
Channelopathies in the Brain 
Ion channels that are associated with ion disturbance in neurological disorders are of 
two types; either ligand-gated or voltage-gated ion channels. Epilepsy, seizures and the highly 
age-related conditions of Alzheimer’s and Parkinson’s diseases have been associated with 
mutated or dysfunction of ligand-gated channels such as mutated nAChRs, ionotropic 
glutamate receptors, GABA receptors (an inhibitory neurotransmitter), and P2X receptors. 
Besides, ataxia, epilepsy, and periodic paralysis are caused by defects in sodium channels; 
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SCN2A, SCN8A, and SCN9A. Potassium channel mutations have been linked to diseases such 
as epilepsy, ataxia, and seizures. Also, ataxia, paralysis, migraine and Alzheimer’s disease 
have been associated with abnormalities in calcium channels, reviewed here (Behr et al., 
2008). As an example, Ca2+ channels play significant roles in different tissues. Generally, Ca2+ 
ion channelopathies in any excitable tissues result in a periodic disruption of rhythmic activity 
that leads to a specific function impairment. For instance, mutations in the CACNA1A gene 
that encode for ion-pore and voltage sensor-containing α1 subunit of the P/Q-type voltage-
gated calcium channels lead to several distinct diseases including but not limited to migraine, 
episodic ataxia type 2 and spinocerebellar ataxia type 6. Among the most common 
neurological disorders in the elderly are Alzheimer’s disease (N-methyl-D-aspartic 
acid/NMDA receptor, ryanodine receptor and calcium-sensing receptor) and Parkinson’s 
disease (Cav1.3 L-type calcium channel). In the related Huntington’s disease, there are 
mutations in the IP3 receptor and store-operated calcium channel. For instance, in 
Alzheimer’s disease, more evidence points toward changes in the cellular Ca2+ homeostasis 
at very early stages of the disease pathogenesis. Most studied Ca2+ ion channels in this 
disease are the ryanodine and IP3 receptors that have been highly expressed in the brain 
(cortical and hippocampal) regions. Those regions are associated with learning and memory 
functions (Chakroborty and Stutzmann, 2014).  
So ion channels are involved in a range of disorders of joints, blood vessels, and brain 




1.4 Aims  
In the light of the above evidence, I hypothesised that expression of a common set of 
inflammatory and/or ion channel genes may alter with age across tissues. To address this 
aim, transcriptomics; RNA deep-sequencing, of a number of different ageing models, were 
used. These models included both genuine ageing (tissue from young and old rat blood 
vessels, synovial joints and brain) and an inflammageing model (addition of IL-1ß/TNFα).  
These large datasets were bioinformatically analysed and validation of ion channels took 
place where practical.  
 Specifically, the main aims were to: 
1) Identify changes in a) the whole transcriptome and b) ion channel gene transcription 
in young and old rat aorta, FLS and PVN tissue. 
 
2) Identify changes in a) the whole transcriptome and b) ion channel gene transcription 
of control and cytokine (IL-1ß/TNFα) treated aortic smooth muscle cells and FLS. 
 
In the future, it may be possible to identify markers of early ageing that may be risk 










2.1  Tissues and Cell culture  
Tissues and cells were obtained from male Wistar Kyoto skeletally mature young rats 
(approximately 2 to 3 months unless otherwise stated), culled for associated projects. It is 
known that rats develop quickly and it has been estimated that every month of rats’ life 
approximately equals 2.5 years of human life. This means that the rats used for the ageing 
study, aged of 24 months+, were equivalent to a human age of 60-65 years (Van Gulick et al., 
2019).  
FLS  
Culture protocol  
FLS cells culture was prepared from synovial tissues of normal rat knee joints from the 
synovial membrane. Tissues were cultured in low-glucose DMEM X1 with 4mM Glutamine 
and pyruvate (gibco, life technologies) containing 20% Heat inactivated Fetal Bovine Serum 
(Gibco, Life technologies cat#: 10500-064), 100U/ml penicillin and 100µg/ml streptomycin 
(Sigma life science cat#: P4333), and 2.5 µg/ml Amphotericin B (Gibco, life technologies, cat#: 
15290-029). For days 1-7, DMEM X1 medium was replaced daily. After day 7, the synovial 
tissues were discarded, and cells were allowed to grow for two more days. To detach cells 
from the plates, cells were washed with DMEM X1 (as above but without FBS), pre-warmed 
1X trypsin (sigma life science, cat#: T4174) was used to detach cells, incubated at 37°C in 
5%CO2 for 2-5 minutes, trypsin was quenched with DMEM X1 containing FBS (as above), 
centrifuged at 1500 rpm for 5 minutes, and the pellet was resuspended in DMEM X1 
containing FBS and sub-cultured. Thereafter, cells were seeded according to the experiments 
to be carried out. Cells between passage 3 to 6 were used for all experiments.  
VSMC  
Culture protocol 
The thoracic aorta is dissected from rat, cleaned and snipped into branches on ice-
cold dissection solution containing (in mM) 134 NaCl (Sigma Cat#: S7653), 6 KCl (Sigma Cat#: 
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P-4504), 0.42 Na2HPO4 (Sigma Cat#: S-0876), 1 MgCl2 (BDH VWR International Ltd., Cat#: 
22093 3M). 2 CaCl2 (Fluka Analytical Cat#: 21114-1L), 10 HEPES (Sigma Cat#: H3375-500G), 
and 10 glucose (Sigma Cat#: G-4500), adjusted with NaOH to pH 7.4. Then, these branches 
were transferred into another dissection solution in which CaCl2 is reduced to 0.1 mM (low-
Ca2+ solution) and warmed to 35-37OC for 10 min. After that, branches were removed to a 
digestion buffer containing low-Ca2+ solution with papain (1.4mg/ml, Sigma Cat#: 76220-
25G), 4-dithioerythritol (0.9 mg/ml, Sigma Cat#: D8255-5G) and bovine serum albumin (BSA)  
(0.9 mg/ml, Sigma Cat#: A9647-10G) for 25-30 min at 37OC. Branches were then washed 3x 
in a pre-warmed low-Ca2+ solution containing 1 mg/ml BSA. Because branches are very fragile 
now, they were carefully transferred into a fresh low-Ca2+ solution containing 1 mg/ml BSA 
for cell dispersion by gentle trituration through a sterile plastic Pasteur pipette. Then, 
connective tissues were discarded, the solution containing VSMCs was split over 2 wells of 
the 12-well plate and fresh pre-warmed high glucose 1x DMEM complete media (containing 
15% Fetal Bovine Serum, 50U/ml Penicillin, 50µg/ml Streptomycin and 2.5µg Amphotericin B 
(Fungizone), these components were from the same company ) added to each well. Cells 
were allowed to adhere for up to 6 hours in 37OC in a humidified atmosphere (10% CO2) 
before the media changed. After 24 hours, the media was changed again and every day 
afterwards. Once cells grew and became 80-90% confluent, they were washed with PBS or 
serum free-medium, 1x trypsin/EDTA added, incubated at 37OC for 15 min, trypsin then 
quenched with complete medium and split into new culture flask/plate as per experiment 
requirement. Cells between passage 3 to 6 were used for the experiments. 
2.2 Electrophysiology  
Fire-polished pipettes, fabricated from thick-walled 1.5 mm o.d. borosilicate glass 
capillary tubes (Sutter Instrument, Novato CA, USA supplied by Intracel, UK) were used. 
These were prepared using a two-stage vertical pipette puller (Narishige, Japan) and then 
filled with the intracellular solution. When filled, they had pipette resistance of 
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approximately 8 MΩ. Recordings were made with a Cairn Optopatch amplifier is largely in 
voltage-clamp mode (Cairn Research, UK), command potentials controlled with a window 
PC running WinWCP V5.3.4 (John Dempster, University of Strathclyde). Currents were low-
pass filtered (1 kHz) and digitized at 5 kHz with CED1401 interface.  
Intracellular solution was 115 mM Gluconic acid/Potassium salt (Sigma Cat#: G-
4500), 26 mM KCl, 1 mM MgCl2 (BDH, VWR International Ltd), 5 mM Ethylene glycol tetra-
acetic acid (EGTA) (Sigma Cat#: E-0396), 10 mM HEPES, pH 7.2. Extracellular (bath) solution 
was 140 mM NaCl, 5 mM KCl, 2 mM CaCl2 (Fluka Analytical cat#: 21114), 1 mM MgCl2, 10 mM 
HEPES, and 5 mM Glucose, pH of 7.4. The bath (extracellular) solution is continuously 
changed through a flow-system in order to maintain the pH of the bath solution. All drugs 
were mixed well with the extracellular solution depending on their required final 
concentration that depends on the nature of the experiment. Then, perfused into the bath 
at a flow rate of ~3ml/min, left there to exert effects before recordings started. Cells, 
intracellular and extracellular solutions, and the microscope are all contained within a 
Faraday cage to minimize the noise signals and for earthing. All recordings were made at RT. 
All components of intracellular and extracellular solutions were from Sigma unless otherwise 
stated.  
There are different recording configurations, in this project the whole-cell voltage-
clamp configuration was used to look at the effects of different potentials and drugs on all 
cellular channels. Whole-cell current-clamp was used to record membrane potentials.  
1.3 Next-generation sequencing (NGS) 
This is one of the ways to look at the expression of the cellular genes in response to 
variable signals. I used whole transcriptomic profile. To be able to establish such experiments, 
RNA samples must be extracted from cells/tissues. Next, I will cover the RNA extraction from 
different tissues before and after optimization of the protocol.  
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RNA extraction  
FLS  
Cells were washed with serum-free media, 1x trypsin/EDTA added, incubated at 37OC 
for up to 5 min, quenched with complete medium and centrifuged (1500rpm) for 5 min. RNA 
extraction kit (RNeasy plus micro kit, cat# 74034) was used to extract RNA from FLS cells. The 
manufacturer protocol was followed with some additional modifications to increase RNA 
yields. FLS cells pellet was resuspended in 350 µl of RLT buffer containing 2β-
Mercaptoethanol (Sigma Cat#M6250-100ML) (1ml:10µl ratio, respectively), syringed (>30x) 
using a sterile RNase-free 1ml syringe connected to an RNase-free 19” G needle with 40mm 
length and stored at -80OC for at least 2 hours to make crystals that would increase cell lysis 
resulting in increased RNA yields. Cell lysates were then defrosted on ice, briefly spun at full 
speed for 40-50 seconds to bring down everything, transferred cell lysates into gDNA 
eliminator spin column, closed the lid and spun at full speed for 30sec. An equal volume of 
70% Ethanol added to the flow-through, mixed well by up and down pipetting, transferred 
into MinElute spin column, closed the lid and spun at full speed for 30 seconds to trap RNA. 
The flow-through was discarded and the column was placed in a new 2ml collection tube. 
700 µl of RW1 buffer added to the column, closed the lid and spun at full speed for 30 
seconds. Flow-through was discarded and the column was placed in a new 2ml collection 
tube. 500µl of RPE buffer added to the column closed the lid and spun at full speed for 30 
seconds. Flow-through was discarded and the column was transferred into a new 2 ml 
collection tube. 500 µl of 80% ethanol added to the column, closed the lid and spun at full 
speed for 2 minutes. Flow-through was discarded and the column was placed in a new 2ml 
collection tube. The column was then centrifuged at full speed for 5 minutes with the lid open 
to dry the membrane of the column. The MinElute spin column was transferred into a new 
1.5ml collection tube. 14µl of RNase-free water added to the column closed the lid and spun 
at full speed for 1 minute. The last step was repeated in order to elute more RNA. RNA 
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quantity and purity were measured by NanoDrop 2000 spectrophotometer (Thermo 
Scientific). The replicate number used in this study with FLS for the next-generation 
sequencing was 4 for control, 4 for cytokine treatment, 4 for young and 4 for old rat samples.  
Vascular smooth muscle cells (VSMC) 
RNA extraction Protocol  
Cells were washed with PBS and completely removed. RNA extraction kit (RNeasy 
plus micro kit, cat# 74034) was used to extract RNA from FLS cells. The manufacturer protocol 
was followed with some additional modifications to increase RNA yields. About 500 µl of lysis 
buffer (RLT buffer + 2β mercaptoethanol, 1ml:10µl ratio, respectively) and distributed evenly. 
Using cell scraper, cells were scrapped, gathered at the lower edge of the flask and 
transferred to labelled 15ml tubes. About 450-500µl of lysis buffer added to wash, collect 
anything left behind, gathered at the lower edge and transferred to the same tubes. Tubes 
were placed on ice until all cells were collected from all samples. Tubes opening closed with 
parafilm, RNase-free 1ml syringe connected to RNase-free (~40-50mm) 19” gauge is inserted 
into the tubes through parafilm, syringed (20-30x), placed on ice and repeated for all samples. 
Stored at -80 deg for 30-60min or -20 deg overnight to freeze down cell lysates in order to 
form crystals to lyse un-lysed cells and increase the RNA yields. Cell lysates were defrosted 
on ice, briefly spun at full speed for 30-40sec to bring everything to the bottom, transferred 
cell lysates into labelled gDNA Eliminator spin columns closed the lids and spun at full speed 
for 30sec. Discarded the column and mixed the flow-through with equal volumes of 70% 
Ethanol, transferred into labelled MinElute spin columns, closed the lids and spun at full 
speed for 30 sec. The last step was repeated as the sample volume exceeded 700µl which is 
the maximum volume the column can take. Discarded flow-through and placed MinElute spin 
columns into new 2ml collection tubes, added 700µl of RW1 buffer, closed the lids and spun 
at full speed for 30 seconds. Discarded flow-through and placed MinElute spin columns into 
new 2ml collection tubes, added 500µl of RPE buffer, closed the lids and spun at full speed 
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for 30 seconds. Discarded flow-through and placed MinElute spin columns into new 2ml 
collection tubes, added 500µl 80% EtOH, closed the lids and spun at full speed for 2min. 
Discarded flow-through and placed MinElute spin columns into new 2ml collection tubes and 
spun with open lids at full speed for 5min to dry membranes of MinElute spin columns. 
Discarded flow-through and placed MinElute spin columns into new labelled 1.5ml collection 
tubes, added 14µl of RNase-free water, closed lids and spun at full speed for 1min. Repeated 
the last step one more time to elute more RNA. Finally, measured RNA quantity and purity 
by NanoDrop 2000 Spectrophotometer. The replicate number used in this study with VSMC 
for the next-generation sequencing was 4 for control, and 4 for cytokine treatment samples. 
AORTA  
RNA extraction Protocol 
AORTA tissues were extracted from rats, placed in RNALater, and stored at -80OC. 
Later on, the tissue was defrosted on ice, taken into a mortar containing liquid nitrogen and 
powdered by a pistol. 500µl of Trizol (Ambion Ref#: 15596018) added to the mortar to collect 
the powder, then collected in 1.5ml RNAse-free tube. Another 500µl was added to the mortar 
to collect anything left behind and poured into the same 1.5ml tube. Because of the effects 
of liquid nitrogen, the Trizol added turned into a frozen state where I had to scrap to collect 
it. Trizol helps in tissue lysis. After that, samples were syringed for more than 30x for more 
lysis, vortexed and left at RT inside fume hood for 10min. 200µl of Chloroform (Sigma Cat#: 
C0549-1PT) was added to separate RNA from the rest of the sample components, mixed and 
centrifuged at full speed for 10min at 40C. RNA in the aqueous (clear) phase was removed 
into a new 1.5ml RNAse-free tube. 500µl of Iso-propanol (Sigma Cat#: I-9516) added (to 
precipitate RNA), left at RT inside fume hood for 10min, centrifuged for 15min at full speed 
at 4ºC. Then, Isopropanol discarded and 200µl of 80% Ethanol added (to wash RNA and help 
in drying it in the next step), centrifuged at full speed for 2min at 4ºC. Ethanol was discarded 
and the pellet was left to dry at RT inside the fume hood. RNA was eluted in RNAse free water 
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(15-20µl). finally, the concentration of RNA was measured by NanoDrop 2000 
Spectrophotometer. The replicate number used in this study with Aorta for the next-
generation sequencing was 3 for young, and 3 for old samples. 
PVN 
RNA extraction Protocol  
  PVN was defrosted on ice. Then, transferred into a cover of a small dish containing 
about 500µl of Trizol. The tissue was cut into as small pieces as possible and then moved to 
a 1.5ml tube. Another 500µl of Trizol added to the small dish’s cover to wash, collect any 
pieces left behind and transferred into same 1.5ml tube. Tissues were gently syringed for 
complete homogenization followed by harsh syringing to lyse cells and release RNA. Cells 
were then vortexed and left at room temperature (RT) inside fume hood for 10-15 min. 200µl 
of Chloroform added, mixed by up and down pipetting and centrifuged for 10 min at full 
speed at 4OC. The aqueous phase (top transparent) containing RNA was removed into a new 
15ml tube. 500µl of Iso-propanol added, mixed by up and down pipetting and let to 
precipitate RNA at RT inside fume hood for 10 min followed by centrifugation at full speed 
for 15 min at 4OC. The supernatant containing Isopropanol was discarded, 200µl of 80% 
Ethanol added to the RNA pellet and centrifuged at full speed for 2min at 4OC. Ethanol was 
discarded and the RNA pellet was let to dry at RT inside the fume hood. RNA was resuspended 
in 20µl of RNase-free water and the concentration was measured by NanoDrop 2000 
Spectrophotometer. The replicate number used in this study with PVN for the next-
generation sequencing was 3 for young, and 3 for old samples. 
RNA-Seq data analysis steps 
RNA samples were extracted as described above. Sequencing of large (>200 
nucleotides) messenger RNA (mRNA) enriched with polyA-tail was outsourced with >30M 
sequencing depth Figure 8. A 50-150bp paired-end read sequencing was carried out on 
illumine platform. High-quality raw data was delivered as FASTQ files containing sequences 
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and quality scores. Reads were aligned/mapped with the reference-based assembly tool, 
Hisat2 (Kim et al., 2015) that covers the splice junctions (Reference Genome: Rat Jul. 2014 
(RGSC 6.0/rn6) database).  The resulting BAM (a compressed binary version of SAM 
(Sequence Alignment Map)) was then passed to either StringTie (Pertea et al., 2015)  and 
CuffDiff (Trapnell et al., 2010) or the newer DESeq2 (Trapnell et al., 2010)  tools/packages to 
generate gene abundance estimates (Coverage, FPKM and TPM) or differentially expressed 
genes, respectively.  
Quantification of gene expression took place using StringTie transcript assembly and 
quantification tool/package. This tool uses BAM and an annotation (GFF3) files as input to 
generates these files; assembled transcripts, gene abundance estimates [normalised FPKM 
(Fragments per kilobase exon per million reads mapped) and normalised TPM (Transcripts 
per kilobase million)], coverage data, transcript counts and gene counts. As state above, 
differentially expressed genes were detected using the older CuffDiff or newer DESeq2 
packages. These assess group differences. They input BAM and GFF3 files as output a Gene 
Differential Expression Testing file that provides information such as fold change, p-values 
and adjusted q-values (False Discovery Rate (FDR)). For library normalisation, a geometric 
method was used. The FDR was less 0.05. Ion channel genes were identified and analysed 
separately for their gene/transcript abundance and differential expression using several 
reference servers such as Genenames.org, HUGO Gene Nomenclature Committee and locally 
edited scripts in MATLAB, Python and or R-studio. Ingenuity pathway analysis (IPA) was used 
to predict the upstream ligands/affectors, downstream targets and cell functions that were 






Figure 8: NGS data analysis pipeline.  
Cells/tissues were obtained from animals as described in the text. Cells were subjected to ±72hrs of 10ng/ml of IL-1β+TNFα. Cells were then used for experiments; Next-Generation 
sequencing (NGS), Electrophysiology, quantitative polymerase chain reaction (qPCR), western blot (WB) and/or tissue typing through Immunocytochemistry (ICC). For NGS, RNA 
samples were extracted, sequenced with illumina and raw data files which had their adaptors trimmed were uploaded using a FTP client to a bioinformatics platform or in home 
servers for analysis. Within the bioinformatics platform, phred quality score was measured for all samples which was found to be around 37 or greater. Reads were then 
aligned/mapped with Hisat2 package using the reference genome Rat Jul. 2014 (RGSC 6.0/rn6) (rn6). The resulting BAM files along with an annotation file (Rat GFF3) were used to 
assemble mapped reads and quantify gene expression. Such assembly and quantification took place to generate gene abundance estimates and gene/transcript counts (StringTie 
package) and differentially expressed genes (CuffDiff/DESeq2 packages). After that, using several servers and a local custom-script in MATLAB software allowed us to hunt ion channel 
genes for further analysis. 1 File Transfer Protocol, 2 General Feature Format, 3 Fragments per kilobase exon per million reads mapped and 4 Transcripts per kilobase million. 
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1.4  Immunocytochemistry (ICC) 
FLS 
Detection of FLS cell marker; CD248 also known as TEM1, took place through 
immunocytochemistry. First, cells were prepared onto 100% Ethanol sterilised coverslips in 
24-well plate and allowed to dry. 1 ml of cell suspension at a density of 2.5x104 cell/ml was 
transferred into each well and incubated overnight. Next day, the medium was removed, cells 
were fixed with ~3 ml fixative (2% paraformaldehyde in PBS X1, pH 7.4), and incubated at 
room temperature (RT) for 10 minutes. Then, the medium was removed and fixative was 
quenched by 10 minutes incubation with ~ 3 ml of glycine solution (100mM, pH 7.4), at RT. 
After that, the medium was discarded and ~ 3ml of permeabilization solution (for each 100ml, 
10 ml of PBS X10 and 0.1 ml of Triton-X100 were used, pH adjusted for 7.4) was used and 
allowed to incubate at RT for 10 minutes. The medium was then discarded and cells were 
washed with PBS X1, three times, 5 minutes/each. After that, non-specific binding was 
blocked by incubating cells in each well with 200 µl of antibody (Ab) diluting solution [for 
each 10 ml of pH 7.2; 0.5 ml of Sodium/Sodium Citrate SSC X20 (150 mM NaCl and 15 mM 
Na3Citrate), 0.2 ml of donkey serum, 1% bovine serum albumin (0.1 g), and 0.05% Triton-
X100 (5 µl)] for 30 minutes at RT. Ab diluting solution was discarded and cells were incubated 
in the fridge with primary antibody solution (RAT Ab, 1 in 200 Ab diluting solution ), overnight. 
Next day, primary antibody (Ab) solution was removed and cells were washed three times 
with Ab wash solution (for every 100 ml of pH 7.2, 5 ml of SSC X20 and 0.05 ml of Triton-
X100) for 10 minutes each time. After that, secondary antibody (Anti-RAT Ab, 1 in 500 Ab 
diluting solution) was added and incubated in dark at RT for 1-2 hrs. Next, cells were washed 
with Ab wash solution three times for 10 minutes each time in the dark. Then, slides were 
dipped into two separate universals of distilled water, air-dried in the dark, mounted with 
mounting media, and left in the dark overnight until visualised under a microscope.  
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1.5  qPCR  
The same RNA samples used for NGS experiments were used for qPCR experiments for 
confirmation purposes of the expression of ANO1 channel gene. The amount 500ng/sample 
of RNA (shown in Table 2) was used for cDNA synthesis.  
Table 2: amounts of RNA samples used for qPCR experiment. 
Samples Amount per μL (ng) Volume for 500 ng (μL) RNase - free water (μL) 
VSMC_17C 2433.00 0.21 9.79 
VSMC_17T 1506.00 0.33 9.67 
VSMC_18C 150.00 3.33 6.67 
VSMC_18T 324.00 1.54 8.46 
VSMC_13C 203.40 2.46 7.54 
VSMC_13T 367.20 1.36 8.64 
VSMC_12C 300.00 1.67 8.33 
VSMC_12T 486.00 1.03 8.97 
 
 
The cDNA synthesis materials were RT buffer (5X First-strand Buffer, P/N y02321 
from Invitrogen), DTT (0.1M, 500µl, P/N Y00147 from Invitrogen), dNTP (), SuperScript ®II 
Reverse Transcriptase (P/N 100004925, 10000U “200U/µl”), RiboLock RNAse inhibitor 
(Ref#EO0381, 2500U, 40U/µl, from Thermo Scientific), RNAse-free Water (Mat. No. 1012888, 
from Qiagen), and as per the manufacturer’s instructions, the 1st step was mixing  RNA (500 
ng) + H2O (Sigma) + 1 μl random hexamers, and incubated for 10 min at 65˚C. the second 
step starts with the preparation of the reaction mixture (Total reaction mix = (9 μL x No. of 
samples) + 1 (for pipetting error)) as follows: 4 μl RT buffer (5x First-Strand Buffer), 2 μl DTT, 
1 μl dNTP (10 mM), 1 μl Superscript II, 1 μl RNase Inhibitor (Ribolock), and incubate for 60 
minutes at 42˚C. Then, the cDNA was diluted 10 times (+180 μl Sigma water = 200 μl).  
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Then, the qPCR master mix was prepared. The components of this master mix are 
the SYBER GREEN (FastStart Essential DNA Green Master, REF#06402712001), β-Actin 
primers Forward and Reverse (from Sigma). For F, (Cat#1158, SY170426580-084, F sequence 
5’-TCCTTCCTGGGTATGGAAT-CCT at 100µM, O.D= 6.7, 225.4µg, 33.7nmol, 0µm,  Tm=66.6ºC, 
33.6 µg/OD, MW=6692, 0µL) while R, (Cat#1158, SY170426580-085, R sequence 5’-
AGCTCAGTAACAGTCCGCCT at 100µM, O.D= 8.2, 262.9µg, 43.4nmol, 0µM, Tm=63ºC, 32.1 
µg/OD, MW=6062, 0µL). HRPT1 primers Forward and Reverse (from Sigma). For F, (Cat#1158, 
SY170426580-088, F sequence 5’-TCCTCCTCAGACCGCTTTTC at 100µM, O.D= 6.7, 238.1µg, 
40.0nmol, 0µM,  Tm=65.7OC, 35.5 µg/OD, MW=5955, 0µL) while R, (Cat#1158, SY170426580-
089, R sequence 5’-ATCACTAATCACGACGCTG-GG at 100µM, O.D= 7.8, 245.3µg, 38.2nmol, 
0µM, Tm=66.1OC, 31.4 µg/OD, MW=6415, 0µL). the amounts prepared were:   
For the ANO1 gene, a primer (1µl *30= 30µl) was mixed with RNAse free H2O (4µl 
*30= 120µl), and SYBER green (10µl *30=300µl). For housekeepers (β-actin and HPRT1) 
genes,  
of primer (2µl *30=60µl), RNAse free H2O (3 µl *30= 90 µl), and SYBER green (10µl *30=300 
µl). After that, 15 µl of each mix from above aliquoted into its appropriately assigned well 




Table 3: qPCR samples/plate layout. Each sample (C=control and T=treatment “IL-1β+TNFα”) was run in triplicate. 
  
1 2 3 4 5 6 7 8 9 10 11 12 
ANO-1 A 17C 17C 17C 18C 18C 18C 13C 13C 13C 12C 12C 12C 
ANO-1 B 17T 17T 17T 18T 18T 18T 13T 13T 13T 12T 12T 12T 
ACTB C 17C 17C 17C 18C 18C 18C 13C 13C 13C 12C 12C 12C 
ACTB D 17T 17T 17T 18T 18T 18T 13T 13T 13T 12T 12T 12T 
HPRT1 E 17C 17C 17C 18C 18C 18C 13C 13C 13C 12C 12C 12C 




















   
 
H 
            
The loading/negative controls were actb=β-actin (), hprt1= Hypoxanthine 
Phosphoribosyltransferase 1 () and PCR reaction for a sample without the target (ANO1 = 
Anoctamin1) primers (Cat#63914 from PRIMER DESIGN). 
 
the plate was sealed, briefly centrifuged and then placed in the qPCR machine (Biorad). The 
running protocol started with pre-incubation at 95ºC for 600sec. Then, 3 steps of 
amplification (95ºC for 10sec, 60ºC for 10sec, and 72ºC for 10sec). This was followed by 
another 3 steps of amplification (95ºC for 10sec, 65ºC for 10sec, and 97ºC for 1sec (5 
reading/continuous ºC)).   
2.6 Chemicals and materials 
Media (DMEM 1X with Ref#31885-023, DMEM (1X) GlutaMax with Ref#61965-026), Heat 
Inactivated FBS (Fetal Bovine Serum, Ref# 10500-064, from gibco by life technologies),  
Penicillin/Streptomycin (Cat# P4333-100ML, from Sigma), Amphotericin B (Ref#15290-026 
from gibco by life technologies), Trypsin-EDTA (Cat# T4174-100ML from Sigma), IL-1β 
(Cat#501-RL/CF, from R&D), TNFα recombinant protein (Cat#PRC3014 from gibco), Calcium 
Chloride solution (cat# 21114-1L from Fluka Analytical), Ethylene glycol-bis(β-
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aminoethyleneether)-N,N,N’,N’-tetraacetic acid (EGTA) (Cat#E-0396 from Sigma), D-Gluconic 
Acid (cat#G-4500 from Sigma), HEPES (Cat#H3375-500G from Sigma), Sodium Chloride 
(Cat#S7653-1KG from Sigma-Aldrich), Trizma® hydrochloride (Cat#T3253-1KG), Sodium 
Phosphate (Dibasic Anhydrous, Cat#S-0876), Sodium Phosphate (Monobasic Anhydrous, 
Cat#S-2554), Tween-20 (Code#233362500 from ACROS ORGANICS), Papain from Canica 
papaya (Cat#76220-25G), Bovine Serum Albumin (Cat#A9647-10G from Sigma), 1,4-
Dithioerythritol (DTT) (Cat#D8255-5G),  
RNA extraction kit (RNeasy plus micro kit, cat# 74034), Trizol reagent (cat#15596018 
from Ambion by life technologies), Chloroform: Isoamyl alcohol 24:1 (cat#C0549-1PT from 
Sigma), Isopropanol (cat# I-9516 from Sigma),  
Paxiline (Cat#2006 from TOCRIS bioscience), ANO-1 inhibitor (CaCCinh-AO1, Cat#0916-
5MG, from Sigma), Magnesium Chloride Solution (Cat# 220931.0M stock, from BDH), Triton 
X-100 (Cat#30632 from BDH Chemicals Ltd Poole England), D-(+)-Glucose (Cat#G7528-250G 
from Sigma), POTASSIUM CHLORIDE (Cat# P-4504 from Sigma) 
Donkey Serum (Cat#D-9663 from Sigma), VECTASHIELD (hard set, mounting medium, H-
1500 from Vector laboratories Inc.), Antibody for CD248 also known as TEM1 (Abcam, cat#: 
ab67273), Fluorescein (FITC) conjugated AffinintyPure Donkey Anti-Rabbit IgG (Cat#711-095-
152 from Jackson immune Research),  
These chemicals and materials were used in different techniques and methods in my 
project.  
 




2.7 Methods Troubleshooting  
Protocols described above were optimized. However, the issues encountered while 
carrying out the experiments are described in this section either for tissue culture or RNA 
extraction for NGS experiments.  
Tissue cultures 
Issues with VSMC culture 
After dispersing and culturing VSMC cells in a plate, they grew fast and became 
confluent. However, after the first passage, they stopped proliferation. Changing medium 
daily and trying a different fetal calf serum did not solve the problem. Changing DMEM high 
glucose (with 4500 mg/L glucose and Sodium Bicarbonate but without L-glutamine and 
Sodium Pyruvate, Sigma D5671 -500ml) medium to a DEME (1X) + GlutaMax (with 4.5g/L D-
Glucose and without Pyruvate) solved the problem. Because GlutaMax has a dipeptide 
Alanine and Glutamine that requires an enzyme to be produced by the cells to breakdown 
the peptide bond between these two amino acids and consume each one individually, this 
had guaranteed enough energy supply for the cells for a long time and less ammonia 
accumulation in the media which is toxic to cells. Of course, the proliferation rate of VSMC is 
now slower but cells grew eventually.  
RNA extraction  
Issues with low RNA yields from VSMC 
Once cells are ready for RNA extraction, they were washed with PBS and completely 
removed, 1x trypsin/EDTA added, incubated at 37ºC for up to 30 min and cells still adhered. 
After that, cells were scrapped, and the flask left in a vertical position to bring everything 
down. Then, transferred into 15ml tube, spun at 1500 rpm for 5 min to make cells’ pellet. 
However, no observed pellet was seen. This eventually resulted in very low RNA 
concentrations. The possible reason was that cells were lost either in the transfer from flask 
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to 15ml tubes or during the centrifugation step as some might have lysed and discarded with 
the supernatant.  
AORTA 
Sometimes, the separation of RNA with chloroform did not go well because of the 
AORTA tissue size. In these cases, the tissue was cut into 2 pieces and each one was run 
individually and combined after elution step. Trying a different method to improve 
homogenization, I used a fastmini-prep method where tissues pieces are loaded into a 1.5ml 
tube containing small beads that run in a controllable speed for seconds to minutes to make 
sure tissue pieces are completely homogenized. This improved the homogenization but not 
the quantity or purity.  
Additionally, to improve purity, the trizol method with the RNA extraction kit (RNeasy 
plus micro kit, cat# 74034) were combined. First, the trizol method was followed until RNA  
was separated in the aqueous phase and removed into a gDNA eliminator column of the RNA 
extraction kit. Then, the manual’s instructions of the kit were followed. However, the purity 
slightly improved but the quantity dropped. Therefore, the trizol method alone was used as 
it proved to be the best method for RNA extraction from rat AORTA tissues stored in RNALater 
at -80oC. 
Issues with RNA extraction from PVN 
PVN in RNALater stored at -80OC was defrosted on ice. Tissue was then snipped into 
small pieces either in RNALater or lysis buffer (RLT buffer from Qiagen kit + 2β-
Mercaptoethanol), moved to a new 15ml tube and syringed. Then, frozen down at -80OC for 
30min to make crystals to lyse the possibly un-lysed cells to increase RNA yields. After that, 
cell lysate was briefly centrifuged to bring everything to the bottom, then transfer into gDNA 
Eliminator spin column and follow the kit’s protocol. With this, I used to get low RNA yields 
with mice or rats tissues that were used for optimization purposes only. Eventually, I tried a 






Chapter 3 – Changes of ion channels in Fibroblast-like 
Synoviocytes (FLS)  
85 
 
3.1 Introduction  
As discussed in Chapter 1, FLS cells are key cells in maintaining healthy articular joint and 
will be treated, in this thesis, as an example of a musculoskeletal tissue that may change its 
phenotype with age. FLS work as a barrier between the articular joint and the blood 
circulation. These cells provide nutrients to the joint tissues (i.e. chondrocytes), synovial fluid 
to lubricate surfaces and help in removing cellular by-products from the joint. When these 
cells are inflamed, pro-inflammatory cytokines signalling become activated which can affect 
the whole joint through increased production of these cytokines and these cells lose their 
significant feature as a barrier which increases the permeability for high molecular weight 
proteins and molecules across the joint. Thus, the main components of the synovial fluid (i.e., 
HA and lubricin) can escape the joint and the levels in plasma increase. Consequently, the 
viscosity of the affected joints decreases and level of friction between the surfaces increases 
which can be very painful and can impair with normal functions of the joint as seen in the 
elderly. These cells may interact with sensory neurons and have been described as 
“amplifiers” of neuropeptide mediated inflammation and pain. Roles of ion channels of FLS 
in osteoarthritis (OA) have not been extensively studied.  
The synovium is an obvious target for the development of novel interventions in both 
RA and OA.  The role of synovitis, low-grade inflammation of the synovial lining of the joint, 
in OA progression is gradually emerging. Therefore, in this work, the pathophysiology of 




• Which global FLS transcripts change with natural ageing in rats (transcriptome). 
• Which FLS ion channel genes change with natural ageing in rats (channelome). 
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Then, the inflammageing model is used to investigate: 
• Which global FLS transcripts change with TNF and IL1 cytokines treatment in vitro 
(transcriptome).  
• Which FLS ion channel transcripts change with TNF and IL1 cytokines treatment in 
vitro (channelome). 
• Whether there are detectable electrophysiological changes with TNF and IL1 
cytokines treatment. 
Finally, the investigation will cover 
• Similarities and differences between the FLS natural ageing and cytokine 
inflammageing models. 
A combination of Next-Generation RNA Sequencing (NGS), qPCR and patch-clamp 
electrophysiology is used to uncover several changes in potassium channel gene expression 
together with changes in cellular phenotype which can be explained as a phenotypic switch 




3.2 Materials and methods   
Tissue culture  
FLS cells were isolated, cultured, passaged and used for experiments as described in 
the materials and methods in chapter 2.  
RNA extraction  
 RNA extraction methods were described in the materials and methods of chapter 2 
in details. RNA concentrations of FLS cells are shown in Appendix 1.  
Next-generation sequencing (NGS) 
First, it is vital to determine the integrity of the starting material of RNA when 
performing gene expression analysis. One of the methods used these days is the 
measurement of RNA Integrity Number (RIN) using Agilent Bioanalyzer systems which 
became standard in RNA quality and quantity analysis. RNA samples are electrophoretically 
separated on microfabricated chips and detected by a laser that induces fluorescence. The 
output of this machine includes electropherogram, gel-like image, provide information on 
sample concentration and ribosomal ratio. The electropherogram offers a visualized 
assessment of the RNA quality. The ribosomal ratio used to be useful in determining the RNA 
intactness although it does not provide accurate information about the integrity of the RNA. 
Therefore, researchers mostly rely on the electropherogram more than the ribosomal ratio 
to see a detailed picture of the distribution of different sizes of RNA fragments (Mueller).   
Although RNA degradation is slow, once starts more fragments (Appendix 2-A) can be 
seen and a band ratio between 18S and 28S will decrease while the baseline signal between 
the two ribosomal peaks and the lower marker will increase (Mueller).  
The introduction of RIN has solved the issue by taking the entire electrophoretic trace 
into account and using an algorithm for classification that generates a number from 1 to 10 
with 1 being most degraded and 10 most intact. This ensures good interpretation, 
comparison between samples, and repeatability of the experiments.  
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Appendix 2-B was generated after testing around 1300 RNA samples from different 
species and using algorithms. The experts who found this, identified the most important 
information from RNA samples and they came up with this figure showing Pre-Region, 
Marker, 5S region, Fast region, 18S region, Inter region, 28S region, Precursor region and Post 
region. These are the regions of the electropherogram. The RIN number takes into account 
the values of all of these regions. With that, if an unexpected spike appears in the Fast region 
the software will not compute the RIN. On the other hand, if a spike appeared in the Post 
region the RIN will be computed.  
The height of the 18S and 28S peaks is positively correlated to the RNA concentrations. 
The higher the RIN number the larger the 28S compared to 18S while others are much smaller 
to non-visible. The X-axis represents the nucleotides (nt) and the Y-axis represents 
Fluorescence Unit (FU).  
Appendix 3 shows electropherogram, gel-like image, RNA Integrity number and rRNA 
ratio of 28S/18S for each sample (FLS young and old).   
A Phred quality score is used as a measurement of the quality of the identification of 
nucleobases that are generated by the automated DNA sequencing. The score is assigned to 
each nucleotide base call in automated sequencer traces (Ewing et al., 1998, Ewing and 
Green, 1998). Phred quality score has become popular and widely accepted as a measure of 
the quality of DNA sequences as well as to compare different sequencing methods. As shown 
in the figures, the graph is divided into different colours with bases fall into the red colour 
have higher error rates (1 in 10). Error rates decrease as I go to yellow and green with error 
rates of 1 in 100 and 1 in 1000 for yellow and green, respectively. As the error rates decrease 
the accuracy increases (Ewing et al., 1998, Ewing and Green, 1998).  
After RNA-Seq experiments took place, raw data files were received, the quality check 
(Phred quality score) of the raw data files “Fastq” was carried out using FASTQC software as 
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shown in Appendix 4. Then, different tools were used to align/map (HiSAT2), assemble and 
quantify (StringTie), and detect differentially expressed genes (CuffDiff or Deseq2) as 
described in the materials and methods chapter 2.  
Immunocytochemistry (ICC)  
Tissue typing using ICC for FLS cells with CD248 took place as described in the 
materials and methods in chapter 2.  
 
Electrophysiology  
FLS cells were patch clamped using a borosilicate fire-polished glass pipette filled with 
intracellular solution, a seal was made with a target healthy cell in a bath solution and current 
recording took place with Cairn Optopatch amplifier after challenging the cell with a series of 
different potentials ranging from -120 to 120mV. More details can be found in the materials 
and methods in chapter 2. 
Resting membrane potential was read directly from the CAIRN Optopatch amplifier by 
switching to current clamp protocol (I=0) and recorded in millivolts (mV). 
For the drugs used to activate (NS1619) or block (Paxilline) BK channels, the extracellular 
solution that filled the bath was replaced by an extracellular solution containing the drug 
(either NS1619 or Paxilline) at a flow rate of 3ml/min. Then, cells were challenged with the 
same voltage step protocol (-120 to +120 mV at 10mV increment) and whole-cell currents 







NGS data analysis  
Only those reads that passed FastQC with Phred tests, with quality scores of greater 
than 30 were retained. The data analyses steps; mapping, assembly and quantification, and 
detection of differentially expressed genes are described in the materials and methods 
chapter 2.  
Ageing FLS NGS data analysis 
This project started with ageing FLS cells by carrying out NGS experiments for young 
and old FLS samples. FLS cells from young and old rats were dissected, cultured and RNA 
samples were extracted as described in the methods. Then, RNA samples were sequenced at 
150bp, >30M sequencing depth as paired-end (Illumina platform). The quantity of RNA in FLS 
samples are shown in (Appendix 1). The first 4 samples (FLS_Y1C1, FLS_Y3C, FLS_Y6C, and 
FLS_Y4C1) are the young samples while the last 4 (FLS_O1C2, FLS_O2C2, FLS_O5C1 and 
FLS_O4C1) are the old FLS samples. The quality of these RNA samples was also checked and 
electropherograms were generated. A representative example of such electropherograms 
and the gel-like image is shown in (Appendix 2-A and -B) and the actual figures of the RNA 
samples are shown in the (Appendix 3-A and -B).   
Ageing FLS Differentially expressed Genes 
NGS detected approximately 22038 genes per group.  Differential expression testing 
of all genes identified 242 genes with p-val for differential <0.05 (Table 4 shows top 10) and 
1 gene (Eml1; Echinoderm microtubule-associated protein-like 1) with Benjamini Hochberg 





Table 4: Top 10 differentially expressed (p-value<0.05) genes in young and old FLS cells.  
ID log2 F.C. p-value p-adj Gene Name Gene symbol 
ENSRNOG00000043143 -1.93896 4.70E-07 0.006 
Echinoderm microtubule-
associated protein-like 1 
Eml1 
ENSRNOG00000016346 -1.51981 4.90E-05 0.224 Protein kinase C delta type  Prkcd  
ENSRNOG00000009329 1.540407 7.12E-05 0.244 
Nuclear receptor subfamily 
1 group D member 1  
Nr1d1  
ENSRNOG00000061814 -1.45418 9.18E-05 0.252 
DiGeorge syndrome critical 
region gene 2  
Dgcr2  
ENSRNOG00000027124 0.880773 0.000168 0.384 Thymine-DNA glycosylase Tdg 
ENSRNOG00000055281 1.085596 0.000244 0.479 




ENSRNOG00000018582 -1.34473 0.000323 0.548 Exosome component 6 Exosc6 
ENSRNOG00000054118 1.292525 0.000372 0.548 
Tubulin polyglutamylase 
complex subunit 2 
Tpgs2 
ENSRNOG00000047447 0.53261 0.000398 0.548 Uncharacterized protein  
ENSRNOG00000020044 1.272062 0.000453 0.551 MOB kinase activator 2  Mob2  
Data obtained from the DESeq2 tool.   
Ageing FLS Differentially expressed ion channel Genes 
Filtering gene lists for ion channels grepping the word “channel” in the official 
Ensemble gene description (excluding channel “interacting proteins”, “potassium 
tetramerization domain” and “intracellular” channels) returned 95 genes with greater than 
zero RNA abundance. Table 5 shows the most abundant 10 channel genes. Of these 95 
channel genes, 2 were differentially expressed (pval<0.05) and these are (1) Potassium 
channel subfamily K member 4 (Kcnk4) (log2 fold change= 0.70, p-value=0.03) and (2) 
Potassium channel subfamily K member 2 (outward rectifying potassium channel protein 







Table 5: Top 10 differentially expressed channel genes in young and old FLS samples.  
No. ID Gene Name 
Gene 
symbol 
1 ENSRNOG00000021140 Potassium channel subfamily K member 4  Kcnk4 
2 ENSRNOG00000002653 
Potassium channel subfamily K member 2 (Outward rectifying 
potassium channel protein TREK-1)   
Kcnk2  
3 ENSRNOG00000003104 
Transient receptor potential cation channel subfamily V 
member 2 
Trpv2 
4 ENSRNOG00000019985 Acid-sensing ion channel 4  Asic4  
5 ENSRNOG00000007705 ATP-sensitive inward rectifier potassium channel 10 Kcnj10 
6 ENSRNOG00000019368 Amiloride sensitive sodium channel alpha1 subunit  Scnn1a  
7 ENSRNOG00000021102 Sodium channel subunit beta-1 Scn1b 
8 ENSRNOG00000020360 Chloride channel CLIC-like 1 Clcc1 
9 ENSRNOG00000014714 
Transient receptor potential cation channel subfamily V 
member 6  
Trpv6  
10 ENSRNOG00000051621 Catsper channel auxiliary subunit zeta Catsperz  
 
 
Ageing FLS Multivariate analysis of all Genes 
To investigate whether there were changes in clusters of genes rather than individual 
genes, PCA with 7 PCs was used. Figure 9-A shows the scree plot of these PCs and the 
percentages of explained variance by each one. The contribution of each sample to the PCs 
is shown in Figure 9-B where the first sample (O1; old-1) contributes most to the variability. 
A comparison of PCs took place via comparing PC1 with PC2 (Figure 10-A), PC1 with PC3 
(Figure 10-B) and PC2 with PC3 (Figure 10-C). A clear separation was found with PC1 vs PC3 
and PC2 vs PC3, and when the data are considered in 3 dimensions simultaneously with a 3D 
plot (Figure 10-D). The contributing genes to the separation between PC1 and 3 in Figure 10-




Table 6: Example of Gene contribution to the separation between PC1 and PC3 of young and old FLS samples. 









1 ENSRNOG00000019525 Hspa9 
heat shock 


















1 alpha 1-like  
0.0368 
3 ENSRNOG00000008843 Eci1 
enoyl-CoA delta 
isomerase 1  
0.0518 
3 ENSRNOG00000011167 Wdhd1 
WD repeat and 
HMG-box DNA 
binding protein 1  
0.0511 
3 ENSRNOG00000015741 Slc2a13 
solute carrier 
family 2 member 
13 
0.0497 
3 ENSRNOG00000016630 Tln1 talin 1  0.0491 
3 ENSRNOG00000051623 Exosc8 
exosome 
component 8  
0.0491 
Data obtained from the PCA package.  
Functional annotation of PC1 and PC3 on David Bioinformatics Resources 6.8 
revealed no pathway statistically significantly enriched on the KEGG (Kyoto Encyclopedia of 
Genes and Genomes) pathway. There were several enriched GOs such as “focal adhesion” 
(GO:0005925, p=7.4x10-4), “extracellular exosome” (GO:0070062, p=0.005), and 
“extracellular matrix” (GO:0031012, p=0.006).    
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Table 7: Gene contribution to the separation between PC2 and 3 of young and old FLS samples. 
PC Gene stable ID Gene name Gene description 
Contribution 
value 
2 ENSRNOG00000003174 Tapt1 
transmembrane 
anterior posterior 
transformation 1  
0.0512 
2 ENSRNOG00000007060 Plin2 perilipin 2  0.0498 
2 ENSRNOG00000025497 Fbxl6 
F-box and leucine-
rich repeat protein 
6  
0.0495 
2 ENSRNOG00000049785 Ranbp3 
RAN binding 
protein 3  
0.0493 





3 ENSRNOG00000008843 Eci1 
enoyl-CoA delta 
isomerase 1  
0.0518 
3 ENSRNOG00000011167 Wdhd1 
WD repeat and 
HMG-box DNA 
binding protein 1  
0.0511 
3 ENSRNOG00000015741 Slc2a13 
solute carrier 
family 2 member 
13 
0.0497 
3 ENSRNOG00000016630 Tln1 talin 1  0.0491 
3 ENSRNOG00000051623 Exosc8 
exosome 
component 8  
0.0491 
Data obtained from the PCA package.  
 This list of genes (PC2 and PC3) were enriched with only one GO which is “RNA 












Figure 9: Scree and contribution plots for PCA for Young and Old adult rat FLS. 
A. shows the scree plot for the 7 principle components used to reduce the dimensionality of the FLS Control and Cytokine (IL-1β+TNFα) treated datasets, approximately 22038 variables (genes) 
reduced to 7 variables (PCs) with 8 subjects; 4 young and 4 old male rats.  PCA Component 1 alone accounts for approximately 21% of the variance in the data.  B. Contribution plot showing the 
relative contributions of each of the eight subjects to the variance. The first 3 principal components (O1, 3, and 4 are old FLS).  The red dotted line indicates the mean contribution. The first subject 





Figure 10: Principle component, k-mean clustering and combined scatter plot. 
A, B and C show plots of PC1 vs PC2, PC1 vs PC2 and PC2 vs PC3 (Dim=PC).  The shaded circles show the unsupervised k mean cluster 95% confidence intervals thus there is a clear statistical 
separation between young and old when combining PC1 and PC3, or PC2 and 3.  D. 3D plot showing all three principal components plotted against each other. 
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For Control and cytokine treated FLS 
Then, the work proceeded to the young control and cytokine treated FLS samples. 
The raw data were analysed as described above in the materials and methods section NGS.  
 
Next-generation sequencing data analysis of gene expression of control and cytokine 
treated FLS 
RNA-seq detected 33251 transcripts and the full data are available on the EBI Array 
Express database with Accession Number: E-MTAB-7798. The top (highest FPKM) expressed 
10 genes were similar between control and cytokine treated cells, but with distinct 
differences (Table 8 and Table 9).  
Table 8: Genes with the highest expression levels in control of FLS cells. 
Rank Gene symbol 
(rank in cytokine) 
Official name* FPKM/1000 (CI)** 
1 Col3a1 (18) collagen type III alpha 1 chain 5138 (3314-7965) 
2 Sparc (5) secreted protein acidic and cysteine-
rich 4519 (3355-6085) 
3 Eef2 (1) eukaryotic translation elongation 
factor 2 3993 (2951-5404) 
4 Serpine1 (2) serpin family E member 1 3721 (2295-6035) 
5 Bgn (3) biglycan 3455 (3050-3914) 
6 Actb (4) -actin 2898 (2099-4003) 
7 Thbs1 (48) thrombospondin 1 2388 (1031-5532) 
8 Rplp0 (8)  Large ribosomal protein, P0 2668 (2256-3155) 
9 Thbs2 (14) thrombospondin 2 2218 (1483-3316) 
10 Gja1 (24) gap junction protein  1 2265 (1678-3057) 
Ordering from Cuffdiff (see methods). *Supplied by the Rat Genome Project 
https://rgd.mcw.edu/nomen/nomen.shtml. **Geometric mean and 95% CI n=4. 
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Table 9: Genes with the highest expression levels in cytokine (10ng/ml TNFα and IL-1β ) treated FLS cells. 
Rank Gene symbol 
(rank in control) 
Official name* FPKM/1000 (CI)** 
1 Eef2 (3) eukaryotic translation elongation 
factor 2 4705 (3644-6076) 
2 Serpine1 (4) serpin family E member 1 2801 (1427-5497) 
3 Bgn (5) biglycan 3177 (2635-3831) 
4 Dcn (35) decorin 2486 (1100-5617) 
5 Sparc (2) secreted protein acidic and cysteine-
rich 2609 (1509-4511) 
6 Lrp1 (11) LDL receptor related protein 1 2305 (1147-4630) 
7 Ctsb (13) cathepsin B 2495 (2027-3071) 
8 Rplp0 (8) Large ribosomal protein, P0 2487 (1906-3245) 
9 Actb (6) -actin 2401 (2028-2844) 
10 Grem1 (16) gremlin 1, DAN family BMP antagonist 1985 (967-4076) 
Ordering from Cuffdiff (see methods). *Supplied by the Rat Genome Project 
https://rgd.mcw.edu/nomen/nomen.shtml. **Geometric mean and 95% CI n=4. 
 
Next-generation sequencing data analysis of ion channel gene expression of control 
and cytokine treated FLS 
RNA-seq experiments were intended to give a transcriptome-wide, unbiased, 
assessment of ion channel changes in cytokine treated FLS.  190 channel genes were 
identified, including porins, connexins and ion-channel isoform genes (including  - to -
subunits), but excluded interacting proteins, other regulatory proteins and the so-called 
potassium tetramerization domain proteins.  The top 50 genes, in terms of FPKM are given 
for control and cytokine treated datasets in Table 10 and Table 11 respectively. 
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Official name* FPKM/1000 
(CI)** 
1 Gja1 (1) Gap junction channels 2265 (1678-
3057) 
2 aqp1 (6) aquaporin 1 (Colton blood group) 369 (223-609) 
3 piezo1 (2) piezo type mechanosensitive ion channel 
component 1 289 (236-355) 
4 vdac2 (4) voltage dependent anion channel 2 175 (157-195) 
5 vdac1 (5) voltage dependent anion channel 1 192 (142-258) 
6 clic1 (10) chloride intracellular channel 1 150 (117-191) 
7 trpv2 (9) transient receptor potential cation channel 
subfamily v member 2 130 (85-199) 
8 p2rx4 (11) purinergic receptor p2x 4 89 (67-117) 
9 clic4 (14) chloride intracellular channel 4 90 (77-105) 
10 trpm7 
(12) 
transient receptor potential cation channel 
subfamily m member 7 77 (72-82) 
11 clcn7 (15) chloride voltage-gated channel 7 62 (55-70) 
12 cacnb3 
(13) 
calcium voltage-gated channel auxiliary subunit 
beta 3 44 (28-71) 
13 kcnk2 (21) potassium two pore domain channel subfamily 
k member 2 47 (37-58) 
14 tpcn1 (17) two pore segment channel 1 49 (40-61) 
15 clcc1 (16) chloride channel clic like 1 44 (40-49) 
16 scn1b (22) sodium voltage-gated channel beta subunit 1 41 (31-55) 
17 clns1a 
(19) 
chloride nucleotide-sensitive channel 1a 
40 (29-54) 
18 clcn6 (20) chloride voltage-gated channel 6 32 (25-40) 
19 kcnq5 
(18) 
potassium voltage-gated channel subfamily q 
member 5 27 (18-39) 
20 cacfd1 
(24) 




transient receptor potential cation channel 
subfamily m member 4 20 (17-24) 
22 clcn5 (26) chloride voltage-gated channel 5 20 (17-23) 
23 Gjb2 (42) Gap junction channels 16 (10-26) 
24 kcnd1 
(32) 
potassium voltage-gated channel subfamily d 





potassium two pore domain channel subfamily 
k member 12 10 (3-29) 
26 clcn3 (27) chloride voltage-gated channel 3 10 (7-14) 
27 Gjc1 (33) Gap junction channels 10 (7-13) 
28 kcnd3 
(38) 
potassium voltage-gated channel subfamily d 
member 3 7 (3-16) 
29 clic2 (45) chloride intracellular channel 2 8 (6-12) 
30 cacna1g 
(43) 
















hydrogen voltage-gated channel 1 
7 (6-8) 
35 p2rx5 (37) purinergic receptor p2x 5 5 (2-13) 
36 kcna4 
(31) 
potassium voltage-gated channel subfamily a 
member 4 4 (1-14) 
37 tpcn2 (39) two pore segment channel 2 6 (5-8) 
38 Gja5 (28) Gap junction channels 2 (0-11) 
39 cacna1b 
(44) 




transient receptor potential cation channel 
subfamily m member 3 3 (1-6) 
41 trpm1 
(53) 
transient receptor potential cation channel 
subfamily m member 1 2 (1-7) 
42 kcnn4 
(52) 
potassium calcium-activated channel subfamily 
n member 4 3 (2-5) 
43 kcnma1 
(41) 
potassium calcium-activated channel subfamily 
m alpha 1 2 (1-6) 
44 trpv4 (50) transient receptor potential cation channel 
subfamily v member 4 3 (2-4) 
45 kcne4 
(49) 
potassium voltage-gated channel subfamily e 
regulatory subunit 4 2 (1-6) 
46 catsper2 
(55) 
cation channel sperm associated 2 
3 (2-3) 
47 scn2a (58) sodium voltage-gated channel alpha subunit 2 2 (2-3) 
48 kcnj2 (60) potassium inward rectifier j member 2 2 (1-3) 
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49 clic3 (57) chloride intracellular channel 3 2 (2-2) 
50 ano1 (75) anoctamin 1 0 (0-1) 
Ordering from Cuffdiff (see methods). *Supplied by the Rat Genome Project 
https://rgd.mcw.edu/nomen/nomen.shtml. **Geometric mean and 95% CI n=4. 
 
Table 11: Channel genes with the highest RNA expression levels in cytokine (10ng/ml TNFα and IL-1β) treated FLS 
cells. 
Rank Gene  
(control 
rank) 
Official name* FPKM/1000 
(CI)** 
1 Gja1 (1) Gap junction channels 1489 (930-2385) 
2 piezo1 (3) piezo type mechanosensitive ion channel 
component 1 276 (247-308) 
3 vdac2 (5) voltage dependent anion channel 2 181 (142-233) 
4 vdac1 (6) voltage dependent anion channel 1 227 (169-306) 
5 aqp1 (2) aquaporin 1 (colton blood group) 144 (86-242) 
6 vdac3 (7) voltage dependent anion channel 1 pseudogene 
5 155 (121-200) 
7 trpv2 (9) transient receptor potential cation channel 
subfamily v member 2 115 (77-172) 
8 clic1 (8) chloride intracellular channel 1 125 (108-146) 
9 p2rx4 
(10) 




transient receptor potential cation channel 
subfamily m member 7 85 (75-97) 
11 clic4 (11) chloride intracellular channel 4 79 (68-93) 
12 clcn7 (14) chloride voltage-gated channel 7 64 (52-79) 
13 clcc1 (18) chloride channel clic like 1 52 (42-65) 
14 tpcn1 
(17) 




potassium voltage-gated channel subfamily q 
member 5 34 (17-68) 
16 clns1a 
(20) 
chloride nucleotide-sensitive channel 1a 
36 (34-38) 
17 clcn6 (21) chloride voltage-gated channel 6 34 (27-44) 
18 kcnk2 
(16) 
potassium two pore domain channel subfamily k 
member 2 25 (12-49) 
19 scn1b 
(19) 














transient receptor potential cation channel 
subfamily m member 4 19 (13-27) 
23 clcn5 (25) chloride voltage-gated channel 5 19 (16-23) 
24 clcn3 (31) chloride voltage-gated channel 3 15 (9-27) 
25 Gja5 (43) Gap junction channels 2 (0-20) 
26 kcna4 
(41) 
potassium voltage-gated channel subfamily a 
member 4 4 (0-32) 
27 kcnd1 
(27) 
potassium voltage-gated channel subfamily d 
member 1 12 (9-15) 
28 Gjc1 (32) Gap junction channels 11 (9-13) 
29 cacna1a 
(36) 




potassium two pore domain channel subfamily k 
member 12 8 (3-20) 
31 cacna1c 
(37) 








potassium voltage-gated channel subfamily d 
member 3 2 (0-12) 
34 tpcn2 
(42) 








potassium calcium-activated channel subfamily 
m alpha 1 2 (0-13) 
37 Gjb2 (26) Gap junction channels 4 (1-12) 
38 cacna1g 
(35) 




calcium voltage-gated channel subunit alpha1 b 
5 (3-6) 
40 clic2 (34) chloride intracellular channel 2 3 (1-8) 
41 trpm3 
(46) 
transient receptor potential cation channel 
subfamily m member 3 3 (1-6) 
42 kcne4 
(51) 
potassium voltage-gated channel subfamily e 
regulatory subunit 4 2 (1-7) 
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43 trpv4 (50) transient receptor potential cation channel 
subfamily v member 4 3 (1-6) 
44 kcnn3 
(72) 
potassium calcium-activated channel subfamily n 
member 3 1 (0-7) 
45 kcnn4 
(48) 
potassium calcium-activated channel subfamily n 
member 4 2 (1-6) 
46 trpm1 
(47) 
transient receptor potential cation channel 
subfamily m member 1 2 (1-5) 
47 noct (57) anoctamin 1 3 (2-3) 
48 catsper2 
(52) 




potassium calcium-activated channel subfamily n 
member 1 2 (2-2) 
50 clic3 (56) chloride intracellular channel 3 2 (1-2) 
Ordering from Cuffdiff (see methods). *Supplied by the Rat Genome Project 
https://rgd.mcw.edu/nomen/nomen.shtml. **Geometric mean and 95% CI n=4. 
 
Next-generation sequencing data analysis of ion channel Differential expression 
20 ion channel genes, undetectable in control conditions became detectable or 
‘appeared’ after cytokine treatment Table 12), of which, the top expressed of these was 
trpc3.  Conversely, 7 ion channel genes became undetectable or “disappeared” following 
cytokine treatment (Table 13).  Following cytokine treatment, an additional 15 genes to be 
down by -1.5 (log2) or more and 21 genes 1.5 (log2) greater than control (Table 14 and Table 
15 respectively) were also found. I used tissue from 4 animals for the NGS study each animal 
tissue split into test and control groups; the “n” presented in the legends refers to the number 
of biological replicates (= animals). 
Table 12: All channel genes "appearing" in cytokine (10ng/ml TNFα and IL-1β) treated FLS cells (undetectable in 
controls). 
Gene Official Name FPKM (95% CI) 
kcnip2 potassium voltage-gated channel interacting protein 2 166.5 (110.9-249.9) 
trpc3 transient receptor potential cation channel subfamily c 
member 3 8.3 (0.7-98.2) 
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kcng3 potassium voltage-gated channel modifier subfamily g 
member 3 7 (0.7-71.7) 
scnn1g sodium channel epithelial 1 gamma subunit 5.9 (0.7-46.8) 
kcnmb3 potassium calcium-activated channel subfamily m 
regulatory beta subunit 3 5.1 (0.8-33.1) 
Gja3 Gap junction type a3 4.6 (0.8-27.3) 
kcnj11 potassium inward rectifier j member 11 (Kir6.2) 3.3 (0.3-37.4) 
asic5 acid-sensing ion channel subunit family member 5 2.9 (0.3-24.9) 
clca1 chloride channel accessory 1 2.6 (0.4-18.4) 
kcnc2 potassium voltage-gated channel subfamily c member 2 2.6 (0.4-18.4) 
kcnj5 potassium voltage-gated channel subfamily j member 5 2.6 (0.4-18.4) 
trpm2 transient receptor potential cation channel subfamily m 
member 2 2.6 (0.4-18.4) 
cacna2d4 calcium voltage-gated channel auxiliary subunit 
alpha2delta 4 2.5 (0.4-15.3) 
kcnk13 potassium two pore domain channel subfamily k 
member 13 2.5 (0.4-15.3) 
trpc4 transient receptor potential cation channel subfamily c 
member 4 2.2 (0.4-11.2) 
p2rx1 purinergic receptor p2x 1 2.2 (0.5-10.9) 
scn11a sodium voltage-gated channel alpha subunit 11 2.2 (0.5-10.9) 
Gja8 Gap junction type a8 2.1 (0.5-9.1) 
kcnj13 potassium voltage-gated channel subfamily j member 
13 1 (1-1) 
Data are presented in rank order; top FPKM genes in the presence of cytokine first. None had 
any expression in control (i.e., non-cytokine treated = 0±0 FPKM n=4). Overall, n=4 treated 
and 4 control animals. 
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Table 13: Channel genes "disappearing" in cytokine (10ng/ml TNFα and IL-1β) treated FLS cells (undetectable in 
cytokine). 
Gene Official Name FPKM (95% CI) 
ano2 anoctamin 2 6 (0.8-48.5) 
kcnv2 potassium voltage-gated channel subfamily a member 2 5.3 (0.8-36.3) 
kcna2 potassium voltage-gated channel modifier subfamily v 
member 2 
2.8 (0.4-21) 
kcnmb2 potassium calcium-activated channel subfamily m regulatory 
beta subunit 2 
2.6 (0.4-18.2) 
trpm5 transient receptor potential cation channel subfamily m 
member 5 
2.3 (0.4-12.5) 
kcne5 potassium voltage-gated channel subfamily e regulatory 
subunit 5 
2.3 (0.4-11.9) 
cacna1e calcium voltage-gated channel subunit alpha1 e 2.2 (0.5-10.4) 
Data are presented in rank order; top FPKM genes in the presence of cytokine first. None 
had any expression in cytokine treated animals (i.e., cytokine treated = 0±0 FPKM n=4). 
Overall, n=4 treated and 4 control animals. 
Table 14:FLS channel gene RNA expression lower after cytokine (10ng/ml TNFα and IL1) treatment. 
Gene Official Name Log2 (95% CI) 
kcnj15 potassium inward-rectified channel subfamily j member 15 -5.51 (-9.57 to -2.48) 
ano2 anoctamin 2 -2.59 (-5.5 to 0) 
kcnb1 potassium voltage-gated channel subfamily b member 1 -2.44 (-1.85 to -1) 
kcnv2 potassium voltage-gated channel modifier subfamily v member 2 -2.4 (-4.85 to 0) 
kcnip1 potassium voltage-gated channel interacting protein 1 -2.36 (-3.88 to -0.88) 
kcnmb1 potassium calcium-activated channel subfamily m regulatory beta 
subunit 1 -1.98 (-3.28 to 0.69) 
kcns1 potassium voltage-gated channel modifier subfamily s member 1 -1.88 (-6.84 to -0.42) 
kcnj8 potassium inward rectifier j member 8 (Kir6.1) -1.79 (-4.71 to 2.17) 
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kcnd3 potassium voltage-gated channel subfamily d member 3 -1.78 (-2.63 to 0.29) 
nalcn sodium leak channel, non-selective -1.77 (-3.43 to -0.85) 
clca2 chloride channel accessory 2 -1.76 (-6.72 to 0.65) 
kcne3 potassium voltage-gated channel subfamily e regulatory subunit 3 -1.67 (-1.84 to -0.15) 
asic1 acid sensing ion channel subunit 1 -1.64 (-6.44 to 0) 
clcn4 chloride voltage-gated channel 4 -1.61 (-2.61 to -0.95) 
trpm8 trpm8 channel associated factor 1 -1.61 (-2.09 to -0.99) 
Qualification cytokine log2 (geometric mean) <-1.5 of control (=approx. 33%), n=4 control 
and 4 cytokine treated samples (from 4 animals). 
Table 15: FLS channel gene RNA expression increased after cytokine (10ng/ml TNF and IL1) treatment. 
Gene ID Official Name Log2 (95% CI) 
kcnc1 potassium voltage-gated channel subfamily c member 1 4.32 (0.68 to 
5.93) 
kcnc3 potassium voltage-gated channel subfamily c member 3 3.46 (0.76 to 
5.94) 
trpc3 transient receptor potential cation channel subfamily c 
member 3 
3.06 (3.73 to 
6.5) 
catsper3 cation channel sperm associated 3 2.83 (0.14 to 
5.75) 
kcng3 potassium voltage-gated channel modifier subfamily g 
member 3 
2.81 (2.77 to 
6.65) 
tmc7 transmembrane channel-like 7 2.77 (1.99 to 
5.53) 
gjc3 gap junction protein gamma 3 2.75 (0.03 to 
4.35) 




asic2 acid-sensing ion channel subunit 2 2.52 (0.66 to 
4.65) 
kcnmb3 potassium calcium-activated channel subfamily m 
regulatory beta subunit 3 
2.34 (0 to 
4.73) 
cracr2a calcium release activated channel regulator 2a 2.32 (0.01 to 
1.96) 
kcnn3 potassium calcium-activated channel subfamily n member 
3 
2.07 (0.57 to 
4.09) 
tmc4 transmembrane channel like 4 1.94 (0.27 to 
2.47) 
asic4 acid-sensing ion channel subunit family member 4 1.75 (0.52 to 
2.76) 
kcnj11 potassium inward rectifier j member 11 (Kir6.2) 1.74 (0 to 
6.56) 
trpv6 transient receptor potential cation channel subfamily v 
member 6 
1.7 (0.01 to 
5.43) 
hvcn1 hydrogen voltage gated channel 1 1.69 (0.98 to 
2.84) 
trpv1 transient receptor potential cation channel subfamily v 
member 1 
1.61 (0.98 to 
2.07) 
kcnk7 potassium two pore domain channel subfamily k member 7 1.6 (-1.85 to 
1.03) 
cacna1d calcium voltage-gated channel subunit alpha1 d 1.57 (0.32 to 
2.09) 
asic5 acid-sensing ion channel subunit family member 5 1.55 (0 to 
5.78) 
Qualification cytokine log2 (geometric mean) >1.5 of control (=approx. 300%), n=4 control 




Cytokines treated FLS Multivariate analysis of all genes 
To investigate whether there were changes in clusters of genes rather than individual 
genes, the start was with 7 PCs in PCA. Figure 11-A shows the percentages of explained 
variance for each PC in which approximately 37% of the variance is explained by the first 
component. Figure 11-B shows the contribution of each sample to the difference and T1 
(cytokine treated sample 1) contributes most to this variance. Figure 12 (A, B, C and C), shows 
that there is no clear separation between the control and cytokine treated groups. Therefore,  
DA-PCA was used.  Little population difference was detectable until 5 PCs were used (Figure 
13), and so the rest of this section models expression changes with 5 principle components. 
Since there are only two groups (control and cytokine treated FLS) there is only one 
discriminant function (LD1). DA-PCA (5 PCs) discriminated the control and cytokine treated 
gene populations well as shown by the kernel density plot (Figure 13-A) using RStudio. The 
heatmap (Figure 13-B) shows that the 3 control and 2 groups are successfully separated and 
the prediction of each sample to their group belonging. Next, loading values for the 
discriminant function were drawn-out, which quantifies the relative contribution of all genes 
to the differences in control and cytokine treated gene populations. Only the top 50 genes 
were filtered and the top 15 were displayed in  (Figure 13-C) which are considered the most 
contributing genes to the multivariate population difference. 
Enriched pathway in FLS cells  
The genes primarily discriminating the treatment and control populations are largely 
those well established to be important for joint function, including several collagens and a 
Matrix metallopeptidase (MMP2). Ingenuity Pathway (IPA) Analysis (Qiagen, UK) was then 
used to identify the upstream regulators of the global differential expression pattern. This 
analysis predicted the top two regulators to be TNFα and IL1β (p-values 3e-17 and 6e-13 
respectively), this is unsurprising since this was indeed the treatment regimen.  
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Figure 14 shows the canonical calcium signalling pathway (p<0.5e-7), which was 
enriched following cytokine treatment. Also, the rheumatoid (p<5e-13) and osteoarthritis 
(p<1e-9) pathways and cellular movement and proliferation canonical pathways (predicted 
activation, p<1e-13 in both cases) were also enriched following cytokine treatment (data not 
shown). In all cases, TNFα was determined to be the top causal agent, but four ion channels 
were also significant causal regulators (adjusted p<0.05) of the transcript-wide treatment 
changes; CLCN5, TRPV4, TRPV1, KCNN4.  
qPCR 
To add further support to the unbiased RNA-seq ion channel analysis, my group 
colleagues performed qPCR by on sets of control and IL1β/TNFα treated FLS with panels of 
Ca2+-potassium channels (Kcnma1, Kcnn1, Kcnn2, Kcnn3) and other genes, I have performed 
the analyses of these data.  Not all primers for all the potassium channel genes identified by 
next-generation sequencing were available.  Three potassium genes were differentially 
expressed; Two voltage-gated potassium channels kcna6 and kcnc2 significantly decreased 
(p<0.05, n=4,4), whereas the large calcium potassium channel kcnma1 was upregulated 
(p<0.05, n=4,4).  A correlation analysis between qPCR and NGS data for those genes analysed 








Figure 11: Scree and contribution plots for PCA for Control and Cytokine (IL-1β+TNFα) treated adult rat FLS. 
A. shows the scree plot for the 7 principle components used to reduce dimensionality of the, FLS Control and Cytokine (IL-1β+TNFα) treated datasets, approximately 22038 variables (genes) 
reduced to 7 variables (PC) with 8 subjects; 4 control and 4 cytokine treated male rats.  PCA Component 1 alone accounts for approximately 37% of the variance in the data.  B. Contribution plot 
showing the relative contributions of each of the seven subjects to the variance. The first 2 principle components (T4 and T2 are cytokine treated FLS).  The red dotted line indicates the mean 





Figure 12: Principle component, k-mean clustering and combined scatter plot.  
A, B and C show plots of PC1 vs PC2, PC1 vs PC2 and PC2 vs PC3 (Dim=PC).  The shaded circles show the unsupervised k mean cluster 95% confidence intervals thus there is no clear statistical 






Figure 13: Discriminant Analyses of Global IL-1β TNFα Treatment Effects   
A. Shows the kernel density plots of the discriminant component co-ordinates for the control and IL-1β /TNFα treatment groups; co-ordinates on the x-axis and density on the y-axis; Individual 
co-ordinate centre points are illustrated by the vertical line and circle.  There is clear separation between control and cytokine treated FLS samples. B. A graphical confusion matrix showing the 
actual group membership (y-axis) and predicted cluster membership (on the y-axis).  All groups are correctly clustered with greater than 0.9 probability. C. The top 15 contributors to the linear 
discriminator function; Fn-1=fibronectin 1, Col1a1=collagen type I alpha 1 chain, Col3a1=collagen type III alpha 1 chain, Lcn2=lipocalin 2, PAI=Serpine1, Grem1=Gremlin 1, Mmp2=Matrix 
metallopeptidase 2, Thbs2=Thrombospondin 2, Cxcl12=C-X-C motif chemokine ligand 12, Mgp=Matrix Gla protein, C3=Complement C3, Col1a2=Collagen type I alpha 2 chain, Sod2=Superoxide 




Figure 14: Enriched Calcium regulation pathway.  
The nodes differentially expressed within the calcium signalling canonical pathway, identified with IPA. Many Ca2+ activated channels, cytoplasmic proteins and gene activation processes are 
shown. Calcium pathways have several effects on the cellular functions including activation of cell growth, development, cell-cell interaction, and slow muscle fibre development. Red coloured 




Figure 15: Correlation test between different conditions and techniques of FLS genes. 
A. shows the correlation between Control and cytokine in NGS expression data. A strong correlation was found between control and cytokine treated (72 hrs of IL-1β+TNFα ) channel expression 
data. Each point represents the intersection of 4 control and 4 test values.  In B, the correlation between qPCR (ΔΔCts) and NGS ratio (FPKM values) are shown. Data suggest that there only a 
weak linear correlation between qPCR and NGS. P-value=0.3. R=0.29. n=14. Genes that were upregulated in both datasets are indicated in red. Outliers (lower in Cyto) are AQP1 and the gap-




This type of experiments usually confirms the right type of cells were used for 
experiments especially when working with primary cells because purity is questionable. 
Therefore, one common marker for FLS cells is the CD248 and this was used in this project. 
CD248 is a membrane protein, expressed in stromal fibroblast and thought to play a role in 
tumorigenesis. FLS expressed this marker as shown in (Figure 16-A). 
Electrophysiology  
 Neither RNA nor protein expression studies can confirm changes in functional ion 
channel expression or, functional changes resulting from post-translational changes. 
Furthermore, several different potassium channel isoforms were identified, of which some 
upregulated and some downregulated.  Therefore, to investigate the effect of cytokine 
treatment on electrophysiological fingerprint, functional assays of ion channel expression 
with patch-clamp electrophysiology were conducted. The primary changes observed in the 
more limited qRT-PCR data would predict overall loss of voltage-gated potassium ion channel 
activity and increase in the less voltage-dependent calcium-activated potassium channels.   
Resting membrane potential (RMP) 
 Following cytokine treatment, the resting membrane potential of FLS cells was 
measured by the CAIRN Optopatch amplifier by flicking the dial into the current clamp (I=0) 
mode and read it directly from the digital screen of the amplifier. The RMP was found to be 
decreased (depolarized) from -48.6±1.7 to -38.6±2.8 mV (Figure 16-B), junction potential 
corrected (p≤0.05, unpaired t-test).  
Current-voltage curves  
 As seen in Figure 17-A, some cells exhibited clear transient and sustained 
components whereas others exhibited only the sustained component of the current.  
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Therefore, analysis of both the transient and sustained components of the current took place 
separately in all cases. 
  No overall change in the maximum amplitude of the transient (Figure 17-B) or 
sustained (Figure 17-C) current responses following cytokine treatment was found, although 
the current-voltage curve of the sustained current appeared shifted to the right. To 
investigate this systematically sustained current-voltage curves transformed into voltage-
conductance curves and fitted these with the Boltzmann equation, which allows the 
derivation of voltage gating parameters.  This analysis shows large shifts in the shape of the 
currents: Whilst the maximum conductance (“gmax”) was not significantly changed (Control: 
1.20±0.28nS, n=30. Treated: 1.10±0.23nS, n=26 p=0.8), the mid-point for current activation 
was shifted significantly to the right (Control: 38.64±5.38mV, n=30. Treated: 75.7±7.9mV, 
n=26 p<0.0005) and the slope of this activation was flattened (Control: 20.86±2.12 mV, n=30. 
Treated: 31.49±2.29 mV, n=26 p<0.005). To characterise the nature of the conductance 
apparently inhibited by cytokine treatment I calculated the difference current for cytokine 
treatment (Figure 17-D).  This revealed a strongly voltage-gated current with mid-point for 
activation 40±1.2 mV and slope 17.6±1.2 mV, n=25.  
 Even within the sustained current phase, currents from this population of cells 
was quite variable and so I performed unbiased K-means clustering analysis on our Boltzmann 
data. I fit data with 2, 3, 4 and 5 K-means 3 dimensional clusters and used silhouette analysis 
to determine that fitting with 2 clusters was optimal for our data. Cluster 1 had a centroid of 
Gmax=1.19±0.26nS, V1/2 =31.65±3.45mV, k=22.44±1.75 and cluster 2 had centroid of 
Gmax=1.67±0.43nS, V1/2 =107.76±5.97mV, k=33.43±2.39. For this sustained data, a 
significant association between a cluster and cytokine treatment (Fisher Exact test p<0.05, 
odds ratio 4.5; 95 %CI: 1.98-10.13, n=35), (Figure 18), was found.   
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This was repeated for the transient current and found there was no significance in any of the 
Boltzmann parameters for the transient currents and it was not associated with cytokine 
treatment. Boltzmann parameters for these conductances (transient current) were; Control: 
Gmax =1.28±0.49 nS, V1/2 =5.49 ±6.28mV, k =8.88 ±3.24mV and cytokine treated: 
Gmax=1.76±0.65nS, V1/2 =1.09±5.62mV, k=14.50±2.56mV (p>0.05, n=4,4). 
Pharmacological Interaction with KCNMA1 (BK) 
 To investigate relative constitutive BK channel activity in control and cytokine 
treated cells, standard voltage protocol (see methods section) in the presence of 1µM of the 
BK channel inhibitor paxilline was performed. No significant effect of cytokines was found on 
the size of currents in the present of paxilline (Figure 19); control 1.72± 0.62nS vs cytokine 
1.80±0.43nS n=20, 25) or the V1/2 values (control 53.2± 3.8mV v cytokine 48.4±5.7mV 
n=20,25). However, I found that the slope of the Boltzmann was shallower in cytokine treated 
paxilline (i.e., BK free) currents (control 24.6±4.5 v cytokine 36.7±11.6, n=20,25 p≤0.01 
students t-test).   
 To investigate if the maximum possible BK current is altered in cytokine 
treatment, voltage protocol was repeated in the presence of 1µM of the BK channel opener 
NS1619 (Figure 19-B) and found a large NS1619 activated current in control cells, but 
significantly less in cytokine treated (Difference current at +70mV was 66.18±19.82pA 






Figure 16: Tissue typing and resting membrane potential (RMP) of FLS cells. 
A. Expression of CD248 in FLS cells with ICC. The concentrations were 1:100 for the primary antibody (CD248) and the secondary antibody concentration was 1:500. The left shows the CD248 
alone (green colour) while the middle figure shows the DAPI which is a nuclear counterstain (blue colour) and the right figure shows the final merged CD248 and DAPI. Scale is at 100µm. B. The 
RMP of FLS cells was decreased (depolarized) following cytokines (IL-1β+TNFα) treatment. The measurements of the RMP were taken from the CAIRN Optopatch amplifier on current clamp (I=0). 





Figure 17: Whole-cell voltage-gated currents from control and cytokine treated FLS. 
A. Top panels show the voltage step protocols and the evoked currents are shown below for control (left) and IL-1β+TNFα (right) conditions. Note that FLS exhibit both transient and sustained 
currents. These phases of current were then analyzed separately as indicated. B. Current-voltage curves (left) and Boltzmann transformed conductance voltage curves (right) from the transient 
currents recorded in a number of experiments such as that illustrated in (A).  The solid lines represent Boltzmann fits (see text).  There was no significant difference between control and treated 
transient currents.  Data points are shown as mean ± SEM (n=18 for control and n=11 for IL-1β+TNFα). C. Current (left) and conductance (right) curves as (B), but from the sustained currents.  
The red line in the current-voltage curve is the difference current for control-cytokine treated. D. Difference conductance-voltage curve for the cytokine difference current shown in (C).  The line 










Figure 18: Control and cytokine current family clusters. 
K-means cluster analysis shows two clusters of voltage-gated ‘sustained’ 
currents. Clusters 1 and 2 significantly associated to control and cytokine 
treatments. (A) Top panels show the voltage step protocols and the evoked 
currents are shown below for cluster 1 current family (left) and cluster 2 
current family (right) conditions.  (B) Left, Current-voltage curve for cluster 
one and two. Right, Boltzmann transformed conductance voltage curves for 
cluster one and two current families illustrated in (A). The solid line 
represents the Boltzmann curve fits to the data.  These are significantly 
different. For this sustained data, a significant association between the 
cluster and cytokine treatment (Fisher Exact test p<0.05, odds ratio 4.5; 95 





Figure 19: Effects of BK channel drugs on FLS whole-cell currents. 
A. Voltage step protocols used with control ± drugs (top) and cytokines (IL-1β+TNFα) ± drugs (bottom). B. Representative examples of untreated (control) cells before (left) and in the presence of 
1μM of the BK channel opener NS1619 (left). C. Current-voltage curves from a number of cells such as that shown in (A).  Current is significantly greater in the presence of NS1619, p<0.05, n= 6 
and 6. D. Difference currents for control and cytokine treated cells in the presence of NS1619 (i.e., current in the presence of NS1619- vehicle control. E. Representative raw example current 
families of cytokine (10ng/ml IL1β+TNFα) treated cells in the absence (left) and presence (right) of 1μM NS1619. F. Current-voltage curves for a number of cells such as that shown in (C).  These 
two curves are not significantly different from each other n= 6 and 6. (G, H) There was no significant different of current amplitude in the presence of the BK inhibitor paxilline (F. control vs 
cytokine OR G. paxilline vs no paxilline). I.  Numerical simulation of data from Clark et al 2017 model. To quantify the degree of change of BK channel modulation taking place with this treatment 
we used the model of (Clark, Schmidt, Sachse, Boyle, Firestein & Giles, 2017) verbatim with the exception that we varied the inherent BK channel Ca2+ sensitivity parameter kd. In this simulation, 
the independent variable kd is plotted on the x-axis and the predicted BK current midpoint (V1/2) is plotted on the y-axis.  In blue we have added the midpoint we recorded in control conditions, 
and in red that following cytokine treatment.  The complete MATLAB code for this simulation is included in the supplementary data (2).  
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Comparison of control vs cytokine treated vs young vs old FLS of NGS data 
A comparison between all FLS samples (control, cytokine treated, young and old) was 
done. Again, a multivariate analysis (PCA) was used here with 10 PCs. Figure 20-A shows the 
scree plot presenting the percentage of explained variance by each dimension. Most of the 
variabilities are explained by dimension 1 (approximately 66%). The contribution of each 
sample to the difference between groups is shown in Figure 20-B. T4 (treated sample 4) 
contributes most to the difference. When comparing the dimensions (PC1, PC2, and PC3) 
with each other, there was good and clear separation between control and cytokine from 
young and old as shown by PC1 vs PC2 (Figure 21-A). The other PCs, PC1 with PC3, and PC2 
with PC3 did not show such nice separation (Figure 21-B and -C). Figure 21-D shows the 3D 
plot of all these samples and it shows a clear separation between control and cytokine 
compared to young and old. The contributing genes to the separation between sample 
groups using PC1 and PC2 are shown in Table 16.  
Table 16: Contributing genes to the difference between all samples in PC1 vs PC2.  






1 ENSRNOG00000001597 Atf2 activating transcription factor 2  0.008799919 
1 ENSRNOG00000004556 Dcaf5 DDB1 and CUL4 associated factor 5  0.008808127 
1 ENSRNOG00000004577 Fez2 
fasciculation and elongation protein 
zeta 2 
0.008797673 
1 ENSRNOG00000007224 Bmt2 
base methyltransferase of 25S rRNA 
2 homolog  
0.008795777 
1 ENSRNOG00000007333 Wdr20 WD repeat domain 20 0.008799587 
1 ENSRNOG00000009781 Dync1i2 
dynein cytoplasmic 1 intermediate 
chain 2  
0.008802714 
1 ENSRNOG00000010967 Cdc37l1 cell division cycle 37-like 1  0.008810146 
1 ENSRNOG00000018176 Rab6a 
RAB6A, member RAS oncogene 
family  
0.008798605 
1 ENSRNOG00000019649 Cul4a cullin 4A 0.008796222 
1 ENSRNOG00000025269 Slc25a44 solute carrier family 25, member 44  0.00880108 
2 ENSRNOG00000000861 Zic3 Zic family member 3  0.04440599 
2 ENSRNOG00000003039 Wnt3a Wnt family member 3A  0.04259736 
2 ENSRNOG00000007907 Tmem178a transmembrane protein 178A  0.04284819 
2 ENSRNOG00000016358 Apba2 
amyloid-beta precursor protein-
binding family A member 2 
0.04411142 
2 ENSRNOG00000017484 Gja5 gap junction protein, alpha 5  0.0433594 
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2 ENSRNOG00000017783 Sfrp1 secreted frizzled-related protein 1  0.04421027 
2 ENSRNOG00000026902 Lyve1 
lymphatic vessel endothelial 
hyaluronan receptor 1  
0.04279164 
2 ENSRNOG00000031675 Panx3 pannexin 3  0.04343534 
2 ENSRNOG00000052205 Fgf23 fibroblast growth factor 23  0.04429612 












Figure 20: PCA of FLS cells at different conditions and ages. 
A. shows the scree plot for the 10 principle components used to reduce the dimensionality of FLS Young, Old, Control, and Cytokine (IL-1β+TNFα) treated datasets, approximately 22038 variables 
(genes) reduced to 10 variables (PC) with 16 subjects; 4 young, 4 old, 4 Cytokine treated and 4 Control male rats.  PCA Component 1 alone accounts for approximately 66% of the variance in the 
data.  B. Contribution plot showing the relative contributions of each of the sixteen subjects to the variance. The red dotted line indicates the mean contribution. The first 2 subjects contribute 





Figure 21: Principle component, k-mean clustering and combined scatter plot of FLS cells at different conditions and ages. 
Principle component, k-mean clustering and combined scatter plot. A, B and C show plots of PC1 vs PC2, PC1 vs PC2 and PC2 vs PC3 (Dim=PC).  The shaded circles show the unsupervised k mean 
cluster 95% confidence intervals. Thus, there is a clear statistical separation between young and old from cytokine treated and control samples when combining PC1 and PC2. D. 3D plot showing 
all three principal components plotted against each other. 
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3.4 Discussion  
In this study, two models were used to investigate the effects of ageing on FLS. Both 
natural ageing of Wistar rats and an in vitro model which was intended to recapitulate some 
aspects of musculoskeletal inflammageing were used. A number of genetic changes in both 
were detected.  Of particular note is that IL1β and TNFα treatment of FLS cells resulted in 
profound changes in arthritic, inflammatory and Ca2+ regulatory pathways and differential 
expression of several ion channels. In this model our RNA sequencing and qPCR show an 
upregulation of KCNMA1 channels and electrophysiological experiments show that while the 
constitutive activity of the channel is not changed, regulation by voltage and drugs are 
significantly altered.  
Global transcriptomic changes in naturally aged rodents’ FLS 
The only gene differentially expressed, taking the most rigorous approach, 
straightforward comparison with BH corrected FDR was Eml1.  Eml1 is involved with mitosis 
(Richards et al., 2014) I are not aware of any previously reported direct role of this in ageing 
or joint disease, but a loss of this gene is associated with a series of genetic diseases including 
congenital deafness (Kaplan et al., 1992)  and some brain diseases (Oegema et al., 2019). 
There are also reports of this gene being involved with cancer (De Keersmaecker, 2005). 
Further investigation will be needed to discover its role in joint ageing.  In terms of my 
multivariate analyses of differential gene expression, several extracellular systems were 
significantly regulated, focal adhesion, extracellular exosome, extracellular matrix together 
with RNA processing.  This suggests that there have been major changes, perhaps to the 
entire structure of resulting tissues. That said, transcriptomics always needs a caveat 
attached that change mRNA whilst probably always important does not necessarily correlate 




Ion channel “channelome” changes in naturally aged rodents’ FLS 
The FDR calculated by Deseq2 for transcriptome-wide comparisons is not useful when 
investigating changes in a subset of genes, such as ion channel genes, chosen a priori.  
Therefore, here ion channel genes with a p-value below 0.05 were looked for; there were 
two and interestingly both were members of the KCNK family. Both were upregulated by 
more than 1.5 log2 fold change. This is a fascinating discovery since this channel was recently 
reported to be a key regulator of FLS function Clark et al 2018 (Clark et al., 2017). 
Tissue typing by ICC 
It is important to be able to confirm the type of cells that were used for experiments. 
For example, in this part of the project, the FLS cells were used and CD248 was used as a 
marker to identify these cells by ICC. CD248 is a transmembrane glycoprotein. It is 
dynamically expressed on fibroblasts during tissue development and inflammation. 
Additionally, it is one of the markers that are used to identify FLS cells (Teicher, 2019). The 
expression of this marker in FLS cells used in this project was almost in all cells. Also, its 
expression was increased (log2 fold change was 0.614) in the NGS data in this project. 
Although ICC of other markers (fibronectin and prolyl 4-hydroxylase) of FLS (Teicher, 2019) 
could not be done due to technical issues (including costs), the expression level with NGS 
data was interesting. For example, fibronectin was upregulated with log2 fold change of 
0.727 and prolyl 4-hydroxylase was slightly upregulated with log2 fold change of 0.071. This 
increases the possibility of the high purity of the cell population (FLS) used in this project.  
 
The pathophysiological validity of the 72hr IL1β and TNFα model 
There is no established in vitro model of ageing per se, but the treatment of tissue 
with TNF and IL1 should recapitulate at least some aspects of inflammageing. In terms of 
joint tissue, the clear and obvious age-related pathology is arthritis. In in vitro studies of 
inflammatory arthritis, tissues are typically exposed to between 10ng/ml of TNF and IL1 
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for between 2 to 7 days.  In the present study, the lower end of the concentration range was 
used, 10ng and treat for 72hrs (Williams et al., 2011, Stevens et al., 2009, Stevens et al., 2008, 
Pretzel et al., 2009, De Ceuninck et al., 2004, Williams, 2014). This regime causes will activate 
inflammatory pathways and yet there will be no cytokine remaining by the time of the 
electrophysiological experiments that could cause confounding direct effects. FLS cells were 
treated with the pro-inflammatory cytokines IL1β and TNFα in order to understand the 
cellular changes that occur when these FLS are subjected to higher-than-normal levels of 
these cytokines in vivo, for example in arthritis. This model has distinct advantages of 3Rs, 
consistency, reproducibility and allowing the investigation of distinct pathways in isolation 
but since it is an acute model it may lack some chronic features of in vivo models. Our 
transcriptome analysis demonstrated that pathways were activated in common with 
arthritis; movement of cells, proliferation and both rheumatoid and osteoarthritis. Taken 
together with the changes in Ca2+ signalling, I show that our in vitro model does capture 
several features of the inflammatory joint phenotype and that FLS have been “activated” as 
observed in animal models of arthritis.  
Causal analysis is a relatively new mathematical technique that allows one to move 
from the probability of agreement or simple correlation towards the probability of causation 
in networks (Kramer et al., 2014). The IPA implementation of this identified both IL1β and 
TNFα as master-regulators of the changes I observe and considering our experimental design 
included time-matched controls, this strongly supports a suitable dosage and incubation 
time. Whilst both IL1β and TNFα were identified by IPA as “master regulators”, TNFα 
transcriptome-wide causation was stronger than that of IL1β.   
Previous studies of differential expression of membrane ion channels in the 
synovium 
Until very recently, little was known of the FLS ion channel complement (the 
“channelome”) compared to that of another central joint cell, the chondrocyte (Barrett-Jolley 
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et al., 2010). One of the best-studied families of ion channels in FLS, however, is the Ca2+ -
activated potassium channel family. The high conductance member of this family termed BK 
(KCa1.1 or KCNMA1 (Hu et al., 2012a, Tanner et al., 2015b)) and the “intermediate” 
conductance member (“IK”, or KCa3.1) are both expressed and have roles in invasive 
migration, proliferation, cytokine and MMP release (Friebel et al., 2014, Hu et al., 2012a). 
Interestingly, inhibitors of BK decrease the signs of joint degeneration in the pristane-induced 
arthritis model (Tanner et al., 2015b). These channels are therefore potential drug targets to 
protect against joint degeneration as well as being putative biomarkers. Whilst the BK 
channel β- subunit (KCNMB1) was slightly increased in transcript abundance in the Lambert 
et al., 2014 data (Lambert et al., 2014)  (similar seen by Huber et al., 2008 (Huber et al., 
2008)), both of the two BK -subunit (KCNMA1) probes on the chip exhibit small decreases 
in expression.  It should be noted that the expression of BK channel β- subunits confer 
modulation of ion channel activity, in many cases decreasing its sensitivity to, for example, 
Ca2+ ions (Lippiat et al., 2003, Mobasheri et al., 2012).   
A recent study by Kondo et al (Kondo et al., 2018) demonstrated human FLS express 
high levels of both intermediate (KCa3.1) and large (BK/KCa1.1/KCNMA1) Ca2+-activated 
potassium channels.  The other most highly expressed ion channels identified by Kondo et al 
(2018) (Kondo et al., 2018) were KCNK2, ANO6, ANO10 and KCNK6.  KCNK2/6 are members 
of the two-pore-domain potassium channel family and are particularly thought of as 
molecular sensors, whereas the ANO (anoctamin) channels are members of the large chloride 
channel family. The family is relatively understudied compared to potassium channels, but 
ANO6 (TMEM16F) is, interestingly, thought to be a Ca2+-activated chloride channel as well as 
a lipid “scramblease”(Scudieri et al., 2015), therefore, likely to be activated in parallel to Ca2+-
activated potassium channels.  
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Changes in BK channels in the present study 
The phenotype of FLS current recorded by whole-cell patch-clamp was quite variable 
in terms of the presence of transient and sustained components of current, as seen in Figure 
17. Furthermore, even the sustained current fell into statistically separable clusters, Figure 
18.  The two “clusters” of sustained current families were present in both control and 
cytokine treated cells, however, there was a statistically significant correlation between 
cluster number and cytokine treatment, implying that cytokine treatment tended to push 
cells into a certain cluster phenotype (in our case, cluster 2).  The basis of these different 
clusters is unknown, but it could represent different states of the same cell type.  This 
hypothesis would fit well with our global transcriptomic analysis that indicated that both 
proliferative and migratory canonical pathways were activated by cytokines.   
Significant increases in RNA expression of the BK α-subunit gene, Kcnma1 was found 
following cytokine treatment (both by next-generation sequencing (NGS) and qPCR), but 
there was no overall increase in whole-cell voltage currents in a protocol that would be 
expected to be heavily dominated by calcium-activated potassium channels.  Indeed, in this 
study the resting membrane potential was depolarised following treatment with cytokines; 
a phenomenon that could result from either loss of constitutive K+ conductivity or increase 
in Cl- or non-specific channel conductance. The families of currents are, of course, from native 
cells that also express a number of other ion channels such as TRP channels (for example 
Trpm7/Trpv2 identified by our NGS) and also other potassium channels, such as the two-pore 
channel (for example Kcnk2 detected by our NGS) or voltage-gated potassium channels (for 
example Kcnq5 detected by our NGS).  Pro-inflammatory cytokine treatment caused a 
notable shift in voltage-gated current from left to right which corresponds to reduced 
activation of current under any reasonable physiological condition.  These voltage-activation 
midpoints (V1/2), are in the range expected for BK channels recorded with the presence of 
intracellular EGTA and thus very low (nanomolar) resting Ca2+ concentrations(Cui et al., 
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1997). Note that with elevated, thus physiological intracellular Ca2+ concentrations, these 
would likely lie to the left of where they lay in our experiments. However, our patch-clamp 
conditions allow a more direct comparison between fundamental BK ion channel properties, 
than for example, sharp-electrode work which would allow change in Ca2+ occur 
simultaneously changes in ion channel properties, and thus be a confounding variable. The 
difference current between treated and untreated conditions is similar to many common 
voltage-gated channels, which includes the KCa which in can be activated by voltage even in 
the virtual absence of Ca2+ ions(Cui et al., 2009).  One apparently simple question would be 
whether the difference current was sensitive to BK channel block, with paxilline.  I found that 
both the BK channel activator (NS-1619) and inhibitor (paxilline) were ineffective following 
cytokine treatment.  This could be for two possible reasons: (i) That there were no longer any 
KCNMA1 channels expressed; except that would be diametrically opposed to that data I have 
RNA level (and I would expect to see generally smaller whole-cell currents), so far more likely 
is (ii) that the channel is still present, but is no longer sensitive to these drugs. This is an 
exciting interpretation and is strongly supported by the RNA data, since there is a clear shift 
from RNA-expression of β1 (and β2) subunits to β3 and sensitivity to voltage, calcium AND 
drugs is well-known to be conveyed by co-expression of the β subunits(Uebele et al., 2000, 
Yang et al., 2009, McManus et al., 1995).  The simple (K+ channel focussed) FLS 
electrophysiological model of Clark (Clark et al., 2017) allows using numerical simulation to 
estimate the change in BK channel Ca2+ that would be required to shift the conductance curve 
by the degree reported in the present work (Figure 19-H).  It was found that retaining all the 
parameters of(Clark et al., 2017) except the Ca2+ kd itself, data would be the equivalent to 
increasing Kd from 0.46µM to approximately 1.05µM. The upstream pathway (beyond the 
activation of the cytokine pathway including NFκB etc) for these changes is difficult to identify 
from these data, especially since there are relatively few ion channel interaction data in the 
IPA databases. It is notable, however, that there were significant changes in the calcium 
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signalling pathway (Figure 14) and so change in calcium-activated potassium channel 
expression may follow this, by way of compensatory expression.   
Role of ion channels in pro-inflammatory cytokine production and secretion 
Ion channels are involved not just in the response to cytokines, but can also 
contribute to their production.  For example, ionotropic NMDA and kainite glutamate 
receptors contribute to synovial inflammation by increasing expression of the inflammatory 
cytokine IL-6(Flood et al., 2007) and nicotinic acetylcholine receptor activation reduces the 
synovial production of IL-6, IL-8, TNF and several other cytokines(Waldburger et al., 2008, 
van Maanen et al., 2009).  P2X7 is an established conduit for the release of mediators such 
as IL1β(Mortaz et al., 2012). I saw little P2X7 RNA, but there is evidence that in chondrocytes 
P2X1, may subserve the same function(Varani et al., 2008) and I detected RNA for this 
channel only after cytokine treatment. In a previous report inhibition of the small Ca2+ 
activated potassium ion channel decreased the production of cytokines IL-6, IL-8 and MCP1 
in response to TGF-1β, but they did not examine secretion of IL1β or TNF(Friebel et al., 
2014).  In other-words activation of Ca2+ potassium ion channel is essentially a secretion 
trigger.  This result is somewhat counter-intuitive since one would expect activation of a 
potassium channel to hyperpolarise and decrease secretion.  One possible explanation is that 
activation of Ca2+ potassium ion channels draws in additional Ca2+  by increasing the driving 
force for Ca2+  entry.  
Ca2+ entry α (Vm-EqCa2+)  
Where negative values are equivalent to the inward driving force for Ca2+, Vm is the 
membrane potential and EqCa2+ is the equilibrium potential for Ca2+.  
Enrichment analysis of FLS cells (ageing and cytokine effects) 
For the GOs, it seems that our model of “inflammageing” was close to the real model 
of ageing (FLS from old rats) when comparing NGS data. For example, focal adhesion, 
extracellular exosome, and extracellular matrix were all enriched GOs in aged FLS. On the 
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other hand, the effects of cytokines (10ng/ml IL-1β+TNFα) treatment showed enrichment in 
genes involved in joint function such as collagens and Mmp2. They were all focused on the 
extracellular space. As mentioned earlier, the model of “inflammageing” in this study has 
already captured some features of inflammatory joint phenotype and FLS cells have been 
activated as observed in animal models of arthritis. A note of caution should be added, to 
meta-analyses, however. Note that in Figure 20, PCA of four groups Control, Treatment, 
Young and Old have been shown.  Since the Control and Treated are both FLS from Young 
animals, one would have expected Young and Control to be tightly grouped (or the same), 
but in fact, in PCA terms over all three dimensions, Young and Old are the most similar and 
both very different from Control. This implies that in the case of FLS cultured cells, the 
different strain of rats, time, weather (other confounding factors) may have had a greater 
effect on the cell phenotype than ageing itself.  This could reflect the fact that the cells are 
first cultured before RNA extraction. It will be interesting to investigate the same 
phenomenon in the aortic tissue (next chapter) where a similar experimental design has been 
followed. 
3.5 Conclusions 
To our knowledge, this is the first report using a combined NGS and patch-clamp 
electrophysiological approach to (1) understanding the control of potassium channels in 
inflammageing in joint tissues, (2) to combine such powerful experiments to track changes of 
the gene expression and ion channels in the inflammatory model of ageing and compare with 
natural ageing rats. Differences between young and old FLS were found. Also an increased 
RNA expression of the BK potassium gene KCNMA1 was found, but the constitutive activity 
of the channel was not increased.  The decreased sensitivity to voltage activation and to drugs 
is likely to be explained by a switch of the RNA expression of β-subunits KCNMB1, 2 and 3. 
Also, a lot of similarities of enriched GOs between cytokine treated and aged FLS were 
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detected. In terms of individual gene analysis, Gja1 was decreased with cytokine treatment 







Chapter 4 – Age-related changes in vascular smooth muscle 




4.1 Introduction  
As an example of a cardiovascular tissue that might change with age, the vascular 
smooth muscle was chosen. The structure and function have been described in the 
introduction of chapter 1. In this chapter, two models will be used, the first one is an ageing 
model in which aged Wistar Kyoto rats will be used and the other model is an inflammageing 
model where VSMC are isolated from the thoracic aorta, cultured and exposed to cytokines.  
With ageing, the balance between pro- and anti-inflammatory cytokines is disturbed. 
This leads to increased levels of pro-inflammatory cytokine by 2-3 fold compared to normal 
leading to several age-related diseases (Pedersen, 2006a). Increased levels of cytokines are 
risk factors for age-related diseases such as cardiovascular diseases (Clarke et al., 2018). 
As discussed in Chapter 1, ion channels are important regulators of blood vessels’ 
contractile functions. Several channel types play roles in the vessel’s main function. Examples 
of such channels are K (Kv, KCa, KATP, and inward-rectifier potassium (Kir) channels), Ca 
signalling, Na (Nav channels), and Cl- (voltage- or Ca2+ dependent) [(Cowled and Fitridge, 
2011, Fan et al., 2019, Orlov et al., 2017, Kuriyama et al., 1998). There have been several 
reports of blood vessel dysfunction associated with ageing [(Laina et al., 2018, Ungvari et al., 
2018, Cheng et al., 2019), many of these surround the phenomenon of atherosclerosis, but 
even allowing for this there are reported cases involving ionic imbalance and VSMC 
membrane potential changes [(Cheng et al., 2019).  
Hypertension, one of the most common diseases of ageing is thought to be 
genetically determined (Stewart et al., 2017, Brozovich et al., 2016) although the exact 
mechanisms are often not known. The complex mechanisms of vasorelaxation and the 
importance of this process to the maintenance of blood pressure mean that there is a 
constant need to discover new therapeutic targets in VSM.   
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To investigate this, two complementary models were used. The first model was an 
“inflammageing” model that was developed by exposing VSMC cells to 10ng/ml IL-1β+TNFα 
for 72hrs. The second model was a real ageing model where old rats were grown and then 
used for the study.  
Aims  
The aims of this chapter were:   
• To investigate the change of vascular smooth muscle ion channels with cytokine 
treatment as a model of inflammageing or ageing itself.    
• To investigate whether any other key regulatory genes had a differential expression.  





4.2 Materials and methods  
Aorta dissection  
Aorta tissues from young and old Wistar Kyoto rats were dissected, cleaned with 
forceps and placed in RNALater, stored at -80OC as described in chapter 2 – materials and 
methods section RNA extraction, Aorta. These aorta tissues were defrosted later on and RNA 
was extracted for NGS as described in chapter 2 materials and methods.  
Tissue culture  
VSMC isolation and culture have already been described in chapter 2 materials and 
methods. But briefly thoracic aorta was dissected from rat, cleaned and snipped into 
branches on ice-cold dissection solution, these branches were transferred into low Ca++ 
solution and warmed to 35-37OC for 10 min. After that, branches were digested for 25-30 min 
at 37OC followed by 3x wash with pre-warmed low-Ca++ solution. Cells were then dispersed 
by gentle trituration through a sterile plastic Pasteur pipette. Then, connective tissues were 
discarded and cells were cultured in fresh pre-warmed high glucose 1x DMEM complete 
media. Once cells grew and became 80-90% confluent, they were passaged and experiments 
took place after passage 3.  
RNA extraction  
RNA from aorta tissues and VSMC were extracted as described in chapter 2 – 
materials and methods. RNA quantity and purity were measured by NanoDrop 2000 
Spectrophotometer before submitting samples to the CGR centre for sequencing. The 
quantities of RNA from Aorta (appendix 5) and VSMC (appendix 8) were measured.  
RNA-Sequencing (Next-Generation Sequencing (NGS)) 
After RNA was extracted as described above, sequencing of large (>200 nucleotides) 
messenger RNA (mRNA) enriched with polyA-tail was outsourced with a >30M sequencing 
depth and 50-150bp read length and was run as paired-end. The QC summary of RNA from 
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FLS samples are shown in appendix 6 and appendix 9 from aorta and VSMC, respectively. Raw 
data was delivered as FASTQ files containing sequences and quality scores. Then, the quality 
of reads was checked out by FastQC software that provides Phred quality scores as shown in 
appendix 7 and appendix 10 for aorta and VSMC, respectively. After that, reads are 
aligned/mapped, assembled and quantified, and differentially expressed genes are detected 
as described in chapter 2-materials and methods. 
Electrophysiology  
Electrophysiology methods with VSMC were similar to those of FLS and described in 
full in materials and methods of FLS chapter 3, section “Electrophysiology” but briefly, cells 
were sealed with fire-polished boro-silicate glass pipette filled with intracellular solution. 
Then, cells that are in the extracellular solution were challenged with a broad range of 
potentials ranging from -120 to +120mV. The current is recorded in the whole-cell 
configuration. After that, data were analyzed with different softwares including but not 
limited to Excel, Sigma Plot, RStudio, Python, and MATLAB. All recordings took place at RT.  
Solutions described in Chapter 2. 
For the ANO1 inhibitor drug (CaCCinh-AO1), the extracellular solution that filled the bath 
was replaced by an extracellular solution containing the drug at a flow rate of 3ml/min. Then, 
cells were challenged with the same voltage step protocol (-120 to +120 mV at 10mV 







Changes in Vascular smooth muscle transcriptome (aorta) with age 
Aorta Differentially expressed Genes 
The work in this part started with next-generation sequencing of the aorta from 
young and old rats (ages), aorta dissected, prepared and RNA extraction took place as 
described in the methods. NGS [FastQC, HiSAT2, and StringTie tools) detected approximately 
32695 genes per group. Differential expression testing (CuffDif tools) of all genes identified 
441 genes with a p-value for differential <0.05 and 29 genes with Benjamini Hochberg 
corrected gene expression FDR <0.05. Table 17 shows the top 29 genes with p-value <0.05 




Table 17: Top 29 differentially expressed aorta genes with p-value<0.05 and FDR<0.05.  
No. Gene stable ID Gene name Gene description p_value q_value 
1 ENSRNOG00000002459 Fbxo40 F-box protein 40 5.00E-05 0.02 
2 ENSRNOG00000002555 Serpinb7 serpin family B member 7  5.00E-05 0.02 
3 ENSRNOG00000002911 Alb albumin  5.00E-05 0.02 
4 ENSRNOG00000003245 Cacng1 
calcium voltage-gated channel 
auxiliary subunit gamma 1  
5.00E-05 0.02 
5 ENSRNOG00000003435 Mcf2 
MCF.2 cell line derived 
transforming sequence  
5.00E-05 0.02 
6 ENSRNOG00000004768 Myf5 myogenic factor 5  5.00E-05 0.02 
7 ENSRNOG00000006146 Trim54 tripartite motif-containing 54  5.00E-05 0.02 
8 ENSRNOG00000006776 Smyd1 
SET and MYND domain 
containing 1 
5.00E-05 0.02 
9 ENSRNOG00000007059 Atp1b4 
ATPase Na+/K+ transporting 
family member beta 4  
5.00E-05 0.02 
10 ENSRNOG00000007229 Nr0b2 
nuclear receptor subfamily 0, 
group B, member 2  
5.00E-05 0.02 
11 ENSRNOG00000008050 Stac3 
SH3 and cysteine rich domain 
3  
5.00E-05 0.02 
12 ENSRNOG00000008176 Nppa natriuretic peptide A 5.00E-05 0.02 
13 ENSRNOG00000008210 Ky kyphoscoliosis peptidase  5.00E-05 0.02 
14 ENSRNOG00000008310 Mpo myeloperoxidase  5.00E-05 0.02 
15 ENSRNOG00000010478 LOC500712 Ab1-233  5.00E-05 0.02 
16 ENSRNOG00000013552 Scd stearoyl-CoA desaturase  5.00E-05 0.02 
17 ENSRNOG00000015155 Tnnc2 troponin C2, fast skeletal type  5.00E-05 0.02 
18 ENSRNOG00000015279 Vtcn1 
V-set domain containing T cell 
activation inhibitor 1 
5.00E-05 0.02 
19 ENSRNOG00000019390 Klhl40 kelch-like family member 40  5.00E-05 0.02 
20 ENSRNOG00000019404 Hhatl hedgehog acyltransferase-like  5.00E-05 0.02 
21 ENSRNOG00000020332 Tnnt3 troponin T3, fast skeletal type  5.00E-05 0.02 




23 ENSRNOG00000031331 Fpr3 formyl peptide receptor 3 5.00E-05 0.02 
24 ENSRNOG00000032461 Bin2a beta-galactosidase-like protein  5.00E-05 0.02 
25 ENSRNOG00000033529 Amy1a amylase, alpha 1A  5.00E-05 0.02 
26 ENSRNOG00000037645 Tceal7 
transcription elongation factor 
A like 7  
5.00E-05 0.02 
27 ENSRNOG00000042445 AC130970.1   5.00E-05 0.02 
28 ENSRNOG00000049695 Myh2 myosin heavy chain 2  5.00E-05 0.02 
29 ENSRNOG00000049942 RGD1564899 
similar to chromosome 10 
open reading frame 71  
5.00E-05 0.02 
These data were obtained by CuffDiff package.   
Functional annotating clustering for those genes on David’s Bioinformatics Resources 
6.8 returned GOs that were mainly related to the muscle differentiation or function such as 
“skeletal muscle contraction” (GO:0003009, p=8.28x10-4), “regulation of muscle 
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contraction” (GO:0006937, p=0.03), “positive regulation of myoblast differentiation” 
(GO:0045663, 0.04), “skeletal muscle fibre development” (GO:0048741, p=0.04), “troponin 
complex” (GO:0005861, p=0.01), and “extracellular space” (GO:0005615, p=0.03). No KEGG 
pathways were significantly enriched but the top to pathways was “Carbohydrate digestion 
and absorption” with a p-value of 5.2x10-2, and “cardiac muscle contraction” with a p-value 
of 9.6x10-2.   
Aorta Differentially expressed ion channel Genes 
The primary aim was the discovery of differentially expressed ion channels. 
Therefore, gene lists were filtered for ion channels grepping the word “channel” in the official 
Ensemble gene name excluding “intracellular”, “tetramerization domain”, and “interacting 
protein”. This returned 248 channel genes. Of these 7 were considered differentially 
expressed (pval<0.05) (Table 18).  
Table 18: Differentially expressed channel genes in the aorta.  
No.  Ensemble IDs SYMBOL p-val FDR 
1 ENSRNOG00000004518 Cacnb1 0.00085 0.238354 
2 ENSRNOG00000009797 Aqp3 0.0141 0.999086 
3 ENSRNOG00000019750 Kcna1 0.0201 0.999086 
4 ENSRNOG00000009686 Aqp7 0.0203 0.999086 
5 ENSRNOG00000000805 Gja1 0.02855 0.999086 
6 ENSRNOG00000013463 Kcnj8 0.0326 0.999086 
7 ENSRNOG00000021128 Kcnj11 0.04445 0.999086 
Data obtained by CuffDiff package. 
Aorta Multivariate analysis of Genes 
To investigate whether there were changes in clusters of genes rather than individual 
genes, DA-PCA was used.  Little population difference was detectable until 4 PCA were used 
( 
Figure 22-A and -B), and so the rest of this section models expression changes with 4 
principle components. Given That there are only two groups (young and old), there is only 
one discriminant function (LD1).  
145 
 
DA-PCA (4 PCs) discriminated the young and old gene populations well (Figure 23-A).  
The heatmap (Figure 23-B) shows that the 3 control and 2 groups are successfully separated. 
The mean posterior p-value for the null hypothesis (the groups are undesignable) was 
statistically significant.  
Next, loading values were drawn-out for the discriminant function, which quantifies 
the relative contribution of all genes to the differences in young and old gene populations. 
Filteration of all genes took place to return just the top 50 genes and the top 15 of them are 
displayed in (Figure 23-C).  These data show that of all the genes detected in our aorta 
experiments; the genes contributing most powerfully to the multivariate population 
difference are shown in Table 19. 
Table 19: The most contributing genes to the differences between young and old in aorta samples.  
Gene stable ID Gene name Gene description 
ENSRNOG00000019778 Cavin1 caveolae associated protein 1  
ENSRNOG00000002419 Plp1 proteolipid protein 1  
ENSRNOG00000003338 Pmp22 peripheral myelin protein 22  
ENSRNOG00000029886 Hba-a2 hemoglobin alpha, adult chain 2  
ENSRNOG00000012840 Sparc secreted protein acidic and cysteine-rich  
ENSRNOG00000003171 Mpz myelin protein zero 
ENSRNOG00000009439 Eef1a1 eukaryotic translation elongation factor 1 alpha 1  
ENSRNOG00000014070 Krt13 keratin 13 
ENSRNOG00000003897 Col1a1 collagen type I alpha 1 chain  
ENSRNOG00000016945 Pla2g2a phospholipase A2 group IIA  
ENSRNOG00000016516 Mbp myelin basic protein  
ENSRNOG00000006604 Thy1 Thy-1 cell surface antigen  
ENSRNOG00000018795 Rpl18a ribosomal protein L18A  
ENSRNOG00000019556 Cd9 CD9 molecule  
ENSRNOG00000057569 Ahnak AHNAK nucleoprotein  
 
Aorta Multivariate analysis of Ion channels 
To investigate the population-wide differences in ion channels, the DA-PCA with ion 
channels was repeated filtering gene lists for the word “channel” in the official gene 
description. Primarily, the separation between the young and old (Figure 24-A, and B) was 
not good until 5 principal components were used that showed good discrimination (Figure 
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25A) with only one discriminant function. Just as with the gene-wide analysis heatmap (Figure 
25-B) shows successful separation based on just ion channel expression.  
The ion channel loadings of LD1 are shown in Figure 25-C (filtered for the top 50 ion 
channels) and the top 15 ion channel genes are shown in this figure. These data show that of 
all the 261 ion channel genes detected in our aorta experiments the genes contributing most 
to the multivariate ion channel population difference are shown in Table 20.  
Table 20: Top 15 channel genes contributing to the differences between young and old Aorta.  
Gene ID Gene name Gene description 
ENSRNOG00000029342 Scn7a sodium voltage-gated channel alpha subunit 7  
ENSRNOG00000006375 Vdac1 voltage-dependent anion channel 1  
ENSRNOG00000006639 Scn9a sodium voltage-gated channel alpha subunit 9 
ENSRNOG00000000728 Clic2 chloride intracellular channel 2  
ENSRNOG00000019750 Kcna1 potassium voltage-gated channel subfamily A member 1  
ENSRNOG00000056697 Kcnab1 
potassium voltage-gated channel subfamily A member 
regulatory beta subunit 1  
ENSRNOG00000013463 Kcnj8 potassium voltage-gated channel subfamily J member 8  
ENSRNOG00000019277 Vdac3 voltage-dependent anion channel 3  
ENSRNOG00000057221 Scn3b sodium voltage-gated channel beta subunit 3 
ENSRNOG00000013505 Vdac2 voltage-dependent anion channel 2 
ENSRNOG00000033531 Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1  
ENSRNOG00000046231 Cacna1s calcium voltage-gated channel subunit alpha1 S  
ENSRNOG00000018285 Kcna2 potassium voltage-gated channel subfamily A member 2 
ENSRNOG00000015184 Clic3 chloride intracellular channel 3 














Figure 22: Discriminant Analyses of ageing Effects on Aorta (all genes) - poor discrimination. 
A. Shows the kernel density plots of the discriminant component coordinates for the young and old aorta groups; co-ordinates on the x-axis and density on the y-axis; Individual co-
ordinate centre points are illustrated by the vertical line and circle.  There is poor discrimination between young and old aorta samples with less than 4 PCs. B. A graphical confusion 
matrix showing the actual group membership (x-axis) and predicted cluster membership (on the y-axis).  Groups were not correctly clustered with probabilities ranging from 0.02 






Figure 23: Discriminant Analyses of ageing Effects on Aorta (all genes) - good discrimination. 
A. Shows the kernel density plots of the discriminant component coordinates for the young and old aorta groups; co-ordinates on the x-axis and density on the y-axis; Individual co-
ordinate centre points are illustrated by the vertical line and circle. There is clear discrimination between young and old aorta samples with 4 PCs and a probability of belonging of 
1. B. A graphical confusion matrix showing the actual group membership (y-axis) and predicted cluster membership (on the y-axis).  Groups were correctly clustered with probability 
1. C. The contributors to the linear discriminator function in aorta samples (young and old); Cavin1; caveolae associated protein 1, Plp1; proteolipid protein 1, Pmp22; peripheral 
myelin protein 22, Hba-a2; haemoglobin alpha, adult chain 2, Sparc; secreted protein acidic and cysteine-rich, Mpz; myelin protein zero, Eef1a1; eukaryotic translation elongation 
factor 1 alpha 1, Krt13; keratin 13, Col1a1; collagen type I alpha 1 chain, Pla2g2a; phospholipase A2 group IIA, Mbp; myelin basic protein, Thy1; Thy-1 cell surface antigen, Rpl18a; 






Figure 24:Discriminant Analyses of ageing Effects on Aorta (channel genes) - poor discrimination.  
A. Shows the kernel density plots of the discriminant component coordinates for the young and old channel groups; co-ordinates on the x-axis and density on the y-axis; Individual 
co-ordinate centre points are illustrated by the vertical line and circle.  There is poor discrimination between young and old aorta samples with less than 5 PCs. B. A graphical 









Figure 25:Discriminant Analyses of ageing Effects on Aorta (channel genes) - good discrimination. 
A. Shows the kernel density plots of the discriminant component coordinates for the young and old aorta channel groups; co-ordinates on the x-axis and density on the y-axis; 
Individual co-ordinate centre points are illustrated by the vertical line and circle.  There is clear discrimination between young and old aorta samples with 5 PCs. B. A graphical 
confusion matrix showing the actual group membership (y-axis) and predicted cluster membership (on the y-axis).  Groups were correctly clustered with a probability of 1. C. Ion 
channel contributors to the linear discriminator function; Scn7a; sodium voltage-gated channel alpha subunit 7, Vdac1; voltage-dependent anion channel 1, Scn9a; sodium voltage-
gated channel alpha subunit 9, Clic2; chloride intracellular channel 2, Kcna1; potassium voltage-gated channel subfamily A member 1, Kcnab1; potassium voltage-gated channel 
subfamily A member regulatory beta subunit 1, Kcnj8; potassium voltage-gated channel subfamily J member 8, Vdac3; voltage-dependent anion channel 3, Scn3b; sodium voltage-
gated channel beta subunit 3, Vdac2; voltage-dependent anion channel 2, Cacna2d1; calcium voltage-gated channel auxiliary subunit alpha2delta 1, Cacna1s; calcium voltage-
gated channel subunit alpha1 S, Kcna2; potassium voltage-gated channel subfamily A member 2, Clic3; chloride intracellular channel 3, and Clns1a; chloride nucleotide-sensitive 
channel 1A.  
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Transcriptomic changes in cytokine treated vascular smooth muscle cell (VSMC)  
The ageing model is true ageing because rats were at the age of 24+ months (the equivalent of 
60+ years of human life) at the time of experiments, but there are a number of limitations with that model 
(see discussion), so similar analysis to the above with VSMC in culture and cytokine treatment was 
performed. One strength of this culture model is the ability to do electrophysiology.  
VSMC Differentially expressed Genes 
This section of work was started by growing VSMC in vitro to be control and treated with 10ng/ml 
TNFα+IL-1β cytokines for 72hrs. Then, RNA was extracted as described in the method (section RNA 
extraction) and did next-generation sequencing of these VSMC. NGS detected approximately 22038 genes 
per group. Differential expression testing of all genes identified 115 genes with a p-value for differential 
<0.05 and 115 genes with Benjamini Hochberg corrected gene expression FDR <0.05 (Table 21). 
Table 21: Differentially expressed genes in VSMC tissue.  
Rank Ensemble Gene ID Log2 p-value q-value Symbol 
1 ENSRNOG00000000805 -1.37492 0.00005 0.0016 Gja1 
2 ENSRNOG00000001229 -1.31925 0.00005 0.0016 Col18a1 
3 ENSRNOG00000001627 2.5513 0.00005 0.0016 Abi3bp 
4 ENSRNOG00000001633 2.54698 0.00005 0.0016 Tfg 
5 ENSRNOG00000002525 -3.61343 0.00005 0.0016 Ptgs2 
6 ENSRNOG00000003809 -1.7908 0.00005 0.0016 Sat1 
7 ENSRNOG00000004210 -1.63214 0.00005 0.0016 Osr1 
8 ENSRNOG00000004532 1.28379 0.00005 0.0016 Dipk1b 
9 ENSRNOG00000006302 -1.47753 0.00005 0.0016 Gclc 
10 ENSRNOG00000006623 1.83443 0.00005 0.0016 Cd302 
11 ENSRNOG00000007726 -2.14197 0.00005 0.0016 Mcam 
12 ENSRNOG00000008012 2.80961 0.00005 0.0016 Abcb1b 
13 ENSRNOG00000009094 2.03807 0.00005 0.0016 Nudt4 
14 ENSRNOG00000009779 -2.74207 0.00005 0.0016 Krt8 
15 ENSRNOG00000011644 2.4425 0.00005 0.0016 Slc1a7 
16 ENSRNOG00000011718 2.50895 0.00005 0.0016 C1rl 
17 ENSRNOG00000011796 1.97599 0.00005 0.0016 C1r 
18 ENSRNOG00000011971 3.37302 0.00005 0.0016 C1s 
19 ENSRNOG00000012868 -1.50957 0.00005 0.0016 Uaca 
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20 ENSRNOG00000013442 1.49046 0.00005 0.0016 Ciz1 
21 ENSRNOG00000013589 3.05591 0.00005 0.0016 Cxcl12 
22 ENSRNOG00000014333 2.56278 0.00005 0.0016 Vcam1 
23 ENSRNOG00000014532 4.36226 0.00005 0.0016 Lbp 
24 ENSRNOG00000016156 -2.49298 0.00005 0.0016 Nptxr 
25 ENSRNOG00000017420 -2.04281 0.00005 0.0016 Nudt6 
26 ENSRNOG00000019048 3.8891 0.00005 0.0016 Sod2 
27 ENSRNOG00000019184 2.28964 0.00005 0.0016 Npr3 
28 ENSRNOG00000019422 -3.1011 0.00005 0.0016 Egr1 
29 ENSRNOG00000020679 1.47094 0.00005 0.0016 Icam1 
30 ENSRNOG00000021802 1.57144 0.00005 0.0016 Isg15 
31 ENSRNOG00000026053 -1.35774 0.00005 0.0016 Grem1 
32 ENSRNOG00000026951 -1.92488 0.00005 0.0016 Susd5 
33 ENSRNOG00000027124 1.96378 0.00005 0.0016 Tdg 
34 ENSRNOG00000028892 1.5264 0.00005 0.0016 Prr36 
35 ENSRNOG00000031406 3.42862 0.00005 0.0016 Hps3 
36 ENSRNOG00000032018 1.63193 0.00005 0.0016 Tmem200b 
37 ENSRNOG00000032297 -2.14566 0.00005 0.0016 Msmo1 
38 ENSRNOG00000039668 -1.25645 0.00005 0.0016 Col8a1 
39 ENSRNOG00000049402 1.65937 0.00005 0.0016 Nbl1 
40 ENSRNOG00000049560 1.40386 0.00005 0.0016 Glul 
41 ENSRNOG00000049900 -2.07275 0.00005 0.0016 Irf2bp2 
42 ENSRNOG00000058068 2.54099 0.00005 0.0016 Obscn 
43 ENSRNOG00000001979 -2.01077 0.0001 0.002904 Rcan1 
44 ENSRNOG00000016870 1.22926 0.0001 0.002904 Pcif1 
45 ENSRNOG00000030118 -1.32044 0.0001 0.002904 Msn 
46 ENSRNOG00000033192 1.96112 0.0001 0.002904 Osmr 
47 ENSRNOG00000059013 1.37127 0.0001 0.002904 <NA> 
48 ENSRNOG00000008529 2.15631 0.00015 0.00392 Foxs1 
49 ENSRNOG00000016326 1.73196 0.00015 0.00392 Cx3cl1 
50 ENSRNOG00000017765 1.26319 0.00015 0.00392 Net1 
51 ENSRNOG00000018748 1.70836 0.00015 0.00392 Slc16a11 
52 ENSRNOG00000056819 1.24722 0.00015 0.00392 Susd1 
53 ENSRNOG00000000748 -2.35907 0.0002 0.0049 <NA> 
54 ENSRNOG00000002403 -1.25204 0.0002 0.0049 Fam129a 
55 ENSRNOG00000005924 -1.29616 0.0002 0.0049 Dstnl1 
56 ENSRNOG00000013963 1.33671 0.0002 0.0049 Il6st 
57 ENSRNOG00000010103 1.08204 0.00025 0.005939 Eif4b 
58 ENSRNOG00000014453 -1.13249 0.00025 0.005939 Anxa5 
59 ENSRNOG00000002615 1.26214 0.0003 0.006918 Pmm2 
60 ENSRNOG00000010797 -2.83425 0.0003 0.006918 Esm1 
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61 ENSRNOG00000000488 -2.67647 0.00035 0.00784 Hmga1 
62 ENSRNOG00000014320 -1.28019 0.00035 0.00784 Inhba 
63 ENSRNOG00000011648 -1.1141 0.00045 0.0098 Aqp1 
64 ENSRNOG00000027736 -1.29691 0.00045 0.0098 Cnn1 
65 ENSRNOG00000033862 2.33425 0.0005 0.010595 Olr836 
66 ENSRNOG00000048706 -1.26356 0.0005 0.010595 Nox1 
67 ENSRNOG00000002052 1.39993 0.00055 0.011056 Ccdc80 
68 ENSRNOG00000007329 -1.22224 0.00055 0.011056 Frmd6 
69 ENSRNOG00000010017 1.26807 0.00055 0.011056 Wee1 
70 ENSRNOG00000014230 -1.083 0.00055 0.011056 Map1a 
71 ENSRNOG00000010170 -1.95337 0.0007 0.01372 Tubb4b 
72 ENSRNOG00000060130 1.1218 0.0007 0.01372 Ypel4 
73 ENSRNOG00000007799 1.3105 0.00075 0.014342 Fam151a 
74 ENSRNOG00000012956 4.01254 0.00075 0.014342 Tgm2 
75 ENSRNOG00000005678 -1.00306 0.0008 0.014758 Lamb1 
76 ENSRNOG00000015239 1.19588 0.0008 0.014758 Ginm1 
77 ENSRNOG00000016695 1.02315 0.0008 0.014758 Mmp2 
78 ENSRNOG00000020865 -1.2131 0.00085 0.015498 Ano1 
79 ENSRNOG00000021752 -1.19469 0.00095 0.016927 Foxq1 
80 ENSRNOG00000015514 -1.14488 0.00095 0.016927 Bcat1 
81 ENSRNOG00000014964 2.97864 0.001 0.017422 Hp 
82 ENSRNOG00000019162 1.05849 0.001 0.017422 Emc9 
83 ENSRNOG00000004912 -1.14024 0.00105 0.018092 Itgav 
84 ENSRNOG00000011913 2.4218 0.0012 0.020452 Cp 
85 ENSRNOG00000014128 1.11964 0.00125 0.020851 Ecsit 
86 ENSRNOG00000020599 1.27651 0.00125 0.020851 Tssk6 
87 ENSRNOG00000023226 -1.46104 0.00145 0.023933 S100a10 
88 ENSRNOG00000017166 1.1573 0.0015 0.0245 Mycbp 
89 ENSRNOG00000005533 1.0638 0.0016 0.0256 LOC686013 
90 ENSRNOG00000009274 1.01158 0.0016 0.0256 Fut11 
91 ENSRNOG00000016243 -1.15987 0.0017 0.026925 Casq2 
92 ENSRNOG00000002146 -0.93539 0.0019 0.029208 Pkd2 
93 ENSRNOG00000017852 -1.09098 0.0019 0.029208 Nars 
94 ENSRNOG00000033271 1.53996 0.0019 0.029208 <NA> 
95 ENSRNOG00000018237 -1.02427 0.002 0.030447 Gstp1 
96 ENSRNOG00000012270 1.07023 0.00205 0.030613 Med26 
97 ENSRNOG00000033110 1.03323 0.00205 0.030613 Svep1 
98 ENSRNOG00000052506 1.18051 0.0022 0.032543 Ak3 
99 ENSRNOG00000000466 1.80548 0.00235 0.034119 Hsd17b8 
100 ENSRNOG00000052498 0.928334 0.00235 0.034119 Grb14 
101 ENSRNOG00000024751 0.987036 0.00245 0.034924 H2afy2 
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102 ENSRNOG00000015904 -1.73194 0.00255 0.036022 Wfdc1 
103 ENSRNOG00000004577 -1.32427 0.0027 0.0378 Fez2 
104 ENSRNOG00000042446 1.01227 0.00275 0.038159 Ankrd63 
105 ENSRNOG00000003546 -3.02722 0.0028 0.038512 Tnfrsf12a 
106 ENSRNOG00000011413 1.06696 0.00295 0.040223 Scp2 
107 ENSRNOG00000020716 -0.99421 0.00305 0.040875 Axl 
108 ENSRNOG00000045649 1.32266 0.00305 0.040875 Arrdc3 
109 ENSRNOG00000008816 0.95582 0.0032 0.042522 Gpnmb 
110 ENSRNOG00000002835 0.949708 0.00335 0.044141 Luc7l3 
111 ENSRNOG00000014519 1.07198 0.0034 0.044427 Slc35g3 
112 ENSRNOG00000019892 -0.9202 0.00365 0.047299 Lrrfip1 
113 ENSRNOG00000016885 -1.24797 0.00375 0.048197 Klf6 
114 ENSRNOG00000013286 -1.10906 0.0038 0.048442 Pdcl3 
115 ENSRNOG00000030170 1.14501 0.0039 0.049316 Krt10 
Data obtained by CuffDiff package.  
Then, functional annotation clustering and enrichment analysis using David’s Bioinformatics 
Resources 6.8 were done. GOs enriched were “extracellular exosome” (GO:0070062, p=4.83x10-10), 
“angiogenesis” (GO:0001525, p=7.24x10-8), “extracellular space” (GO:0005615, p=1.18x10-6), “aging” 
(GO:0007568, p=0.002), and “signal transduction” (GO:0007165, p=0.02).  
KEGG pathways returned several statistically significant pathways with p-values of less than 0.05. 
these pathways are “NF-kappa B signaling pathway” (rno04064, p=0.0022), “TNF signaling pathway” 
(rno04668, p=0.03) and “Cytokine-cytokine receptor interaction” (rno04060, p= 0.034).  
VSMC Differentially expressed ion channel Genes 
Filtering gene lists for ion channels grepping the word “channel” in the official Ensemble gene 
description excluding “intracellular”, “tetramerization domain”, and “interacting protein”. Only 3 ion 






Table 22: Differentially expressed ion channel genes in VSMC.  
No. Ensemble Gene ID Log2 p-value q-value Symbol Description 
1 ENSRNOG00000000805 -1.37492 0.00005 0.0016 Gja1 Gap junction 





3 ENSRNOG00000002146 -0.93539 0.0019 0.029208 Pkd2 Polycystin 2 
This table was obtained by CuffDiff package.  
VSMC Multivariate analysis of Genes 
To investigate whether there were changes in clusters of genes rather than individual genes, DA-
PCA was used.  Little population difference was detectable until 4 PCs were used, and so the rest of this 
section models expression changes with 4 principle components.  Since there are only two groups (control 
and treated) there is only one discriminant function (LD1). 
The kernel density plot of DA-PCA shows that with (4 PCs) there is good discrimination of the 
control and treated gene populations (Figure 26-A). The heatmap (Figure 26-B) shows how well the 
category of sample is predicted for the two groups (control or cytokine treated). The predicted probability 
of belonging was successful with greater than 0.9.  
Next, loading values for the discriminant function, which quantifies the relative contribution of all 
genes to the differences in control and treated gene populations, were drawn-out. Then, out of all genes, 
only the top 50 genes were filtered out and of those the top 15 are displayed in (Figure 26-C).  These data 
show that of all the genes detected in our VSMC experiments the genes contributing most to the 





Table 23: The most contributing genes to the differences between control and cytokine treated VSMC samples. 
Ensemble IDs Gene name Gene description 
ENSRNOG00000047907 LOC100912585 mitogen-activated protein kinase 7-like  
ENSRNOG00000037894 <NA>  Unknown gene 
ENSRNOG00000014288 Fn1 fibronectin 1  
ENSRNOG00000012660 Postn periostin  
ENSRNOG00000020346 Best1 bestrophin 1  
ENSRNOG00000001469 Eln elastin  
ENSRNOG00000013987 Sbno2 strawberry notch homolog 2  
ENSRNOG00000046836 <NA>  Unknown gene 
ENSRNOG00000012579 Tlcd1 TLC domain containing 1  
ENSRNOG00000024779 Polr2b RNA polymerase II subunit B  
ENSRNOG00000000506 Tead3 TEA domain transcription factor 3 
ENSRNOG00000046313 Basp1 brain abundant, membrane attached signal protein 1  
ENSRNOG00000058068 
Obscn 
obscurin, cytoskeletal calmodulin and titin-interacting 
RhoGEF  
ENSRNOG00000012840 Sparc secreted protein acidic and cysteine-rich 
ENSRNOG00000016488 Pltp phospholipid transfer protein 
 
VSMC Multivariate analysis of Ion channels 
To investigate the population-wide differences in ion channels, the DA-PCA was repeated but with 
ion channels only. Again, 3 principal components were needed to see good discrimination and there is 
only one discriminant function. DA-PCA (3 PCs) discriminated the control and treated ion channel 
populations well (Figure 27-A). Just as with the gene-wide analysis, heatmap (Figure 27-B) shows a 
successful separation of the samples based on just ion channel expression.  
The ion channel loadings of LD1 were filtered for the top 50 ion channels and the top 15 ion 
channel genes are shown in (Figure 27-C). These data show that of all the ion channel genes detected in 
our VSMC experiments the genes contributing most to the multivariate ion channel population difference 




Table 24: The most contributing ion channel genes to the differences between control and cytokine treated VSMC samples.  
Ensemble IDs Gene name Gene description 
ENSRNOG00000002146 Pkd2 polycystin 2, transient receptor potential cation channel  
ENSRNOG00000025489 Pkd2l2 polycystin 2 like 2, transient receptor potential cation channel  
ENSRNOG00000014714 Trpv6 transient receptor potential cation channel, subfamily V, member 6 
ENSRNOG00000038784 Piezo2 piezo-type mechanosensitive ion channel component 2  
ENSRNOG00000010771 Pkd1 polycystin 1, transient receptor potential channel interacting  
ENSRNOG00000018109 Clic4 chloride intracellular channel 4  
ENSRNOG00000060528 Cacna1g calcium voltage-gated channel subunit alpha1 G  
ENSRNOG00000001270 Hvcn1 hydrogen voltage-gated channel 1 
ENSRNOG00000059765 Asic1 acid-sensing ion channel subunit 1  
ENSRNOG00000013505 Vdac2 voltage-dependent anion channel 2  
ENSRNOG00000015184 Clic3 chloride intracellular channel 3 
ENSRNOG00000005985 Kcnma1 potassium calcium-activated channel subfamily M alpha 1  
ENSRNOG00000019277 Vdac3 voltage-dependent anion channel 3  
ENSRNOG00000033531 Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1  







Figure 26: Discriminant Analyses of cytokine effects on VSMC samples (all genes).  
A. Shows the kernel density plots of the discriminant component coordinates for the control and treatment groups of VSMC; co-ordinates on the x-axis and density on the y-axis; 
Individual co-ordinate centre points are illustrated by the vertical line and circle.  There is clear discrimination between control and treated VSMC samples. B. A graphical confusion 
matrix showing the actual group membership (y-axis) and predicted cluster membership (on the y-axis).  Groups were correctly clustered with a probability of 1. C. Gene 
contributors to the linear discriminator function; LOC100912585; mitogen-activated protein kinase 7-like, AABR07068042.1, Fn1; fibronectin 1, Postn; periostin, Best1; bestrophin 
1, Eln; elastin, Sbno2; strawberry notch homolog 2, AC133403.1, Tlcd1; TLC domain containing 1, Polr2b; RNA polymerase II subunit B, Tead3; TEA domain transcription factor 3, 
Basp1; brain abundant, membrane attached signal protein 1, Obscn; obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF, Sparc; secreted protein acidic and cysteine-




Figure 27: Discriminant Analyses of cytokine effects on VSMC samples (channels genes).   
A. Shows the kernel density plots of the discriminant component coordinates for the channels of the control and treatment groups of VSMC; co-ordinates on the x-axis and density 
on the y-axis; Individual co-ordinate centre points are illustrated by the vertical line and circle.  There is clear discrimination between control and treated VSMC samples. B. A 
graphical confusion matrix showing the actual group membership (y-axis) and predicted cluster membership (on the y-axis).  Groups were correctly clustered with greater than 0.94  
probability. C. Gene contributors to the linear discriminator function; Pkd2; polycystin 2, transient receptor potential cation channel, Pkd2l2; polycystin 2 like 2, transient receptor 
potential cation channel, Trpv6; transient receptor potential cation channel, subfamily V, member 6, Piezo2; piezo-type mechanosensitive ion channel component 2, Pkd1; polycystin 
1, transient receptor potential channel interacting, Clic4; chloride intracellular channel 4, Cacna1g; calcium voltage-gated channel subunit alpha1 G, Hvcn1; hydrogen voltage-
gated channel 1, Asic1; acid-sensing ion channel subunit 1, Vdac2; voltage-dependent anion channel 2, Clic3; chloride intracellular channel 3, Kcnma1; potassium calcium-activated 
channel subfamily M alpha 1, Vdac3; voltage-dependent anion channel 3, Cacna2d1; calcium voltage-gated channel auxiliary subunit alpha2delta 1, and Kcnj9; potassium voltage-
gated channel subfamily J member 9. 
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Electrophysiological changes in cytokine treated vascular smooth muscle cells (VSMC) 
One of the advantages of the culture model is it makes cell electrophysiology more practical.  In 
terms of animals needed, for example, it reduces the number required immeasurably. The study of FLS 
was now repeated using VSMC to see if that ANO1 was differentially expressed and to investigate this by 
electrophysiology.  
Electrophysiological Characterization of VSMC in culture 
Patch-clamp electrophysiology was performed on isolated VSMC cells as published previously and 
described in the methods (section electrophysiology). Whole-cell currents were recorded in voltage-clamp 
mode patch-clamp with voltage steps applied from a holding potential of -80mV to a range of command 
potentials (Vc) from -120mV to +120mV. Figure 28-A shows an example representative record from a cell 
recorded under control conditions.  Figure 28-C shows the equivalent in a cytokine treated example.  Since 
CuffDiff suggested that there may be differences in expression of the ANO1 ion channel, the effect of 
calcium-activated chloride channel (CaCCinh-AO1) inhibitor on these currents in both control and cytokine 
treated conditions Figure 29-A and Figure 29-C, respectively, was tested. 
To get a broad overview of whole-cell properties, the first features analyzed were the slope of the 
positive phase of the current-voltage curves and reversal potential of this component.  Note that this is 
not a true equilibrium potential but does give an indication of the ion permeabilities contributing to this 
current-voltage curve.  Since there are several groups (control, cytokine treated, control with inhibitor 
and cytokine (10 ng/ml IL-1β+TNFα) treated with inhibitor), a clustering analysis to detect trends in the 
ion channel behaviours (Figure 30 (A-E)) took place.  A plot of Vrev against slope conductance was created 
for the rising current phase against each other and then followed by analysis with a k-means clustering 
script based on Scikit-Learn written in Python 3 by RBJ.  The first task with clustering analysis is to 
determine the optimal number of clusters.  This can be done with silhouette analysis.  Silhouette analyses 
(Figure 30-F) shows the optimal numbers of clusters to be 2.  There is clearly no separation of control and 
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cytokine treated data. Most data points in the presence of inhibitor CaCCinh-AO1 cluster into cluster 1 
(Figure 31), but most data in the absence of inhibitor fall into cluster 2.  To test if this is a significant 
association, a Fisher Exact test was used.  This returned an odds ratio of 4.9 (inhibitor data 4.9x as likely 
to be clustered together in cluster 1 than in cluster 2), however, this association was not statistically 
significant (p=0.09) and may, therefore, be a chance occurrence.  The mean slope conductance in full 
control conditions (no cytokine and no drug) was 536.5±281.3 pS/pF and not significantly different 
following cytokine treatment 293.2±86.4pS/pF (Figure 32-A and -B). There was also no significant 
difference in the Vrev calculated parameter (control; -21.9±26.4mV vs cytokine; 16.3±12.6mV, n=27,26). 
Following treatment with the 1 µM ion channel inhibitor CaCCinh-AO1, slope conductance was smaller, 
but not significantly so (164.2±36.5pS/pF). In the presence of cytokine treatment slope conductance was 
very similar (160.0±39.3pS/pF), but not significant to the equivalent value (above) under control 
conditions.  There was, however, a significant rightward shift of Vrev in the presence of the channel 
inhibitor (-7.1±5mV, p<0.05, n=25,26) and this effect was lost following cytokine treatment of the cells (-
20±2.2mV, p>0.05, n=26,18). 
Current-voltage (I-V) curves of VSMC 
As seen in Figure 28 (B and D) and Figure 29 (B and D), VSMC exhibited different phases of 
currents. These are sustained and peak currents. Both phases were analyzed. In the absence of the 
CaCCinh-AO1, there was a difference between control and cytokine (10 ng/ml IL-1β+TNFα) treated VSMC. 
In fact, there was a shift to the left of the I-V curve with sustained current and shift to the right with peak 
current after cytokine treatment. In the presence of the 1 µM of CaCCinh-AO1, there was a clear shift to 
the left of the cytokine treated VSMC after -70mV command potential in the sustained current while there 
were barely any changes with the peak current. The amplitude of the sustained currents in both control 
and cytokine treated VSMC was increased in the presence of the CaCCinh-AO1 but decreased in both with 




Figure 28: Whole-cell voltage-gated currents from control and cytokine (10ng/ml IL-1β+TNFα) treated VSMC.   
A. Top panels show the voltage step protocols and the evoked currents are shown below for control VSMC. Note that VSMC exhibit both sustained and peak currents. These phases 
were then analyzed separately as indicated. B. The current-voltage curve of the sustained current of control and cytokine treated VSMC. C. Top panels show the voltage step 




Figure 29: Whole-cell voltage-gated currents from control and cytokine (10ng/ml IL-1β+TNFα) treated VSMC in the presence of CaCCinh-AO1. 
A. Top panels show the voltage step protocols and the evoked currents are shown below for control VSMC plus CaCCinh-AO1. B. The current-voltage curve of the sustained current 
of control and cytokine treated VSMC in the presence of CaCCinh-AO1. C. Top panels show the voltage step protocols and the evoked currents are shown below for cytokine treated 





Figure 30: Clustering of electrophysiology data (conductance vs reversal potential) of VSMC.   
To look for clusters of cell electrophysiology phenotype, we plot conductance (x-axis) vs Vrev (y-axis) (scaled) of control and cytokines treated (± CaCCinh-AO1), A-E. Then, the 
script calculates the silhouette graph score (A-E). After that, a Chi-square test is used for the association. The best cluster is presented by the red circle in the silhouette graph (F). 
Silhouette analysis is a method to study the separation distance between clusters. The Silhouette value measures how similar an object is to its own cluster compared to other 
clusters. Clustered data is fit to K means algorithms and then each observed value is clustered with the nearest k mean. The silhouette ranges from -1 to +1. A high value (coefficient) 
indicates that the object is well matched to its own cluster and poorly matched to the neighbouring clusters. When most objects have high values, then the clustering configuration 
is appropriate. On the other hand, if many objects have low or negative values, then the clustering configuration may have too many or wrongly clustered. In this study, the 
silhouette analysis is used to choose an optimal value for n clusters. For the data in this project, the silhouette plot shows that the n cluster value of 4, 5 and 6 are bad choices due 
to the presence of clusters with below-average silhouette scores and also due to wide fluctuations in the size of the silhouette plots. The thickness of the silhouette plot reflects 
the size of the cluster. Silhouette analysis shows that the best options are between 2 and 3 clusters. However, (F) shows a high silhouette score (coefficient) for 2 clusters than 3 
clusters. Therefore, the optimum clustering is 2 clusters. More details are found in the text. From A-E, on the left side shown is the silhouette plot for the various clusters while on 






Figure 31: PCA of k means of conductance and Vrev in all VSMC samples of the optimum 2 clusters. 
This graph shows the optimum clustering of control and cytokine (10ng/ml IL-1β+TNFα) treated ± CaCCinh-AO1. This is a coloured visualization of the clustered data of the optimum 
2 clusters from the previous figure (A) of data from all VSMC samples. The combination of PCA and k means is a way of analysing huge amounts of data. The main steps here are 
to reduce dimensionality, cluster and visualize data. Therefore, features are taken and projected onto a lower-dimensional space to find the optimal number of components that 
capture the greatest amount of variance in the data. This step reduces data down to just a few important principal components. Then, cluster data. In this step, the important 
principal components identified from the first step are fit to the k means algorithms to determine the best number of clusters. The last step is to visualize these data. More details 
are found in the text. K means of scaled slope conductance is shown on the x-axis while the k means scaled reversal potential (Vrev) are shown on the y-axis. This analysis was 








Figure 32: Representation of a broad view of electrophysiological data of VSMC. 
A. Slope conductance (pA/pF) of VSMC samples; control and cytokine (10ng/ml, IL-1β+TNFα, 72hrs) treated VSMC ± CaCCinh-AO1. In the absence of CaCCinh-AO1 (drug), slope 
conductance of control was 536.5±281.3 pS/pF and following cytokines treatment the slope conductance decreased to 293.2±86.4 pS/pF but was not statistically significant. In the 
presence of CaCCinh-AO1 (drug), the slope conductance of control was 164.2±36.5 pS/pF and with cytokines treatment was 160.0±39.3 pS/pF and not statistically significant. B. 
Reversal potential (Vrev in mV) of the same samples ± CaCCinh-AO1. In the absence of CaCCinh-AO1 (drug), the Vrev of control was 21.9 ±26.4 mV and following cytokines treatment 
was 16.3±12.6 mV but not statistically significant. A significant rightward shift of the Vrev was observed in the presence of CaCCinh-AO1 (drug) with the control (-7.1±5 mV, p<0.05, 




Comparison of Boltzmann parameters in control and cytokine treated VSMC 
Since the earlier work with FLS showed changes in potassium conductances, the Boltzmann 
transformation of current-voltage curves took place and followed by a comparison of these in control and 
cytokine conditions. There were no significant differences. Gmax: Control 59.5±2.4 pS/pF vs cytokine 
treated 74.9±6.0 pS/pF. Midpoints: Control 52.9±1.7mV vs treated 63.5±2.2mV. Slopes: Control 26.1±0.4 
mV vs treated 25.5±0.4mV.  n=25,17 control vs cytokine treated. P>0.05 for all parameters. 
Analysis of Inward rectified-type currents 
A number of potassium channels, namely from the KCNJ family (such as KCNJ8 and KCNJ11 were 
differentially expressed) exhibit inwardly rectifying currents. That is, currents that are more negative, at 
negative potentials than would be expected from Ohms law.  The presence of these currents in some 
traces (data not shown) was observed and therefore examined if the presence of these was increased by 
cytokine.  Inward rectification was calculated by subtracting the y=mx+c predicted current at -120mV from 
the actual current at -120mV.  Y=mx+c was calculated in excel from the data in the straight-line portion of 
the current-voltage curve at -50 to -10mV.  The inwardly rectifying current so defined in control conditions 
was 33.5±32pA/pF, n=27 and 69.5±33.5pA/pF, n=24 after cytokine treatment (not significantly different). 
These data included many cells that had no inward rectifier current at all (ie., current at -120mV was 
positive to that predicted from a straight-line as expected for the presence of a dominant voltage-gated, 
for example, potassium current). To control for this, I analyzed just those cells for which there was a 
negative inwardly rectifying current. With this caveat, there was a significant reduction in (negative) 





4.5 Discussion  
Changes with gene expression in aorta tissues 
In this study, the expression of both the channelome and the whole transcriptomic profile of Aorta 
and VSMC was tested. Also, a functional analysis of the VSMC channels using patch-clamp 
electrophysiology in the whole-cell configuration was performed. The ageing model itself provides a closer 
view of the changes that take place in gene expression but lacks pathway-specific details as the input to 
such changes is limitless due to the presence of different cell populations. On the other hand, the cultured 
VSMC offers a unique feature in which patch-clamp electrophysiology experiments can be conducted. It 
also provides inflammation specific pathways on only VSMC that could not be controlled with real aged 
tissues.  
Aorta tissues showed some differentially expressed genes such as Alb, Trim54, Mpo, LOC500712, 
Scd, Tnnc2, Tnnt3, and Myh2. These genes are mainly involved in the regulation of albumin, binding and 
stabilizing microtubules, myeloperoxidase, localization to the ECM, biosynthesis of membrane lipids TG 
and energy homeostasis, cardiac proteins for regulation of muscle growth, muscle fibres and contraction, 
and proteins responsible for the generation of mechanical force. Such changes may lead to overactivation 
of muscle growth and muscle fibres leading to cardiac or cardiovascular disorders. One example of such 
diseases is atherosclerosis. Many factors play roles in the development of this disease. Among these 
factors is the switch in the VSMC phenotype from contractile to synthetic or even to less differentiated 
forms of VSMC ((Bennett et al., 2016, Rudijanto, 2007).  Different physiological conditions including injury 
can be involved in this event. Not only this but also other factors such as increased lipid biosynthesis and 
recruitment of macrophages increased levels of cytokines and growth factors can induce this phenotypic 
switch (Bennett et al., 2016, Rudijanto, 2007). Some genes such as those mentioned above (Macdonald 
et al., 2009) were detected in the aorta tissue in this project.  
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Additionally, functional annotating clustering for these differentially expressed genes took place 
using David’s Bioinformatics Resources 6.8. which enriched extracellular space “p-value of 2.9x10-2. The 
KEGG pathways that were enriched by these genes were “Carbohydrate digestion and absorption” with a 
p-value of 5.2x10-2, “bile secretion” with a p-value of 8.8x10-2, and “cardiac muscle contraction” with a p-
value of 9.6x10-2. It is interesting to find out that one of these pathways was related to cardiac muscle 
contraction although statistically not significant.  
Ion channel genes in the aorta  
Also, there were some differentially expressed ion channel genes such as calcium channels 
(Cacnb1), aquaporin channels (Aqp3 and Aqp7), potassium channels (kcna1, kcnj8 and kcnj11), gap 
junction channel (Gja1), and sodium channel (Scn1b).   
These differentially expressed ion channel genes in ageing aorta seem to be responsible for 
several cellular/tissue functions including their responsibilities for the presence of the pore-forming 
subunits of the active channels [such as Cancb1 (Williams et al., 1992, Brust et al., 1993, Cohen et al., 
2005), and Scn1b (Makita et al., 1994, Qin et al., 2003)], the flow of K+ ions into the cell 
(hyperpolarization/repolarization) [such as Kcna1 and kcnj11 (Babenko et al., 1998)], muscle contraction 
and relaxation [such as kcnj8 that may play role in vasodilation (relaxation) (Kane et al., 2006)], providing 
energy to the cell during starvation [such as Aqp7 (Agre, 2006)], facilitating water transport [such as Aqp3 
(Sasaki et al., 1998, Agre, 2006)] and cell-to-cell communications [such as Gja1 (Cx43) (Rama et al., 2006)]. 
These should enhance the functions of the cells and the overall health of the tissue and the 
microenvironment. However, the expression of genes responsible for such functions can be inferred as 
there is (could be strong) need for them due to loss with ageing.  
Changes with gene expression in VSMC  
It was not surprising to find out that the enriched KEGG pathways were “NF-kB signalling 
pathway” with a p-value of 0.0022, “Leukocyte endothelial migration” with a p-value of 0.0058, “TNF 
170 
 
signalling pathway” with a p-value of 0.03 and “Cytokine-cytokine receptor interaction” with a p-value of 
0.034 because TNFα (along with IL-1β) was one of the cytokines used in this study to create an 
inflammatory model of ageing “inflammageing”,  TNFα interacts with its membrane receptor and can 
transduce signalling through NF-kB signalling pathway.  
Ion channels in VSMC 
Only three channel genes were differentially expressed in the VSMC after cytokine (10ng/ml IL-
1β+TNFα, 72hrs) treatment. These genes are Gap junction (Gja1), Calcium-activated chloride channel 
(ANO1), and Polycystin 2 (Pkd2).  
Gja1 (Cx43) is an important gene in cell-to-cell communications and it plays a role in VSMC 
differentiation (Rama et al., 2006). ANO1 has a significant role in controlling smooth muscle contraction 
(Jensen et al., 2018). Based on the functional significance, it was speculated that the localization of the 
Pkd2 is in ER of VSMC and it has been suggested that Pkd2 mutation plays a pathogenic role in the 
complication of the autosomal-dominant polycystic kidney disease (ADPKD) (Torres et al., 2001).  
 
Differences and similarities between Aorta and VSMC 
Although, there were some differentially expressed (both p-value and FDR<0.05) genes; 29 genes 
and 7 channel genes in the aged aorta, they were not like the VSMC which had 115 differentially expressed 
genes and only 3 channel genes. Also, genes contributed to the differences between the young and old 
aorta and those between control and cytokine treated VSMC were also different.  
The similarities appeared in terms of enriched GOs and individual genes. As mentioned above, 
aorta GOs showed terms that were mostly related to the muscle contraction/regulation in addition to 
extracellular space, VSMC GOs were related to signal transduction and angiogenesis. They both shared 
some extracellular enrichment GOs. For example, extracellular space enriched GO appeared in both in 
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addition to extracellular exosome and ageing in VSMC. This shows that our model of “inflammageing” was 
once again able to show some similarities with the real ageing model (old rats).  
For individual genes, Gap junction (Gja1) gene was found to be differentially expressed with p-
values of 0.02855 and 0.00005 in aorta and VSMC, respectively. Gja1 plays a role in cell to cell 
communication. With ageing aorta, it seems that the function of this gene is altered which triggered its 
expression to compensate for the decrease. In VSMC, cells were challenged with cytokine for 72hrs to 
create the inflammatory model of ageing “inflammageing”. This may also have triggered its expression, 
especially that in the culture system the cells were left to be confluent of 70-80% which allowed the 
formation of a monolayer of cells, unlike aorta tissue that is multi-layers.  
Previous studies on Anoctamin-1 (ANO1, also known as Ca2+ activated Chloride channel) 
expression   
Expression of TMEM16A is variable in different tissues as follows; portal vein > thoracic aorta > 
carotid artery > brain and it was found to be robustly expressed in murine vascular smooth muscle cells 
(Davis et al., 2010). ANO1; also known as TMEM16A is essential for Ca2+ activated chloride channel 
conductance in VSM (Jensen et al., 2018). Several studies have been conducted to inhibit this channel. For 
example,  TMEM16A inhibitor called T16A(inh) -A01 was used in a study and found that it inhibited the 
Ca2+ activated chloride channel current in aorta relaxed murine and human blood vessels (Davis et al., 
2013). Also, ANO1 gene was knocked out and the gene was floxed to eliminate the Ca2+ activated chloride 
channel current and confirmed by comparison of this knocked out mice with WT using patch-clamp 
electrophysiology. The blood pressure of the knocked out mice in this study was reduced compared to 
the WT (Heinze et al., 2014). siRNA against TMEM16A was also tested to eliminate the currents from this 
channel in mice (defined as transgenic mice (TG) in this study). There was no difference in blood pressure 
and heart rate in TG compared to WT. However, it was suggested that ANO1 modulates the arterial 
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contractility; at least in part, indirectly by the control of CACNA1C (vascular L-type Ca2+ channel) 
expression (Jensen et al., 2018).  
In this study, a down-regulation (log2 F.C. = -1.2131, p-value=0.00085) of the ANO1 expression 
after cytokine (10ng/ml IL-1β+TNFα) treatment was observed. Therefore, testing its role on the whole-
cell current of the VSMC using its inhibitor (CaCCinh-AO1) seemed interesting. First, the current of the 
VSMC in both control and cytokine treated cells without the inhibitor was measured. Then, the same cells 
were challenged with the inhibitor and the currents were measured in a whole-cell configuration of the 
patch-clamp electrophysiology.  
Changes in TMEM16A (AO1) channel electrophysiology  
The slope of the positive phase of the current-voltage curves and projection of the reversal 
potential of this component helps obtain a broad overview and assessment of the whole-cell 
electrophysiological data. Clustering data usually provide a different way of examination by which close 
or similar data can be clustered and analyzed together to reduce variabilities within the cluster. Using 2, 
3, 4, 5, and 6 Kmeans clustering of slope conductance against reversal potential allowed us to find the 
optimum cluster with silhouette score which turned out to be 2 clusters in the absence of the CaCCinh-
AO1 with an odds ratio of 4.9x and the p-value of association of 0.09 meaning that the association of data 
to be clustered in cluster 1 (but not cluster 2) in the presence of CaCCinh-AO1 could have occurred by 
chance. This test of association was done by Fisher Exact test. Then, the analysis of the recordings of VSMC 
took place. 
VSMC like other cells can exhibit different phases of currents. In this study, different phases of 
currents were noticed; sustained and peak. In order to get a better understanding, analysis of these two 
phases of currents took place. The sustained current showed a shift to the left after cytokine treatment. 
This kind of shift in VSMC could be due to the presence of different ion channels such as acid-sensing, 
sodium, Kv, Kir, BK, channels. The trend was remained even after inhibiting the Ca2+ activated chloride 
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channels with 1 µM CaCCinh-AO1. The current amplitude; however, was slightly increased in the presence 
of the inhibitor. On the other hand, the peak current showed a shift to right with cytokine treatment but 
could not sustain that in the presence of CaCCinh-AO1. Instead, the amplitude of the control and cytokine 
treated currents was decreased with the inhibitor. This means that the cause of such shifts in the first 
place could be due to the loss of the current toward the sustained current or the activity of other channels 
such as sodium channels.  
Cl- channels are a major depolarizing mechanism in vascular smooth muscle (Davis et al., 2010). 
The slope conductance of all conditions (control and cytokine treated VSMC with/out channel blocker 
(CaCCinh-AO1) was not significantly different from one another. Additionally, the Vrev was not 
significantly different between control and cytokine treated VSMC except when the CaCCinh-AO1 was 
used as it showed a significant reduction (control -5.1±1.2 pA/pF and -1.7±-0.6pA/pF) with a p-value<0.05. 
This could be explained by depolarization of the cell membrane in which intracellular Ca2+ concentration 
increased and K+ channels closed. This can lead to vasoconstriction which, if persist for a longer time, will 






To our knowledge, this is the first time that NGS is combined with electrophysiology to study aorta 
(young and old) and VSMC (control with cytokine treated). With NGS data analysis, gene expression of the 
young aorta was different than the old aorta. Also, cytokine affected gene expression of VSMC. Both 
ageing and cytokine effects had different gene expression based on the nature of the tissue or cell. 
However, there were some similarities in terms of GO enrichment in which both were enriched for 
extracellular space. Also, Gja1 gene was differentially expressed in both aorta and VSMC, this is 
particularly interesting since it was also elevated in my FLS transcriptomic study. Electrophysiology results 
showed an increase in sustained currents of both control and cytokine treated VSMC compared to the 
peak current in the presence of ANO1 inhibitor. Also, inwardly rectifying potassium (such as kcnj8 and 









5.1 Introduction  
The paraventricular nucleus (PVN) is a key nucleus in the hypothalamus sometime referred to as the 
“autonomic master controller” (Loewy and McKellar, 1980, Loewy, 1991). It is one of the most important 
hypothalamic autonomic control centres with a variety of physiological roles ((Feetham et al., 2018)). 
There are well-established changes in autonomic control in older people (Hotta and Uchida, 2010, 
Parashar et al., 2016, Fu et al., 2006, Pal et al., 2014), I investigate in this chapter whether I can detect 
genetic changes that might explain this autonomic change.  
The PVN was described in the main Introduction, but briefly, it is composed of magnocellular and 
parvocellular neurons that can be seen with their respective sub-divisions. subdivisions in (Figure 2Error! 
Reference source not found.).  In general terms, the magnocellular sub-division is involved with control 
of the pituitary and release of hormones to the circulatory system (Ferguson et al., 2008, Swanson and 
Sawchenko, 1983, Hosoya et al., 1991, Simmons and Swanson, 2008), whereas the parvocellular sub-
nucleus contains neurones that project to the medulla and spinal cord and directly control the 
sympathetic nervous system (Swanson et al., 1980, Coote, 1995, Jansen et al., 1995, Badoer, 1996).  This 
latter function includes control of cardiovascular function (i.e. regulation of blood volume, circadian 
regulation of blood pressure, cardiovascular response to stress), regulatory functions for hepatic glucose 
control, circadian pacemaker in mammals, role in osmoregulation and thermoregulation (Feetham et al., 
2018, Nunn et al., 2011). 
Dysfunction of sympathetic pre-autonomic neurons (usually hyperactivity) has been linked to several 
serious age-related diseases such as hypertension and heart failure (Julius, 1993). Additionally, there is 
considerable evidence directly linking ion channel (or their regulators) changes in the PVN with 
cardiovascular disease, especially heart failure (Zhang et al., 1997, Zhang et al., 1998, Felder et al., 2000, 
Patel et al., 2000, Julius, 1993).  
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In this chapter genuine ageing will be used; comparing gene expression between relatively young ~7-
8 months old and ~24 months old Wistar rats.  Healthy ageing animals rather than one of the 
hypertensives of other variants were chosen. Changes that will be detected should be genuinely 
associated with healthy ageing.  As in previous chapters, the start will be with the analyses of genome-
wide genetic changes and then filter down to the main objective which is to identify any changes in PVN 
wide ion channel expression.  Several ion channels have already been identified in the PVN, by both 
electrophysiology and by qPCR, and these include such major super-families as the amino acid receptor 
channels (the primary neurotransmitters of the brain generally), transient receptor potential channels 
(TRP), potassium channels, sodium channels, voltage-gated Ca2+ channels, and other channels like 
purinergic membrane receptor family, acid-sensing channels (ASICs), proton-gated voltage insensitive 






In this chapter, the investigation of transcriptomic changes that take place in the PVN of younger and 
older Wister rats by RNA-sequencing and bioinformatics will take place. More specifically: 
• Is there a detectible over-all difference between transcriptome of young and old PVN 
transcriptome?  
• What genes are significantly changed in the PVN with ageing? 
• What functional clusters of genes are associated with PVN ageing? 
• Is there a change in overall ion channel gene expression in the PVN with ageing? 
• Which specific ion channel genes change with PVN ageing? 
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5.2 Materials and methods   
Tissue 
Rats were housed at 22-24°C in a 12 h light/dark cycle-controlled facility with ad libitum access to 
food and water. Animals were sacrificed by Schedule 1 methods for all in vitro work by my colleague 
Dr.Fiona O’Brien. Coronal brain slices were prepared using a Brain Slicer Matrix (World Precision 
Instruments, UK) and the PVN was located based on location and specific markers such as fornix and third 
ventricle. The PVN was ‘punched’ out using a 3 mm biopsy punch (Kai Medical, UK) and samples were 
deep-frozen at -80C in RNA-Later until RNA-extraction.   
 
RNA extraction  
PVN tissues were defrosted and RNA was extracted as described in the materials and methods 
chapter 2.  
 
Next-generation sequencing (RNA-sequencing) 
Isolation and preparation of PVN samples must precede the isolation methods. RNA from PVN 
samples were extracted as described in methods. They were placed in RNALater overnight and then into 
-80˚C until the experiment. RNA was extracted from these samples as described in materials and methods. 
RNA samples were sent for sequencing at the Center for Genomic Research (CGR, University of Liverpool, 
UK) which took place with >30M sequencing depth, 150bp, paired-end. RNA-sequencing data analysis 
took place as described in the RNA-sequencing pipeline in materials and methods (chapter 2).  
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RNA-sequencing Quality Control 
Before RNA sequencing, RNA isolation was run about 14 times repeating to optimise quality 
measured by NanoDrop 2000 Spectrophotometer using different methods. After this, different 
concentrations with good quality RNA were achieved.   
Before the sequencing experiments took place, the quantity (Appendix 11) and quality of the 
submitted RNA samples was checked. Usually, an electropherogram and gel-like image are produced for 
each sample as presented in Appendix 12.  
Once raw data received, they were checked for quality of reads using FastQC software as shown 
in Appendix 13. These figures show the high quality of reads as their Phred quality scores fall into the 
green zone >30 which means that the error rate is 1 in 1000bp. Next, these reads were analysed as 
described in the materials and methods chapter 2. But briefly, they were aligned/mapped to a reference 
genome with HiSat2 tool (Kim et al., 2015) using a reference genome (Rat Jul. 2014 (RGSC 6.0/rn6)(rn6) 
database), assembled and quantified using StringTie tool (Pertea et al., 2015) and differentially expressed 
genes were detected with DESeq2 tool (Trapnell et al., 2010). Using several reference servers such as 
Genenames.org, HUGO Gene Nomenclature Committee and locally edited script in MATLAB, ion channel 







PVN tissues were harvested from 3 “young” (3-5 months) and 3 “old” (24 months) male Wistar 
Kyoto rats.  Up until culling, animals were visually healthy.  After isolation of PVN and extraction of RNA, 
these samples were sequenced, and the focus was on the analyses of assembled genes rather than 
individual transcripts.  Following rigorous quality control testing (see methods and Appendix), 17397 
genes were detected by RNA-sequencing. 
Is there a detectible over-all difference between transcriptome of young and old PVN 
transcriptome?  
The standard approach to investigate over-all changes in transcription is to use multivariate 
analyses.  principal components analysis (PCA) was the first to use.  This reduced the approximately 17,000 
variables (genes) to just 5 variables (5 principal components/dimension); a scree plot shows that nearly 
40% of the variance can be accounted for with the first principal component (Figure 33-A). A contributions 
bar graph illustrates that the young and old subjects contribute relatively similarly to the population 
variance (Figure 33-B).  To investigate natural clustering of young and old phenotypes, the first, second 
and third principal components were then plotted against each other (Figure 34).  Remarkably, 
(unsupervised) clustering of just the first and second I then plotted component demonstrates significant 
separation of the two populations (Figure 34-A).  There was no separation between groups when plotting 
principal components 1 and 3 (Figure 34-B), but again statistically significant separation of young and old 
clusters when plotting principal components 2 and 3 (Figure 34-C).  Figure 34-D shows the first three 
principal components all plotted against each other.  This type of analyses is entirely unsupervised and 
that the groups young and old separate well confirms that there are distinct differences between young 
and old PVN.  Further insight can be gained by using a supervised equivalent to PCA; so-called discriminant 
analyses of principal components (DAPC).  This method allows the user to define the clusters first and 
then algorithmically search for a single function that optimally discriminates between the two groups.  
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Applying this technique to our PVN ageing data (Figure 35), a remarkably clear separation of young and 
old groups with just 3 principal components (Figure 35-A) was found. Bayesian statistics within the DAPC 
package (Jombart et al., 2010) can then be used to answer the question; if I did not know from which 
group (young or old) one of our samples came from, how likely is it that our discriminant function would 
correctly classify it?  In the case of the PVN ageing data and 1 discriminant function based on 3 principal 
components, all samples were successfully classified with greater than 99% accuracy (Figure 35-B).  Finally, 
in this section of the work, an investigation took place to find out the relative contributions of each gene 
in our dataset to the overall DAPC function.  i.e., which cluster of genes is most strongly associated with 
ageing in the PVN. These are shown in Figure 35-C; the top specific gene was that for production of the 
apolipoprotein and calmodulin 1. 
What genes are significantly changed in the PVN with ageing? 
The DAPC shows influential clusters of genes, but now analyses switched to individual genes.  
Differential expression analysis was carried out using the robust recent DESeq2 tool in R and found that 
2577 genes were differentially expressed between the young and old samples, with p-val <0.05.  Then, a 
Benjamini-Hochberg correction was applied to these data to correct for potential multiple comparison 
errors and calculated “q-values” (aka adjusted p-values or false detection rate, FDR <0.05). Following this 
procedure, the 811 genes were still found to be differentially expressed.  The top 50 differentially 
expressed genes are given in Table 25 excluding those with absolute log2 fold change of less than 1.5, 
equivalent to approximately a 3-fold change.   
Table 25: The top 50 differentially expressed genes excluding those with absolute log2 fold change of less than 1.5, equivalent to 
approximately a 3-fold change. 
log2 
change 
p-value padj symbol Gene name 
-5.5 3.2E-19 5.3E-15 Caps2 calcyphosine 2 
-8.4 1.5E-17 1.3E-13 Pmch pro-melanin-concentrating hormone 
1.5 3.7E-15 2.0E-11 Rmdn3 regulator of microtubule dynamics 3 
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-10.4 4.2E-14 1.7E-10 
LOC100
911365 
Parkinson disease 7 domain-containing protein 1-
like 
-10.0 1.3E-13 4.4E-10 Brs3 bombesin receptor subtype 3 
2.6 1.6E-13 4.4E-10 Hapln1 hyaluronan and proteoglycan link protein 1 
-2.3 1.3E-12 3.0E-09 Fbxo36 F-box protein 36 
2.1 1.9E-12 3.9E-09 Plekhh1 pleckstrin homology, domain containing H1 
-8.9 7.2E-12 1.3E-08 Ttr transthyretin 
-9.9 5.1E-11 7.6E-08 Hcrt hypocretin neuropeptide precursor 
1.6 6.8E-11 9.3E-08 Arrdc3 arrestin domain containing 3 
-9.1 1.2E-10 1.5E-07 Prmt6 protein arginine methyltransferase 6 
-4.5 5.1E-10 5.8E-07 Tac3 tachykinin 3 
-1.6 7.0E-10 7.2E-07 Ifitm3 interferon induced transmembrane protein 3 
1.9 8.4E-10 7.7E-07 Mal mal, T-cell differentiation protein 
2.4 1.3E-09 1.1E-06 Tnfaip6 TNF alpha induced protein 6 
-2.6 1.5E-09 1.1E-06 Fank1 fibronectin type III and ankyrin repeat domains 1 
-1.7 1.8E-09 1.2E-06 
RGD130
5645 
similar to RIKEN cDNA 1500015O10 
-8.9 2.0E-09 1.3E-06 Arhgap8 Rho GTPase activating protein 8 
-2.9 2.7E-09 1.7E-06 Lrriq1 leucine-rich repeats and IQ motif containing 1 
1.6 3.6E-09 2.1E-06 Mtmr2 myotubularin related protein 2 
-2.0 3.7E-09 2.1E-06 Syt10 synaptotagmin 10 
-2.8 3.8E-09 2.1E-06 Slc44a4 solute carrier family 44, member 4 
1.6 4.4E-09 2.3E-06 Trim16 tripartite motif-containing 16 
-3.5 5.3E-09 2.6E-06 Lepr leptin receptor 
-9.7 9.9E-09 4.8E-06 Adipoq adiponectin, C1Q and collagen domain containing 
2.2 1.2E-08 5.4E-06 Ugt8 UDP glycosyltransferase 8 
-1.6 1.3E-08 5.7E-06 Nppa natriuretic peptide A 
-3.5 1.4E-08 6.0E-06 Gzmm granzyme M 
1.9 2.1E-08 8.7E-06 Plp1 proteolipid protein 1 
-2.6 2.2E-08 9.0E-06 Erich2 glutamate-rich 2 
-2.4 2.8E-08 1.1E-05 Tekt1 tektin 1 
2.5 3.4E-08 1.3E-05 
Kcnip3 potassium voltage-gated channel interacting 
protein 3 
-2.8 4.7E-08 1.7E-05 Ccdc190 coiled-coil domain containing 190 
-2.5 6.1E-08 2.1E-05 Krt18 keratin 18 
-2.7 7.6E-08 2.5E-05 Scn7a sodium voltage-gated channel alpha subunit 7 
-2.2 8.6E-08 2.7E-05 Anxa1 annexin A1 
Top 50 genes by p-value; excluding those genes with absolute log2 fold ratio changes of less than 1.5 
 
What functional clusters of genes are associated with PVN ageing? 
One of the most useful features of RNA-seq compared to traditional gene-by-gene analyses is the 
ability to look for functional clusters.  This analysis was performed with the GOSeq package in R (Young et 
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al., 2010).  The first step was to correct the differential expression lists for bias associated with very long 
genes (that are more likely to be detected by RNA-sequencing and thus have greater detection power).  
This was done by plotting gene length against the probability of a gene being differentially expressed 
(Figure 36-A) and deriving a probability weighting function that could then be applied as a correction 
factor for functional enrichment.  After this, differentially expressed gene list from this study was 
submitted to the GO database to investigate enrichment for “biological processes” (Figure 36-B), 
“molecular functions” (Figure 36-C) and cell compartments (Figure 37-A).  In terms of biological processes, 
interestingly, development was the key processes, and in particular, myelination and neurone 
ensheathing were significantly enriched.  In terms of molecular functions, protein binding, including 
signalling receptor binding and Ca2+ binding were all enriched.  Regarding cellular components, the several 
GO plasma membrane classifications were enriched.  
Pathways altered in the ageing PVN were investigated.  Given the strict detection criterion 
adjusted p-value <0.05 and >1.5 log2 fold change (up or down), just two KEGG pathways were significantly 
enriched (Figure 37-B). The first one termed “neuroactive ligand-receptor interaction” and the second 
was “phototransduction”.  The individual differentially expressed genes from these groups were then 
mapped to the KEGG pathway for neuroactive ligand-receptor interaction (Figure 38) and 
phototransduction (Figure 39).  Several hormones and elements of signal transduction are altered by 
ageing. 
 
Is there a change in overall ion channel gene expression in the PVN with ageing? 
To investigate whether there are clusters of significantly altered ion channel genes in the aged 
PVN, filtration of our FPKM files (read files) for just those ion channel genes known to be ion channels and 
subunit proteins took place.  In this way, 223 genes were detected. Table 26 shows the top 50 (greatest 
abundance channel gene reads).  Again, I used the DAPC multivariate technique analysis to see whether 
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there was a pattern of change in over-all ion channel gene expression (Figure 40).  Figure 40-A shows the 
kernel density plot with clear separation of the PVN samples based only on ion channel genes and 
confirmed by correct prediction using the confusion matrix/ heatmap (Figure 40-B).  Figure 40-C shows 
the channel genes contributing most strongly to this separation; most influential are Scn2a, Kcnd3 and 
Cacna2d1.  
Table 26: Top 50 detected ion channels genes.   
Gene ID pval Gene description 
Scn7a 3.62E-08 Sodium channel protein 
Kcnj10 1.68E-06 ATP-sensitive inward rectifier potassium channel 10 
Kcng4  9.46E-06 Potassium voltage-gated channel modifier subfamily G member 
4 (Potassium voltage-gated channel, subfamily G, member 4 
(Predicted)) 
Cacna2d1 1.78E-05 Voltage-dependent calcium channel subunit alpha-2/delta-1 
Kcnk1 5.50E-05 Potassium channel subfamily K member 1 (Inward rectifying 
potassium channel protein TWIK-1) (rTWIK) (Potassium channel 
K2P1) 
Tmem37 6.69E-05 Voltage-dependent calcium channel gamma-like subunit 
Kcns3 0.000108 Potassium voltage-gated channel subfamily S member 3 
(Delayed-rectifier K(+) channel alpha subunit 3) (Voltage-gated 
potassium channel subunit Kv9.3) 
Cacnb3 0.000212 Voltage-dependent L-type calcium channel subunit beta-3 
(CAB3) (Calcium channel voltage-dependent subunit beta 3) 
Scn9a 0.00023 Sodium channel protein type 9 subunit alpha (Peripheral sodium 
channel 1) (PN1) (Sodium channel protein type IX subunit alpha) 
(Voltage-gated sodium channel subunit alpha Nav1.7) 
Cacna2d2 0.000413 Voltage-dependent calcium channel subunit alpha-2/delta-2 
Clcn4  0.000447 Chloride channel protein 
Kcnab3 0.000501 Voltage-gated potassium channel subunit beta-3 (K(+) channel 
subunit beta-3) (Kv-beta-3) (RCK beta3) 
Kcna1 0.000859 Potassium voltage-gated channel subfamily A member 1 (RBKI) 
(RCK1) (Voltage-gated potassium channel subunit Kv1.1) 
Scn2a 0.001162 Sodium channel protein 
Kcne2 0.003513 Potassium voltage-gated channel subfamily E member 2 (MinK-
related peptide 1) (Minimum potassium ion channel-related 
peptide 1) (Potassium channel subunit beta MiRP1) 
Kcnj5 0.004431 G protein-activated inward rectifier potassium channel 4 (GIRK-
4) (Cardiac inward rectifier) (CIR) (Heart KATP channel) 
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Cacna1c 0.005244 Voltage-dependent L-type calcium channel subunit alpha 
Kcnn1 0.011869 Small conductance calcium-activated potassium channel protein 
1 
Scn3a 0.013498 Sodium channel protein 
Asic4  0.01575 Acid-sensing ion channel 4 (Amiloride-sensitive cation channel 4, 
pituitary, isoform CRA_a) 
Cacna1b 0.015889 Voltage-dependent N-type calcium channel subunit alpha 
Cacfd1 0.01657 Calcium channel flower homolog (Calcium channel flower 
domain-containing protein 1) 
Trpv3 0.016852 Transient receptor potential cation channel, subfamily V, 
member 3 
Kcnc1 0.017028 Potassium voltage-gated channel subfamily C member 1 (NGK2) 
(RAW2) (Voltage-gated potassium channel subunit Kv3.1) 
(Voltage-gated potassium channel subunit Kv4) 
Kcnd3 0.018429 Potassium voltage-gated channel subfamily D member 3 
Kcna3 0.024902 Potassium voltage-gated channel subfamily A member 3 (RCK3) 
(RGK5) (Voltage-gated potassium channel subunit Kv1.3) 
(Voltage-gated potassium channel subunit Kv3) 
Trpv4  0.025997 Transient receptor potential cation channel subfamily V member 
4 (TrpV4) (Osm-9-like TRP channel 4) (OTRPC4) (Vanilloid 
receptor-related osmotically-activated channel) (VR-OAC) 
Catsperg 0.026949 Cation channel sperm-associated auxiliary subunit gamma 
Scn1a 0.029337 Sodium channel protein 
Kcnt2 0.031272 Potassium channel subfamily T member 2 
Kcnk2  0.034713 Potassium channel subfamily K member 2 (Outward rectifying 
potassium channel protein TREK-1) 
Kcnj8 0.039421 ATP-sensitive inward rectifier potassium channel 8 (Inward 
rectifier K(+) channel Kir6.1) (Potassium channel, inwardly 
rectifying subfamily J member 8) (uKATP-1) 
Kcnab2 0.046071 Voltage-gated potassium channel subunit beta-2 
Kcne3 0.04779 Potassium voltage-gated channel subfamily E member 3 (MinK-
related peptide 2) (Minimum potassium ion channel-related 
peptide 2) (Potassium channel subunit beta MiRP2) 
Kcnh6 0.048659 Potassium voltage-gated channel subfamily H member 6 
Cacng2 Stg 0.049214 Voltage-dependent calcium channel gamma-2 subunit (Neuronal 
voltage-gated calcium channel gamma-2 subunit) (Stargazin) 
(Transmembrane AMPAR regulatory protein gamma-2) (TARP 
gamma-2) 
Kcnk13 0.053493 Potassium channel subfamily K member 13 (Potassium channel, 
subfamily K, member 13) 
Kcnc3 0.055728 Potassium voltage-gated channel subfamily C member 3 
Kcnh7 0.062349 Potassium voltage-gated channel subfamily H member 7 
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Scn4b 0.0642 Sodium channel subunit beta-4 
Scn5a 0.067009 Sodium channel protein 
Scn3b 0.077066 Sodium channel subunit beta-3 
Cacnb2  0.08413 Calcium channel, voltage-dependent, beta 2 subunit, isoform 
CRA_d (Voltage-dependent L-type calcium channel subunit beta-
2) 
Scnm1 0.084661 Sodium channel modifier 1 (Sodium channel modifier 1 
(Predicted), isoform CRA_a) 
Clcc1 0.085171 Chloride channel CLIC-like 1, isoform CRA_c (Chloride channel 
CLIC-like protein 1) 
Cngb1 0.08554 Cyclic nucleotide-gated channel beta 1 
Clca1  0.092138 Chloride channel accessory 1 (Chloride channel calcium 
activated 3 (Predicted)) 
Unc79 0.098502 Unc-79 homolog, NALCN channel complex subunit 
Clcn6  0.101184 Chloride channel protein 
Kcnh8 0.104129 Potassium voltage-gated channel subfamily H member 8 









Figure 33: PCA analysis of young and old PVN. 
A. shows the scree plot for the 5 principle components used to reduce the dimensionality of the PVN young old datasets, approximately 16,000 variables (genes) reduced to 5 
variables (PC) with 6 subjects; 3 young and 3 old male rats.  PCA Component 1 alone accounts for approximately 37% of the variance in the data.  B. Contribution plot showing the 
relative contributions of each of the six subjects to the principal components.  The red dotted line indicates the mean contribution.  The first Old subject contributes most to the 







Figure 34: Principle component, k-mean clustering and combined scatter plot of young and old PVN. 
A, B and C show plots of PC1 vs PC2, PC1 vs PC3 and PC2 vs PC3 (Dim=PC).  The shaded circles show the unsupervised k mean cluster 95% confidence intervals thus there is a clear 





Figure 35: Discriminant (DA-PCA) analysis of ageing effects on PVN (all genes).  
A. Kernel density plots of the discriminant component coordinates for the young and old groups; co-ordinates on the x-axis and density on the y-axis. There is a good clear separation 
between young and old samples. B. A graphical confusion matrix showing the actual group membership (y-axis) and predicted cluster membership (given by colour and x-axis).  All 
groups are correctly clustered with greater than 0.9 probability. C. The top 15 contributors to the linear discriminator function; Plp1; proteolipid protein 1, Mbp; myelin basic protein, 
Ttr; transthyretin, Tf; transferrin, Enpp2; ectonucleotide pyrophosphatase/phosphodiesterase 2, Apod; apolipoprotein D, Glul; glutamate-ammonia ligase, Tubb4a; tubulin, beta 4A 
class IVa, Ptgds; prostaglandin D2 synthase, Hbb; haemoglobin subunit beta, Cnp; 2',3'-cyclic nucleotide 3' phosphodiesterase, Scd2; stearoyl-Coenzyme A desaturase 2, Mal; mal, 





Figure 36: Analysis of Gene Ontology (GOs) of young and old PVN. 
A. Probability weighting function curve relating the length of the gene (x-axis) to the proportion of differentially expressed (DE) genes (y-axis), for that length bias. This curve is fit 
with the GESEQ package to allow subsequent enrichment analyses to eliminate bias due to the length of the gene. B. Top 10 enriched biological processes (by p-value) between 
young and old PVN tissue. The x-axis “Hits %”, is the number of DE in each category/total number of genes (present) in that category. C. Top 10 enriched molecular functions, all 







Figure 37:Analysis of GO and functional pathways comparing young and old PVN. 
A.  Top 10 enriched cellular components (by p-value) between young and old PVN tissue. The x-axis “Hits %”, is the number of DE in each category/total number of genes (present) 









Figure 38: Scheme of the top enriched KEGG pathway comparing young and old PVN. 
Several neuropeptides, hormones and prostanoids are changed in the dataset. Official KEGG ID rno04080, P-value 7.05E-08 adjusted p-value 1.83E-05. 31 genes present out of a 


















Figure 39: Schema of the second-top enriched KEGG pathway of 
young and old PVN. 
Although classed as “phototransduction”, the gene members 
themselves are all signalling molecules in other contexts too. 
Official KEGG ID, rno04744. 7/261 genes present.  P-value 7.00E-





Figure 40: Discriminant Analyses (DA-PCA) of ageing effects on ion channels of young and old PVN. 
A. Kernel density plots of the discriminant component coordinates for the young and old groups; co-ordinates on the x-axis and density on the y-axis. There is a good clear separation 
between young and old samples based on just their ion channels. B. A graphical confusion matrix showing the actual group membership (x-axis) and predicted cluster membership 
colouration (y-axis). All groups are correctly clustered with greater than 0.95 probability. C. Loading graph showing the contributions of the most powerful contributors for the 
discriminant function. The most contributing genes are Scn2a; sodium voltage-gated channel alpha subunit 2, Kcnd3; potassium voltage-gated channel subfamily D member 3, and 




Which specific ion channel genes change with PVN ageing? 
In total, 38 ion channel genes were differentially expressed with (pval<0.05) (Table 27).  The top 
10 channel genes (in terms of log2 fold change of 1.5, equivalent to approximately a 3-fold change) that 
were decreased in expression with age are shown in Table 28 while the top 10 channel genes that were 
increased by ageing are shown on Table 29.  
 
Table 27: The 38 ion channel genes that were differentially expressed (pval<0.05).  
Gene ID Gene description p-value 
Scn7a Sodium channel protein 3.62E-08 
Kcnj10 ATP-sensitive inward rectifier potassium channel 10 1.68E-06 
Kcng4  Potassium voltage-gated channel modifier subfamily G member 4 
(Potassium voltage-gated channel, subfamily G, member 4 
(Predicted)) 
9.46E-06 
Cacna2d1 Voltage-dependent calcium channel subunit alpha-2/delta-1 1.78E-05 
Kcnk1 Potassium channel subfamily K member 1 (Inward rectifying 
potassium channel protein TWIK-1) (rTWIK) (Potassium channel 
K2P1) 
5.50E-05 
Tmem37 Voltage-dependent calcium channel gamma-like subunit 6.69E-05 
Kcns3 Potassium voltage-gated channel subfamily S member 3 (Delayed-
rectifier K(+) channel alpha subunit 3) (Voltage-gated potassium 
channel subunit Kv9.3) 
0.000108 
Cacnb3 Voltage-dependent L-type calcium channel subunit beta-3 (CAB3) 
(Calcium channel voltage-dependent subunit beta 3) 
0.000212 
Scn9a Sodium channel protein type 9 subunit alpha (Peripheral sodium 
channel 1) (PN1) (Sodium channel protein type IX subunit alpha) 
(Voltage-gated sodium channel subunit alpha Nav1.7) 
0.00023 
Cacna2d2 Voltage-dependent calcium channel subunit alpha-2/delta-2 0.000413 
Clcn4  Chloride channel protein 0.000447 
Kcnab3 Voltage-gated potassium channel subunit beta-3 (K(+) channel 
subunit beta-3) (Kv-beta-3) (RCK beta3) 
0.000501 
Kcna1 Potassium voltage-gated channel subfamily A member 1 (RBKI) 
(RCK1) (Voltage-gated potassium channel subunit Kv1.1) 
0.000859 
Scn2a Sodium channel protein 0.001162 
Kcne2 Potassium voltage-gated channel subfamily E member 2 (MinK-
related peptide 1) (Minimum potassium ion channel-related peptide 
1) (Potassium channel subunit beta MiRP1) 
0.003513 
Kcnj5  G protein-activated inward rectifier potassium channel 4 (GIRK-4) 
(Cardiac inward rectifier) (CIR) (Heart KATP channel)  
0.004431 
Cacna1c Voltage-dependent L-type calcium channel subunit alpha 0.005244 
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Kcnn1 Small conductance calcium-activated potassium channel protein 1 0.011869 
Scn3a Sodium channel protein 0.013498 
Asic4  Acid-sensing ion channel 4 (Amiloride-sensitive cation channel 4, 
pituitary, isoform CRA_a) 
0.01575 
Cacna1b Voltage-dependent N-type calcium channel subunit alpha 0.015889 
Cacfd1 Calcium channel flower homolog (Calcium channel flower domain-
containing protein 1) 
0.01657 
Trpv3 Transient receptor potential cation channel, subfamily V, member 3 0.016852 
Kcnc1 Potassium voltage-gated channel subfamily C member 1 (NGK2) 
(RAW2) (Voltage-gated potassium channel subunit Kv3.1) (Voltage-
gated potassium channel subunit Kv4) 
0.017028 
Kcnd3 Potassium voltage-gated channel subfamily D member 3 0.018429 
Kcna3 Potassium voltage-gated channel subfamily A member 3 (RCK3) 
(RGK5) (Voltage-gated potassium channel subunit Kv1.3) (Voltage-
gated potassium channel subunit Kv3) 
0.024902 
Trpv4 Transient receptor potential cation channel subfamily V member 4 
(TrpV4) (Osm-9-like TRP channel 4) (OTRPC4) (Vanilloid receptor-
related osmotically-activated channel) (VR-OAC) 
0.025997 
Catsperg Cation channel sperm-associated auxiliary subunit gamma 0.026949 
Scn1a Sodium channel protein 0.029337 
Kcnt2 Potassium channel subfamily T member 2 0.031272 
Kcnk2  Potassium channel subfamily K member 2 (Outward rectifying 
potassium channel protein TREK-1)  
0.034713 
Kcnj8 ATP-sensitive inward rectifier potassium channel 8 (Inward rectifier 
K(+) channel Kir6.1)  
0.039421 
Kcnab2 Voltage-gated potassium channel subunit beta-2 0.046071 
Kcnj2  Inward rectifier potassium channel 2 (Inward rectifier K(+) channel 
Kir2.1) (IRK-1) (RBL-IRK1) (Potassium channel, inwardly rectifying 
subfamily J member 2) 
0.046817 
Kcne3 Potassium voltage-gated channel subfamily E member 3 (MinK-
related peptide 2) (Minimum potassium ion channel-related peptide 
2) (Potassium channel subunit beta MiRP2) 
0.04779 
Kcnh6 Potassium voltage-gated channel subfamily H member 6 0.048659 
Cacng2 Voltage-dependent calcium channel gamma-2 subunit (Neuronal 







10 ion channel genes lowered by log2 FC with ageing:  
Table 28: 10 ion channel genes lowered by log2 FC with ageing.  
Gene ID Gene description pvalue log2 F.C. 
Scn7a Sodium channel protein 3.62E-08 -1.977638569 
Tmem37 Voltage-dependent calcium channel gamma-like subunit 6.69E-05 -1.459356853 
Scn9a 
Sodium channel protein type 9 subunit alpha (Peripheral sodium 
channel 1) (PN1) (Sodium channel protein type IX subunit alpha) 
(Voltage-gated sodium channel subunit alpha Nav1.7) 0.00023 -1.244866794 
Kcne2 
Potassium voltage-gated channel subfamily E member 2 (MinK-
related peptide 1) (Minimum potassium ion channel-related 
peptide 1) (Potassium channel subunit beta MiRP1) 0.003513 -1.159645202 
Cacna2d1 Voltage-dependent calcium channel subunit alpha-2/delta-1 1.78E-05 -1.144505451 
Cacnb3  
Voltage-dependent L-type calcium channel subunit beta-3 
(CAB3) (Calcium channel voltage-dependent subunit beta 3) 0.000212 -1.004811765 
Kcnj5  
G protein-activated inward rectifier potassium channel 4 (GIRK-
4) (Cardiac inward rectifier) (CIR) (Heart KATP channel)  0.004431 -0.992261906 
Trpv4  
Transient receptor potential cation channel subfamily V 
member 4 (TrpV4) (Osm-9-like TRP channel 4) (OTRPC4) 
(Vanilloid receptor-related osmotically-activated channel) (VR-
OAC) 0.025997 -0.940472599 
Cacna1c Voltage-dependent L-type calcium channel subunit alpha 0.005244 -0.926429678 
Kcnt2 Potassium channel subfamily T member 2 0.031272 -0.864399306 
 
10 ion channel genes increased by log2 FC with ageing: 
Table 29: 10 ion channel genes increased by log2 FC with ageing.  
Gene ID Gene description pvalue log2 F.C. 
Kcnj10 ATP-sensitive inward rectifier potassium channel 10 1.68E-06 1.548474713 
Kcns3 Potassium voltage-gated channel subfamily S member 3 (Delayed-
rectifier K(+) channel alpha subunit 3) (Voltage-gated potassium 
channel subunit Kv9.3) 
0.000108 1.526071011 
Kcnab3 Voltage-gated potassium channel subunit beta-3 (K(+) channel 
subunit beta-3) (Kv-beta-3) (RCK beta3) 
0.000501 1.321511049 
Kcng4  Potassium voltage-gated channel modifier subfamily G member 4 
(Potassium voltage-gated channel, subfamily G, member 4 
(Predicted)) 
9.46E-06 1.212143787 
Kcnk1 Potassium channel subfamily K member 1 (Inward rectifying 
potassium channel protein TWIK-1) (rTWIK) (Potassium channel K2P1) 
5.50E-05 1.067982226 
Trpv3 Transient receptor potential cation channel, subfamily V, member 3 0.016852 0.976391231 
Cacna2d2 Voltage-dependent calcium channel subunit alpha-2/delta-2 0.000413 0.973709449 
Asic4  Acid-sensing ion channel 4 (Amiloride-sensitive cation channel 4, 




Kcnn1 Small conductance calcium-activated potassium channel protein 1 0.011869 0.899366819 
Kcna1 Potassium voltage-gated channel subfamily A member 1 (RBKI) (RCK1) 




5.4 Discussion  
In this chapter, RNA-sequencing from young and old rat PVN was carried out. Analysis of these 
data bioinformatically with a range of the latest powerful genomic tools took place.  Major alterations in 
gene expression generally and also specifically in the expression of ion channel genes were found.  In 
terms of association with functional pathways, KEGG analysis revealed that many genes associated with 
neuropeptide signalling were altered.  
The PVN ageing model 
 
The first point of note from this work is to clarify that genuine ageing is studied here, rats allowed 
to naturally grow to old age in a way not usually done with laboratory animals for ethical reasons.  Our 
group has a Home Office licence to allow this and as far as I could see there was no evidence of pathology 
in our old rats.  So, this model seems to be healthy ageing.  Rodents do suffer a number of age-related 
diseases just like humans (Bellantuono and Potter, 2016), but in fact, there is little evidence of them 
naturally developing hypertension.  This is interesting since the PVN is a key centre for control of the blood 
pressure and clearly many genetic changes in the elderly PVN were found. There is a caveat to this study, 
however, compared to in vitro models of ageing in that,  by necessity, a punch of whole-tissue was used 
here. This means that it is expected to have had a mixed population of cells with, for example, glial cells, 
neurones, blood vessels and ependymal cells present.  Despite this, it is noticeable that the majority of 
changes to see with functional enrichment and pathway analyses are those one might expect associated 
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with neurones; such as neuropeptide signalling and myelination.   RNA-sequencing is still a relatively new 
technology, but perhaps in future, a study similar to this could be performed which used the even newer 
technique of single-cell sequencing (Ziegenhain et al., 2017).  In that way it would theoretically be possible 
to get profiles of the ageing transcriptome of different types of cells; glia, neurone and so on.   
 
Over-all changes in gene expression 
The effective with multivariant analyses to separate the young and old populations based on the 
transcriptomic data is remarkable.  In our aorta and vascular smooth muscle study, for example, many 
principal components were needed to apply to get good separation, but here the simplest model was 
effective.  The conclusion here is that the elderly PVN is very different from the young PVN. Perhaps 
changes in the brain are more striking than changes in the peripheral nervous system. Functional 
clustering revealed that myelination is changed in ageing, it would be interesting to investigate whether 
this phenomenon also occurs in people.  Myelin allows neurones to conduct faster and so loss of myelin 
could slow conduction rates in the older brain although myelination has been observed throughout life 
(Callaghan et al., 2014, Peters, 2002, Nasrabady et al., 2018, Hill et al., 2018). The changes in 
neurotransmitters and receptors (“neuroactive ligand and receptors”) are also remarkable since these are 
the control elements of all neurones and in the future, it may be possible to input these changes into 
models of paraventricular neurone control (Lewis et al., 2010) to see if these changes contribute to the 
changes in autonomic control well established in the literature (Hotta and Uchida, 2010, Parashar et al., 
2016, Fu et al., 2006, Pal et al., 2014).  The changes identified in the GO enrichment are of course 
associations/correlations, not causation.  One cannot tell from these data whether the changes contribute 
towards ageing dysfunction or result from dysfunction.  Causal analysis is now possible, however (Kramer 
et al., 2014, Pearl, 2009) and this is implemented in Ingenuity Pathway Analysis (IPA) software (QIAGEN 
Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) marketed by Qiagen 
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(Qiagen Inc., UK). The list of differentially expressed genes is entered into IPA to probe upstream regulator, 
those factors that could cause the changes to see.  IPA returned many of these, but in terms of upstream 
regulators, TNF was amongst the top hits (activation z-score -3.2, p-value 0.000006).  In terms of causal 
regulators vasopressin, a key PVN regulator involved with activation of the sympathetic nervous system 
(Rossi and Maliszewska-Scislo, 2008) was also identified to have reduced activity (z-score -3.3, p-value 
1.74E-10).  Also, there was a reduction in hydrocortisone influence, a key regulator of stress. These 
changes in upstream causal regulators could be said to be the opposite to that potentially expected in an 
aged rat. 
 
Changes in ion channel expression (decreases) 
 
The first point of note here is that our data show that there is definitively a change in overall ion 
channel expression. DAPC shows a clear separation of populations (young versus old) with just 3 PCA.  Our 
tables also show a number of differentially expressed genes in the PVN with ageing.  
Among those channels that were lowered by log2 FC are sodium channels (Scn7a and Scn9a), calcium 
channels (Tmem37, Cacna2d1, Cacnb3 and Cacna1c), potassium channels (Kcne2, Kcnj5 and Kcnt2) and 
TRPV4.  On the other hand, the top 10 channel genes that were increased by log2 FC are potassium 
channels (Kcnj10, Kcns3, Kcnab3, Kcng4, Kcnk1, Kcnn1 and Kcna1), TRPV3, ASIC4 and calcium channel 
(Cacna2d2).  With the ion channels, functional clustering was not done because most channels have quite 
well-known functions already and the GO databases are not well populated with ion channels.  So, for 
example, of the decreased ion channels, sodium channels are mainly responsible for the rising phase of 
action potentials (Novakovic et al., 2001).  
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Sodium ion channels (decreases) 
Scn7a and Scn9a are voltage-gated sodium channels and since they are lowered with ageing, this 
could mean that the rise in action potential is expected to be altered. Scn7a encodes for a common 
isoform of voltage-gated sodium channels (O'Leary et al., 2016) that play roles in the proper functioning 
of neurons and muscles during action potential as they direct the diffusion of the Na+ ions for membrane 
depolarization. Scn9a has been linked to several human channelopathies such as erythromelalgia, 
paroxysmal extreme pain disorder (PEPD), and channelopathy-associated insensitivity to pain (Bennett et 
al., 2019). In summary, these two voltage-gated sodium channels play roles in a proper action potential 
in neurons and muscles (Vargas-Alarcon et al., 2012).  
Calcium ion channels (decreases) 
Calcium channels are very critical channels and they carry out important functions at the cellular 
and tissue levels including the activation of calcium-dependent enzymes, muscle contraction, secretion of 
neurotransmitters and hormones, and gene transcription (Zamponi, 2016, Simms and Zamponi, 2014, 
Zamponi et al., 2015). Interestingly, all calcium channels (Tmem37, Cacna2d1, Cacnb3 and Cacna1c) that 
had lowered expression were voltage-gated channels. Therefore, the release of neurotransmitter may be 
affected due to the decreased expression of these channels. Less is known about the role of Cacna1c (L-
type calcium channels) in the brain. This channel is responsible for prolonged action potential in the 
cardiac cell (which is also known as DHP receptors), dendrites and dendritic spines of cortical neurons; 
however, Cacna1c does also play a role in neural stem cell neurogenesis once activated (Zhu et al., 2019a). 
So, it’s change could be linked to the developmental changes identified in the GO biological processes 
functional mapping.  Cacna2d1 regulates calcium current density and activation/inactivation kinetics of 
the calcium channel and It has also been linked to epilepsy (Vergult et al., 2015). The Cacnb3 gene encodes 
the regulatory beta subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents 
(Collin et al., 1994). Therefore, contribute to the regulation of surface expression and gating of calcium 
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channels and may also play a role in the regulation of transcription factors and calcium transport (O'Leary 
et al., 2016). TMEM37 is also a Ca ion channel (O'Leary et al., 2016). It is thought that it acts to stabilize 
the calcium channel in an inactivated (closed) state. It may also modulate calcium current when co-
expressed with CACNA1G (O'Leary et al., 2016).  
Potassium ion channels (decreases) 
Potassium channels that were lowered with ageing in these samples are voltage-gated (kcnj5 and 
kcne2) and sodium activated (kcnt2).  Kcnj5 is Potassium Inwardly Rectifying Channel Subfamily J Member 
5. It encodes an integral membrane protein which belongs to one of seven subfamilies of inward-rectifier 
potassium channel proteins now termed potassium channel subfamily J (Doupnik et al., 1995). The 
encoded protein is a subunit of the potassium channel and has a greater tendency to allow potassium to 
flow into a cell rather than out of a cell (O'Leary et al., 2016).  Kcne2 is potassium voltage-gated channel 
subfamily E regulatory subunit 2. Their diverse functions include regulating neurotransmitter release and 
neuronal excitability and cell volume (Pruitt et al., 2007).  In non-neuronal tissues, they have roles 
modulating heart rate, insulin secretion, epithelial electrolyte transport, smooth muscle contraction 
(Pruitt et al., 2007) which may be replacements for “excitability” in neurones.  Interestingly, this gene 
encodes a member of the potassium channel, voltage-gated that assembles with the KCNH2 gene product, 
a pore-forming protein, to alter its function and is expressed in nerve cells. This gene was upregulated by 
a one-fold change in our dataset. The final potassium channel gene differential expressed in ageing PVN 
tissue is Kcnt2.  This is a potassium sodium-activated channel subfamily T member 2. Kcnt2 is an outward 
rectifying potassium channel and produces rapidly activating outward rectifier K+ currents (Bhattacharjee 
et al., 2003).  It is unusual in that it is activated by high intracellular sodium and chloride levels (Terrar, 





Transient receptor potential ion channels (decreases) 
The transient receptor potential cation channel subfamily V member 4 (Trpv4) was also decreased 
In PVN ageing.  Trpv4 is a non-selective calcium permeant cation channel involved in osmotic sensitivity 
and mechanosensitivity (Garcia-Elias et al., 2008).  It is well known in the PVN and has been studied by 
our group where it links osmolarity to sympathetic activity (Feetham et al., 2015a, Feetham et al., 2015b).  
Change in this gene with age is very interesting since it may explain some of the changes in the 
sympathetic activity described earlier, but further experiments will be required to determine how. 
Changes in ion channel expression (increases) 
10 ion channel genes that were increased by log2 FC; potassium channels (Kcnj10, Kcns3, Kcnab3, 
Kcng4, Kcnk1, Kcnn1 and Kcna1), TRPV3, ASIC4 and calcium channel (Cacna2d2). In addition to these 10 
channel genes, Gja1 was also increased by log2FC of 0.46 which is equivalent to approximately 3-fold 
change. 
Potassium ion channels (increases)  
The potassium channels that were increased in PVN with ageing are of different types; voltage-
gated potassium channels (Kcnj10, Kcns3, Kcna1, Kcnab3 and Kcng4), calcium-activated potassium 
channels (Kcnn1), and two-pore domain potassium channel (Kcnk1).  
Kcnj10 encodes ATP-sensitive inward rectifier potassium channel 10. It may be responsible for 
potassium buffering action of glial cells in the brain as these channels are characterized by a greater 
tendency to allow potassium to flow into the cell rather than out of it (Pruitt et al., 2007). Their voltage 
dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, 
the voltage range of the channel opening shifts to more positive voltages. The inward rectification is 
mainly due to the blockage of outward current by internal magnesium (Pruitt et al., 2007). Since these 
channels may also be involved with control of, or response to, glucose levels in the brain (Rivera-Aponte 
et al., 2015), their change may also indicate some disturbance to glucose regulation in older rats.  
205 
 
Potassium voltage-gated channel subfamily S member 3 (Kcns3) form the largest and most diversified 
class of ion channels and are present in both excitable and non-excitable cells (Stocker and 
Kerschensteiner, 1998). Their main functions are associated with the regulation of the resting membrane 
potential and the control of the shape and frequency of action potentials (Stocker and Kerschensteiner, 
1998). Increased levels of these channels indicate hyperactivity of PVN (Georgiev et al., 2016).   Potassium 
voltage-gated channel subfamily A member 1 (Kcna1) play role in repolarisation of membranes (Pruitt et 
al., 2007) and its disturbance is another indication of the major changes in neuronal control that appear 
to have occurred in the older rat brain.  
Other ion channels (increases)  
Transient receptor potential cation channel, subfamily V, member 3 (TRPV3) is one of the 
nonselective cation channels that function in a variety of processes such as temperature sensation and 
vasoregulation (Xu et al., 2002). Increased levels may indicate that dysregulation of temperature sensation 
as well as vasculature may lead to diseases such as hypertension due to blood vessels abnormality.  Acid-
sensing ion channel 4 (ASIC4) is expressed in the nervous system (Grunder et al., 2000, Hoshikawa et al., 
2017). The pore of the channel through which ions selectively flow from the extracellular side into the 
cytoplasm is formed by the three TM2 regions of the trimer (Hanukoglu, 2017). They are cation channels 
with high permeability for sodium. In vitro, has no proton-gated channel activity (Grunder et al., 2000). 
They play roles in mechanosensation, chemosensation, nociception, and regulation of blood volume and 
pressure. These channels look and function like a tripartite funnel that directs the flow of Na+ ions into 
the cytoplasm via the channel pore in the membrane (Hanukoglu, 2017). Since they change in ageing, this 
may contribute to age-related changes in chronic pain and blood pressure. The alpha-2/delta subunit of 
voltage-dependent calcium (Cacna2d2) channels was also increased.  This channel regulates calcium 
current density and activation/inactivation kinetics of the calcium channel (Pruitt et al., 2014). Acts as a 
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regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR 
CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis  (Carboni et al., 2003).  
To summarize looking at the overall change in expression of ion channel genes in the ageing PVN, 
it seems that there is a tendency toward the loss of control of normal action potential, variability in 
hyperpolarization and depolarization, dysregulation of the osmotic and mechanosensitivity, and abnormal 
up-regulation of genes responsible for cell-to-cell communications which I may see with ageing.  Future 
analyses will be needed to determine whether these are causal to, or resultant to the well-known 
neurodegeneration of ageing. 
5.5 Conclusions  
There are many changes that I have seen in this study with ageing PVN. For the individual gene 
analysis, it was interesting to find out that Gja1 (a gap junction) gene was upregulated in the old PVN. The 
functional annotation and pathway analysis showed changes that one might expect associated with 
neurons such as neuropeptide signalling and myelination which would be interesting to investigate 
whether this phenomenon also occurs in people. Thus, the elderly (rat) PVN is very different from the 









6.1 Introduction  
NGS experiments provide powerful and extremely large amounts of data which can be useful in 
terms of gene expression studies. In this study, I utilized this technique to study the expression level in 
three different systems. These are musculoskeletal (FLS and Chondrocytes), cardiovascular (VSMC and 
Aorta) and nervous (PVN) systems. The expression level of different genes in these systems is expected to 
be different to suit specific functions according to anatomical locations. I created an “inflammageing” 
model by exposing rats to cytokines (10ng/ml IL-1β+TNFα) for 72hrs. I also used old rats as a natural ageing 
model. In this chapter, by comparing these together, considering the appropriate conditions (control vs 
cytokine) and age (young vs old), I hope to determine how close my inflammageing model to the real 
ageing model as well as detecting cross-tissue cytokine or age-related differential expression.  
Usually, genes do not just change and express their effects individually. They usually affect the 
expression level of other genes either by upregulation, downregulation or sometimes there are no effects. 
Therefore, multivariate analysis is necessary, together with looking for changes in networks of genes 
including signalling pathways.  
In this chapter, all samples will be grouped based on their condition, age, or both. Then, a 
combination of files will take place. Files of samples of the same group will be combined into one file for 
proper data processing. Next, a run of multivariate analysis for those samples will take place and will 
compare them with each other to track any significant changes in genes and more specifically the ion 
channel genes.  
Aims  
The aims in this chapter were to do a meta-analysis of NGS data by comparing all NGS data obtained 
from all samples with each other as follows:  
• Compare all previous young samples against old samples 
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• Compare all previous control samples against cytokine (10ng/ml IL-1β+TNFα) treated 
samples  
• Does the cytokine treatment regime follow the natural ageing, therefore; group 1 (Control 



















6.2 Materials and methods   
Next-generation sequencing (NGS) 
Analyses were performed on RNA samples described earlier and extracted as described in the 
methods of chapter 2 and each chapter for specific optimization of the protocol. Chondrocyte RNA-
sequencing data (from colleagues) was also added to this analysis. Multivariate analysis was performed 
for specific groups as follows; 1) young vs old samples, 2) control vs cytokine treated samples, and 3) 
comparison between two groups; group 1 (control and young) vs group 2 (cytokine and old). The analysis 
was started with PCA and where appropriate, linear discriminant analysis of PCA (DA-PCA) was used and 
increased the number of principal components until clear separation was obtained.  For DA-PCA, to 
calculate false detection rate (FDR) data matrices were shuffled 100 or more times in R and the analyses 
re-run on each detection. 
6.3 Results 
Multivariate analysis of all young and old samples  
In this chapter, a broader overview of the transcriptome profile that changes with ageing models 
was the goal to obtain. Again, one of the best ways of looking at this is by looking at clustered genes 
because when gene expression changes it does not have an individual effect. Instead, a group of genes 
change together, they cluster together, and this can be detected with multivariate analysis.  
At the beginning, the multivariate analysis started with a PCA of 20 individuals (samples), 22038 
genes and 10 principal components. This generated a scree plot (Figure 41-A) that shows percentages of 
explained variance by dimensions and 47% of the variance are explained by dimension 1 and samples’ 
(individual) contribution to the difference between the two groups (Figure 41-B). The separation was not 
clear between PC1 and PC2 (Figure 42-A), PC1 and PC3 (Figure 42-B), or PC2 and PC3 (Figure 42-C) while 
(Figure 42-D) shows all the three-dimensions (PC1, PC2 and PC3) plotted against each other. An algorithm 
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is used to tell if the clusters are significant in n umber of dimensional space. Then, supervised multivariate 
analysis was performed with DA-PCA. As shown in (Figure 43-A), the better separation was obtained with 
10 PCs and 1 discriminant function. Thus 10 PCs were used for DA-PCA throughout the rest of the study. 
To visualize the successful assignment of groups, a heatmap (Figure 43-B) was generated, and this shows 
that each sample was correctly predicted to its assigned (real) group with prediction probability of 
belonging (average p-value was 0.039).  The prediction probability in this part was greater than 0.8, the 
closer to 1 the higher the accuracy while probability closer to zero is the less likely for a sample to be from 
that group. To calculate an FDR for this level of significance, a script was used which repeatedly shuffled 
the data matrix and then re-ran the analysis 1000 simulations of this returned none with mean p-value < 
0.04 and so the FDR here is <0.01 and this gave the top 50 contributing genes to this discriminant function 
as shown on (Table 30) while (Figure 43-C) quantifies the top 15 contributors.  
To look at the functions of these genes, a functional annotating clustering in David Bioinformatics 
Resources 6.8 was done. These genes were explained by 7 clusters with cluster 1 having the highest 
enrichment score (4.6 a.u.) and these genes were mainly involved with the extracellular space with a p-
value of 3.5x10-8. Also, several pathways were enriched with KEGG pathway including “proteoglycans in 
cancer” (rno05205, p=3.9x10-4), “PI3K-Akt signalling pathway” (rno04151, p=0.02), “Focal adhesion” 
(rno04510, p=0.03), and “ECM-receptor interaction” (rno04512, p=0.03).  Gene ontology (GO) enrichment 
for young and old samples revealed a list of GOs in which 6 out of top 10 were related to “extracellular”. 
Some of the GOs enrichment will be presented here; for example, “extracellular matrix” (GO: 0031012, 
p=4.48x10-9), “extracellular space” (GO:0005615, p=6.24x10-7), “ageing” (GO:0007568, p=5.3x10-6), 
“extracellular exosome” (GO:0070062, p=2.93x10-5), “response to cytokine” (GO:0034097, p=0.001), and 
“cellular response to interleukine-1” (GO:0071347, p=0.02). Also, protein classification of these genes was 
sought in David Bioinformatics Resources 6.8 which utilises the InterPro database. This database utilises 
several other databases to compare identifiable features to functionally classify new proteins. The main 
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enriched proteins returned were Fibronectin, type II, collagen-binding (IPR000562, p=3.52x10-4), Kringle-
like fold1 (IPR013806, p=0.002) (Patthy et al., 1984), and small leucine-rich proteoglycan, class I, 
decorin/asporin/byglycan (IPR016352, p=0.009).  
Multivariate analysis of channel genes of all young and old samples  
Also, DA-PCA for channel genes with 10 PCs to separate groups was performed. It turned out a 
clear separation (Figure 44-A). Also, a heatmap was generated that shows the correct belonging prediction 
of each sample to each group (Figure 44-B) with the probability of belonging of greater than 0.8. The top 
15 contributing genes to this separation are shown in (Figure 44-C) while the top 50 genes contributing to 
the difference between all young and old are shown in Table 30 
Table 30: top 50 genes contributed to the DA-PCA of all young and old samples.  
Ensemble ID Gene ID LD1 GENE NAME 
ENSRNOG00000001469 Eln 0.13142108 elastin 
ENSRNOG00000012660 Postn 0.07869047 periostin 
ENSRNOG00000012579 Tlcd1 0.073747397 TLC domain containing 1 
ENSRNOG00000019414 Tmem79 0.054747875 transmembrane protein 79 
ENSRNOG00000046313 Basp1 0.047793873 brain abundant, membrane attached signal protein 1 
ENSRNOG00000046834 C3 0.045407123 complement C3 
ENSRNOG00000053025 NA 0.041489768 NA 
ENSRNOG00000016539 Mxd3 0.036130552 Max dimerization protein 3 
ENSRNOG00000037894 NA 0.035376935 NA 
ENSRNOG00000013442 Ciz1 0.021033757 CDKN1A interacting zinc finger protein 1 
ENSRNOG00000000506 Tead3 0.017880638 TEA domain transcription factor 3 
ENSRNOG00000003357 Col3a1 0.013672632 collagen type III alpha 1 chain 
ENSRNOG00000039315 Cfap157 0.012637055 cilia and flagella associated protein 157 
ENSRNOG00000024779 Polr2b 0.012610184 RNA polymerase II subunit B 
ENSRNOG00000012840 Sparc 0.012275292 secreted protein acidic and cysteine-rich 
ENSRNOG00000019992 Cnbd2 0.009221728 cyclic nucleotide binding domain containing 2 
ENSRNOG00000048733 Nup62 0.009126601 nucleoporin 62 
ENSRNOG00000026053 Grem1 0.008701938 gremlin 1, DAN family BMP antagonist 
ENSRNOG00000008415 Nab2 0.008314069 Ngfi-A binding protein 2 
ENSRNOG00000003931 Arsg 0.008303714 arylsulfatase G 
 




ENSRNOG00000020389 Capn12 0.007851615 calpain 12 
ENSRNOG00000023668 Scyl1 0.007526158 SCY1 like pseudokinase 1 
ENSRNOG00000011971 C1s 0.006745817 complement C1s 
ENSRNOG00000019052 Ankzf1 0.006590713 ankyrin repeat and zinc finger domain containing 1 
ENSRNOG00000017420 Nudt6 0.005775042 nudix hydrolase 6 
ENSRNOG00000016460 Clu 0.005549064 clusterin 
ENSRNOG00000043451 Spp1 0.005485935 secreted phosphoprotein 1 
ENSRNOG00000019162 Emc9 0.005151075 ER membrane protein complex subunit 9 
ENSRNOG00000015499 Serinc4 0.005077154 serine incorporator 4 
ENSRNOG00000003897 Col1a1 0.004990918 collagen type I alpha 1 chain 
ENSRNOG00000016740 Fam210a 0.004720909 family with sequence similarity 210, member A 
ENSRNOG00000057040 Spns2 0.004712189 sphingolipid transporter 2 
ENSRNOG00000056819 Susd1 0.004396124 sushi domain containing 1 
ENSRNOG00000001414 Serpine1 0.004217473 serpin family E member 1 
ENSRNOG00000018233 Gas6 0.00406451 growth arrest specific 6 
ENSRNOG00000020628 LOC103690068 0.004004462 immortalization up-regulated protein-like 
ENSRNOG00000004094 Ptger1 0.003772715 prostaglandin E receptor 1 
ENSRNOG00000009439 Eef1a1 0.003736281 eukaryotic translation elongation factor 1 alpha 1 
ENSRNOG00000058068 Obscn 0.003647309 obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 
ENSRNOG00000001229 Col18a1 0.003594128 collagen type XVIII alpha 1 chain 
ENSRNOG00000054890 Flna 0.003481199 filamin A 
ENSRNOG00000058560 Col2a1 0.003419738 collagen type II alpha 1 chain 
ENSRNOG00000016488 Pltp 0.003390998 phospholipid transfer protein 
ENSRNOG00000017206 Igfbp5 0.003372693 insulin-like growth factor binding protein 5 
ENSRNOG00000023493 Creb3l4 0.003239972 cAMP responsive element binding protein 3-like 4 
ENSRNOG00000008951 Rasl10a 0.003069361 RAS-like, family 10, member A 
ENSRNOG00000019657 Mk1 0.002888024 Mk1 protein 
ENSRNOG00000019477 Zmynd15 0.002877551 zinc finger, MYND-type containing 15 
ENSRNOG00000008697 Ccn3 0.002804959 cellular communication network factor 3 






Figure 41: PCA analysis of all young and old of FLS, AORTA, and PVN. 
PCA analysis of Young and Old rat FLS, AORTA, and PVN. A. shows the scree plot for the 10 principle components used to reduce the dimensionality of the FLS, AORTA, and PVN young old datasets, 
approximately 22038 variables (genes) reduced to 10 variables (PC) with 20 subjects; 10 young and 10 old male rats.  PCA Component 1 alone accounts for approximately 47% of the variance in 
the data.  B. Contribution plot showing the relative contributions of each of the 20 subjects to the principal components.  The red dotted line indicates the mean contribution. The first four subjects 






Figure 42: Principle component, k-mean clustering and combined scatter plot of all young and old of FLS, AORTA, and PVN. 
A, B and C show plots of PC1 vs PC2, PC1 vs PC3 and PC2 vs PC3 (Dim=PC).  The shaded circles show the unsupervised k mean cluster 95% confidence intervals thus there is no clear statistical 





Figure 43: Discriminant Analyses of ageing Effects on all genes of all young and old of FLS, AORTA, and PVN. 
A. Shows the kernel density plots of the discriminant component coordinates for the young and old groups; co-ordinates on the x-axis and density on the y-axis. There is a good clear separation 
between young and old samples. B. A graphical confusion matrix showing the actual group membership (y-axis) and predicted cluster membership (on the y-axis).  All groups are correctly clustered 
with greater than 0.8 probability except FLS_T1. C. The most powerful contributing genes to the linear discriminator function; Eln; elastin, Postn; periostin, Tlcd1; TLC domain containing 1, 
Tmem79; transmembrane protein 79, Basp1; brain abundant, membrane attached signal protein 1, C3; complement C3, NA; NA, Mxd3; Max dimerization protein 3, NA; NA, Ciz1; CDKN1A 
interacting zinc finger protein 1, Tead3; TEA domain transcription factor 3, Col3a1; collagen type III alpha 1 chain, Cfap157; cilia and flagella associated protein 157, Polr2b; RNA polymerase II 






Figure 44: Discriminant Analyses of ageing Effects on channel genes of all young and old of FLS, AORTA, and PVN. 
A. Shows the kernel density plots of the discriminant component coordinates for the young and old groups; co-ordinates on the x-axis and density on the y-axis. There is a good clear separation 
between young and old samples. B. A graphical confusion matrix showing the actual group membership (y-axis) and predicted cluster membership (on the y-axis).  All groups are correctly clustered 
with greater than 0.8 probability except some FLS samples. C. The most contributing genes to the linear discriminator function; Gja1; gap junction protein, alpha 1, Kctd18; potassium channel 
tetramerization domain containing 18, Cacna1g; calcium voltage-gated channel subunit alpha1 G, Kctd19; potassium channel tetramerization domain containing 19, Hvcn1; hydrogen voltage-
gated channel 1, Pam; peptidylglycine alpha-amidating monooxygenase, Csrp3; cysteine and glycine-rich protein 3, Kcnk4; potassium two pore domain channel subfamily K member 4, Vdac3; 
voltage-dependent anion channel 3, Clic1; chloride intracellular channel 1, Kcmf1; potassium channel modulatory factor 1, Vdac1; voltage-dependent anion channel 1, Pkd2; polycystin 2, transient 
receptor potential cation channel, Chrna3; cholinergic receptor nicotinic alpha 3 subunit, Clic4; chloride intracellular channel 4. 
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Multivariate analysis of all control and cytokine (10ng/ml TNFα+IL-1β for 
72hrs) treated samples  
In this multivariate analysis, NGS data from FLS, Aortic VSMC and chondrocytes 
(unpublished data kindly provided by RBJ group) were included. Again, multivariate analysis 
was used to separate groups (control vs cytokine treated samples). As before, the start was 
with PCA, this time with 22 individuals (samples), 22038 genes and 10 components. This PCA 
with 10 PCs generated a scree plot showing the percentage of explained variance by each 
dimension. Interestingly, more than 58% of the variance was explained by dimension 1 alone 
(Figure 45-A). Contributions of each sample (individual) to the separation is shown in (Figure 
45-B). The separation between control and cytokine treated groups was not clear between 
PC1 and PC2 (Figure 46-A), PC1 and PC3 (Figure 46-B) or PC2 and PC3 (Figure 46-C) while 
Figure 46-D shows the 3D plot of all PCs against each other which again has no obvious 
clustering. Since the separation with PCA was not clear, A supervised multivariate analysis 
DA-PCA was done. 17 PCs were the appropriate number for the separation and since there 
are only two groups, there was only 1 discriminant function. The separation was much better 
as shown in (Figure 47-A). Also, a heatmap (Figure 47--B) shows belonging of each sample to 
their group and correct prediction. The predicted probability of belonging was greater than 
0.9.  The top 50 genes contributing to this separation are shown in Table 31 while (Figure 47-
C) shows the top 15 of these contributing genes.  
To find out the function of these genes, a functional annotating clustering in David 
Bioinformatics Resources 6.8 was used. These genes were explained by 10 clusters with 
cluster 1 having the highest enrichment score of 3.43 and these genes were mainly involved 
with signalling with a p-value of 1.4x10-5. Also, KEGG pathway enrichment showed several 
statistically significant pathways including “ECM-receptor interaction” (rno04512, p=8.4x10-
5), ”Focal adhesion” (rno04510, p=1.99x10-4), ”Protein digestion and absorption” (rno04974, 
p=0.002) and “PI3K-Akt signalling pathway” (rno04151, p=0.002). Five out of the top ten of 
219 
 
the main GO enrichments were again related to the extracellular space/matrix, the common 
GOs will be presented here. For example, ”extracellular matrix” (GO:0031012, p=4.13x10-
10), “cell adhesion” (GO:0007155, p=2.98x10-5), “extracellular matrix organization” 
(GO:0030198, p=7.62x10-5), “angiogenesis” (GO:0001525, p=0.009), “ageing” (GO:0007568, 
p=0.04), and “cellular response to tumor necrosis factor” (GO:0071356, p=0.04) were the 
common GOs. The InterPro database revealed “Collagen triple helix repeat” (IPR008160, 
p=8.4x10-4) and “Fibrillar collagen, C-terminal” (IPR000885, p=0.03). 
Multivariate analysis of differentially expressed channel genes of all control 
and cytokine (10ng/ml TNFα+IL-1β for 72hrs) treated samples  
Next, DA-PCA on the data filtered for channel genes with 16 PCs to separate groups 
was performed. It turned out a clear separation as shown by kernel density plot (Figure 48-
A). Again, a heatmap was generated that shows the correct belonging prediction of each 
sample to each group (Figure 48-B) with a predicted probability of belonging of greater than 
0.9. The top 15 contributing genes to this separation are shown on  (Figure 48-C) while the 
top 50 genes contributing to the difference between all control and cytokines are shown in 
Table 31.   
Table 31: Top 50 genes contributing to the DA-PCA in all control and cytokine treated samples.  
Ensemble ID Gene ID LD1 GENE NAME 
ENSRNOG00000037894 AABR07068042.1 0.190076808 NA (NOT A KNOWN GENE) 
ENSRNOG00000047907 LOC100912585 0.13849575 mitogen-activated protein kinase 7-like 
ENSRNOG00000001469 Eln 0.106064575 elastin 
ENSRNOG00000012660 Postn 0.095500481 periostin 
ENSRNOG00000020389 Capn12 0.06325397 calpain 12 
ENSRNOG00000020346 Best1 0.051078924 bestrophin 1 
ENSRNOG00000046313 Basp1 0.034452234 brain abundant, membrane attached signal protein 1 
ENSRNOG00000043451 Spp1 0.018173454 secreted phosphoprotein 1 
ENSRNOG00000054890 Flna 0.012560313 filamin A 
ENSRNOG00000012840 Sparc 0.011580614 secreted protein acidic and cysteine-rich 
ENSRNOG00000016740 Fam210a 0.008895896 family with sequence similarity 210, member A 
ENSRNOG00000015499 Serinc4 0.008854299 serine incorporator 4 
ENSRNOG00000003357 Col3a1 0.008596346 collagen type III alpha 1 chain 
ENSRNOG00000013987 Sbno2 0.008295102 strawberry notch homolog 2 
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ENSRNOG00000016488 Pltp 0.007805867 phospholipid transfer protein 
ENSRNOG00000017420 Nudt6 0.007148302 nudix hydrolase 6 
ENSRNOG00000046834 C3 0.006931073 complement C3 
ENSRNOG00000011971 C1s 0.005502947 complement C1s 
ENSRNOG00000000506 Tead3 0.005428161 TEA domain transcription factor 3 
ENSRNOG00000053025 AC130391.3 0.005281306 NA (NOT A KNOWN GENE) 
ENSRNOG00000008951 Rasl10a 0.004886079 RAS-like, family 10, member A 
ENSRNOG00000003897 Col1a1 0.004741078 collagen type I alpha 1 chain 
ENSRNOG00000058068 Obscn 0.004578265 
obscurin, cytoskeletal calmodulin and titin-interacting 
RhoGEF 
ENSRNOG00000001229 Col18a1 0.004536439 collagen type XVIII alpha 1 chain 
ENSRNOG00000012579 Tlcd1 0.00397011 TLC domain containing 1 
ENSRNOG00000058618 Dcst2 0.003853329 DC-STAMP domain containing 2 
ENSRNOG00000019657 Mk1 0.003501833 Mk1 protein 
ENSRNOG00000005695 Mgp 0.003157524 matrix Gla protein 
ENSRNOG00000010233 Cald1 0.002827684 caldesmon 1 
ENSRNOG00000017628 Tagln 0.002818038 transgelin 
ENSRNOG00000045829 Thbs1 0.002813471 thrombospondin 1 
ENSRNOG00000013442 Ciz1 0.002738807 CDKN1A interacting zinc finger protein 1 
ENSRNOG00000025689 Abhd1 0.002587131 abhydrolase domain containing 1 
ENSRNOG00000003931 Arsg 0.002525482 arylsulfatase G 
ENSRNOG00000012207 Dst 0.002493232 dystonin 
ENSRNOG00000022619 Fth1 0.002461379 ferritin heavy chain 1 
ENSRNOG00000002052 Ccdc80 0.002416084 coiled-coil domain containing 80 
ENSRNOG00000059504 NA 0.002401354 NA (NOT A KNOWN GENE) 
ENSRNOG00000039668 Col8a1 0.002389889 collagen type VIII alpha 1 chain 
ENSRNOG00000046005 Scd2 0.002221052 stearoyl-Coenzyme A desaturase 2 
ENSRNOG00000018087 Vim 0.002209076 vimentin 
ENSRNOG00000026951 Susd5 0.002204525 sushi domain containing 5 
ENSRNOG00000024779 Polr2b 0.002167036 RNA polymerase II subunit B 
ENSRNOG00000022932 Serhl2 0.002124122 serine hydrolase-like 2 
ENSRNOG00000024657 Mfsd4a 0.001941625 major facilitator superfamily domain-containing 4A 
ENSRNOG00000014287 Stk11 0.001921727 serine/threonine kinase 11 
ENSRNOG00000017206 Igfbp5 0.001885916 insulin-like growth factor binding protein 5 
ENSRNOG00000018033 Ddx19a 0.001862009 DEAD-box helicase 19A 
ENSRNOG00000010966 Itgb1 0.001768046 integrin subunit beta 1 






Figure 45: PCA analysis of all control and cytokines treated rats’ FLS, VSMC, and chondrocytes. 
PCA analysis of Control and Cytokine (IL-1β+TNFα) treated adult rat FLS, VSMC, and chondrocytes. A. shows the scree plot for the 10 principle components used to reduce the dimensionality of 
the FLS, VSMC, and chondrocytes control and cytokine treated datasets, approximately 22038 variables (genes) reduced to 10 variables (PC) with 22 subjects; 11 control and 11 cytokines treated 
male rats. PCA Component 1 alone accounts for approximately 58% of the variance in the data.  B. Contribution plot showing the relative contributions of each of the 22 subjects to the principal 





Figure 46: Principle component, k-mean clustering and combined scatter plot of all control and cytokines treated rats’ FLS, VSMC, and chondrocytes. 
A, B and C show plots of PC1 vs PC2, PC1 vs PC3 and PC2 vs PC3 (Dim=PC).  The shaded circles show the unsupervised k mean cluster 95% confidence intervals thus there is no clear statistical 






Figure 47: Discriminant Analyses of cytokine Effects on all genes of all control and cytokines treated rats’ FLS, VSMC, and chondrocytes. 
A. Shows the kernel density plots of the discriminant component coordinates for the control and cytokine (IL-1β+TNFα) treated groups; co-ordinates on the x-axis and density on the y-axis. There 
is a clear separation between control and cytokine treated samples. B. A graphical confusion matrix showing the actual group membership (x-axis) and predicted cluster membership (on the y-
axis).  All groups are correctly clustered with greater than 0.9 probability. C. The most contributing genes to the linear discriminator function; NA; unidentified variant, LOC100912585; mitogen-
activated protein kinase 7-like, Eln; elastin, Postn; periostin, Capn12; calpain 12, Best1; bestrophin 1, Basp1; brain abundant, membrane attached signal protein 1, Spp1; secreted phosphoprotein 
1, Flna; filamin A, Sparc; secreted protein acidic and cysteine-rich, Fam210a; family with sequence similarity 210, member A, Serinc4; serine incorporator 4, Col3a1; collagen type III alpha 1 chain, 





Figure 48: Discriminant Analyses of cytokine Effects on ion channel genes of all control and cytokines treated rats’ FLS, VSMC, and chondrocytes. 
A. Shows the kernel density plots of the discriminant component coordinates for the control and cytokine (IL-1β+TNFα) treated groups; co-ordinates on the x-axis and density on the y-axis. There 
is a clear separation between control and cytokine treated samples. B. A graphical confusion matrix showing the actual group membership (y-axis) and predicted cluster membership (on the y-
axis).  All groups are correctly clustered with greater than 0.9 probability. C. The most contributing genes to the linear discriminator function; Pkd2; polycystin 2, transient receptor potential 
cation channel, Pkd2l2; polycystin 2 like 2, transient receptor potential cation channel, Trpv6; transient receptor potential cation channel, subfamily V, member 6, Kctd18; potassium channel 
tetramerization domain containing 18, Piezo1; piezo-type mechanosensitive ion channel component 1, Trpv2; transient receptor potential cation channel, subfamily V, member 2, Glud1; 
glutamate dehydrogenase 1, Ano1; anoctamin 1, Gja5; gap junction protein, alpha 5, Hvcn1; hydrogen voltage-gated channel 1, Chrna2; cholinergic receptor nicotinic alpha 2 subunit, Kcnj9; 
potassium voltage-gated channel subfamily J member 9, Clic3; chloride intracellular channel 3, Asic1; acid-sensing ion channel subunit 1, and Clcc1; chloride channel CLIC-like 1. , and 0.007414555; 




Multivariate analysis of differentially expressed genes of all control, cytokine 
(10ng/ml TNFα+IL-1β for 72hrs) treated, young and old samples  
Clustering with PCA of 42 individuals (samples), 22038 genes allowed us to reduce 
the PCs from 22038 to 10 PCs. The generated scree plot showing the percentages of explained 
variance of each dimension is shown in Figure 49-A with more than 35% of the variance is 
explained by dimension 1. Also, the contribution of each sample (individual) to the separation 
between the groups is presented in Figure 49-B. Since the separation was not clear using PC1 
and PC2 (Figure 50-A), PC1 and PC3 (Figure 50-B), or PC2 and PC3 (Figure 50-C) while (Figure 
50-D) shows the 3D plot of all PCs against each other, therefore I moved to DA-PCA.  
A supervised multivariate analysis (DA-PCA) was performed. 27 PCs and 1 
discriminant function were needed to obtain good separation as shown in (Figure 51-A). Also, 
the heatmap (Figure 51-B) was generated that shows group membership of each sample and 
the probability of correct prediction. The probability of belonging was greater than 0.9 on 
average. Mean p-value for this over-all separation was 0.026 and again the bootstrap method 
(described earlier) was used to estimate FDR, this time with 100 simulations with the data 
matrix repeatedly shuffled, none reached statistical significance (therefore FDR<0.01). The 
top 50 contributing genes to this separation are shown on (Table 32) while (Figure 51-C) 
shows the top 15 of them.  
With functional annotating clustering in David Bioinformatics Resources 6.8, these 
genes were explained by 7 clusters with cluster 1 having the highest enrichment score of 4.6 
and these genes were mainly involved with extracellular space with a p-value of 3.5x10-8. The 
following pathways were enriched on KEGG pathway; “Protein digestion and absorption” 
(rno04974, p=5.52x10-5), “ECM-receptor interaction” (rno04512, p=5.52x10-5), “Focal 
adhesion” (rno04510, p=1.19x10-4), and ”PI3K-Akt signalling pathway” (rno04151, p=0.001). 
Again, four out of the top 10 GOs were mainly related to “extracellular”. Examples of GO 
enriched in this group are “extracellular matrix” (GO:0031012, p=8.58x10-9), “extracellular 
226 
 
space” (GO:0005615, p=3.47x10-8), “collagen fibril organization” (GO:0030199, p=9.49x10-
5), “extracellular matrix structural constituent” (GO:0005201, p=1.95x10-4), “angiogenesis” 
(GO:0001525, p=7.24x10-4), “aging” (GO:0007568, p=0.005), “response to cytokine” 
(GO:0034097, p=0.02), and “cellular response to tumor necrosis factor” (GO:0071356, 
p=0.04). The InterPro discovered “Fibrillar collagen, C-terminal” (IPR000885, p=3.28x10-4), 
“Collagen triple helix repeat” (IPR008160, p=7.37x10-4), some of the epidermal-like growth 
factor (binding) such as “EGF-like calcium-binding” (IPR001881, p=0.003), and insulin-like 
growth factors (binding proteins) such as “Insulin-like growth factor binding protein, N-
terminal” (IPR009030, p=0.003).  
Multivariate analysis of differentially expressed channel genes of all control, 
cytokine (10ng/ml TNFα+IL-1β for 72hrs) treated, young and old samples  
In this analysis, 25 DA-PCA  PCs were used to separate groups and this produced clear 
separation as shown by the Kernel density plot (Figure 52-A). Also, a heatmap shows the 
correct prediction of each sample belonging to each group (Figure 52-B) was generated and 
the probability of belonging was greater than 0.9. The top 50 contributing genes to LDA are 
shown in Table 32 while 15 contributing genes to this separation are shown on (Figure 52-C).  
Table 32: Top 50 genes contributing to the LD1 in all groups; control, cytokines (10ng/ml TNFα+IL-1β for 72hrs) 
treated, young and old samples.  
Ensemble IDs LD1 Gene IDs Gene description 
ENSRNOG00000000506 0.017880638 Tead3 TEA domain transcription factor  
ENSRNOG00000001229 0.003594128 Col18a1 collagen type XVIII alpha 1 chain  
ENSRNOG00000001414 0.004217473 Serpine1 serpin family E member 1 
ENSRNOG00000001469 0.13142108 Eln elastin 
ENSRNOG00000003357 0.013672632 Col3a1 collagen type III alpha 1 chain  
ENSRNOG00000003897 0.004990918 Col1a1 collagen type I alpha 1 chain 
ENSRNOG00000003931 0.008303714 Arsg arylsulfatase G  
ENSRNOG00000004094 0.003772715 Ptger1 prostaglandin E receptor 1 
ENSRNOG00000008415 0.008314069 Nab2 Ngfi-A binding protein 2 
ENSRNOG00000008697 0.002804959 Ccn3 cellular communication network factor 3 
ENSRNOG00000008951 0.003069361 Rasl10a RAS-like, family 10, member A  
ENSRNOG00000009439 0.003736281 Eef1a1 eukaryotic translation elongation factor 1 alpha 1  
ENSRNOG00000010529 0.00280402 Thbs2 thrombospondin 2  
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ENSRNOG00000011971 0.006745817 C1s complement C1s  
ENSRNOG00000012579 0.073747397 Tlcd1 TLC domain containing 1  
ENSRNOG00000012660 0.07869047 Postn periostin  
ENSRNOG00000012840 0.012275292 Sparc secreted protein acidic and cysteine-rich 
ENSRNOG00000013442 0.021033757 Ciz1 CDKN1A interacting zinc finger protein 1  
ENSRNOG00000015499 0.005077154 Serinc4 serine incorporator 4 
ENSRNOG00000016460 0.005549064 Clu clusterin  
ENSRNOG00000016488 0.003390998 Pltp phospholipid transfer protein  
ENSRNOG00000016539 0.036130552 Mxd3 RAB24, member RAS oncogene family  
ENSRNOG00000016740 0.004720909 Fam210a family with sequence similarity 210, member A  
ENSRNOG00000017206 0.003372693 Igfbp5 insulin-like growth factor binding protein 5  
ENSRNOG00000017420 0.005775042 Nudt6 nudix hydrolase 6  
ENSRNOG00000018233 0.00406451 Gas6 growth arrest specific 6  
ENSRNOG00000019052 0.006590713 Ankzf1 ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1  
ENSRNOG00000019162 0.005151075 Emc9 ER membrane protein complex subunit 9 
ENSRNOG00000019414 0.054747875 Tmem79 transmembrane protein 79  
ENSRNOG00000019477 0.002877551 Zmynd15 zinc finger, MYND-type containing 15  
ENSRNOG00000019657 0.002888024 Mk1 Mk1 protein  
ENSRNOG00000019992 0.009221728 Cnbd2 cyclic nucleotide binding domain containing 2  
ENSRNOG00000020389 0.007851615 Capn12 calpain 12  
ENSRNOG00000020628 0.004004462 LOC103690068 immortalization up-regulated protein-like  
ENSRNOG00000023493 0.003239972 Creb3l4 cAMP responsive element binding protein 3-like 4  
ENSRNOG00000023668 0.007526158 Scyl1 SCY1 like pseudokinase 1  
ENSRNOG00000024779 0.012610184 Polr2b RNA polymerase II subunit B  
ENSRNOG00000026053 0.008701938 Grem1 gremlin 1, DAN family BMP antagonist  
ENSRNOG00000037894 0.035376935 AABR07068042.1 NA (Not a known gene) 
ENSRNOG00000039315 0.012637055 Cfap157 cilia and flagella associated protein 157  
ENSRNOG00000043451 0.005485935 Spp1 secreted phosphoprotein 1  
ENSRNOG00000046313 0.047793873 Basp1 brain abundant, membrane attached signal protein 1  
ENSRNOG00000046834 0.045407123 C3 complement C3  
ENSRNOG00000048733 0.009126601 Nup62 nucleoporin 62  
ENSRNOG00000053025 0.041489768 AC130391.3  NA (Not a known gene) 
ENSRNOG00000054890 0.003481199 Flna filamin A  
ENSRNOG00000056819 0.004396124 Susd1 sushi domain containing 1  
ENSRNOG00000057040 0.004712189 Spns2 sphingolipid transporter 2  
ENSRNOG00000058068 
0.003647309 Obscn 
obscurin, cytoskeletal calmodulin and titin-interacting 
RhoGEF  





Figure 49: PCA analysis of group 1 (Control + Young) and group 2 (Cytokine (IL-1β+TNFα) treated + Old) rat FLS, Chondrocytes, VSMC, Aorta, and PVN.  
A. shows the scree plot for the 10 principle components used to reduce the dimensionality of the groups’ datasets, approximately 22038 variables (genes) reduced to 10 variables (PC) with 42 
subjects; 21 (group 1) and 21 (group 2) male rats. PCA Component 1 alone accounts for approximately 35% of the variance in the data.  B. Contribution plot showing the relative contributions of 






Figure 50: Principle component, k-mean clustering and combined scatter plot of all samples according to their groups. 
A, B and C show plots of PC1 vs PC2, PC1 vs PC3 and PC2 vs PC3 (Dim=PC).  The shaded circles show the unsupervised k mean cluster 95% confidence intervals thus there is no clear statistical 







Figure 51: Discriminant Analyses of group 1 (Control + Young) and group 2 (Cytokine (IL-1β+TNFα) treated + Old) rat FLS, Chondrocytes, VSMC, Aorta, and PVN.  
A. Shows the kernel density plots of the discriminant component coordinates for the control and cytokine (IL-1β+TNFα) treated groups; co-ordinates on the x-axis and density on the y-axis. There 
is a clear separation between group 1 (control and young ) and group 2 (cytokine treated and old) samples. B. A graphical confusion matrix showing the actual group membership (y-axis) and 
predicted cluster membership (on the y-axis).  All groups are correctly clustered with greater than 0.9 probability except FLS_C4 and FLS-T1. C. The most powerful contributing genes to the linear 
discriminator function; Eln; elastin, Postn; periostin, Tlcd1; TLC domain containing 1, Tmem79; transmembrane protein 79, Basp1; brain abundant, membrane attached signal protein 1, C3; 
complement C3, <NA>; Not a known gene, Mxd3; RAB24, member RAS oncogene family, <NA>; Not a known gene, Ciz1; CDKN1A interacting zinc finger protein 1, Tead3; TEA domain transcription 




Figure 52: Discriminant Analyses of CHANNELS of group 1 (Control + Young) and group 2 (Cytokine (IL-1β+TNFα) treated + Old) rat FLS, Chondrocytes, VSMC, Aorta, and PVN.  
A. Shows the kernel density plots of the discriminant component coordinates for the control and cytokine (IL-1β+TNFα) treated groups; co-ordinates on the x-axis and density on the y-axis. There 
is a clear separation between group 1 (control and young ) and group 2 (cytokine treated and old) samples. B. A graphical confusion matrix showing the actual group membership (y-axis) and 
predicted cluster membership (on the y-axis).  All groups are correctly clustered with greater than 0.9 probability except FLS_C1, FLS_C2 and FLS-T3. C. The top 15 contributors to the linear 
discriminator function; Pkd2l2; polycystin 2 like 2, transient receptor potential cation channel, Pkd2; polycystin 2, transient receptor potential cation channel, Clic3; chloride intracellular channel 
3, Trpv6; transient receptor potential cation channel, subfamily V, member 6, Cacna1g; calcium voltage-gated channel subunit alpha1 G, Ano1; anoctamin 1, Piezo1; piezo-type mechanosensitive 
ion channel component 1, Kctd18; potassium channel tetramerization domain containing 18, Hvcn1; hydrogen voltage-gated channel 1, Glud1; glutamate dehydrogenase 1, Clic2; chloride 
intracellular channel 2, Cracr2b; EF-hand calcium-binding domain-containing protein 4A-like, Kcnma1; potassium calcium-activated channel subfamily M alpha 1, Vdac2; voltage-dependent anion 




6.4 Discussion  
In this chapter, bioinformatic analyses of all the NGS data from the previous chapters was 
performed together with a chondrocyte dataset collected in parallel by colleagues.  Over-all the most 
common changes observed were in the extracellular matrix.  
The comparison took place by comparing a group containing all young with a group containing all 
old samples, a group containing all control samples with a group containing all cytokine treated samples, 
and the last comparison took place by comparing all samples together where control and young samples 
considered as a group and all cytokine treated and old samples as one group.  
With the real aged tissue, there were 20 samples and approximately 22,000 variables (genes). This 
was reduced to 6 PCs for PCA while DA-PCA method needed 10 PCs to obtain better separation with the 
groups of samples containing young and old only (FLS, VSMC, and PVN). The next group was of control 
and cytokine (10ng/ml IL-1β+TNFα) treated samples (FLS, VSMC, and Chondrocytes), 22 samples analysed, 
5 PCs were used first for the separation, but it needed more to obtain nice and clear separation with DA-
PCA. For the last group that contains all control and young as group 1 and cytokine treated with old 
samples as group 2, the number of samples was bigger (42 samples). Therefore,  5 PCs with PCA were not 
enough to obtain a clear separation but 27 PCs produced nicer discrimination. For all samples, they were 
all represented by 22038 genes.  
Differences  
First groups for comparison were all young and old samples. In this group, the enrichment was 
“extracellular space” with a p-value of 3.5x10-8. Extracellular space means, according to “QuickGO” 
(Ashburner et al., 2000, 2019), any structure that is lying outside the cell that either support or provide 
biochemical or biomechanical indications for the cells. The same finding was also repeated when 
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comparing all samples together [group1 (young and control) vs group2 (old and cytokine treated)]  while 
all control and cytokine (10ng/ml IL-1β+TNFα) treated samples had “signalling” enrichment with a p-value 
of 1.4x10-5. This may indicate that the largest contribution to the separation between groups of all samples 
came from all young and old samples whereas groups containing control and cytokine treated cells did 
not contribute significantly. This may also indicate that the “inflammageing model” that was established 
in this study did not 100% match the real inflammageing model (and see later) although changes have 
been seen in terms of gene expression and functional analysis with electrophysiology. The reason for that, 
as hypothesized in this study, was because young FLS and VSMC cells were treated with cytokines to create 
this model and it seemed that the anti-inflammatory mechanism might have been more efficient in these 
cells because of their young age in addition to the fact that not all changes that usually take place with 
ageing had these cells been exposed to.  
A final, but important detail on the differences between [young and old] vs [“control” and cytokine 
treated] comes from the PCA where all samples were compared, but the age and age model (=cytokine 
treated) groups were annotated separately. From this it is strikingly apparent that there was, in 
multivariate PCA terms, a much bigger separation between the combined [young and old] group and the 
[“control” and cytokine treated] than there was between either [young] vs [old] or [“control”] vs [cytokine 
treated].  This is interesting because in theory it is expected that [young] and [“control”] to be near 
identical even if [old] and [cytokine treated] were not similar. This is because [“control”] was cells from 
young animals from a similar strain (Wistar versus Wistar Kyoto). One explanation for the difference 
between [young] and [“control”] would be that there is a true difference between Wistar and Wistar 
Kyoto, however, it seems implausible that such a difference would be greater than the difference between 
[“control”] and [cytokine treated]. Another, possibility is methodological in that all the [“control”] and 
[cytokine treated] RNA came from were cultured cells whilst that of [young] and [old] came from frozen, 
non-cultured tissue sections.  Both systems have their advantages and disadvantages.  Culturing cells 
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could decrease the numbers of animals required (because 4 animals supply 4 cultures that can be then 
split to create paired test and control groups, whereas with young and old they need to be 4 animals of 
each), also since culture experiments have paired samples the statistical power should be greater. 
Cultured cells also have the advantage of being (more likely to be) a homogenous population of cells 
compared to whole tissue samples that must contain mixed cell populations.  A clear advantage of tissue 
sections, however, is they are frozen at source and thus there should be none of the phenotypic switching 
established for long term cultured cells with changes in ion channels and other genes well document 
(Hdud et al., 2012, Benya and Shaffer, 1982).  Culture periods were minimised to ameliorate this issue, 
but the inference from the PCA is that it may still have been an issue.  
Similarities  
There were however many other similarities between young and old samples, control and 
cytokine treated cells, and all samples group1 (control and young) and group2 (cytokine and old). For 
example, on KEGG pathways, focal adhesion, ECM-receptor interaction and PI3K-Akt signalling pathways 
were common between the compared groups. Also, GO revealed some similarities as well. For example, 
extracellular matrix and ageing were commonly enriched GOs in all groups. Also, the “response to tumour 
necrosis factor” was of noteworthy and was not surprising as this what was used; in addition to IL-1β, to 
treat cells to create the “inflammageing” model. The InterPro proteins were mainly related to the 
extracellular proteins such as collagens.  
Looking at the genes enriched in these KEGG pathways in this study, it was interesting to see some 
genes that regulated extracellular space/matrix such as collagens, beta-actin, and Mmp2 contributing to 
the separation between groups as they had been changed according to treatment or age. These genes 
could have mediated cell-to-cell communications, played roles in healthy microenvironment between 
cells, and altered membrane receptor interactions through different receptors including ion channels (i.e. 
mechanosensitive cation channels such as TRPV4 (Guilak et al., 2010)) that eventually altered intracellular 
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signalling. Most of the enriched GOs and InterPro proteins were related to ageing and extracellular areas 
of the cells involving their proteins such as collagens.  
Previous studies on some of these genes  
Collagens are considered the backbone of tissues which also include other proteins such as 
laminins and elastin (Karsdal, 2016). The synthesis and degradation of these proteins are tightly regulated 
to ensure tissues health and homeostasis. Collagens are divided into several subgroups containing fibrillar 
and networking collagens. The latter were mostly studied (Karsdal, 2016). Some of these collagens such 
as Col1a1, Col2a1, Col3a1, Col18a1 as well as Mmp2, and Fn1 that were differentially expressed in this 
project will be covered. 
A study conducted on Col1a1 found that collagen fibres were highly straightened with age (Van 
Gulick et al., 2019, Misra et al., 2007). Also, age-related changes of Col2a1 and Fn1 were observed in a 
way that they were far more reduced than in the young subjects (Madej et al., 2016). Col3a1 is another 
gene that participated in the pathway enrichment was reported to be differentially expressed with ageing 
in other tissues along with inflammatory processes (Sandovici et al., 2016, Misra et al., 2007).  
Col18a1 is a naturally occurring agent. It is known for inhibiting angiogenesis and endothelial cell 
migration. Several hypotheses have been described for that including the blockage of the binding of 
VEGFA to its receptor (KDR), binding to heparan sulfate proteoglycans involved in the growth factor 
signalling, and modulation of integrin-dependent endothelial cell migration including integrin itgb1 
(Ständker et al., 1997, Kuo et al., 2001).  
Matrix metalloproteinase 2 (Mmp2), also changed in most aged samples, is an enzyme 
responsible for the degradation of native collagen types such as IV, V, VII and X as well denatured collagens 
and elastins affecting the mechanical properties of the blood vessel wall. It may also play a helpful role in 
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the migration of VSMC in response to arterial injury which may naturally increase with the age (or 
inflammatory state) of any older animal (McNulty et al., 2005).  
6.5 Conclusions  
There are many similarities in the KEGG pathways, GOs and InterPro proteins between young and 
old compared to control and cytokine treated cells in NGS data in this project. This indicates that the 
“inflammageing” model that was created in this project is close to the real ageing model presented by the 
old rats; at least, in terms of gene expression. This also shows that the time (72hrs) and the dose of the 
cytokine (10ng/ml IL-1β+TNFα) treatment were appropriate based on the above-mentioned data. 
Future work  
There are a number of interesting directions follow-up studies could take, for example, future 
studies could; 
• Validate the NGS data with mass-spec proteomics where possible 
• Validate the pathways and InterPro proteins with proteomics 
• Produce functional models to investigate how these changes may affect overall tissue and cell 
function 
• Validate these experimental studies with pre-clinical trials on human subjects, where possible.  














Chapter 7 – General discussion 
Next-generation sequencing (NGS) is a powerful technique generating a huge amount of data and 
allowing insight into global cellular changes that previously were impossible. Therefore, the effects of 
ageing on FLS, Aorta and PVN cells/tissues’ gene expression with NGS were studied. Then, a comparison 
of the outcomes of within and between groups (cells/tissues) was followed. later on, these experiments 
were repeated and data analysis with FLS, Chondrocytes (chondrocytes analysis only, raw data from a 
colleague), and VSMC cells after cytokine (10 ng/ml IL-1β+TNFα, for 72hrs) treatment took place. Next, 
another comparison took place of all young with all old samples, all control with all cytokine treated cells, 
and lastly all samples together through grouping them into group 1 (all control and young) against group2 
(all cytokine treated and old). NGS data of specific channel genes (i.e. BK in FLS and ANO1 in VSMC) was 
confirmed with qPCR.  
To test the function of (potential) differentially expressed ion channels, whole-cell patch-clamp 
electrophysiology comparing control with cytokine treatment was performed. Then, the effects of drugs 
on specific channels were tested. the effects of BK channel opener (NS1619) and blocker (paxilline) on FLS 
cells were examined. The calcium-activated chloride channel (also known as ANO1) blocker (CaCCinh-
AO1) was tested in both control and cytokine treated VSMC. It was difficult to test the function of ion 
channels in PVN because in practice it is only possible to culture neurones from very young animals. 
Therefore, only NGS was carried out for PVN.   
In this project, The main changes in terms of pathways and clusters of biological functions are 





Table 33: Summary of the main changes of KEGG pathways and GOs in this project.  





KEGG pathways GOs 
FLS 
C vs T 
canonical calcium signalling 
pathway, the rheumatoid and 
osteoarthritis, and cellular 
movement and proliferation 
canonical pathways 
extracellular space, extracellular region, 
integrin-mediated signalling pathway, 
regulation of the apoptotic process, 
apoptotic process, immune response, and 
inflammatory response 
Y vs O None statistically significant 
Focal adhesion, Extracellular exosome, and 
Extracellular matrix, RNA processing 
VSMC C vs T 
NF-kappa B signalling pathway, 
TNF signalling pathway and 
Cytokine-cytokine receptor 
interaction  
extracellular exosome, angiogenesis, 
extracellular space, ageing and signal 
transduction 
Aorta Y vs O 
Carbohydrate digestion and 
absorption and cardiac muscle 
contraction 
skeletal muscle contraction, regulation of 
muscle contraction, positive regulation of 
myoblast differentiation, skeletal muscle 
fibre development, troponin complex, and 
extracellular space  




involved were hormones and 
elements of signal transduction  
biological processes; development 
(myelination and neurone ensheathing), 
molecular functions; protein binding, 
 2+ng and Caincluding signalling receptor bindi




All C vs T 
ECM-receptor interaction, Focal 
adhesion, Protein digestion and 
absorption and PI3K-Akt 
signalling pathways 
extracellular matrix, cell adhesion, 
extracellular matrix organization, 
angiogenesis, ageing and cellular response to 
tumour necrosis factor 
All Y vs O 
proteoglycans in cancer, PI3K-
Akt signalling pathway, Focal 
adhesion and ECM-receptor 
interaction 
extracellular matrix, and extracellular space, 
ageing, extracellular exosome, response to 
cytokine and cellular response to 
interleukine-1 
All C+Y vs 
T+O 
Protein digestion and 
absorption, ECM-receptor 
interaction, Focal adhesion, and 
PI3K-Akt signalling pathway 
extracellular matrix, extracellular space, 
collagen fibril organization, extracellular 
matrix structural constituent, angiogenesis, 
ageing, response to cytokine and cellular 
response to tumour necrosis factor 
Data obtained from Davids Bioinformatics Resources 6.8. Genes were uploaded, enrichment 
analysis took place and results were obtained. The top enrichments for groups compared with each other 
were presented in this table. 
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In this table, although tissue-specific pathways (osteoarthritis for FLS, the contraction for aorta 
and VSMC and neuroactive ligand-receptor interaction for the PVN) can be seen, the extracellular related 
enrichments are common among all tissue functions.  Examples of genes involved in such enrichments 
are collagens, beta-actin and Mmp2. However, additionally, in terms of individual gene differential 
expression, the key gene changed was Gja1. Its level decreased after cytokine treatment in FLS and VSMC 
(statistically significant) and increased with ageing in FLS, Aorta and PVN (statistically significant). In the 
following sections, Gja1 and the main changes in the pathways and GOs will be covered.  
Gap junctions are membrane channels that allow ions and small molecules to pass through 
between the cytoplasmic contents of adjacent cells. This kind of communication results in different 
physiological functions including growth regulation and development, and tissue homeostasis (Fraser et 
al., 1987, Peters et al., 1994, Goodenough and Paul, 2009, Meşe et al., 2007, Giepmans, 2004). Any 
abnormal changes in gap junction expression or function result in an impaired cell to cell communication 
and subsequent disruption of the intracellular signalling leading to diseases such as re-entry arrhythmias 
of the heart (Watanabe et al., 2004)). It also has been associated with Alzheimer’s disease  (Kajiwara et 
al., 2018). Gja1 is expressed in the musculoskeletal system in tissues such as bone, cartilage, skeletal 
muscle and synovium. Dysfunction of the Gja1 can contribute to the joint diseases such as rheumatoid 
arthritis, osteoarthritis, skeletal muscle atrophy (reviewed here (Donahue et al., 2017)). Beker et al 
(Becker et al., 2015) demonstrate that transient downregulation of Gja1 (Cx43) or block of this 
hemichannel can decrease inflammation. Additionally, innexin genes encoding gap junction subunits have 
been linked with ageing. Innexin unc-9 loss increases lifespan (longevity) as described in the study on 
C.elegans (Vladis et al., 2019). In this project, downregulation of Gja1 after cytokine (10ng/ml TNFα+IL-β, 
72hrs) treatment has been associated with downregulation of some inflammatory markers such as IL-6, 
CXCL16, CXCL1. Although changes in the expression of different genes have been seen, this 
downregulation of Gja1 and the inflammatory markers could be attributed to the cells’ ability to oppose 
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the inflammatory mechanisms to restore normal cellular homeostasis after they have been exposed to 
the inflammatory cytokines for 72hrs. These cells were in fact young, exposed to cytokines and their anti-
inflammatory mechanisms may still be effective unlike older cells. Further investigation to find out the 
pattern of this downregulation of the Gja1 in response to such cytokines is needed.  
For the ageing tissues/cells, the opposite has been seen in terms of Gja1 expression level. It was 
increased compared to the young. These old rats were visually healthy but biochemically may have not 
reached the chronic low-grade pro-inflammatory status in which pro-inflammatory cytokine levels are 2-
3-fold above normal levels. Gja1 levels are tightly regulated and Gja1 has a short half-life of about 3.5hrs. 
In case of rapid response is needed, the rate of Gja1 synthesis increases while the degradation of this 
protein is inhibited (Ribeiro-Rodrigues et al., 2017). Ageing can affect the expression of several genes and 
proteins. Therefore, the hypothesis that was made here was that the increased level of Gja1 associated 
with ageing in this study could be attributed to the inhibited degradation or increased rate of synthesis of 
this gene. Further investigation of the synthesis, degradation, and functions of this gene as well as its 
related protein in the process of ageing is required.  
For the channel families, variabilities in gene expression have been observed. Important and 
interesting changes in ion channels discovered in this project will be covered.  
K+ channels are important channels in almost all cells. Inwardly rectifying potassium channels 
were upregulated in VSMC following cytokines treatment in this project. These channels allow potassium 
ions to flow into rather than out of the cell.  When hyperpolarization of the VSMC takes place, this type 
of channels becomes activated. As a result, more K+ ions move into the cell from the extracellular space 
to neutralize the hyperpolarization trigger. These channels are also important players in the equilibrium 
potential of potassium. (Cowled and Fitridge, 2011). Rarely, this type of channels conducts small outward 
rectifying K+ currents when the membrane potential is more negative than the equilibrium potential of 
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the K+ ions. This usually involves other types of channels such as 3Na+/2K+ ATPase channels (Cowled and 
Fitridge, 2011). Upregulation of inwardly rectifying potassium channels following cytokines treatment in 
VSMC could be due to activation of an inflammatory pathway. Additionally, this type of channels may play 
a critical role in vasodilation and regulation of the sympathetic nervous system leading to blood pressure 
regulation as suggested by Geraldes et al (Geraldes et al., 2014). Moreover, these channels were 
upregulated in the ageing aorta. Therefore, upregulation of inwardly rectifying potassium channels could 
an indicator of ageing of VSMC.  
Two pore domain potassium channels were upregulated following cytokines treatment in FLS. 
These channels are responsible for controlling the membrane potential of chondrocytes (Clark et al., 2011) 
and dorsal root ganglion (Kim et al., 2012). Also, these channels have been linked to pain and inflammation 
(Qiu et al., 2020). Besides, these channels are sensitive to the pH (Lesage and Lazdunski, 2000). Expression 
of acid-sensing channels has also been changed in FLS cells in this project. Upregulation of two-pore 
domain potassium channels following cytokines treatment could be an indicator of ageing especially, that 
it has been associated with upregulation of these channels in the ageing FLS in this study.  
Acid-sensing channels (ASICs) were also upregulated in FLS following cytokines treatment. ASICs 
are a family of extracellular H+-activated ligated-gated ion channels. These channels play significant roles 
in the physiology and pathology of several conditions. These channels have been reported to regulate cell 
apoptosis, differentiation and autophagy. Not only this but also have been involved in degenerative 
disorders such as Parkinson's disease and arthritis (Zhou et al., 2016). In addition to upregulation of ASICs 
following cytokines treatment, these channels were upregulated in ageing FLS. Therefore, it seems that 
upregulation of ASICs following cytokines treatment could be an indicator of ageing in FLS cells.  
For the GOs enrichment, the effects of both cytokine (10ng/ml TNFα+IL-β, 72hrs) treatment and 
ageing resulted in enrichment of extracellular space/matrix genes in this project. TNFα along with IL-1β 
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has been shown to play roles in the classically age-related disease osteoarthritis, through chondrocytes 
which respond to such cytokines stimulus through the production of catabolism of type II collagen and 
proteoglycan which compromises the extracellular matrix integrity and tissue homeostasis (Goldring and 
Goldring, 2007). TNFα also promotes the production of other cytokines and chemokines from other cells 
such as synoviocytes which ensures the renewal of the inflammatory mediators (Lee et al., 2011). Also, 
TNFα has been associated with loss of type II collagen (Lee et al., 2011). Age-related changes in the 
extracellular matrix are among the common changes that elderly experience (Li et al., 2013). Mainly, 
chondrocytes play major roles in the maintenance of the homeostasis of the articular joints. This function 
is altered with ageing leading to the impaired ability for chondrocytes to maintain the extracellular matrix. 
Not only this but also, the synthetic ability of the chondrocyte is decreased as well while proteoglycans 
become smaller and irregular (Li et al., 2013).  Together, our results showed similarities between 
inflammageing model and the natural ageing in several ways. Inflammatory cytokines affect not only the 
intracellular signalling but also the extracellular space/matrix. Ageing also affects the extracellular 





Future work  
 
• For FLS,   
o Tissue typing can be carried out by flow cytometry (FC) which could detect population 
differences, even after just passage 3.  Our present analysis only takes into account the 
one, majority, cell type being present.  Cell separation techniques would probably allow 
reduced variance within groups and thus increase the possibility of seeing between-group 
variability. To do this, I will need CD90.2 and CD248 markers for FLS cells and 
macrophages CD14, CD16 or CD68 (Hardy et al., 2013). Do FC using these antibodies as 
well as light scatter to separate cells (Jayasuriya et al., 2018). Then, pull FLS with anti-FITC 
microbeads as described here (Hamada et al., 2013). Again, repeat the FC to confirm the 
purity of cells but having only one population of cells which FLS.  
o Tissue-specific knock out (KO) of BK channel in FLS cells from articular joints because BK 
activation has been associated with increased migration and invasion in RA disease. 
Therefore, KO of this channel is expected to limit this these functions and improve the 
prognosis of this disease (Hu et al., 2012b, Pethő et al., 2016, Tanner et al., 2015a). To do 
tissue-specific BK channel KO, 
FLS specific gene is selected. Then, the promoter of this gene is cloned into the plasmid 
that will drive the expression of the Cas-9 enzyme and gRNA that will direct the enzyme 
to the BK gene. The expression of this plasmid will only occur in the FLS cells and via the 
gRNA, cleavage at the BK channel gene will result in tissue-specific BK KO.  The insertion 
and expression of the CRISPR/Cas9 machinery will occur at the zygote level (Meltzer et 
al., 2019). Although the in vitro method has a success rate of 1-10% in which the 
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environment is more controlled, the in vivo KO is expected to be more challenging 
because the input will be from different environments that I can barely control.  
• For Aorta and VSMC 
o Also, single-cell RNA-sequencing would allow greater resolution from aortic tissue itself 
(see below “PVN”). 
o Investigating the inherent changes in the contractile force and phenotype of the VSMC 
cells using a photoelasticity-based method using retardation that is related to the 
difference between the first and the second principal stress as well as their orientation. 
Cells are first treated with calyculin A and Y-27632 which produce large and small cell 
retardation. Actin filaments of the cell co-localize with areas of high retardation. Treated 
cells will have different retardation compared to the control. As cells grow in passage 
number, the retardation of contractile cells decreases because cell switch to synthetic 
phenotype (Sugita et al., 2019).  
• For PVN,  
o With ageing, TRPV3 channel is thermosensitive in the PVN (reviewed here (Caterina, 
2007)). Further investigation of how it’s upregulation in ageing would be interesting; 
perhaps by targeted up-regulation in vivo using small activating RNA method(Kwok et al., 
2019). Or indeed computationally using the model of Feetham et al.  (Feetham et al., 
2015b). Technically patch-clamp validation experiments of the PVN changes would be 
difficult.  Old brain tissue is rarely used due to the technical difficulty and even isolation 
of neurones from older brains is rarely achieved successfully.  
o Single-cell next-generation sequencing (Hwang et al., 2018, Haque et al., 2017, Stevenson 
and Uversky, 2019, Anaparthy et al., 2019). This technique requires some method of cell 
isolation, perhaps microfluidics (Ma et al., 2017, Demaree et al., 2018) and then each 
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cell’s RNA is individually amplified and sequenced.  This would be ideal for the PVN study, 
but it is currently very expensive (3x the price of NGS). It would allow separation of 
neurones and glia (and perhaps other minor cell types such as blood vessel cells) and may 
also allow the separation of different types of neurones.  For model parameterisation 
(e.g., (Feetham et al., 2015b)) it would impart tremendous scientific power to detect 





Our powerful bioinformatics approach using the inflammatory model of ageing “inflammageing” 
showed many similarities with the natural ageing model (old rats) presented by the enrichment of 
different KEGG pathways and GOs. Extracellular matrix/space and ageing were among the most common 
enriched GOs. Although expression of common sets of ion channels has not been found to be linked with 
ageing in this study, expression of some ion channel families can be counted as indicators of ageing. 
Common patterns of Gja1 gene expression is very interesting especially in light of recent findings that 
knockdown of gap junctions resulted in the extension of lifespan in worms. The roles that these gap 
junctions play with ageing process require further investigations. All our data will be publicly shared and 




































Concentrations (quantities) of RNA from FLS young and old samples. The quantities (ng) were high (the last column). Young samples are 










Gel-like image and electropherogram of RNA samles. A. A total RNA sample was degraded for different times. Then, analyzed on Agilent 2100 
Bioanalyzer. As we move to the right, there is a shift toward more small fragments as the degradation progresses. B. Electropherogram 





Appendix 3: Gel-like image of RNA of young and old FLS samples. 
 
Gel-like electrophoresis of FLS young and old samples. A. Bands of the ribosomal subunits (18S and 28S) are shown around 2000 and 4000 
nt, respectively. X-axis shows ladder (L) and FLS samples while y-axis presents nucleotides (nt). B. Electropherograms of RNA QC from PVN 
young and old samples. RNA integrity number is shown in the right side of each sample’s graph. 18S (at ~2000nt) and 28S (~4000nt) peaks are 
shown in the figure where (x-axis) represents nucleotides (nt) and (y-axis) represents the fluorescence unit (FU). Young samples are FLS_Y1C1, 




Appendix 4: QC summary of young and old FLS reads. 
 
Per base quality-Phred quality score of young and old FLS reads. The Phred score is greater than 30 which reflects high quality reads (green 
area), more accurate and there is less rate of error (<1:1000). X-axis represents the position of the base pair in read and y-axis is the phred 
score from 1-40. Once quality hits the green zone, it is not necessary to show higher scores which can reach 60.  
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Concentrations (quantities) of RNA from Aorta young and old samples. The quantities (ng) were low. Samples were DNase treated, cleaned 
with RNAClean XP purification kit, and eluted in 9 µl. The final quantities are shown on the last column. Young aorta samples are AORTA-





Appendix 6: QC summary of RNA of young and old Aorta samples. 
 
Quality check of RNA of young and old Aorta samples. A. Gel-like electrophoresis of Aorta young and old samples. Bands of the ribosomal 
subunits (18S and 28S) are shown around 2000 and 4000 nt, respectively. X-axis shows ladder (L) and Aorta samples while y-axis presents 
nucleotides (nt). B. Electropherograms of RNA QC from Aorta young and old samples. RNA integrity number is shown in the right side of each 
sample’s graph. 18S (at ~2000nt) and 28S (~4000nt) peaks are shown in the figure where (x-axis) represents nucleotides (nt) and (y-axis) 




Appendix 7: QC check of Aorta reads.  
 
QC summary of young and old Aorta reads. Per base quality-Phred quality score of young and old Aorta reads. The Phred score is greater than 
30 which reflects high quality reads (green area), more accurate and there is less rate of error (<1:1000). X-axis represents the position of the 
base pair in read and y-axis is the phred score from 1-40. Once quality hits the green zone, it is not necessary to show higher scores which  can 
reach 60.  
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Concentrations (quantities) of RNA from VSMC control and cytokine treated samples. The quantities (ng) were high. Control samples of 







Appendix 9: Gel-like image of RNA of control and cytokine treated VSMC samples. 
 
Quality check of RNA of young and old VSMC samples . A. Gel-like electrophoresis of VSMC of young and old samples. Bands of the ribosomal 
subunits (18S and 28S) are shown around 2000 and 4000 nt, respectively. X-axis shows ladder (L) and VSMC samples while y-axis presents 
nucleotides (nt). B. Electropherograms of RNA QC from VSMC young and old samples. RNA integrity number is shown in the right side of each 
sample’s graph. 18S (at ~2000nt) and 28S (~4000nt) peaks are shown in the figure where (x-axis) represents nucleotides (nt) and (y-axis) 
represents the fluorescence unit (FU). 17C, 18C, 13C, AND 12C are control samples whereas 17T, 18T, 13T, and 12T are cytokine treated 
samples. Control samples of VSMC are VSMC_17C, VSMC_18C, VSMC_13C and VSMC_12C while cytokines treated VSMC are VSMC_17T, 
VSMC_18T, VSMC_13T and VSMC_12T.  
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Appendix 10: QC summary of control and cytokine treated VSMC reads. 
 
Per base quality-Phred quality score of young and old Aorta reads. The Phred score is greater than 30 which reflects high quality reads (green 
area), more accurate and there is less rate of error (<1:1000). X-axis represents the position of the base pair in read and y-axis is the phred 
score from 1-40. Once quality hits the green zone, it is not necessary to show higher scores which  can reach 60.  
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Concentrations (quantities) of RNA from PVN young and old samples. The quantities (ng) were low. Samples were DNase treated, cleaned with 




Appendix 12: QC summary of RNA of PVN young and old samples. 
 
Gel-like electrophoresis and electropherogram of PVN young and old samples. A. Bands of the ribosomal subunits (18S and 28S) are shown 
around 2000 and 4000 nt, respectively. X-axis shows ladder (L) and PVN samples while y-axis presents nucleotides (nt). B. Electropherograms of 
RNA QC from PVN young and old samples. RNA integrity number is shown in the right side of each sample’s graph. 18S (at ~2000nt) and 28S 




Appendix 13: Summary of QC of PVN young and old reads.  
 
Per base quality-Phred quality score of young and old PVN reads. The Phred score is greater than 30 which reflects high quality reads (green 
area), more accurate and there is less rate of error ( <1 in 1000). X-axis represents the position of the base pair in read. Each read is 150bp. Y-axis 




2019. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Research, 47, D330-
D338. 
ABDUL KADIR, L., STACEY, M. & BARRETT-JOLLEY, R. 2018. Emerging Roles of the Membrane Potential: 
Action Beyond the Action Potential. Frontiers in Physiology, 9. 
ACKERMANN, M., CHAO, L., BERGSTROM, C. T. & DOEBELI, M. 2007. On the evolutionary origin of aging. 
Aging Cell, 6, 235-244. 
AGRE, P. 2006. The Aquaporin Water Channels. 3, 5-13. 
AHMED, M. S., IKRAM, S., BIBI, N. & MIR, A. 2017. Hutchinson–Gilford Progeria Syndrome: A Premature 
Aging Disease. Molecular Neurobiology. 
AKHURST, R. J. & HATA, A. 2012. Targeting the TGFβ signalling pathway in disease. Nature Reviews Drug 
Discovery, 11, 790-811. 
ALBARWANI, S. A., MANSOUR, F., KHAN, A. A., AL-LAWATI, I., AL-KAABI, A., AL-BUSAIDI, A.-M., AL-
HADHRAMI, S., AL-HUSSEINI, I., AL-SIYABI, S. & TANIRA, M. O. 2016. Aging Reduces L-Type Calcium 
Channel Current and the Vasodilatory Response of Small Mesenteric Arteries to Calcium Channel 
Blockers. Frontiers in Physiology, 7. 
AMIN, A. S., TAN, H. L. & WILDE, A. A. 2010. Cardiac ion channels in health and disease. Heart Rhythm, 7, 
117-26. 
ANAPARTHY, N., HO, Y. J., MARTELOTTO, L., HAMMELL, M. & HICKS, J. 2019. Single-Cell Applications of 
Next-Generation Sequencing. Cold Spring Harb Perspect Med, 9. 
ANGULO, E., NOE, V., CASADO, V., MALLOL, J., GOMEZ-ISLA, T., LLUIS, C., FERRER, I., CIUDAD, C. J. & 
FRANCO, R. 2004. Up-regulation of the Kv3.4 potassium channel subunit in early stages of 
Alzheimer's disease. J Neurochem, 91, 547-57. 
ANON 2000. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 
update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis 
Rheum, 43, 1905-15. 
ARITA, M., OHIRA, T., SUN, Y. P., ELANGOVAN, S., CHIANG, N. & SERHAN, C. N. 2007. Resolvin E1 selectively 
interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol, 
178, 3912-7. 
ARMSTRONG, M. E., ALEXANDER, H. D., RITCHIE, J. L., MCMILLAN, S. A. & REA, I. M. 2001. Age-related 
alterations in basal expression and in vitro, tumour necrosis factor alpha mediated, upregulation 
of CD11b. Gerontology, 47, 180-5. 
ASHBURNER, M., BALL, C. A., BLAKE, J. A., BOTSTEIN, D., BUTLER, H., CHERRY, J. M., DAVIS, A. P., DOLINSKI, 
K., DWIGHT, S. S., EPPIG, J. T., HARRIS, M. A., HILL, D. P., ISSEL-TARVER, L., KASARSKIS, A., LEWIS, 
S., MATESE, J. C., RICHARDSON, J. E., RINGWALD, M., RUBIN, G. M. & SHERLOCK, G. 2000. Gene 
Ontology: tool for the unification of biology. Nature Genetics, 25, 25-29. 
ASPINALL, R. 2006. T cell development, ageing and Interleukin-7. Mech Ageing Dev, 127, 572-8. 
BABENKO, A. P., GONZALEZ, G., AGUILAR-BRYAN, L. & BRYAN, J. 1998. Reconstituted Human Cardiac KATP 
Channels : Functional Identity With the Native Channels From the Sarcolemma of Human 
Ventricular Cells. 83, 1132-1143. 
BADOER, E. 1996. Cardiovascular role of parvocellular neurons in the paraventricular nucleus of the 
hypothalamus. News in Physiological Sciences, 11, 43-47. 
BAE, E., CHA, R. H., KIM, Y. C., AN, J. N., KIM, D. K., YOO, K. D., LEE, S. M., KIM, M. H., PARK, J. T., KANG, S. 
W., PARK, J. Y., LIM, C. S., KIM, Y. S., YANG, S. H. & LEE, J. P. 2017. Circulating TNF receptors predict 
cardiovascular disease in patients with chronic kidney disease. Medicine (Baltimore), 96, e6666. 
263 
 
BARDAK, S., TURGUTALP, K., KOYUNCU, M. B., HARI, H., HELVACI, I., OVLA, D., HOROZ, M., DEMIR, S. & 
KIYKIM, A. 2017. Community-acquired hypokalemia in elderly patients: related factors and clinical 
outcomes. Int Urol Nephrol, 49, 483-489. 
BARRETT-JOLLEY, R., LEWIS, R., FALLMAN, R. & MOBASHERI, A. 2010. The Emerging Chondrocyte 
Channelome. Frontiers in Physiology, 1, 1-11. 
BARTOK, B. & FIRESTEIN, G. S. 2010. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. 
Immunological Reviews, 233, 233-255. 
BAUER, J. 1989. Regulation of interleukin 6 receptor expression in human monocytes and monocyte-
derived macrophages. Comparison with the expression in human hepatocytes. Journal of 
Experimental Medicine, 170, 1537-1549. 
BAUGE, C., GIRARD, N., LHUISSIER, E., BAZILLE, C. & BOUMEDIENE, K. 2014. Regulation and Role of 
TGFbeta Signaling Pathway in Aging and Osteoarthritis Joints. Aging Dis, 5, 394-405. 
BECKER, D. L., PHILLIPS, A. R., DUFT, B. J., KIM, Y. & GREEN, C. R. 2015. Translating connexin biology into 
therapeutics. 
BEHR, E. R., DALAGEORGOU, C., CHRISTIANSEN, M., SYRRIS, P., HUGHES, S., TOME ESTEBAN, M. T., 
ROWLAND, E., JEFFERY, S. & MCKENNA, W. J. 2008. Sudden arrhythmic death syndrome: familial 
evaluation identifies inheritable heart disease in the majority of families. Eur Heart J, 29, 1670-80. 
BELLANTUONO, I. & POTTER, P. K. 2016. Modelling ageing and age-related disease. Drug Discovery Today: 
Disease Models, 20, 27-32. 
BELLOCQ, C., VAN GINNEKEN, A. C., BEZZINA, C. R., ALDERS, M., ESCANDE, D., MANNENS, M. M., BARO, I. 
& WILDE, A. A. 2004. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. 
Circulation, 109, 2394-7. 
BENNETT, D. L., CLARK, A. J., HUANG, J., WAXMAN, S. G. & DIB-HAJJ, S. D. 2019. The Role of Voltage-Gated 
Sodium Channels in Pain Signaling. Physiol Rev, 99, 1079-1151. 
BENNETT, M. R., SINHA, S. & OWENS, G. K. 2016. Vascular Smooth Muscle Cells in Atherosclerosis. 
Circulation Research, 118, 692-702. 
BENYA, P. D. & SHAFFER, J. D. 1982. Dedifferentiated chondrocytes reexpress the differentiated collagen 
phenotype when cultured in agarose gels. Cell, 30, 215-24. 
BERENBAUM, F. 2013. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). 
Osteoarthritis and Cartilage, 21, 16-21. 
BHATTACHARJEE, A., JOINER, W. J., WU, M., YANG, Y., SIGWORTH, F. J. & KACZMAREK, L. K. 2003. Slick 
(Slo2.1), a Rapidly-Gating Sodium-Activated Potassium Channel Inhibited by ATP. The Journal of 
Neuroscience, 23, 11681-11691. 
BODA, E., HOXHA, E., PINI, A., MONTAROLO, F. & TEMPIA, F. 2012. Brain expression of Kv3 subunits during 
development, adulthood and aging and in a murine model of Alzheimer's disease. J Mol Neurosci, 
46, 606-15. 
BODMAN, M. A. & VARACALLO, M. 2019. Diabetic Neuropathy. StatPearls. Treasure Island (FL). 
BORASCHI, D., ITALIANI, P., WEIL, S. & MARTIN, M. U. 2018. The family of the interleukin-1 receptors. 
Immunol Rev, 281, 197-232. 
BOSCO, P., FERRI, R., SALLUZZO, M. G., CASTELLANO, S., SIGNORELLI, M., NICOLETTI, F., NUOVO, S. D., 
DRAGO, F. & CARACI, F. 2013. Role of the Transforming-Growth-Factor-beta1 Gene in Late-Onset 
Alzheimer's Disease: Implications for the Treatment. Curr Genomics, 14, 147-56. 
BROZOVICH, F. V., NICHOLSON, C. J., DEGEN, C. V., GAO, Y. Z., AGGARWAL, M. & MORGAN, K. G. 2016. 
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment 
of Smooth Muscle Disorders. Pharmacological Reviews, 68, 476-532. 
BRUST, P. F., SIMERSON, S., MCCUE, A. F., DEAL, C. R., SCHOONMAKER, S., WILLIAMS, M. E., VELICELEBI, 
G., JOHNSON, E. C., HARPOLD, M. M. & ELLIS, S. B. 1993. Human neuronal voltage-dependent 
264 
 
calcium channels: studies on subunit structure and role in channel assembly. Neuropharmacology, 
32, 1089-102. 
BRUUNSGAARD, H. 2002. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. 
Eur Cytokine Netw, 13, 389-91. 
BRUUNSGAARD, H., ANDERSEN-RANBERG, K., HJELMBORG, J. V. B., PEDERSEN, B. K. & JEUNE, B. 2003a. 
Elevated levels of tumor necrosis factor alpha and mortality in centenarians. 115, 278-283. 
BRUUNSGAARD, H., LADELUND, S., PEDERSEN, A. N., SCHROLL, M., JORGENSEN, T. & PEDERSEN, B. K. 
2003b. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old 
people. Clin Exp Immunol, 132, 24-31. 
BRUUNSGAARD, H., SKINHOJ, P., PEDERSEN, A. N., SCHROLL, M. & PEDERSEN, B. K. 2000. Ageing, tumour 
necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol, 121, 255-60. 
BURKE, D., KIERNAN, M. C. & BOSTOCK, H. 2001. Excitability of human axons. Clin Neurophysiol, 112, 1575-
85. 
BURKS, T. N. & COHN, R. D. 2011. Role of TGF-beta signaling in inherited and acquired myopathies. Skelet 
Muscle, 1, 19. 
BURMESTER, G. R., DIMITRIU-BONA, A., WATERS, S. J. & WINCHESTER, R. J. 1983. Identification of three 
major synovial lining cell populations by monoclonal antibodies directed to Ia antigens and 
antigens associated with monocytes/macrophages and fibroblasts. Scand J Immunol, 17, 69-82. 
CAMPBELL, L. M., MAXWELL, P. J. & WAUGH, D. J. 2013. Rationale and Means to Target Pro-Inflammatory 
Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals (Basel), 6, 929-59. 
CANNON, S. C. 2015. Channelopathies of skeletal muscle excitability. Compr Physiol, 5, 761-90. 
CARBONI, G. L., GAO, B., NISHIZAKI, M., XU, K., MINNA, J. D., ROTH, J. A. & JI, L. 2003. CACNA2D2-mediated 
apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and 
disruption of mitochondria membrane integrity. Oncogene, 22, 615-626. 
CARRIERI, G., MARZI, E., OLIVIERI, F., MARCHEGIANI, F., CAVALLONE, L., CARDELLI, M., GIOVAGNETTI, S., 
STECCONI, R., MOLENDINI, C., TRAPASSI, C., DE BENEDICTIS, G., KLETSAS, D. & FRANCESCHI, C. 
2004. The G/C915 polymorphism of transforming growth factor β1 is associated with human 
longevity: a study in Italian centenarians. Aging Cell, 3, 443-448. 
CARUSO, C., CANDORE, G., CIGNA, D., DILORENZO, G., SIRECI, G., DIELI, F. & SALERNO, A. 1996. Cytokine 
production pathway in the elderly. Immunol Res, 15, 84-90. 
CARVALHO-DE-SOUZA, J. L., VARANDA, W. A., TOSTES, R. C. & CHIGNALIA, A. Z. 2013. BK Channels in 
Cardiovascular Diseases and Aging. Aging Dis, 4, 38-49. 
CASTRO, D. & SHARMA, S. 2019. Hypokalemia. StatPearls. Treasure Island (FL). 
CATERINA, M. J. 2007. Transient receptor potential ion channels as participants in thermosensation and 
thermoregulation. American Journal of Physiology-Regulatory, Integrative and Comparative 
Physiology, 292, R64-R76. 
CAVALLONE, L., BONAFE, M., OLIVIERI, F., CARDELLI, M., MARCHEGIANI, F., GIOVAGNETTI, S., DI STASIO, 
G., GIAMPIERI, C., MUGIANESI, E., STECCONI, R., SCIACCA, F., GRIMALDI, L. M., DE BENEDICTIS, G., 
LIO, D., CARUSO, C. & FRANCESCHI, C. 2003. The role of IL-1 gene cluster in longevity: a study in 
Italian population. Mech Ageing Dev, 124, 533-8. 
CHAKROBORTY, S. & STUTZMANN, G. E. 2014. Calcium channelopathies and Alzheimer's disease: insight 
into therapeutic success and failures. Eur J Pharmacol, 739, 83-95. 
CHATTERJEE, A., SHARMA, A., CHEN, M., TOY, R., MOTTOLA, G. & CONTE, M. S. 2014. The pro-resolving 
lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth 
muscle and endothelial cells. PLoS One, 9, e113480. 
CHENG, J., WEN, J., WANG, N., WANG, C., XU, Q. & YANG, Y. 2019. Ion Channels and Vascular Diseases. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 39. 
265 
 
CHENG, W., SUN, C. & ZHENG, J. 2010. Heteromerization of TRP channel subunits: extending functional 
diversity. Protein & Cell, 1, 802-810. 
CHIURCHIU, V., LEUTI, A. & MACCARRONE, M. 2018. Bioactive Lipids and Chronic Inflammation: Managing 
the Fire Within. Front Immunol, 9, 38. 
CHRISTOPHER, DEREK & CHARLES 2014. Proresolving Lipid Mediators and Mechanisms in the Resolution 
of Acute Inflammation. Immunity, 40, 315-327. 
CHRYSAFIDES, S. M. & SHARMA, S. 2019. Physiology, Resting Potential. StatPearls. Treasure Island (FL). 
CHUNG, H. Y., CESARI, M., ANTON, S., MARZETTI, E., GIOVANNINI, S., SEO, A. Y., CARTER, C., YU, B. P. & 
LEEUWENBURGH, C. 2009. Molecular inflammation: underpinnings of aging and age-related 
diseases. Ageing Res Rev, 8, 18-30. 
CHUNG, K. F. 2009. Cytokines. Elsevier. 
CLARK, R. B., SCHMIDT, T. A., SACHSE, F. B., BOYLE, D., FIRESTEIN, G. S. & GILES, W. R. 2017. Cellular 
electrophysiological principles that modulate secretion from synovial fibroblasts. J Physiol, 595, 
635-645. 
CLARKE, R., VALDES-MARQUEZ, E., HILL, M., GORDON, J., FARRALL, M., HAMSTEN, A., WATKINS, H. & 
HOPEWELL, J. C. 2018. Plasma cytokines and risk of coronary heart disease in the PROCARDIS 
study. Open Heart, 5, e000807. 
COHEN, R. M., FOELL, J. D., BALIJEPALLI, R. C., SHAH, V., HELL, J. W. & KAMP, T. J. 2005. Unique modulation 
of L-type Ca2+ channels by short auxiliary beta1d subunit present in cardiac muscle. Am J Physiol 
Heart Circ Physiol, 288, H2363-74. 
COLLIN, T., LORY, P., TAVIAUX, S., COURTIEU, C., GUILBAULT, P., BERTA, P. & NARGEOT, J. 1994. Cloning, 
chromosomal location and functional expression of the human voltage-dependent calcium-
channel beta3 subunit. 220, 257-262. 
COLLINS, J. S., PERRY, R. T., WATSON, B., JR., HARRELL, L. E., ACTON, R. T., BLACKER, D., ALBERT, M. S., 
TANZI, R. E., BASSETT, S. S., MCINNIS, M. G., CAMPBELL, R. D. & GO, R. C. 2000. Association of a 
haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH 
Alzheimer Disease Genetics Initiative. Am J Med Genet, 96, 823-30. 
COMMINS, S., STEINKE, J. W. & BORISH, L. 2008. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, 
IL-24, IL-26, IL-28, and IL-29. Journal of Allergy and Clinical Immunology, 121, 1108-1111. 
COOTE, J. H. 1995. Cardiovascular function of the paraventricular nucleus of the hypothalamus. Biological 
Signals, 4, 142-149. 
COOTE, J. H. 2005. A role for the paraventricular nucleus of the hypothalamus in the autonomic control 
of heart and kidney. Experimental physiology, 90, 169-73. 
COOTE, J. H. 2007. Landmarks in understanding the central nervous control of the cardiovascular system. 
Experimental Physiology, 92, 3-18. 
COWLED, P. & FITRIDGE, R. 2011. Pathophysiology of Reperfusion Injury. In: FITRIDGE, R. & THOMPSON, 
M. (eds.) Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. Adelaide 
(AU). 
CUI, J., COX, D. H. & ALDRICH, R. W. 1997. Intrinsic voltage dependence and Ca2+ regulation of mslo large 
conductance Ca-activated K+ channels. J Gen Physiol, 109, 647-73. 
CUI, J., YANG, H. & LEE, U. S. 2009. Molecular mechanisms of BK channel activation. Cell Mol Life Sci, 66, 
852-75. 
DANE, E. L. & GRINSTAFF, M. W. 2012. Poly-amido-saccharides: Synthesis via Anionic Polymerization of a 
β-Lactam Sugar Monomer. 134, 16255-16264. 
DANIIL, G., FERNANDES-ROSA, F. L., CHEMIN, J., BLESNEAC, I., BELTRAND, J., POLAK, M., JEUNEMAITRE, 
X., BOULKROUN, S., AMAR, L., STROM, T. M., LORY, P. & ZENNARO, M. C. 2016. CACNA1H 




DAVIS, A. J., FORREST, A. S., JEPPS, T. A., VALENCIK, M. L., WIWCHAR, M., SINGER, C. A., SONES, W. R., 
GREENWOOD, I. A. & LEBLANC, N. 2010. Expression profile and protein translation of TMEM16A 
in murine smooth muscle. Am J Physiol Cell Physiol, 299, C948-59. 
DAVIS, A. J., SHI, J., PRITCHARD, H. A., CHADHA, P. S., LEBLANC, N., VASILIKOSTAS, G., YAO, Z., VERKMAN, 
A. S., ALBERT, A. P. & GREENWOOD, I. A. 2013. Potent vasorelaxant activity of the TMEM16A 
inhibitor T16A(inh) -A01. Br J Pharmacol, 168, 773-84. 
DAY, M. J. 2010. Ageing, immunosenescence and inflammageing in the dog and cat. J Comp Pathol, 142 
S1, S60-9. 
DE CEUNINCK, F., DASSENCOURT, L. & ANRACT, P. 2004. The inflammatory side of human chondrocytes 
unveiled by antibody microarrays. Biochem Biophys Res Commun, 323, 960-9. 
DE HOOGE, A. S., VAN DE LOO, F. A., BENNINK, M. B., ARNTZ, O. J., DE HOOGE, P. & VAN DEN BERG, W. B. 
2005. Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. 
Osteoarthritis Cartilage, 13, 66-73. 
DE KEERSMAECKER, K. 2005. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic 
t(9;14)(q34;q32). 105, 4849-4852. 
DEMAREE, B., WEISGERBER, D., LAN, F. & ABATE, A. R. 2018. An Ultrahigh-throughput Microfluidic 
Platform for Single-cell Genome Sequencing. Journal of Visualized Experiments. 
DEUTCH, A. Y. & WINDER, D. G. 2006. A channel to neurodegeneration. Nat Med, 12, 17-8. 
DI IORIO, A., FERRUCCI, L., SPARVIERI, E., CHERUBINI, A., VOLPATO, S., CORSI, A., BONAFE, M., 
FRANCESCHI, C., ABATE, G. & PAGANELLI, R. 2003. Serum IL-1beta levels in health and disease: a 
population-based study. 'The InCHIANTI study'. Cytokine, 22, 198-205. 
DIDION, S. P., KINZENBAW, D. A., SCHRADER, L. I., CHU, Y. & FARACI, F. M. 2009. Endogenous Interleukin-
10 Inhibits Angiotensin II-Induced Vascular Dysfunction. 54, 619-624. 
DINARELLO, C. A. 2006. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging 
process. Am J Clin Nutr, 83, 447S-455S. 
DINARELLO, C. A. 2018. Overview of the IL-1 family in innate inflammation and acquired immunity. 
Immunol Rev, 281, 8-27. 
DINARELLO, C. A., NOLD-PETRY, C., NOLD, M., FUJITA, M., LI, S., KIM, S. & BUFLER, P. 2016. Suppression of 
innate inflammation and immunity by interleukin-37. Eur J Immunol, 46, 1067-81. 
DONAHUE, H. J., QU, R. W. & GENETOS, D. C. 2017. Joint diseases: from connexins to gap junctions. Nature 
Reviews Rheumatology, 14, 42-51. 
DONG, C. 2008. Regulation and pro-inflammatory function of interleukin-17 family cytokines. 226, 80-86. 
DOUPNIK, C. A., DAVIDSON, N. & LESTER, H. A. 1995. The inward rectifier potassium channel family. 5, 
268-277. 
DOYLE, K. P., CEKANAVICIUTE, E., MAMER, L. E. & BUCKWALTER, M. S. 2010. TGFbeta signaling in the brain 
increases with aging and signals to astrocytes and innate immune cells in the weeks after stroke. 
J Neuroinflammation, 7, 62. 
DOYLE, S. L., OZAKI, E., BRENNAN, K., HUMPHRIES, M. M., MULFAUL, K., KEANEY, J., KENNA, P. F., 
MAMINISHKIS, A., KIANG, A. S., SAUNDERS, S. P., HAMS, E., LAVELLE, E. C., GARDINER, C., FALLON, 
P. G., ADAMSON, P., HUMPHRIES, P. & CAMPBELL, M. 2014. IL-18 attenuates experimental 
choroidal neovascularization as a potential therapy for wet age-related macular degeneration. Sci 
Transl Med, 6, 230ra44. 
EKKENS, M. J., SHEDLOCK, D. J., JUNG, E., TROY, A., PEARCE, E. L., SHEN, H. & PEARCE, E. J. 2007. Th1 and 
Th2 cells help CD8 T-cell responses. Infect Immun, 75, 2291-6. 
ENYEDI, P. & CZIRJAK, G. 2010. Molecular background of leak K+ currents: two-pore domain potassium 
channels. Physiol Rev, 90, 559-605. 
267 
 
ERRO, R., BHATIA, K. P., ESPAY, A. J. & STRIANO, P. 2017. The epileptic and nonepileptic spectrum of 
paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies. Mov Disord, 
32, 310-318. 
ERSHLER, W. B. 1993. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc, 41, 176-81. 
ETCHEBERRIGARAY, R., ITO, E., OKA, K., TOFEL-GREHL, B., GIBSON, G. E. & ALKON, D. L. 1993. Potassium 
channel dysfunction in fibroblasts identifies patients with Alzheimer disease. Proc Natl Acad Sci U 
S A, 90, 8209-13. 
EWING, B. & GREEN, P. 1998. Base-Calling of Automated Sequencer Traces UsingPhred.II. Error 
Probabilities. Genome Research, 8, 186-194. 
EWING, B., HILLIER, L., WENDL, M. C. & GREEN, P. 1998. Base-Calling of Automated Sequencer Traces 
UsingPhred. I. Accuracy Assessment. Genome Research, 8, 175-185. 
FAN, G., CUI, Y., GOLLASCH, M. & KASSMANN, M. 2019. Elementary calcium signaling in arterial smooth 
muscle. Channels, 13, 505-519. 
FARAJNIA, S., MEIJER, J. H. & MICHEL, S. 2015. Age-related changes in large-conductance calcium-
activated potassium channels in mammalian circadian clock neurons. 36, 2176-2183. 
FEETHAM, C. H., NUNN, N. & BARRETT-JOLLEY, R. 2015a. The depressor response to 
intracerebroventricular hypotonic saline is sensitive to TRPV4 antagonist RN1734. Front 
Pharmacol, 6, 83. 
FEETHAM, C. H., NUNN, N., LEWIS, R., DART, C. & BARRETT-JOLLEY, R. 2015b. TRPV4 and KCa ion channels 
functionally couple as osmosensors in the paraventricular nucleus. Br J Pharmacol, 172, 1753-68. 
FEETHAM, C. H., O’BRIEN, F. & BARRETT-JOLLEY, R. 2018. Ion Channels in the Paraventricular 
Hypothalamic Nucleus (PVN); Emerging Diversity and Functional Roles. Frontiers in Physiology, 9. 
FELDER, R. B., FRANCIS, J., WEISS, R. M., ZHANG, Z. H., WEI, S. G. & JOHNSON, A. K. Neurohumoral 
regulation in ischemia-induced heart failure - Role of the forebrain. In: CHAPLEAU, M. W. & 
ABBOUD, F. M., eds., Aug 23-27 2000 Iowa City, Iowa. 444-453. 
FERGUSON, A. V., LATCHFORD, K. J. & SAMSON, W. K. 2008. The paraventricular nucleus of the 
hypothalamus – a potential target for integrative treatment of autonomic dysfunction. Expert 
Opinion on Therapeutic Targets, 12, 717-727. 
FERNANDEZ-FALGUERAS, A., SARQUELLA-BRUGADA, G., BRUGADA, J., BRUGADA, R. & CAMPUZANO, O. 
2017. Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances. Biology 
(Basel), 6. 
FERRUCCI, L., CORSI, A., LAURETANI, F., BANDINELLI, S., BARTALI, B., TAUB, D. D., GURALNIK, J. M. & 
LONGO, D. L. 2005. The origins of age-related proinflammatory state. Blood, 105, 2294-2299. 
FERRUCCI, L. & FABBRI, E. 2018. Inflammageing: chronic inflammation in ageing, cardiovascular disease, 
and frailty. Nature Reviews Cardiology, 15, 505-522. 
FICHTLSCHERER, S., BREUER, S., HEESCHEN, C., DIMMELER, S. & ZEIHER, A. M. 2004. Interleukin-10 serum 
levels and systemic endothelial vasoreactivity in patients with coronary artery disease. Journal of 
the American College of Cardiology, 44, 44-49. 
FLAK, J. N., MYERS, B., SOLOMON, M. B., MCKLVEEN, J. M., KRAUSE, E. G. & HERMAN, J. P. 2014. Role of 
paraventricular nucleus-projecting norepinephrine/epinephrine neurons in acute and chronic 
stress. Eur J Neurosci, 39, 1903-11. 
FLAK, J. N., OSTRANDER, M. M., TASKER, J. G. & HERMAN, J. P. 2009. Chronic stress-induced 
neurotransmitter plasticity in the PVN. J Comp Neurol, 517, 156-65. 
FLOOD, S., PARRI, R., WILLIAMS, A., DUANCE, V. & MASON, D. 2007. Modulation of interleukin-6 and 
matrix metalloproteinase 2 expression in human fibroblast-like synoviocytes by functional 
ionotropic glutamate receptors. Arthritis Rheum, 56, 2523-34. 
FRANCESCHI, C. & CAMPISI, J. 2014. Chronic inflammation (inflammaging) and its potential contribution 
to age-associated diseases. J Gerontol A Biol Sci Med Sci, 69 Suppl 1, S4-9. 
268 
 
FRANCESCHI, C., CAPRI, M., MONTI, D., GIUNTA, S., OLIVIERI, F., SEVINI, F., PANOURGIA, M. P., INVIDIA, 
L., CELANI, L., SCURTI, M., CEVENINI, E., CASTELLANI, G. C. & SALVIOLI, S. 2007a. Inflammaging 
and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in 
humans. Mechanisms of Ageing and Development, 128, 92-105. 
FRANCESCHI, C., CAPRI, M., MONTI, D., GIUNTA, S., OLIVIERI, F., SEVINI, F., PANOURGIA, M. P., INVIDIA, 
L., CELANI, L., SCURTI, M., CEVENINI, E., CASTELLANI, G. C. & SALVIOLI, S. 2007b. Inflammaging 
and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in 
humans. Mech Ageing  Devel, 128, 92-105. 
FRASER, S., GREEN, C., BODE, H. & GILULA, N. 1987. Selective disruption of gap junctional communication 
interferes with a patterning process in hydra. 237, 49-55. 
FRAYLING, T. M., RAFIQ, S., MURRAY, A., HURST, A. J., WEEDON, M. N., HENLEY, W., BANDINELLI, S., CORSI, 
A. M., FERRUCCI, L., GURALNIK, J. M., WALLACE, R. B. & MELZER, D. 2007. An interleukin-18 
polymorphism is associated with reduced serum concentrations and better physical functioning 
in older people. J Gerontol A Biol Sci Med Sci, 62, 73-8. 
FREDMAN, G., HELLMANN, J., PROTO, J. D., KURIAKOSE, G., COLAS, R. A., DORWEILER, B., CONNOLLY, E. 
S., SOLOMON, R., JONES, D. M., HEYER, E. J., SPITE, M. & TABAS, I. 2016. An imbalance between 
specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability 
of atherosclerotic plaques. Nature Communications, 7, 12859. 
FRIEBEL, K., SCHONHERR, R., KINNE, R. W. & KUNISCH, E. 2014. Functional role of the KCa3.1 potassium 
channel in synovial fibroblasts from rheumatoid arthritis patients. J Cell Physiol. 
FRIEBEL, K., SCHÖNHERR, R., KINNE, R. W. & KUNISCH, E. 2015. Functional role of the KCa3.1 potassium 
channel in synovial fibroblasts from rheumatoid arthritis patients. 230, 1677-1688. 
FU, C. H., YANG, C. C. & KUO, T. B. 2006. Age-related changes in cerebral hemodynamics and their 
correlations with cardiac autonomic functions. Neurol Res, 28, 871-6. 
GAFFEN, S. L. 2009. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol 
Rep, 11, 365-70. 
GALIONE, A. & DAVIS, L. C. 2018. Revealing the secrets of secretion. Elife, 7. 
GANGEMI, S. 2003. Increased circulating Interleukin-18 levels in centenarians with no signs of vascular 
disease: another paradox of longevity? 38, 669-672. 
GARCIA-ELIAS, A., LORENZO, I. M., VICENTE, R. & VALVERDE, M. A. 2008. IP3 Receptor Binds to and 
Sensitizes TRPV4 Channel to Osmotic Stimuli via a Calmodulin-binding Site. 283, 31284-31288. 
GARLANDA, C., DINARELLO, C. A. & MANTOVANI, A. 2013. The interleukin-1 family: back to the future. 
Immunity, 39, 1003-18. 
GARRETT-SINHA, L. A., JOHN, S. & GAFFEN, S. L. 2008. IL-17 and the Th17 lineage in systemic lupus 
erythematosus. Curr Opin Rheumatol, 20, 519-25. 
GAVRILOV, L. A. & GAVRILOVA, N. S. 2002. Evolutionary Theories of Aging and Longevity. The Scientific 
World JOURNAL, 2, 339-356. 
GEORGIEV, D., YOSHIHARA, T., KAWABATA, R., MATSUBARA, T., TSUBOMOTO, M., MINABE, Y., LEWIS, D. 
A. & HASHIMOTO, T. 2016. Cortical Gene Expression After a Conditional Knockout of 67 kDa 
Glutamic Acid Decarboxylase in Parvalbumin Neurons. Schizophrenia Bulletin, 42, 992-1002. 
GIEPMANS, B. 2004. Gap junctions and connexin-interacting proteins. 62, 233-245. 
GILLIS, S. & WATSON, J. 1981. Interleukin-2 dependent culture of cytolytic T cell lines. Immunol Rev, 54, 
81-109. 
GIUDICESSI, J. R., YE, D., KRITZBERGER, C. J., NESTERENKO, V. V., TESTER, D. J., ANTZELEVITCH, C. & 
ACKERMAN, M. J. 2012. Novel mutations in the KCND3-encoded Kv4.3 K+ channel associated with 
autopsy-negative sudden unexplained death. Hum Mutat, 33, 989-97. 
GOLDRING, M. B. & GOLDRING, S. R. 2007. Osteoarthritis. Journal of Cellular Physiology, 213, 626-634. 
GOODENOUGH, D. A. & PAUL, D. L. 2009. Gap Junctions. 1, a002576-a002576. 
269 
 
GREENWOOD, M. P., GREENWOOD, M., ROMANOVA, E. V., MECAWI, A. S., PATERSON, A., SARENAC, O., 
JAPUNDŽIĆ-ŽIGON, N., ANTUNES-RODRIGUES, J., PATON, J. F. R., SWEEDLER, J. V. & MURPHY, D. 
2018. The effects of aging on biosynthetic processes in the rat hypothalamic osmoregulatory 
neuroendocrine system. Neurobiology of Aging, 65, 178-191. 
GRIDER, M. H., BELCEA, C. Q., COVINGTON, B. P. & SHARMA, S. 2019. Neuroanatomy, Nodes of Ranvier. 
StatPearls. Treasure Island (FL). 
GRIDER, M. H. & GLAUBENSKLEE, C. S. 2019. Physiology, Action Potential. StatPearls. Treasure Island (FL). 
GRUBB, B. D. 2004. Activation of sensory neurons in the arthritic joint. Novartis Found Symp, 260, 28-36; 
discussion 36-48, 100-4, 277-9. 
GRUNDER, S., GEISSLER, H. S., BASSLER, E. L. & RUPPERSBERG, J. P. 2000. A new member of acid-sensing 
ion channels from pituitary gland. Neuroreport, 11, 1607-11. 
GUI, Y. X., WAN, Y., XIAO, Q., WANG, Y., WANG, G. & CHEN, S. D. 2011. Verification of expressions of Kir2 
as potential peripheral biomarkers in lymphocytes from patients with Parkinson's disease. 
Neurosci Lett, 505, 104-8. 
GUILAK, F., LEDDY, H. A. & LIEDTKE, W. 2010. Transient receptor potential vanilloid 4: The sixth sense of 
the musculoskeletal system? Annals of the New York Academy of Sciences, 1192, 404-409. 
HAN, G., LI, F., SINGH, T. P., WOLF, P. & WANG, X. J. 2012. The pro-inflammatory role of TGFbeta1: a 
paradox? Int J Biol Sci, 8, 228-35. 
HANUKOGLU, I. 2017. ASIC and ENaC type sodium channels: conformational states and the structures of 
the ion selectivity filters. The FEBS Journal, 284, 525-545. 
HAQUE, A., ENGEL, J., TEICHMANN, S. A. & LÖNNBERG, T. 2017. A practical guide to single-cell RNA-
sequencing for biomedical research and clinical applications. Genome Medicine, 9. 
HARMS, R. Z., YARDE, D. N., GUINN, Z., LORENZO-ARTEAGA, K. M., CORLEY, K. P., CABRERA, M. S. & 
SARVETNICK, N. E. 2015. Increased expression of IL-18 in the serum and islets of type 1 diabetics. 
Mol Immunol, 64, 306-312. 
HDUD, I. M., EL-SHAFEI, A. A., LOUGHNA, P., BARRETT-JOLLEY, R. & MOBASHERI, A. 2012. Expression of 
transient receptor potential vanilloid (TRPV) channels in different passages of articular 
chondrocytes. International Journal of Molecular Sciences, 13, 4433-4445. 
HE, W., LIU, W., CHEW, C. S., BAKER, S. S., BAKER, R. D., FORTE, J. G. & ZHU, L. 2011. Acid secretion-
associated translocation of KCNJ15 in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol, 
301, G591-600. 
HEINZE, C., SENIUK, A., SOKOLOV, M. V., HUEBNER, A. K., KLEMENTOWICZ, A. E., SZIJÁRTÓ, I. A., 
SCHLEIFENBAUM, J., VITZTHUM, H., GOLLASCH, M., EHMKE, H., SCHROEDER, B. C. & HÜBNER, C. 
A. 2014. Disruption of vascular Ca2+-activated chloride currents lowers blood pressure. 124, 675-
686. 
HERNANDEZ, C. M. & RICHARDS, J. R. 2019. Physiology, Sodium Channels. StatPearls. Treasure Island (FL). 
HIROKAWA, K., UTSUYAMA, M., HAYASHI, Y., KITAGAWA, M., MAKINODAN, T. & FULOP, T. 2013. Slower 
immune system aging in women versus men in the Japanese population. Immunity & Ageing, 10, 
19. 
HOSHIKAWA, M., KATO, A., HOJO, H., SHIBATA, Y., KUMAMOTO, N., WATANABE, M. & UGAWA, S. 2017. 
Distribution of ASIC4 transcripts in the adult wild-type mouse brain. Neuroscience Letters. 
HOSOYA, Y., SUGIURA, Y., OKADO, N., LOEWY, A. & KOHNO, K. 1991. Descending input from the 
hypothalamic paraventricular nucleus to sympathetic preganglionic neurons in the rat. 
Experimental Brain Research, 85, 10-20. 
HOTTA, H. & UCHIDA, S. 2010. Aging of the autonomic nervous system and possible improvements in 
autonomic activity using somatic afferent stimulation. Geriatr Gerontol Int, 10 Suppl 1, S127-36. 
HU, X., LARAGIONE, T., SUN, L., KOSHY, S., JONES, K. R., ISMAILOV, II, YOTNDA, P., HORRIGAN, F. T., GULKO, 
P. S. & BEETON, C. 2012a. KCa1.1 potassium channels regulate key proinflammatory and invasive 
270 
 
properties of fibroblast-like synoviocytes in rheumatoid arthritis. Journal of biological chemistry, 
287, 4014-22. 
HU, X., LARAGIONE, T., SUN, L., KOSHY, S., JONES, K. R., ISMAILOV, I. I., YOTNDA, P., HORRIGAN, F. T., 
GULKO, P. S. & BEETON, C. 2012b. KCa1.1 Potassium Channels Regulate Key Proinflammatory and 
Invasive Properties of Fibroblast-like Synoviocytes in Rheumatoid Arthritis. 287, 4014-4022. 
HUBER, R., HUMMERT, C., GAUSMANN, U., POHLERS, D., KOCZAN, D., GUTHKE, R. & KINNE, R. W. 2008. 
Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression 
profiles in the rheumatoid arthritis synovial membrane. Arthritis Res Ther, 10, R98. 
HUI, A. Y., MCCARTY, W. J., MASUDA, K., FIRESTEIN, G. S. & SAH, R. L. 2012. A systems biology approach 
to synovial joint lubrication in health, injury, and disease. Wiley Interdiscip Rev Syst Biol Med, 4, 
15-37. 
HWANG, B., LEE, J. H. & BANG, D. 2018. Single-cell RNA sequencing technologies and bioinformatics 
pipelines. Experimental & Molecular Medicine, 50. 
IMBRICI, P., LIANTONIO, A., CAMERINO, G. M., DE BELLIS, M., CAMERINO, C., MELE, A., GIUSTINO, A., 
PIERNO, S., DE LUCA, A., TRICARICO, D., DESAPHY, J. F. & CONTE, D. 2016. Therapeutic Approaches 
to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol, 7, 121. 
IORGA, A. & HOROWITZ, B. Z. 2019. Phenytoin Toxicity. StatPearls. Treasure Island (FL). 
IWANAGA, T., SHIKICHI, M., KITAMURA, H., YANASE, H. & NOZAWA-INOUE, K. 2000. Morphology and 
functional roles of synoviocytes in the joint. Arch Histol Cytol, 63, 17-31. 
JANSEN, A. S. P., WESSENDORF, M. W. & LOEWY, A. D. 1995. Transneuronal Labeling of Cns Neuropeptide 
and Monoamine Neurons after Pseudorabies Virus Injections into the Stellate Ganglion. Brain 
Research, 683, 1-24. 
JAVIER CAMACHO, J., CHÁVEZ-LÓPEZ, M., ZÚÑIGA-GARCÍA, V., PÉREZ-CARREÓN, J., AVALOS-FUENTES, A. 
& ESCOBAR, Y. 2016. Eag1 channels as potential early-stage biomarkers of hepatocellular 
carcinoma. Biologics: Targets and Therapy, Volume 10, 139-148. 
JEFFERIS, B. J., PAPACOSTA, O., OWEN, C. G., WANNAMETHEE, S. G., HUMPHRIES, S. E., WOODWARD, M., 
LENNON, L. T., THOMSON, A., WELSH, P., RUMLEY, A., LOWE, G. D. & WHINCUP, P. H. 2011. 
Interleukin 18 and coronary heart disease: prospective study and systematic review. 
Atherosclerosis, 217, 227-33. 
JENSEN, A. B., JOERGENSEN, H. B., DAM, V. S., KAMAEV, D., BOEDTKJER, D., FÜCHTBAUER, E.-M., 
AALKJAER, C. & MATCHKOV, V. V. 2018. Variable Contribution of TMEM16A to Tone in Murine 
Arterial Vasculature. Basic & Clinical Pharmacology & Toxicology. 
JENTSCH, T. J. & GUNTHER, W. 1997. Chloride channels: an emerging molecular picture. Bioessays, 19, 
117-26. 
JENTSCH, T. J., STEIN, V., WEINREICH, F. & ZDEBIK, A. A. 2002. Molecular Structure and Physiological 
Function of Chloride Channels. Physiological Reviews, 82, 503-568. 
JI, M. J. & HONG, J. H. 2019. An overview of carbonic anhydrases and membrane channels of synoviocytes 
in inflamed joints. J Enzyme Inhib Med Chem, 34, 1615-1622. 
JIANG, Y., PICO, A., CADENE, M., CHAIT, B. T. & MACKINNON, R. 2001. Structure of the RCK domain from 
the E. coli K+ channel and demonstration of its presence in the human BK channel. Neuron, 29, 
593-601. 
JOMBART, T., DEVILLARD, S. & BALLOUX, F. 2010. Discriminant analysis of principal components: a new 
method for the analysis of genetically structured populations. BMC Genet, 11, 94. 
JULIUS, S. 1993. Sympathetic Hyperactivity and Coronary Risk in Hypertension. Hypertension, 21, 886-893. 
JYLHA, M., PAAVILAINEN, P., LEHTIMAKI, T., GOEBELER, S., KARHUNEN, P. J., HERVONEN, A. & HURME, M. 
2007. Interleukin-1 receptor antagonist, interleukin-6, and C-reactive protein as predictors of 
mortality in nonagenarians: the vitality 90+ study. J Gerontol A Biol Sci Med Sci, 62, 1016-21. 
271 
 
KAJIWARA, Y., WANG, E., WANG, M., SIN, W. C., BRENNAND, K. J., SCHADT, E., NAUS, C. C., BUXBAUM, J. 
& ZHANG, B. 2018. GJA1 (connexin43) is a key regulator of Alzheimer's disease pathogenesis. Acta 
Neuropathol Commun, 6, 144. 
KANE, G. C., LAM, C. F., O'COCHLAIN, F., HODGSON, D. M., REYES, S., LIU, X. K., MIKI, T., SEINO, S., KATUSIC, 
Z. S. & TERZIC, A. 2006. Gene knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal 
susceptibility to endotoxemia. FASEB J, 20, 2271-80. 
KANG, Y. M., HE, R. L., YANG, L. M., QIN, D. N., GUGGILAM, A., ELKS, C., YAN, N., GUO, Z. & FRANCIS, J. 
2009. Brain tumour necrosis factor-alpha modulates neurotransmitters in hypothalamic 
paraventricular nucleus in heart failure. Cardiovasc Res, 83, 737-46. 
KAPLAN, J., GERBER, S., BONNEAU, D., ROZET, J. M., DELRIEU, O., BRIARD, M. L., DOLLFUS, H., GHAZI, I., 
DUFIER, J. L., FRÉZAL, J. & MUNNICH, A. 1992. A gene for usher syndrome type I (USH1A) maps to 
chromosome 14q. 14, 979-987. 
KARIMI, A. & MILEWICZ, D. M. 2016. Structure of the Elastin-Contractile Units in the Thoracic Aorta and 
How Genes That Cause Thoracic Aortic Aneurysms and Dissections Disrupt This Structure. 
Canadian Journal of Cardiology, 32, 26-34. 
KARSDAL, M. A. 2016. Collagens - Introduction. 
KIM, D., LANGMEAD, B. & SALZBERG, S. L. 2015. HISAT: a fast spliced aligner with low memory 
requirements. Nature Methods, 12, 357-360. 
KIM, J. B. 2014. Channelopathies. Korean J Pediatr, 57, 1-18. 
KINZENBAW, D. A., CHU, Y., PEÑA SILVA, R. A., DIDION, S. P. & FARACI, F. M. 2013. Interleukin-10 protects 
against aging-induced endothelial dysfunction. Physiological Reports, 1, e00149. 
KIRKWOOD, T. B. L. 1977. Evolution of ageing. Nature, 270, 301-304. 
KIRKWOOD, T. B. L. & HOLLIDAY, R. 1979. The Evolution of Ageing and Longevity. 205, 531-546. 
KONDO, C., CLARK, R. B., KIM, T. Y., BELKE, D., BANDERALI, U., SZERENCSEI, R. T., JALLOUL, A. H., 
SCHNETKAMP, P. P. M., SPITZER, K. W. & GILES, W. R. 2018. ATP triggers a robust intracellular 
[Ca(2+) ]-mediated signalling pathway in human synovial fibroblasts. Exp Physiol, 103, 1101-1122. 
KORN, T., BETTELLI, E., OUKKA, M. & KUCHROO, V. K. 2009. IL-17 and Th17 Cells. Annu Rev Immunol, 27, 
485-517. 
KOTIPOYINA, H. R. & WARRINGTON, S. J. 2019. Tetrodotoxin Toxicity. StatPearls. Treasure Island (FL). 
KRAMER, A., GREEN, J., POLLARD, J., JR. & TUGENDREICH, S. 2014. Causal analysis approaches in Ingenuity 
Pathway Analysis. Bioinformatics, 30, 523-30. 
KRIEGLSTEIN, K., MIYAZONO, K., TEN DIJKE, P. & UNSICKER, K. 2012. TGF-beta in aging and disease. Cell 
Tissue Res, 347, 5-9. 
KRISHNAMOORTHY, N., BURKETT, P. R., DALLI, J., ABDULNOUR, R. E., COLAS, R., RAMON, S., PHIPPS, R. P., 
PETASIS, N. A., KUCHROO, V. K., SERHAN, C. N. & LEVY, B. D. 2015. Cutting edge: maresin-1 
engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution 
of lung inflammation. J Immunol, 194, 863-7. 
KUBICZKOVA, L., SEDLARIKOVA, L., HAJEK, R. & SEVCIKOVA, S. 2012. TGF-beta - an excellent servant but a 
bad master. J Transl Med, 10, 183. 
KUMAHASHI, N., NAITOU, K., NISHI, H., OAE, K., WATANABE, Y., KUWATA, S., OCHI, M., IKEDA, M. & 
UCHIO, Y. 2011. Correlation of changes in pain intensity with synovial fluid adenosine 
triphosphate levels after treatment of patients with osteoarthritis of the knee with high-
molecular-weight hyaluronic acid. The Knee, 18, 160-164. 
KUO, C. J., LAMONTAGNE, K. R., GARCIA-CARDEÑA, G., ACKLEY, B. D., KALMAN, D., PARK, S., 
CHRISTOFFERSON, R., KAMIHARA, J., DING, Y.-H., LO, K.-M., GILLIES, S., FOLKMAN, J., MULLIGAN, 
R. C. & JAVAHERIAN, K. 2001. Oligomerization-Dependent Regulation of Motility and 
Morphogenesis by the Collagen Xviii Nc1/Endostatin Domain. 152, 1233-1246. 
272 
 
KURIYAMA, H., KITAMURA, K., ITOH, T. & INOUE, R. 1998. Physiological features of visceral smooth muscle 
cells, with special reference to receptors and ion channels. Physiol Rev, 78, 811-920. 
LAINA, A., STELLOS, K. & STAMATELOPOULOS, K. 2018. Vascular ageing: Underlying mechanisms and 
clinical implications. Experimental Gerontology, 109, 16-30. 
LAKOSKI, S. G., LIU, Y., BROSNIHAN, K. B. & HERRINGTON, D. M. 2008. Interleukin-10 concentration and 
coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) 
study. Atherosclerosis, 197, 443-447. 
LAMBERT, C., DUBUC, J.-E., MONTELL, E., VERGÉS, J., MUNAUT, C., NOËL, A. & HENROTIN, Y. 2014. Gene 
Expression Pattern of Cells From Inflamed and Normal Areas of Osteoarthritis Synovial 
Membrane. Arthritis & Rheumatology, 66, 960-968. 
LANG, F. & HOFFMANN, E. K. 2013. CrossTalk proposal: Cell volume changes are an essential step in the 
cell death machinery. J Physiol, 591, 6119-21. 
LATORRE, R. & BRAUCHI, S. 2006. Large conductance Ca2+-activated K+ (BK) channel: activation by Ca2+ 
and voltage. Biol Res, 39, 385-401. 
LAURENCE, A., TATO, C. M., DAVIDSON, T. S., KANNO, Y., CHEN, Z., YAO, Z., BLANK, R. B., MEYLAN, F., 
SIEGEL, R., HENNIGHAUSEN, L., SHEVACH, E. M. & O'SHEA J, J. 2007. Interleukin-2 signaling via 
STAT5 constrains T helper 17 cell generation. Immunity, 26, 371-81. 
LEE, J. C. & CHOE, S. Y. 2014. Age-related changes in the distribution of transient receptor potential 
vanilloid 4 channel (TRPV4) in the central nervous system of rats. J Mol Histol, 45, 497-505. 
LEE, J. S., LEE, W. W., KIM, S. H., KANG, Y., LEE, N., SHIN, M. S., KANG, S. W. & KANG, I. 2011a. Age-
associated alteration in naive and memory Th17 cell response in humans. Clin Immunol, 140, 84-
91. 
LEE, S. W., SONG, Y. S., LEE, S. Y., YOON, Y. G., LEE, S. H., PARK, B. S., YUN, I., CHOI, H., KIM, K., CHUNG, W. 
T. & YOO, Y. H. 2011b. Downregulation of Protein Kinase CK2 Activity Facilitates Tumor Necrosis 
Factor-α-Mediated Chondrocyte Death through Apoptosis and Autophagy. PLoS ONE, 6, e19163. 
LEVINE, J. D. & ALESSANDRI-HABER, N. 2007. TRP channels: Targets for the relief of pain. Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease, 1772, 989-1003. 
LEWIS, R., ASPLIN, K. E., BRUCE, G., DART, C., MOBASHERI, A. & BARRETT-JOLLEY, R. 2011a. The Role of 
the Membrane Potential in Chondrocyte Volume Regulation. Journal of Cellular Physiology, 226, 
2979-2986. 
LEWIS, R. & BARRETT-JOLLEY, R. 2015. Changes in Membrane Receptors and Ion Channels as Potential 
Biomarkers for Osteoarthritis. Front Physiol, 6, 357. 
LEWIS, R., FEETHAM, C. H. & BARRETT-JOLLEY, R. 2011b. Cell Volume Regulation in Chondrocytes. Cellular 
Physiology and Biochemistry, 28, 1111-1122. 
LEWIS, R., MAY, H., MOBASHERI, A. & BARRETT-JOLLEY, R. 2013. Chondrocyte channel transcriptomics: do 
microarray data fit with expression and functional data? Channels (Austin), 7, 459-67. 
LEWIS, R., MILLS, A. & BARRETT-JOLLEY, R. 2010. Models Of Paraventricular Nucleus (PVN) Sympathetic 
Neurone Modulation by Glucose and Hypoglycaemia. Biophysical Journal - BIOPHYS J, 98. 
LI, Y., WEI, X., ZHOU, J. & WEI, L. 2013. The Age-Related Changes in Cartilage and Osteoarthritis. BioMed 
Research International, 2013, 1-12. 
LI, Y., ZHAO, Z., CAI, J., GU, B., LV, Y. & ZHAO, L. 2017. The Frequency-Dependent Aerobic Exercise Effects 
of Hypothalamic GABAergic Expression and Cardiovascular Functions in Aged Rats. Frontiers in 
Aging Neuroscience, 9. 
LI, Y. F., CORNISH, K. G. & PATEL, K. P. 2003. Alteration of NMDA NR1 receptors within the paraventricular 
nucleus of hypothalamus in rats with heart failure. Circulation Research, 93, 990-997. 
LI, Y. F., JACKSON, K. L., STERN, J. E., RABELER, B. & PATEL, K. P. 2006a. Interaction between glutamate and 
GABA systems in the integration of sympathetic outflow by the paraventricular nucleus of the 
273 
 
hypothalamus. American Journal of Physiology-Heart and Circulatory Physiology, 291, H2847-
H2856. 
LI, Y. F. & PATEL, K. P. Paraventricular nucleus of the hypothalamus and elevated sympathetic activity in 
heart failure: the altered inhibitory mechanisms. Apr 20-24 2002 New Orleans, Louisiana. 17-26. 
LI, Y. F. & PATEL, K. P. 2003. Paraventricular nucleus of the hypothalamus and elevated sympathetic 
activity in heart failure: the altered inhibitory mechanisms. Acta Physio Scand, 177, 17-26. 
LI, Y. F., WANG, W., MAYHAN, W. G. & PATEL, K. P. 2006b. Angiotensin-mediated increase in renal 
sympathetic nerve discharge within the PVN: role of nitric oxide. American Journal of Physiology-
Regulatory Integrative and Comparative Physiology, 290, R1035-R1043. 
LIAO, Z., DONG, J., WU, W., YANG, T., WANG, T., GUO, L., CHEN, L., XU, D. & WEN, F. 2012. Resolvin D1 
attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process 
involving the PPARγ/NF-κB pathway. Respiratory Research, 13, 110. 
LIO, D. 2003. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-
10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. Journal of Medical 
Genetics, 40, 296-299. 
LIPPIAT, J. D., STANDEN, N. B., HARROW, I. D., PHILLIPS, S. C. & DAVIES, N. W. 2003. Properties of BK(Ca) 
channels formed by bicistronic expression of hSloalpha and beta1-4 subunits in HEK293 cells. The 
Journal of membrane biology, 192, 141-8. 
LIU, L. & CHAN, C. 2014. The role of inflammasome in Alzheimer's disease. Ageing Res Rev, 15, 6-15. 
LOEWY, A. 1991. Forebrain nuclei involved in autonomic control. Progress in brain research, 87, 253. 
LOEWY, A. D. & MCKELLAR, S. 1980. The neuroanatomical basis of central cardiovascular control. 
Fed.Proc., 39, 2495-2503. 
LONG, S. B., CAMPBELL, E. B. & MACKINNON, R. 2005a. Crystal structure of a mammalian voltage-
dependent Shaker family K+ channel. Science, 309, 897-903. 
LONG, S. B., CAMPBELL, E. B. & MACKINNON, R. 2005b. Voltage sensor of Kv1.2: structural basis of 
electromechanical coupling. Science, 309, 903-8. 
LOVICK, T. A. & COOTE, J. H. 1988. Effects of volume loading on paraventriculo-spinal neurones in the rat. 
J Auton Nerv Syst, 25, 135-40. 
LOVICK, T. A. & COOTE, J. H. 1989. Circulating atrial natriuretic factor activates vagal afferent inputs to 
paraventriculo-spinal neurones in the rat. J Auton Nerv Syst, 26, 129-34. 
LOVICK, T. A., MALPAS, S. & MAHONY, M. T. 1993. Renal vasodilatation in response to acute volume load 
is attenuated following lesions of parvocellular neurones in the paraventricular nucleus in rats. 
Journal of the Autonomic Nervous System, 43, 247-256. 
LYTTON, J. 2007. Na+/Ca2+ exchangers: three mammalian gene families control Ca2+ transport. Biochem 
J, 406, 365-82. 
MA, S., MURPHY, T. W. & LU, C. 2017. Microfluidics for genome-wide studies involving next generation 
sequencing. Biomicrofluidics, 11, 021501. 
MACDONALD, M. L. E., VAN ECK, M., HILDEBRAND, R. B., WONG, B. W. C., BISSADA, N., RUDDLE, P., 
KONTUSH, A., HUSSEIN, H., POULADI, M. A., CHAPMAN, M. J., FIEVET, C., VAN BERKEL, T. J. C., 
STAELS, B., MCMANUS, B. M. & HAYDEN, M. R. 2009. Despite Antiatherogenic Metabolic 
Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis. 29, 341-
347. 
MACKINNON, R., HEGINBOTHAM, L. & ABRAMSON, T. 1990. Mapping the receptor site for charybdotoxin, 
a pore-blocking potassium channel inhibitor. Neuron, 5, 767-71. 
MACKINNON, R. & MILLER, C. 1989. Mutant potassium channels with altered binding of charybdotoxin, a 
pore-blocking peptide inhibitor. Science, 245, 1382-5. 
274 
 
MADEJ, W., VAN CAAM, A., BLANEY DAVIDSON, E. N., HANNINK, G., BUMA, P. & VAN DER KRAAN, P. M. 
2016. Ageing is associated with reduction of mechanically-induced activation of Smad2/3P 
signaling in articular cartilage. 24, 146-157. 
MAEZAWA, I., JENKINS, D. P., JIN, B. E. & WULFF, H. 2012. Microglial KCa3.1 Channels as a Potential 
Therapeutic Target for Alzheimer’s Disease. International Journal of Alzheimer's Disease, 2012, 1-
8. 
MAGGIO, M., GURALNIK, J. M., LONGO, D. L. & FERRUCCI, L. 2006. Interleukin-6 in aging and chronic 
disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci, 61, 575-84. 
MAKITA, N., BENNETT, P. B., JR. & GEORGE, A. L., JR. 1994. Voltage-gated Na+ channel beta 1 subunit 
mRNA expressed in adult human skeletal muscle, heart, and brain is encoded by a single gene. J 
Biol Chem, 269, 7571-8. 
MALLAT, Z., GOJOVA, A., MARCHIOL-FOURNIGAULT, C., ESPOSITO, B., KAMATE, C., MERVAL, R., FRADELIZI, 
D. & TEDGUI, A. 2001. Inhibition of transforming growth factor-beta signaling accelerates 
atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res, 89, 930-4. 
MALLAT, Z., HEYMES, C., CORBAZ, A., LOGEART, D., ALOUANI, S., COHEN-SOLAL, A., SEIDLER, T., 
HASENFUSS, G., CHVATCHKO, Y., SHAH, A. M. & TEDGUI, A. 2004. Evidence for altered interleukin 
18 (IL)-18 pathway in human heart failure. FASEB J, 18, 1752-4. 
MANSOUR, F. A., HASSAN, M. O., KHAN, A. A. & ALBARWANI, S. 2016. Aging Down Regulates L-Type 
Voltage-gated Calcium Channels in Resistance Coronary Arteries. Faseb Journal, 30. 
MARCON, R., BENTO, A. F., DUTRA, R. C., BICCA, M. A., LEITE, D. F. & CALIXTO, J. B. 2013. Maresin 1, a 
proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective 
actions in murine models of colitis. J Immunol, 191, 4288-98. 
MARTIN, D. S. & HAYWOOD, J. R. 1993. Hemodynamic responses to paraventricular nucleus disinhibition 
with bicuculline in conscious rats. American Journal of Physiology- Heart and Circulatory 
Physiology, 265, H1727-H1733. 
MARTIN, D. S., SEGURA, T. & HAYWOOD, J. R. 1991. Cardiovascular responses to bicuculline in the 
paraventricular nucleus of the rat. Hypertension, 18, 48-55. 
MARTIN, S. J. 2016. Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs 
of the immune system. The FEBS Journal, 283, 2599-2615. 
MARTINEZ, A. H. & MOHIUDDIN, S. S. 2019. Biochemistry, Chloride Channels. StatPearls. Treasure Island 
(FL). 
MARTINSEN, A., DESSY, C. & MOREL, N. 2014. Regulation of calcium channels in smooth muscle: New 
insights into the role of myosin light chain kinase. 8, 402-413. 
MCCUSKER, S. M., CURRAN, M. D., DYNAN, K. B., MCCULLAGH, C. D., URQUHART, D. D., MIDDLETON, D., 
PATTERSON, C. C., MCILROY, S. P. & PETER PASSMORE, A. 2001. Association between 
polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of 
Alzheimer's disease and vascular dementia: a case-control study. 357, 436-439. 
MCKENZIE, B. S., KASTELEIN, R. A. & CUA, D. J. 2006. Understanding the IL-23-IL-17 immune pathway. 
Trends Immunol, 27, 17-23. 
MCMANUS, O. B., HELMS, L. M., PALLANCK, L., GANETZKY, B., SWANSON, R. & LEONARD, R. J. 1995. 
Functional role of the beta subunit of high conductance calcium-activated potassium channels. 
Neuron, 14, 645-50. 
MCNERLAN, S. E., ARMSTRONG, M., ROSS, O. A. & MAEVE REA, I. 2009. Cytokine Expression and 
Production Changes in Very Old Age. In: FULOP, T., FRANCESCHI, C., HIROKAWA, K. & PAWELEC, 
G. (eds.) Handbook on Immunosenescence: Basic Understanding and Clinical Applications. 
Dordrecht: Springer Netherlands. 
275 
 
MCNERLAN, S. E., REA, I. M. & ALEXANDER, H. D. 2002. A whole blood method for measurement of 
intracellular TNF-alpha, IFN-gamma and IL-2 expression in stimulated CD3+ lymphocytes: 
differences between young and elderly subjects. Exp Gerontol, 37, 227-34. 
MCNULTY, M., SPIERS, P., MCGOVERN, E. & FEELY, J. 2005. Aging is associated with increased matrix 
metalloproteinase-2 activity in the human aorta. 18, 504-509. 
MEDVEDEV, Z. A. 1990. AN ATTEMPT AT A RATIONAL CLASSIFICATION OF THEORIES OF AGEING. Biological 
Reviews, 65, 375-398. 
MEERA, P., WALLNER, M., SONG, M. & TORO, L. 1997. Large conductance voltage- and calcium-dependent 
K+ channel, a distinct member of voltage-dependent ion channels with seven N-terminal 
transmembrane segments (S0-S6), an extracellular N terminus, and an intracellular (S9-S10) C 
terminus. 94, 14066-14071. 
MEKLI, K., MARSHALL, A., NAZROO, J., VANHOUTTE, B. & PENDLETON, N. 2015. Genetic variant of 
Interleukin-18 gene is associated with the Frailty Index in the English Longitudinal Study of Ageing. 
44, 938-942. 
MENDONCA, M. M., SANTANA, J. S., DA CRUZ, K. R., IANZER, D., GHEDINI, P. C., NALIVAIKO, E., FONTES, 
M. A. P., FERREIRA, R. N., PEDRINO, G. R., COLUGNATI, D. B. & XAVIER, C. H. 2018. Involvement of 
GABAergic and Adrenergic Neurotransmissions on Paraventricular Nucleus of Hypothalamus in 
the Control of Cardiac Function. Front Physiol, 9, 670. 
MEŞE, G., RICHARD, G. & WHITE, T. W. 2007. Gap Junctions: Basic Structure and Function. Journal of 
Investigative Dermatology, 127, 2516-2524. 
MISRA, V., LEE, H., SINGH, A., HUANG, K., THIMMULAPPA, R. K., MITZNER, W., BISWAL, S. & TANKERSLEY, 
C. G. 2007. Global expression profiles from C57BL/6J and DBA/2J mouse lungs to determine aging-
related genes. 31, 429-440. 
MITNITSKI, A., COLLERTON, J., MARTIN-RUIZ, C., JAGGER, C., VON ZGLINICKI, T., ROCKWOOD, K. & 
KIRKWOOD, T. B. L. 2015. Age-related frailty and its association with biological markers of ageing. 
BMC Medicine, 13. 
MOBASHERI, A., LEWIS, R., FERREIRA-MENDES, A., RUFINO, A., DART, C. & BARRETT-JOLLEY, R. 2012. 
Potassium channels in articular chondrocytes. Channels, 6, 416-425. 
MOCZYDLOWSKI, E., LUCCHESI, K. & RAVINDRAN, A. 1988. An emerging pharmacology of peptide toxins 
targeted against potassium channels. J Membr Biol, 105, 95-111. 
MONK, B. A. & GEORGE, S. J. 2015. The Effect of Ageing on Vascular Smooth Muscle Cell Behaviour--A 
Mini-Review. Gerontology, 61, 416-26. 
MORTAZ, E., ADCOCK, I. M., SHAFEI, H., MASJEDI, M. R. & FOLKERTS, G. 2012. Role of P2X7 Receptors in 
Release of IL-1β: A Possible Mediator of Pulmonary Inflammation. Tanaffos, 11, 6-11. 
MORTH, J. P., PEDERSEN, B. P., TOUSTRUP-JENSEN, M. S., SORENSEN, T. L., PETERSEN, J., ANDERSEN, J. P., 
VILSEN, B. & NISSEN, P. 2007. Crystal structure of the sodium-potassium pump. Nature, 450, 1043-
9. 
MOSKALEV, A., ALIPER, A., SMIT-MCBRIDE, Z., BUZDIN, A. & ZHAVORONKOV, A. 2014. Genetics and 
epigenetics of aging and longevity. 13, 1063-1077. 
MOSMANN, T. R. & SAD, S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol 
Today, 17, 138-46. 
MUELLER, O., LIGHTFOOT, S., SCHROEDER, A. <RNA Integrity Number (RIN) - Standardization of RNA 
Quality Control.pdf>. 
MUN, M. J., KIM, J. H., CHOI, J. Y. & JANG, W. C. 2016. Genetic polymorphisms of interleukin genes and 
the risk of Alzheimer's disease: An update meta-analysis. Meta Gene, 8, 1-10. 
NATHAN, C. 2002. Points of control in inflammation. Nature, 420, 846-52. 
NGUYEN, T. P. & TAYLOR, R. S. 2019. Guillain Barre Syndrome. StatPearls. Treasure Island (FL). 
276 
 
NGUYEN, V., MENDELSOHN, A. & LARRICK, J. W. 2017. Interleukin-7 and Immunosenescence. J Immunol 
Res, 2017, 4807853. 
NIISSALO, S., LI, T. F., SANTAVIRTA, S., TAKAGI, M., HIETANEN, J. & KONTTINEN, Y. T. 2002. Dense 
innervation in pseudocapsular tissue compared to aneural interface tissue in loose totally 
replaced hips. J Rheumatol, 29, 796-803. 
NILSSON, L., SZYMANOWSKI, A., SWAHN, E. & JONASSON, L. 2013. Soluble TNF receptors are associated 
with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One, 8, 
e55477. 
NOLD, M. F., NOLD-PETRY, C. A., ZEPP, J. A., PALMER, B. E., BUFLER, P. & DINARELLO, C. A. 2010. IL-37 is a 
fundamental inhibitor of innate immunity. Nature Immunology, 11, 1014-1022. 
NOSS, E. H. & BRENNER, M. B. 2008. The role and therapeutic implications of fibroblast-like synoviocytes 
in inflammation and cartilage erosion in rheumatoid arthritis. Immunological Reviews, 223, 252-
270. 
NOVAKOVIC, S. D., EGLEN, R. M. & HUNTER, J. C. 2001. Regulation of Na+ channel distribution in the 
nervous system. 24, 473-478. 
NUNN, N., WOMACK, M., DART, C. & BARRETT-JOLLEY, R. 2011. Function and pharmacology of spinally-
projecting sympathetic pre-autonomic neurones in the paraventricular nucleus of the 
hypothalamus. Current neuropharmacology, 9, 262-77. 
O'LEARY, N. A., WRIGHT, M. W., BRISTER, J. R., CIUFO, S., HADDAD, D., MCVEIGH, R., RAJPUT, B., 
ROBBERTSE, B., SMITH-WHITE, B., AKO-ADJEI, D., ASTASHYN, A., BADRETDIN, A., BAO, Y., 
BLINKOVA, O., BROVER, V., CHETVERNIN, V., CHOI, J., COX, E., ERMOLAEVA, O., FARRELL, C. M., 
GOLDFARB, T., GUPTA, T., HAFT, D., HATCHER, E., HLAVINA, W., JOARDAR, V. S., KODALI, V. K., LI, 
W., MAGLOTT, D., MASTERSON, P., MCGARVEY, K. M., MURPHY, M. R., O'NEILL, K., PUJAR, S., 
RANGWALA, S. H., RAUSCH, D., RIDDICK, L. D., SCHOCH, C., SHKEDA, A., STORZ, S. S., SUN, H., 
THIBAUD-NISSEN, F., TOLSTOY, I., TULLY, R. E., VATSAN, A. R., WALLIN, C., WEBB, D., WU, W., 
LANDRUM, M. J., KIMCHI, A., TATUSOVA, T., DICUCCIO, M., KITTS, P., MURPHY, T. D. & PRUITT, K. 
D. 2016. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, 
and functional annotation. Nucleic Acids Research, 44, D733-D745. 
O'MAHONY, L., HOLLAND, J., JACKSON, J., FEIGHERY, C., HENNESSY, T. P. & MEALY, K. 1998. Quantitative 
intracellular cytokine measurement: age-related changes in proinflammatory cytokine 
production. Clin Exp Immunol, 113, 213-9. 
O'MALLEY, H. A. & ISOM, L. L. 2015. Sodium channel beta subunits: emerging targets in channelopathies. 
Annu Rev Physiol, 77, 481-504. 
O'QUINN, D. B., PALMER, M. T., LEE, Y. K. & WEAVER, C. T. 2008. Emergence of the Th17 pathway and its 
role in host defense. Adv Immunol, 99, 115-63. 
OEGEMA, R., MCGILLIVRAY, G., LEVENTER, R., LE MOING, A. G., BAHI‐BUISSON, N., BARNICOAT, A., 
MANDELSTAM, S., FRANCIS, D., FRANCIS, F., MANCINI, G. M. S., SAVELBERG, S., HAAFTEN, G., 
MANKAD, K. & LEQUIN, M. H. 2019. EML1‐ associated brain overgrowth syndrome with ribbon‐
like heterotopia. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 
OKAMOTO, K., IWASAKI, N., DOI, K., NOIRI, E., IWAMOTO, Y., UCHIGATA, Y., FUJITA, T. & TOKUNAGA, K. 
2012. Inhibition of glucose-stimulated insulin secretion by KCNJ15, a newly identified 
susceptibility gene for type 2 diabetes. Diabetes, 61, 1734-41. 
OKAMOTO, K., IWASAKI, N., NISHIMURA, C., DOI, K., NOIRI, E., NAKAMURA, S., TAKIZAWA, M., OGATA, 
M., FUJIMAKI, R., GRARUP, N., PISINGER, C., BORCH-JOHNSEN, K., LAURITZEN, T., SANDBAEK, A., 
HANSEN, T., YASUDA, K., OSAWA, H., NANJO, K., KADOWAKI, T., KASUGA, M., PEDERSEN, O., 
FUJITA, T., KAMATANI, N., IWAMOTO, Y. & TOKUNAGA, K. 2010. Identification of KCNJ15 as a 
Susceptibility Gene in Asian Patients with Type 2 Diabetes Mellitus. 86, 54-64. 
277 
 
ORLOV, S. N., GUSAKOVA, S. V., SMAGLII, L. V., KOLTSOVA, S. V. & SIDORENKO, S. V. 2017. Vasoconstriction 
triggered by hydrogen sulfide: Evidence for Na(+),K(+),2Cl(-)cotransport and L-type Ca(2+) 
channel-mediated pathway. Biochem Biophys Rep, 12, 220-227. 
ORLOV, S. N., MODEL, M. A. & GRYGORCZYK, R. 2013. CrossTalk opposing view: The triggering and 
progression of the cell death machinery can occur without cell volume perturbations. J Physiol, 
591, 6123-5. 
OUYANG, W., RUTZ, S., CRELLIN, N. K., VALDEZ, P. A. & HYMOWITZ, S. G. 2011. Regulation and functions 
of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol, 29, 71-109. 
PAL, R., SINGH, S. N., CHATTERJEE, A. & SAHA, M. 2014. Age-related changes in cardiovascular system, 
autonomic functions, and levels of BDNF of healthy active males: role of yogic practice. Age 
(Dordr), 36, 9683. 
PARASHAR, R., AMIR, M., PAKHARE, A., RATHI, P. & CHAUDHARY, L. 2016. Age Related Changes in 
Autonomic Functions. J Clin Diagn Res, 10, CC11-5. 
PASSTOORS, W. M., BOER, J. M., GOEMAN, J. J., VAN DEN AKKER, E. B., DEELEN, J., ZWAAN, B. J., 
SCARBOROUGH, A., VAN DER BREGGEN, R., VOSSEN, R. H. A. M., HOUWING-DUISTERMAAT, J. J., 
VAN OMMEN, G. J. B., WESTENDORP, R. G. J., VAN HEEMST, D., DE CRAEN, A. J. M., WHITE, A. J., 
GUNN, D. A., BEEKMAN, M. & SLAGBOOM, P. E. 2012. Transcriptional Profiling of Human Familial 
Longevity Indicates a Role for ASF1A and IL7R. 7, e27759. 
PASSTOORS, W. M., VAN DEN AKKER, E. B., DEELEN, J., MAIER, A. B., VAN DER BREGGEN, R., JANSEN, R., 
TROMPET, S., VAN HEEMST, D., DERHOVANESSIAN, E., PAWELEC, G., VAN OMMEN, G. J., 
SLAGBOOM, P. E. & BEEKMAN, M. 2015. IL7R gene expression network associates with human 
healthy ageing. Immun Ageing, 12, 21. 
PASTRANA, J. L., SHA, X., VIRTUE, A., MAI, J., CUETO, R., LEE, I. A., WANG, H. & YANG, X. F. 2012. Regulatory 
T cells and Atherosclerosis. J Clin Exp Cardiolog, 2012, 2. 
PATEL, K. P., ZHANG, K., KENNEY, M. J., WEISS, M. & MAYHAN, W. G. 2000. Neuronal expression of Fos 
protein in the hypothalamus of rats with heart failure. Brain Research, 865, 27-34. 
PATTHY, L., TREXLER, M., VÁLI, Z., BÁNYAI, L. & VÁRADI, A. 1984. Kringles: modules specialized for protein 
binding. 171, 131-136. 
PEARL, J. 2009. Causal inference in statistics: An overview. Statistics Surveys, 3, 96-146. 
PEDERSEN, B. K. 2006a. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular 
disease control. Essays in Biochemistry, Vol 42, 42, 105-117. 
PEDERSEN, B. K. 2006b. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular 
disease control. Essays Biochem, 42, 105-17. 
PERTEA, M., PERTEA, G. M., ANTONESCU, C. M., CHANG, T.-C., MENDELL, J. T. & SALZBERG, S. L. 2015. 
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nature 
Biotechnology, 33, 290-295. 
PES, G. M., LIO, D., CARRU, C., DEIANA, L., BAGGIO, G., FRANCESCHI, C., FERRUCCI, L., OLIVERI, F., SCOLA, 
L., CRIVELLO, A., CANDORE, G., COLONNA-ROMANO, G. & CARUSO, C. 2004. Association between 
longevity and cytokine gene polymorphisms. A study in Sardinian centenarians. Aging Clin Exp 
Res, 16, 244-8. 
PETERS, N. S., SEVERS, N. J., ROTHERY, S. M., LINCOLN, C., YACOUB, M. H. & GREEN, C. R. 1994. 
Spatiotemporal relation between gap junctions and fascia adherens junctions during postnatal 
development of human ventricular myocardium. 90, 713-725. 
PI, Y., GOLDENTHAL, M. J. & MARIN-GARCIA, J. 2007. Mitochondrial channelopathies in aging. J Mol Med 
(Berl), 85, 937-51. 
PINTO, E. 2007. Blood pressure and ageing. Postgraduate Medical Journal, 83, 109-114. 




PRETZEL, D., POHLERS, D., WEINERT, S. & KINNE, R. W. 2009. In vitro model for the analysis of synovial 
fibroblast-mediated degradation of intact cartilage. Arthritis Res Ther, 11, R25. 
PRUITT, K. D., BROWN, G. R., HIATT, S. M., THIBAUD-NISSEN, F., ASTASHYN, A., ERMOLAEVA, O., FARRELL, 
C. M., HART, J., LANDRUM, M. J., MCGARVEY, K. M., MURPHY, M. R., O’LEARY, N. A., PUJAR, S., 
RAJPUT, B., RANGWALA, S. H., RIDDICK, L. D., SHKEDA, A., SUN, H., TAMEZ, P., TULLY, R. E., 
WALLIN, C., WEBB, D., WEBER, J., WU, W., DICUCCIO, M., KITTS, P., MAGLOTT, D. R., MURPHY, T. 
D. & OSTELL, J. M. 2014. RefSeq: an update on mammalian reference sequences. 42, D756-D763. 
PRUITT, K. D., TATUSOVA, T. & MAGLOTT, D. R. 2007. NCBI reference sequences (RefSeq): a curated non-
redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Research, 35, 
D61-D65. 
QIN, N., D'ANDREA, M. R., LUBIN, M. L., SHAFAEE, N., CODD, E. E. & CORREA, A. M. 2003. Molecular cloning 
and functional expression of the human sodium channel beta1B subunit, a novel splicing variant 
of the beta1 subunit. Eur J Biochem, 270, 4762-70. 
RAMA, A., MATSUSHITA, T., CHAROLIDI, N., ROTHERY, S., DUPONT, E. & SEVERS, N. J. 2006. Up-regulation 
of connexin43 correlates with increased synthetic activity and enhanced contractile 
differentiation in TGF-β-treated human aortic smooth muscle cells. 85, 375-386. 
RAMON, S., GAO, F., SERHAN, C. N. & PHIPPS, R. P. 2012. Specialized proresolving mediators enhance 
human B cell differentiation to antibody-secreting cells. J Immunol, 189, 1036-42. 
RAMSEY, I. S., DELLING, M. & CLAPHAM, D. E. 2006. AN INTRODUCTION TO TRP CHANNELS. Annual Review 
of Physiology, 68, 619-647. 
RAO, V., KAJA, S., AND GENTILE, S. 2016. Ion channels in Aging and Age-related Diseases. 
REA, I. M., GIBSON, D. S., MCGILLIGAN, V., MCNERLAN, S. E., ALEXANDER, H. D. & ROSS, O. A. 2018. Age 
and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Front Immunol, 9, 586. 
REA, I. M., STEWART, M., CAMPBELL, P., ALEXANDER, H. D., CROCKARD, A. D. & MORRIS, T. C. 1996. 
Changes in lymphocyte subsets, interleukin 2, and soluble interleukin 2 receptor in old and very 
old age. Gerontology, 42, 69-78. 
RECCHIUTI, A. & SERHAN, C. N. 2012. Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating 
miRNA in Novel Resolution Circuits in Inflammation. Front Immunol, 3, 298. 
REDDY, M. M. & KAR, S. S. 2019. Unconditional probability of dying and age-specific mortality rate because 
of major non-communicable diseases in India: Time trends from 2001 to 2013. Journal of 
postgraduate medicine, 65, 11-17. 
RICHARDS, M. W., LAW, E. W. P., RENNALLS, L. P., BUSACCA, S., O'REGAN, L., FRY, A. M., FENNELL, D. A. & 
BAYLISS, R. 2014. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic 
EML4-ALK by disruption of an atypical  -propeller domain. Proceedings of the National Academy 
of Sciences, 111, 5195-5200. 
RIDKER, P. M., RIFAI, N., PFEFFER, M., SACKS, F., LEPAGE, S. & BRAUNWALD, E. 2000. Elevation of tumor 
necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. 
Circulation, 101, 2149-53. 
RINK, L., CAKMAN, I. & KIRCHNER, H. 1998. Altered cytokine production in the elderly. Mech Ageing Dev, 
102, 199-209. 
RIVERA-APONTE, D. E., MÉNDEZ-GONZÁLEZ, M. P., RIVERA-PAGÁN, A. F., KUCHERYAVYKH, Y. V., 
KUCHERYAVYKH, L. Y., SKATCHKOV, S. N. & EATON, M. J. 2015. Hyperglycemia reduces functional 
expression of astrocytic Kir4.1 channels and glial glutamate uptake. Neuroscience, 310, 216-223. 
ROBERTSON, D. W. & STEINBERG, M. I. 1990. Potassium channel modulators: scientific applications and 
therapeutic promise. J Med Chem, 33, 1529-41. 
ROSASCO, M. G. & GORDON, S. E. 2017. TRP Channels: What Do They Look Like? In: ND & EMIR, T. L. R. 
(eds.) Neurobiology of TRP Channels. Boca Raton (FL). 
279 
 
ROSS, O. 2003. Study of age-association with cytokine gene polymorphisms in an aged Irish population. 
Mechanisms of Ageing and Development, 124, 199-206. 
RUBENHAGEN, R., SCHUTTRUMPF, J. P., STURMER, K. M. & FROSCH, K. H. 2012. Interleukin-7 levels in 
synovial fluid increase with age and MMP-1 levels decrease with progression of osteoarthritis. 
Acta Orthop, 83, 59-64. 
RUDIJANTO, A. 2007. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. 
Acta Med Indones, 39, 86-93. 
RUPARELIA, N., CHAI, J. T., FISHER, E. A. & CHOUDHURY, R. P. 2017. Inflammatory processes in 
cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol, 14, 133-144. 
SANDER, S. E., LEMM, C., LANGE, N., HAMANN, M. & RICHTER, A. 2012. Retigabine, a K(V)7 (KCNQ) 
potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats. 
Neuropharmacology, 62, 1052-61. 
SANDOVICI, I., HAMMERLE, C. M., COOPER, W. N., SMITH, N. H., TARRY-ADKINS, J. L., DUNMORE, B. J., 
BAUER, J., ANDREWS, S. R., YEO, G. S. H., OZANNE, S. E. & CONSTÂNCIA, M. 2016. Ageing is 
associated with molecular signatures of inflammation and type 2 diabetes in rat pancreatic islets. 
59, 502-511. 
SANSONI, P., VESCOVINI, R., FAGNONI, F., BIASINI, C., ZANNI, F., ZANLARI, L., TELERA, A., LUCCHINI, G., 
PASSERI, G., MONTI, D., FRANCESCHI, C. & PASSERI, M. 2008. The immune system in extreme 
longevity. Experimental Gerontology, 43, 61-65. 
SANTI, C. M. 2006. Opposite Regulation of Slick and Slack K+ Channels by Neuromodulators. Journal of 
Neuroscience, 26, 5059-5068. 
SASAKI, S., ISHIBASHI, K. & MARUMO, F. 1998. Aquaporin-2 and -3: representatives of two subgroups of 
the aquaporin family colocalized in the kidney collecting duct. Annu Rev Physiol, 60, 199-220. 
SCANZELLO, C. R. & GOLDRING, S. R. 2012. The role of synovitis in osteoarthritis pathogenesis. Bone, 51, 
249-57. 
SCHELLER, J., CHALARIS, A., SCHMIDT-ARRAS, D. & ROSE-JOHN, S. 2011. The pro- and anti-inflammatory 
properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research, 1813, 878-888. 
SCHOLZ, A. 2002. Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br 
J Anaesth, 89, 52-61. 
SCHREIBER, M. 1998. Slo3, a Novel pH-sensitive K+ Channel from Mammalian Spermatocytes. 273, 3509-
3516. 
SCUDIERI, P., CACI, E., VENTURINI, A., SONDO, E., PIANIGIANI, G., MARCHETTI, C., RAVAZZOLO, R., PAGANI, 
F. & GALIETTA, L. J. V. 2015. Ion channel and lipid scramblase activity associated with expression 
of TMEM16F/ANO6 isoforms. Journal of Physiology-London, 593, 3829-3848. 
SELLAM, J. & BERENBAUM, F. 2010. The role of synovitis in pathophysiology and clinical symptoms of 
osteoarthritis. Nat Rev Rheumatol, 6, 625-35. 
SERHAN, C. N. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510, 92-
101. 
SERHAN, C. N., CHIANG, N. & DALLI, J. 2018. New pro-resolving n-3 mediators bridge resolution of 
infectious inflammation to tissue regeneration. Mol Aspects Med, 64, 1-17. 
SESTI, F. 2016. Oxidation of K+Channels in Aging and Neurodegeneration. 7, 130. 
SHAMIM, D. & LASKOWSKI, M. 2017. Inhibition of Inflammation Mediated Through the Tumor Necrosis 
Factor alpha Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease. J Cent 
Nerv Syst Dis, 9, 1179573517722512. 
SHIH, C. D., AU, L. C. & CHAN, J. Y. 2003. Differential role of leptin receptors at the hypothalamic 
paraventricular nucleus in tonic regulation of food intake and cardiovascular functions. J Biomed 
Sci, 10, 367-78. 
280 
 
SHOCK, N. W. 1964. Ageing: The Biology of Senescence. Journal of Gerontology, 19, 521-522. 
SHORTER, E., SANNICANDRO, A. J., POULET, B. & GOLJANEK-WHYSALL, K. 2019. Skeletal Muscle Wasting 
and Its Relationship With Osteoarthritis: a Mini-Review of Mechanisms and Current Interventions. 
Current Rheumatology Reports, 21. 
SHOU, X., LIN, J., XIE, C., WANG, Y. & SUN, C. 2017. Plasma IL-37 Elevated in Patients with Chronic Heart 
Failure and Predicted Major Adverse Cardiac Events: A 1-Year Follow-Up Study. Dis Markers, 2017, 
9134079. 
SIMMONS, D. M. & SWANSON, L. W. 2008. High-resolution paraventricular nucleus serial section model 
constructed within a traditional rat brain atlas. 438, 85-89. 
SIMMS, B. A. & ZAMPONI, G. W. 2014. Neuronal voltage-gated calcium channels: structure, function, and 
dysfunction. Neuron, 82, 24-45. 
SIMON, L. V., HASHMI, M. F. & FARRELL, M. W. 2019. Hyperkalemia. StatPearls. Treasure Island (FL). 
SIMS, J. E. & SMITH, D. E. 2010. The IL-1 family: regulators of immunity. Nat Rev Immunol, 10, 89-102. 
SMITH, D. E. 2011. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol, 89, 383-92. 
SONG, M. Y. & YUAN, J. X. 2010. Introduction to TRP channels: structure, function, and regulation. Adv 
Exp Med Biol, 661, 99-108. 
SPITE, M., NORLING, L. V., SUMMERS, L., YANG, R., COOPER, D., PETASIS, N. A., FLOWER, R. J., PERRETTI, 
M. & SERHAN, C. N. 2009. Resolvin D2 is a potent regulator of leukocytes and controls microbial 
sepsis. Nature, 461, 1287-1291. 
STÄNDKER, L., SCHRADER, M., KANSE, S. M., JÜRGENS, M., FORSSMANN, W.-G. & PREISSNER, K. T. 1997. 
Isolation and characterization of the circulating form of human endostatin. 420, 129-133. 
STATLAND, J., PHILLIPS, L. & TRIVEDI, J. R. 2014. Muscle channelopathies. Neurol Clin, 32, 801-15, x. 
STEVENS, A. L., WISHNOK, J. S., CHAI, D. H., GRODZINSKY, A. J. & TANNENBAUM, S. R. 2008. A sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis-liquid chromatography tandem mass 
spectrometry analysis of bovine cartilage tissue response to mechanical compression injury and 
the inflammatory cytokines tumor necrosis factor alpha and interleukin-1beta. Arthritis Rheum, 
58, 489-500. 
STEVENS, A. L., WISHNOK, J. S., WHITE, F. M., GRODZINSKY, A. J. & TANNENBAUM, S. R. 2009. Mechanical 
injury and cytokines cause loss of cartilage integrity and upregulate proteins associated with 
catabolism, immunity, inflammation, and repair. Mol Cell Proteomics, 8, 1475-89. 
STEVENSON, K. & UVERSKY, V. N. 2019. Single-cell RNA-Seq: a next generation sequencing tool for a high-
resolution view of the individual cell. J Biomol Struct Dyn, 1-6. 
STEWART, J., MANMATHAN, G. & WILKINSON, P. 2017. Primary prevention of cardiovascular disease: A 
review of contemporary guidance and literature. JRSM Cardiovascular Disease, 6, 
204800401668721. 
STOCKER, M. & KERSCHENSTEINER, D. 1998. Cloning and Tissue Distribution of Two New Potassium 
Channel α-Subunits from Rat Brain. 248, 927-934. 
STOJILKOVIC, S. S., TABAK, J. & BERTRAM, R. 2010. Ion channels and signaling in the pituitary gland. Endocr 
Rev, 31, 845-915. 
SUGITA, S., MIZUTANI, E., HOZAKI, M., NAKAMURA, M. & MATSUMOTO, T. 2019. Photoelasticity-based 
evaluation of cellular contractile force for phenotypic discrimination of vascular smooth muscle 
cells. Scientific Reports, 9. 
SUTTON, S., CLUTTERBUCK, A., HARRIS, P., GENT, T., FREEMAN, S., FOSTER, N., BARRETT-JOLLEY, R. & 
MOBASHERI, A. 2009. The contribution of the synovium, synovial derived inflammatory cytokines 
and neuropeptides to the pathogenesis of osteoarthritis. Vet J, 179, 10-24. 
SWANSON, L. W. & SAWCHENKO, P. E. 1983. Hypothalamic Integration - Organization of the 
Paraventricular and Supraoptic Nuclei. Annual Review of Neuroscience, 6, 269-324. 
281 
 
SWANSON, L. W., SAWCHENKO, P. E., WIEGAND, S. J. & PRICE, J. L. 1980. Separate Neurons in the 
Paraventricular Nucleus Project to the Median-Eminence and to the Medulla or Spinal-Cord. Brain 
Research, 198, 190-195. 
SWARTZ, K. J. 2007. Tarantula toxins interacting with voltage sensors in potassium channels. Toxicon, 49, 
213-30. 
SWARTZ, K. J. & MACKINNON, R. 1997. Hanatoxin Modifies the Gating of a Voltage-Dependent K+ Channel 
through Multiple Binding Sites. Neuron, 18, 665-673. 
TANAKA, T., NARAZAKI, M. & KISHIMOTO, T. 2014. IL-6 in Inflammation, Immunity, and Disease. Cold 
Spring Harbor Perspectives in Biology, 6, a016295-a016295. 
TANG, C.-Y. & CHEN, T.-Y. 2011. Physiology and Pathophysiology of CLC-1: Mechanisms of a Chloride 
Channel Disease, Myotonia. 2011, 1-10. 
TANNER, M. R., HU, X., HUQ, R., TAJHYA, R. B., SUN, L., KHAN, F. S., LARAGIONE, T., HORRIGAN, F. T., 
GULKO, P. S. & BEETON, C. 2015a. KCa1.1 Inhibition Attenuates Fibroblast-like Synoviocyte 
Invasiveness and Ameliorates Disease in Rat Models of Rheumatoid Arthritis. Arthritis Rheumatol, 
67, 96-106. 
TANNER, M. R., HU, X., HUQ, R., TAJHYA, R. B., SUN, L., KHAN, F. S., LARAGIONE, T., HORRIGAN, F. T., 
GULKO, P. S. & BEETON, C. 2015b. KCa1.1 Inhibition Attenuates Fibroblast-like Synoviocyte 
Invasiveness and Ameliorates Disease in Rat Models of Rheumatoid Arthritis. Arthritis & 
Rheumatology, 67, 96-106. 
TERRAR, D. A. 1993. Structure and function of calcium channels and the actions of anaesthetics. Br J 
Anaesth, 71, 39-46. 
THOMAS, K., RAFIQ, S., FRAYLING, T. M., EBRAHIM, S., KUMARI, M., GALLACHER, J., FERRUCCI, L., 
BANDINELLI, S., WALLACE, R. B., MELZER, D., MARTIN, R. M. & BEN-SHLOMO, Y. 2009. Interleukin-
18 polymorphism and physical functioning in older people: a replication study and meta-analysis. 
J Gerontol A Biol Sci Med Sci, 64, 1177-82. 
TIAN, C., ZHU, R., ZHU, L., QIU, T., CAO, Z. & KANG, T. 2014. Potassium channels: structures, diseases, and 
modulators. Chem Biol Drug Des, 83, 1-26. 
TORP, K. D. & SIMON, L. V. 2019. Lidocaine Toxicity. StatPearls. Treasure Island (FL). 
TORRES, V. E., CAI, Y., CHEN, X., WU, G. Q., GENG, L., CLEGHORN, K. A., JOHNSON, C. M. & SOMLO, S. 2001. 
Vascular expression of polycystin-2. J Am Soc Nephrol, 12, 1-9. 
TRAN, D. Q. 2012. TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell 
Biol, 4, 29-37. 
TRAPNELL, C., WILLIAMS, B. A., PERTEA, G., MORTAZAVI, A., KWAN, G., VAN BAREN, M. J., SALZBERG, S. 
L., WOLD, B. J. & PACHTER, L. 2010. Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation. Nature Biotechnology, 
28, 511-515. 
TROMPET, S., DE CRAEN, A. J. M., SLAGBOOM, P., SHEPHERD, J., BLAUW, G. J., MURPHY, M. B., BOLLEN, 
E. L. E. M., BUCKLEY, B. M., FORD, I., GAW, A., MACFARLANE, P. W., PACKARD, C. J., STOTT, D. J., 
JUKEMA, J. W. & WESTENDORP, R. G. J. 2008. Genetic variation in the interleukin-1 -converting 
enzyme associates with cognitive function. The PROSPER study. Brain, 131, 1069-1077. 
TURGUTALP, K., BARDAK, S., HELVACı, I., İŞGÜZAR, G., PAYAS, E., DEMIR, S. & KıYKıM, A. 2016. Community-
acquired hyperkalemia in elderly patients: risk factors and clinical outcomes. 38, 1405-1412. 
UCAR, D., MARQUEZ, E. J., CHUNG, C. H., MARCHES, R., ROSSI, R. J., UYAR, A., WU, T. C., GEORGE, J., 
STITZEL, M. L., PALUCKA, A. K., KUCHEL, G. A. & BANCHEREAU, J. 2017. The chromatin accessibility 
signature of human immune aging stems from CD8(+) T cells. J Exp Med, 214, 3123-3144. 
UEBELE, V. N., LAGRUTTA, A., WADE, T., FIGUEROA, D. J., LIU, Y., MCKENNA, E., AUSTIN, C. P., BENNETT, 
P. B. & SWANSON, R. 2000. Cloning and functional expression of two families of beta-subunits of 
the large conductance calcium-activated K+ channel. J Biol Chem, 275, 23211-8. 
282 
 
ULBRICHT, W. 2005. Sodium Channel Inactivation: Molecular Determinants and Modulation. 85, 1271-
1301. 
UNGVARI, Z., TARANTINI, S., DONATO, A. J., GALVAN, V. & CSISZAR, A. 2018. Mechanisms of Vascular 
Aging. Circulation Research, 123, 849-867. 
VAISHALI, M. P. & SATYA, P. G. 2016. Studies on Chloride Channels and their Modulators. Current Topics 
in Medicinal Chemistry, 16, 1862-1876. 
VAN DER HEIJDEN, T., BOT, I. & KUIPER, J. 2019. The IL-12 cytokine family in cardiovascular diseases. 
Cytokine, 122, 154188. 
VAN GULICK, L., SABY, C., MORJANI, H. & BELJEBBAR, A. 2019. Age-related changes in molecular 
organization of type I collagen in tendon as probed by polarized SHG and Raman 
microspectroscopy. Scientific Reports, 9. 
VAN MAANEN, M. A., STOOF, S. P., VAN DER ZANDEN, E. P., DE JONGE, W. J., JANSSEN, R. A., FISCHER, D. 
F., VANDEGHINSTE, N., BRYS, R., VERVOORDELDONK, M. J. & TAK, P. P. 2009. The alpha7 nicotinic 
acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid 
arthritis patients: a possible role for a key neurotransmitter in synovial inflammation. Arthritis 
Rheum, 60, 1272-81. 
VARANI, K., DE MATTEI, M., VINCENZI, F., TOSI, A., GESSI, S., MERIGHI, S., PELLATI, A., MASIERI, F., 
ONGARO, A. & BOREA, P. A. 2008. Pharmacological characterization of P2X1 and P2X3 purinergic 
receptors in bovine chondrocytes. Osteoarthritis Cartilage, 16, 1421-9. 
VARGAS-ALARCON, G., ALVAREZ-LEON, E., FRAGOSO, J.-M., VARGAS, A., MARTINEZ, A., VALLEJO, M. & 
MARTINEZ-LAVIN, M. 2012. A SCN9A gene-encoded dorsal root ganglia sodium channel 
polymorphism associated with severe fibromyalgia. BMC Musculoskeletal Disorders, 13, 23. 
VASILAKI, A., VAN DER MEULEN, J. H., LARKIN, L., HARRISON, D. C., PEARSON, T., VAN REMMEN, H., 
RICHARDSON, A., BROOKS, S. V., JACKSON, M. J. & MCARDLE, A. 2010. The age-related failure of 
adaptive responses to contractile activity in skeletal muscle is mimicked in young mice by deletion 
of Cu,Zn superoxide dismutase. 9, 979-990. 
VERGULT, S., DHEEDENE, A., MEURS, A., FAES, F., ISIDOR, B., JANSSENS, S., GAUTIER, A., LE CAIGNEC, C. & 
MENTEN, B. 2015. Genomic aberrations of the CACNA2D1 gene in three patients with epilepsy 
and intellectual disability. 23, 628-632. 
VON BANCHET, G. S., RICHTER, J., HUCKEL, M., ROSE, C., BRAUER, R. & SCHAIBLE, H. G. 2007. Fibroblast-
like synovial cells from normal and inflamed knee joints differently affect the expression of pain-
related receptors in sensory neurones: a co-culture study. Arthritis Res Ther, 9, R6. 
WALDBURGER, J. M., BOYLE, D. L., PAVLOV, V. A., TRACEY, K. J. & FIRESTEIN, G. S. 2008. Acetylcholine 
regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor. Arthritis Rheum, 
58, 3439-49. 
WALSTON, J. D. 2012. Sarcopenia in older adults. Current Opinion in Rheumatology, 24, 623-627. 
WANG, H. & WOOLF, C. J. 2005. Pain TRPs. Neuron, 46, 9-12. 
WANG, J., OU, S. W. & WANG, Y. J. 2017. Distribution and function of voltage-gated sodium channels in 
the nervous system. Channels (Austin), 11, 534-554. 
WANG, S., HU, L. F., YANG, Y., DING, J. H. & HU, G. 2005. Studies of ATP-sensitive potassium channels on 
6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating 
Parkinson's disease? Neuropharmacology, 48, 984-92. 
WANG, T. 2015. TNF-alpha G308A polymorphism and the susceptibility to Alzheimer's disease: an updated 
meta-analysis. Arch Med Res, 46, 24-30 e1. 
WANG, X.-Y., HURME, M., JYLHÄ, M. & HERVONEN, A. 2001. Lack of association between human longevity 
and polymorphisms of IL-1 cluster, IL-6, IL-10 and TNF-α genes in Finnish nonagenarians. 
Mechanisms of Ageing and Development, 123, 29-38. 
283 
 
WATANABE, M., ICHINOSE, S. & SUNAMORI, M. 2004. Age-related changes in gap junctional protein of 
the rat heart. Exp Clin Cardiol, 9, 130-2. 
WEI, A., JEGLA, T. & SALKOFF, L. 1996. Eight potassium channel families revealed by the C. elegans genome 
project. Neuropharmacology, 35, 805-29. 
WEI, X. & RICHARDS, J. R. 2019. Physiology, Cardiac Repolarization Dispersion and Reserve. StatPearls. 
Treasure Island (FL). 
WEINERT, B. T. & TIMIRAS, P. S. 2003. Invited Review: Theories of aging. Journal of Applied Physiology, 95, 
1706-1716. 
WEINGARTH, M., PROKOFYEV, A., VAN DER CRUIJSEN, E. A., NAND, D., BONVIN, A. M., PONGS, O. & 
BALDUS, M. 2013. Structural determinants of specific lipid binding to potassium channels. J Am 
Chem Soc, 135, 3983-8. 
WELSH, P., MURRAY, H. M., FORD, I., TROMPET, S., DE CRAEN, A. J. M., JUKEMA, J. W., STOTT, D. J., 
MCINNES, I. B., PACKARD, C. J., WESTENDORP, R. G. J. & SATTAR, N. 2011. Circulating Interleukin-
10 and Risk of Cardiovascular Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 2338-
2344. 
WESTENDORP, R. G., LANGERMANS, J. A., HUIZINGA, T. W., VERWEIJ, C. L. & STURK, A. 1997. Genetic 
influence on cytokine production in meningococcal disease. Lancet, 349, 1912-3. 
WIBBERLEY, A., STAUNTON, C. A., FEETHAM, C. H., VERENINOV, A. A. & BARRETT-JOLLEY, R. 2015. An In 
Vitro Model of Skeletal Muscle Volume Regulation. PLOS ONE, 10, e0127889. 
WIECZOROWSKA-TOBIS, K., NIEMIR, Z. I., PODKOWKA, R., KORYBALSKA, K., MOSSAKOWSKA, M. & 
BREBOROWICZ, A. 2006. Can an increased level of circulating IL-8 be a predictor of human 
longevity? Med Sci Monit, 12, Cr118-21. 
WILDERS, R. 2012. Cardiac ion channelopathies and the sudden infant death syndrome. ISRN Cardiol, 
2012, 846171. 
WILLIAMS, A. 2014. Proteomic studies of an explant 
model of equine articular cartilage in response to proinflammatory and anti-inflammatory stimuli. PhD 
Thesis University of Nottingham. 
WILLIAMS, A., SMITH, J. R., ALLAWAY, D., HARRIS, P., LIDDELL, S. & MOBASHERI, A. 2011. Strategies for 
optimising proteomic studies of the cartilage secretome: establishing the time course for protein 
release and evaluating responses of explant cultures to il-1 beta, tnf-alpha and carprofen. 
Osteoarthritis and Cartilage, 19, S209-S209. 
WILLIAMS, M. E., FELDMAN, D. H., MCCUE, A. F., BRENNER, R., VELICELEBI, G., ELLIS, S. B. & HARPOLD, M. 
M. 1992. Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel 
human neuronal calcium channel subtype. Neuron, 8, 71-84. 
WRIGHT, S. H. 2004. Generation of resting membrane potential. Adv Physiol Educ, 28, 139-42. 
WU, C., YANG, K., LIU, Q., WAKUI, M., JIN, G. Z., ZHEN, X. & WU, J. 2010. Tetrahydroberberine blocks ATP-
sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra 
pars compacta. Neuropharmacology, 59, 567-72. 
XU, H., RAMSEY, I. S., KOTECHA, S. A., MORAN, M. M., CHONG, J. A., LAWSON, D., GE, P., LILLY, J., SILOS-
SANTIAGO, I., XIE, Y., DISTEFANO, P. S., CURTIS, R. & CLAPHAM, D. E. 2002. TRPV3 is a calcium-
permeable temperature-sensitive cation channel. Nature, 418, 181-186. 
YANG, C. T., ZENG, X. H., XIA, X. M. & LINGLE, C. J. 2009. Interactions between beta subunits of the KCNMB 
family and Slo3: beta4 selectively modulates Slo3 expression and function. PLoS One, 4, e6135. 
YANG, Q., WANG, E.-Y., JIA, H.-W. & WANG, Y.-P. 2016. Association between polymorphisms in 
transforming growth factor-β1 and sporadic Alzheimer's disease in a Chinese population. 
International Journal of Neuroscience, 126, 979-984. 
284 
 
YOSHIMURA, A., WAKABAYASHI, Y. & MORI, T. 2010. Cellular and molecular basis for the regulation of 
inflammation by TGF-beta. J Biochem, 147, 781-92. 
YOUNG, M. D., WAKEFIELD, M. J., SMYTH, G. K. & OSHLACK, A. 2010. Gene ontology analysis for RNA-seq: 
accounting for selection bias. Genome Biol, 11, R14. 
YU, F. H. & CATTERALL, W. A. 2003. Overview of the voltage-gated sodium channel family. Genome Biol, 
4, 207. 
YU, F. H., YAROV-YAROVOY, V., GUTMAN, G. A. & CATTERALL, W. A. 2005. Overview of molecular 
relationships in the voltage-gated ion channel superfamily. Pharmacol Rev, 57, 387-95. 
ZAMBRANO-ZARAGOZA, J. F., ROMO-MARTINEZ, E. J., DURAN-AVELAR MDE, J., GARCIA-MAGALLANES, N. 
& VIBANCO-PEREZ, N. 2014. Th17 cells in autoimmune and infectious diseases. Int J Inflam, 2014, 
651503. 
ZAMPONI, G. W. 2016. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. 
Nat Rev Drug Discov, 15, 19-34. 
ZAMPONI, G. W. 2017. A Crash Course in Calcium Channels. ACS Chem Neurosci, 8, 2583-2585. 
ZAMPONI, G. W., STRIESSNIG, J., KOSCHAK, A. & DOLPHIN, A. C. 2015. The Physiology, Pathology, and 
Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. 
Pharmacol Rev, 67, 821-70. 
ZHANG, J. M. & AN, J. 2007. Cytokines, inflammation, and pain. Int Anesthesiol Clin, 45, 27-37. 
ZHANG, K., MAYHAN, W. G. & PATEL, K. P. 1997. Nitric oxide within the paraventricular nucleus mediates 
changes in renal sympathetic nerve activity. American Journal of Physiology-Regulatory 
Integrative and Comparative Physiology, 273, R864-R872. 
ZHANG, K., ZUCKER, I. H. & PATEL, K. P. 1998. Altered number of diaphorase (NOS) positive neurons in the 
hypothalamus of rats with heart failure. Brain Research, 786, 219-225. 
ZHANG, P., WU, X., LI, G., HE, Q., DAI, H., AI, C. & SHI, J. 2017. Tumor necrosis factor-alpha gene 
polymorphisms and susceptibility to ischemic heart disease: A systematic review and meta-
analysis. Medicine (Baltimore), 96, e6569. 
ZHENG, C., ZHOU, X. W. & WANG, J. Z. 2016. The dual roles of cytokines in Alzheimer's disease: update on 
interleukins, TNF-alpha, TGF-beta and IFN-gamma. Transl Neurodegener, 5, 7. 
ZHU, R., SUN, Z., LI, C., RAMAKRISHNA, S., CHIU, K. & HE, L. 2019a. Electrical stimulation affects neural 
stem cell fate and function in vitro. Exp Neurol, 319, 112963. 
ZHU, Y., QU, J., HE, L., ZHANG, F., ZHOU, Z., YANG, S. & ZHOU, Y. 2019b. Calcium in Vascular Smooth Muscle 
Cell Elasticity and Adhesion: Novel Insights Into the Mechanism of Action. Frontiers in Physiology, 
10. 
ZIEGENHAIN, C., VIETH, B., PAREKH, S., REINIUS, B., GUILLAUMET-ADKINS, A., SMETS, M., LEONHARDT, H., 
HEYN, H., HELLMANN, I. & ENARD, W. 2017. Comparative Analysis of Single-Cell RNA Sequencing 
Methods. Molecular Cell, 65, 631-643.e4. 
ZUVICH, R. L., MCCAULEY, J. L., OKSENBERG, J. R., SAWCER, S. J., DE JAGER, P. L., INTERNATIONAL 
MULTIPLE SCLEROSIS GENETICS, C., AUBIN, C., CROSS, A. H., PICCIO, L., AGGARWAL, N. T., EVANS, 
D., HAFLER, D. A., COMPSTON, A., HAUSER, S. L., PERICAK-VANCE, M. A. & HAINES, J. L. 2010. 
Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet, 
127, 525-35. 
ZYKOV, M. V., BARBARASH, O. L., KASHTALAP, V. V., KUTIKHIN, A. G. & BARBARASH, L. S. 2016. Interleukin-
12 serum level has prognostic value in patients with ST-segment elevation myocardial infarction. 





2019. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Research, 47, D330-
D338. 
ABDUL KADIR, L., STACEY, M. & BARRETT-JOLLEY, R. 2018. Emerging Roles of the Membrane Potential: 
Action Beyond the Action Potential. Frontiers in Physiology, 9. 
ACKERMANN, M., CHAO, L., BERGSTROM, C. T. & DOEBELI, M. 2007. On the evolutionary origin of aging. 
Aging Cell, 6, 235-244. 
AGRE, P. 2006. The Aquaporin Water Channels. 3, 5-13. 
AHMED, M. S., IKRAM, S., BIBI, N. & MIR, A. 2017. Hutchinson–Gilford Progeria Syndrome: A Premature 
Aging Disease. Molecular Neurobiology. 
ALBARWANI, S. A., MANSOUR, F., KHAN, A. A., AL-LAWATI, I., AL-KAABI, A., AL-BUSAIDI, A.-M., AL-
HADHRAMI, S., AL-HUSSEINI, I., AL-SIYABI, S. & TANIRA, M. O. 2016. Aging Reduces L-Type Calcium 
Channel Current and the Vasodilatory Response of Small Mesenteric Arteries to Calcium Channel 
Blockers. Frontiers in Physiology, 7. 
AMIN, A. S., TAN, H. L. & WILDE, A. A. 2010. Cardiac ion channels in health and disease. Heart Rhythm, 7, 
117-26. 
ANAPARTHY, N., HO, Y. J., MARTELOTTO, L., HAMMELL, M. & HICKS, J. 2019. Single-Cell Applications of 
Next-Generation Sequencing. Cold Spring Harb Perspect Med, 9. 
ANGULO, E., NOE, V., CASADO, V., MALLOL, J., GOMEZ-ISLA, T., LLUIS, C., FERRER, I., CIUDAD, C. J. & 
FRANCO, R. 2004. Up-regulation of the Kv3.4 potassium channel subunit in early stages of 
Alzheimer's disease. J Neurochem, 91, 547-57. 
ANON 2000. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 
update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis 
Rheum, 43, 1905-15. 
ARMSTRONG, M. E., ALEXANDER, H. D., RITCHIE, J. L., MCMILLAN, S. A. & REA, I. M. 2001. Age-related 
alterations in basal expression and in vitro, tumour necrosis factor alpha mediated, upregulation 
of CD11b. Gerontology, 47, 180-5. 
ASHBURNER, M., BALL, C. A., BLAKE, J. A., BOTSTEIN, D., BUTLER, H., CHERRY, J. M., DAVIS, A. P., DOLINSKI, 
K., DWIGHT, S. S., EPPIG, J. T., HARRIS, M. A., HILL, D. P., ISSEL-TARVER, L., KASARSKIS, A., LEWIS, 
S., MATESE, J. C., RICHARDSON, J. E., RINGWALD, M., RUBIN, G. M. & SHERLOCK, G. 2000. Gene 
Ontology: tool for the unification of biology. Nature Genetics, 25, 25-29. 
BABENKO, A. P., GONZALEZ, G., AGUILAR-BRYAN, L. & BRYAN, J. 1998. Reconstituted Human Cardiac KATP 
Channels : Functional Identity With the Native Channels From the Sarcolemma of Human 
Ventricular Cells. 83, 1132-1143. 
BADOER, E. 1996. Cardiovascular role of parvocellular neurons in the paraventricular nucleus of the 
hypothalamus. News in Physiological Sciences, 11, 43-47. 
BAE, E., CHA, R. H., KIM, Y. C., AN, J. N., KIM, D. K., YOO, K. D., LEE, S. M., KIM, M. H., PARK, J. T., KANG, S. 
W., PARK, J. Y., LIM, C. S., KIM, Y. S., YANG, S. H. & LEE, J. P. 2017. Circulating TNF receptors predict 
cardiovascular disease in patients with chronic kidney disease. Medicine (Baltimore), 96, e6666. 
BARDAK, S., TURGUTALP, K., KOYUNCU, M. B., HARI, H., HELVACI, I., OVLA, D., HOROZ, M., DEMIR, S. & 
KIYKIM, A. 2017. Community-acquired hypokalemia in elderly patients: related factors and clinical 
outcomes. Int Urol Nephrol, 49, 483-489. 
BARRETT-JOLLEY, R., LEWIS, R., FALLMAN, R. & MOBASHERI, A. 2010. The Emerging Chondrocyte 
Channelome. Frontiers in Physiology, 1, 1-11. 
BARTOK, B. & FIRESTEIN, G. S. 2010. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. 
Immunological Reviews, 233, 233-255. 




BEETON, C. 2017. KCa1.1 channels as therapeutic targets for rheumatoid arthritis. Expert Opin Ther 
Targets, 21, 1077-1081. 
BEHR, E. R., DALAGEORGOU, C., CHRISTIANSEN, M., SYRRIS, P., HUGHES, S., TOME ESTEBAN, M. T., 
ROWLAND, E., JEFFERY, S. & MCKENNA, W. J. 2008. Sudden arrhythmic death syndrome: familial 
evaluation identifies inheritable heart disease in the majority of families. Eur Heart J, 29, 1670-80. 
BELLANTUONO, I. & POTTER, P. K. 2016. Modelling ageing and age-related disease. Drug Discovery Today: 
Disease Models, 20, 27-32. 
BELLOCQ, C., VAN GINNEKEN, A. C., BEZZINA, C. R., ALDERS, M., ESCANDE, D., MANNENS, M. M., BARO, I. 
& WILDE, A. A. 2004. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. 
Circulation, 109, 2394-7. 
BENNETT, D. L., CLARK, A. J., HUANG, J., WAXMAN, S. G. & DIB-HAJJ, S. D. 2019. The Role of Voltage-Gated 
Sodium Channels in Pain Signaling. Physiol Rev, 99, 1079-1151. 
BENNETT, M. R., SINHA, S. & OWENS, G. K. 2016. Vascular Smooth Muscle Cells in Atherosclerosis. 
Circulation Research, 118, 692-702. 
BENYA, P. D. & SHAFFER, J. D. 1982. Dedifferentiated chondrocytes reexpress the differentiated collagen 
phenotype when cultured in agarose gels. Cell, 30, 215-24. 
BERENBAUM, F. 2013. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). 
Osteoarthritis and Cartilage, 21, 16-21. 
BHATTACHARJEE, A., JOINER, W. J., WU, M., YANG, Y., SIGWORTH, F. J. & KACZMAREK, L. K. 2003. Slick 
(Slo2.1), a Rapidly-Gating Sodium-Activated Potassium Channel Inhibited by ATP. The Journal of 
Neuroscience, 23, 11681-11691. 
BODA, E., HOXHA, E., PINI, A., MONTAROLO, F. & TEMPIA, F. 2012. Brain expression of Kv3 subunits during 
development, adulthood and aging and in a murine model of Alzheimer's disease. J Mol Neurosci, 
46, 606-15. 
BODMAN, M. A. & VARACALLO, M. 2019. Diabetic Neuropathy. StatPearls. Treasure Island (FL). 
BROZOVICH, F. V., NICHOLSON, C. J., DEGEN, C. V., GAO, Y. Z., AGGARWAL, M. & MORGAN, K. G. 2016. 
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment 
of Smooth Muscle Disorders. Pharmacological Reviews, 68, 476-532. 
BRUST, P. F., SIMERSON, S., MCCUE, A. F., DEAL, C. R., SCHOONMAKER, S., WILLIAMS, M. E., VELICELEBI, 
G., JOHNSON, E. C., HARPOLD, M. M. & ELLIS, S. B. 1993. Human neuronal voltage-dependent 
calcium channels: studies on subunit structure and role in channel assembly. Neuropharmacology, 
32, 1089-102. 
BRUUNSGAARD, H. 2002. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. 
Eur Cytokine Netw, 13, 389-91. 
BRUUNSGAARD, H., ANDERSEN-RANBERG, K., HJELMBORG, J. V. B., PEDERSEN, B. K. & JEUNE, B. 2003a. 
Elevated levels of tumor necrosis factor alpha and mortality in centenarians. 115, 278-283. 
BRUUNSGAARD, H., LADELUND, S., PEDERSEN, A. N., SCHROLL, M., JORGENSEN, T. & PEDERSEN, B. K. 
2003b. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old 
people. Clin Exp Immunol, 132, 24-31. 
BRUUNSGAARD, H., SKINHOJ, P., PEDERSEN, A. N., SCHROLL, M. & PEDERSEN, B. K. 2000. Ageing, tumour 
necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol, 121, 255-60. 
BURKE, D., KIERNAN, M. C. & BOSTOCK, H. 2001. Excitability of human axons. Clin Neurophysiol, 112, 1575-
85. 
BURMESTER, G. R., DIMITRIU-BONA, A., WATERS, S. J. & WINCHESTER, R. J. 1983. Identification of three 
major synovial lining cell populations by monoclonal antibodies directed to Ia antigens and 
antigens associated with monocytes/macrophages and fibroblasts. Scand J Immunol, 17, 69-82. 
CALLAGHAN, M. F., FREUND, P., DRAGANSKI, B., ANDERSON, E., CAPPELLETTI, M., CHOWDHURY, R., 
DIEDRICHSEN, J., FITZGERALD, T. H. B., SMITTENAAR, P., HELMS, G., LUTTI, A. & WEISKOPF, N. 
287 
 
2014. Widespread age-related differences in the human brain microstructure revealed by 
quantitative magnetic resonance imaging. 35, 1862-1872. 
CANNON, S. C. 2015. Channelopathies of skeletal muscle excitability. Compr Physiol, 5, 761-90. 
CARBONI, G. L., GAO, B., NISHIZAKI, M., XU, K., MINNA, J. D., ROTH, J. A. & JI, L. 2003. CACNA2D2-mediated 
apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and 
disruption of mitochondria membrane integrity. Oncogene, 22, 615-626. 
CARVALHO-DE-SOUZA, J. L., VARANDA, W. A., TOSTES, R. C. & CHIGNALIA, A. Z. 2013. BK Channels in 
Cardiovascular Diseases and Aging. Aging Dis, 4, 38-49. 
CASTRO, D. & SHARMA, S. 2019. Hypokalemia. StatPearls. Treasure Island (FL). 
CATERINA, M. J. 2007. Transient receptor potential ion channels as participants in thermosensation and 
thermoregulation. American Journal of Physiology-Regulatory, Integrative and Comparative 
Physiology, 292, R64-R76. 
CATTERALL, W. A. 2011. Voltage-Gated Calcium Channels. Cold Spring Harbor Perspectives in Biology, 3, 
a003947-a003947. 
CAVALLONE, L., BONAFE, M., OLIVIERI, F., CARDELLI, M., MARCHEGIANI, F., GIOVAGNETTI, S., DI STASIO, 
G., GIAMPIERI, C., MUGIANESI, E., STECCONI, R., SCIACCA, F., GRIMALDI, L. M., DE BENEDICTIS, G., 
LIO, D., CARUSO, C. & FRANCESCHI, C. 2003. The role of IL-1 gene cluster in longevity: a study in 
Italian population. Mech Ageing Dev, 124, 533-8. 
CHAKROBORTY, S. & STUTZMANN, G. E. 2014. Calcium channelopathies and Alzheimer's disease: insight 
into therapeutic success and failures. Eur J Pharmacol, 739, 83-95. 
CHENG, J., WEN, J., WANG, N., WANG, C., XU, Q. & YANG, Y. 2019. Ion Channels and Vascular Diseases. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 39. 
CHENG, W., SUN, C. & ZHENG, J. 2010. Heteromerization of TRP channel subunits: extending functional 
diversity. Protein & Cell, 1, 802-810. 
CHRYSAFIDES, S. M. & SHARMA, S. 2019. Physiology, Resting Potential. StatPearls. Treasure Island (FL). 
CHUNG, K. F. 2009. Cytokines. Elsevier. 
CLARK, R. B., KONDO, C., BELKE, D. D. & GILES, W. R. 2011. Two-pore domain K + channels regulate 
membrane potential of isolated human articular chondrocytes. 589, 5071-5089. 
CLARK, R. B., SCHMIDT, T. A., SACHSE, F. B., BOYLE, D., FIRESTEIN, G. S. & GILES, W. R. 2017. Cellular 
electrophysiological principles that modulate secretion from synovial fibroblasts. J Physiol, 595, 
635-645. 
CLARKE, R., VALDES-MARQUEZ, E., HILL, M., GORDON, J., FARRALL, M., HAMSTEN, A., WATKINS, H. & 
HOPEWELL, J. C. 2018. Plasma cytokines and risk of coronary heart disease in the PROCARDIS 
study. Open Heart, 5, e000807. 
COHEN, R. M., FOELL, J. D., BALIJEPALLI, R. C., SHAH, V., HELL, J. W. & KAMP, T. J. 2005. Unique modulation 
of L-type Ca2+ channels by short auxiliary beta1d subunit present in cardiac muscle. Am J Physiol 
Heart Circ Physiol, 288, H2363-74. 
COLLIN, T., LORY, P., TAVIAUX, S., COURTIEU, C., GUILBAULT, P., BERTA, P. & NARGEOT, J. 1994. Cloning, 
chromosomal location and functional expression of the human voltage-dependent calcium-
channel beta3 subunit. 220, 257-262. 
COLLINS, J. S., PERRY, R. T., WATSON, B., JR., HARRELL, L. E., ACTON, R. T., BLACKER, D., ALBERT, M. S., 
TANZI, R. E., BASSETT, S. S., MCINNIS, M. G., CAMPBELL, R. D. & GO, R. C. 2000. Association of a 
haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH 
Alzheimer Disease Genetics Initiative. Am J Med Genet, 96, 823-30. 
COOTE, J. H. 1995. Cardiovascular function of the paraventricular nucleus of the hypothalamus. Biological 
Signals, 4, 142-149. 
COOTE, J. H. 2005. A role for the paraventricular nucleus of the hypothalamus in the autonomic control 
of heart and kidney. Experimental physiology, 90, 169-73. 
288 
 
COOTE, J. H. 2007. Landmarks in understanding the central nervous control of the cardiovascular system. 
Experimental Physiology, 92, 3-18. 
COWLED, P. & FITRIDGE, R. 2011. Pathophysiology of Reperfusion Injury. In: FITRIDGE, R. & THOMPSON, 
M. (eds.) Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. Adelaide 
(AU). 
CUI, J., COX, D. H. & ALDRICH, R. W. 1997. Intrinsic voltage dependence and Ca2+ regulation of mslo large 
conductance Ca-activated K+ channels. J Gen Physiol, 109, 647-73. 
CUI, J., YANG, H. & LEE, U. S. 2009. Molecular mechanisms of BK channel activation. Cell Mol Life Sci, 66, 
852-75. 
DANE, E. L. & GRINSTAFF, M. W. 2012. Poly-amido-saccharides: Synthesis via Anionic Polymerization of a 
β-Lactam Sugar Monomer. 134, 16255-16264. 
DANIIL, G., FERNANDES-ROSA, F. L., CHEMIN, J., BLESNEAC, I., BELTRAND, J., POLAK, M., JEUNEMAITRE, 
X., BOULKROUN, S., AMAR, L., STROM, T. M., LORY, P. & ZENNARO, M. C. 2016. CACNA1H 
Mutations Are Associated With Different Forms of Primary Aldosteronism. EBioMedicine, 13, 225-
236. 
DAVIS, A. J., FORREST, A. S., JEPPS, T. A., VALENCIK, M. L., WIWCHAR, M., SINGER, C. A., SONES, W. R., 
GREENWOOD, I. A. & LEBLANC, N. 2010. Expression profile and protein translation of TMEM16A 
in murine smooth muscle. Am J Physiol Cell Physiol, 299, C948-59. 
DAVIS, A. J., SHI, J., PRITCHARD, H. A., CHADHA, P. S., LEBLANC, N., VASILIKOSTAS, G., YAO, Z., VERKMAN, 
A. S., ALBERT, A. P. & GREENWOOD, I. A. 2013. Potent vasorelaxant activity of the TMEM16A 
inhibitor T16A(inh) -A01. Br J Pharmacol, 168, 773-84. 
DAY, M. J. 2010. Ageing, immunosenescence and inflammageing in the dog and cat. J Comp Pathol, 142 
S1, S60-9. 
DE CEUNINCK, F., DASSENCOURT, L. & ANRACT, P. 2004. The inflammatory side of human chondrocytes 
unveiled by antibody microarrays. Biochem Biophys Res Commun, 323, 960-9. 
DE HOOGE, A. S., VAN DE LOO, F. A., BENNINK, M. B., ARNTZ, O. J., DE HOOGE, P. & VAN DEN BERG, W. B. 
2005. Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. 
Osteoarthritis Cartilage, 13, 66-73. 
DE KEERSMAECKER, K. 2005. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic 
t(9;14)(q34;q32). 105, 4849-4852. 
DEMAREE, B., WEISGERBER, D., LAN, F. & ABATE, A. R. 2018. An Ultrahigh-throughput Microfluidic 
Platform for Single-cell Genome Sequencing. Journal of Visualized Experiments. 
DEUTCH, A. Y. & WINDER, D. G. 2006. A channel to neurodegeneration. Nat Med, 12, 17-8. 
DI IORIO, A., FERRUCCI, L., SPARVIERI, E., CHERUBINI, A., VOLPATO, S., CORSI, A., BONAFE, M., 
FRANCESCHI, C., ABATE, G. & PAGANELLI, R. 2003. Serum IL-1beta levels in health and disease: a 
population-based study. 'The InCHIANTI study'. Cytokine, 22, 198-205. 
DONAHUE, H. J., QU, R. W. & GENETOS, D. C. 2017. Joint diseases: from connexins to gap junctions. Nature 
Reviews Rheumatology, 14, 42-51. 
DOUPNIK, C. A., DAVIDSON, N. & LESTER, H. A. 1995. The inward rectifier potassium channel family. 5, 
268-277. 
ENYEDI, P. & CZIRJAK, G. 2010. Molecular background of leak K+ currents: two-pore domain potassium 
channels. Physiol Rev, 90, 559-605. 
ERRO, R., BHATIA, K. P., ESPAY, A. J. & STRIANO, P. 2017. The epileptic and nonepileptic spectrum of 
paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies. Mov Disord, 
32, 310-318. 
ETCHEBERRIGARAY, R., ITO, E., OKA, K., TOFEL-GREHL, B., GIBSON, G. E. & ALKON, D. L. 1993. Potassium 
channel dysfunction in fibroblasts identifies patients with Alzheimer disease. Proc Natl Acad Sci U 
S A, 90, 8209-13. 
289 
 
EWING, B. & GREEN, P. 1998. Base-Calling of Automated Sequencer Traces UsingPhred.II. Error 
Probabilities. Genome Research, 8, 186-194. 
EWING, B., HILLIER, L., WENDL, M. C. & GREEN, P. 1998. Base-Calling of Automated Sequencer Traces 
UsingPhred. I. Accuracy Assessment. Genome Research, 8, 175-185. 
FAN, G., CUI, Y., GOLLASCH, M. & KASSMANN, M. 2019. Elementary calcium signaling in arterial smooth 
muscle. Channels, 13, 505-519. 
FARAJNIA, S., MEIJER, J. H. & MICHEL, S. 2015. Age-related changes in large-conductance calcium-
activated potassium channels in mammalian circadian clock neurons. 36, 2176-2183. 
FEETHAM, C. H., NUNN, N. & BARRETT-JOLLEY, R. 2015a. The depressor response to 
intracerebroventricular hypotonic saline is sensitive to TRPV4 antagonist RN1734. Front 
Pharmacol, 6, 83. 
FEETHAM, C. H., NUNN, N., LEWIS, R., DART, C. & BARRETT-JOLLEY, R. 2015b. TRPV4 and KCa ion channels 
functionally couple as osmosensors in the paraventricular nucleus. Br J Pharmacol, 172, 1753-68. 
FEETHAM, C. H., O’BRIEN, F. & BARRETT-JOLLEY, R. 2018. Ion Channels in the Paraventricular 
Hypothalamic Nucleus (PVN); Emerging Diversity and Functional Roles. Frontiers in Physiology, 9. 
FELDER, R. B., FRANCIS, J., WEISS, R. M., ZHANG, Z. H., WEI, S. G. & JOHNSON, A. K. Neurohumoral 
regulation in ischemia-induced heart failure - Role of the forebrain. In: CHAPLEAU, M. W. & 
ABBOUD, F. M., eds., Aug 23-27 2000 Iowa City, Iowa. 444-453. 
FERGUSON, A. V., LATCHFORD, K. J. & SAMSON, W. K. 2008. The paraventricular nucleus of the 
hypothalamus – a potential target for integrative treatment of autonomic dysfunction. Expert 
Opinion on Therapeutic Targets, 12, 717-727. 
FERNANDEZ-FALGUERAS, A., SARQUELLA-BRUGADA, G., BRUGADA, J., BRUGADA, R. & CAMPUZANO, O. 
2017. Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances. Biology 
(Basel), 6. 
FERRUCCI, L., CORSI, A., LAURETANI, F., BANDINELLI, S., BARTALI, B., TAUB, D. D., GURALNIK, J. M. & 
LONGO, D. L. 2005. The origins of age-related proinflammatory state. Blood, 105, 2294-2299. 
FERRUCCI, L. & FABBRI, E. 2018. Inflammageing: chronic inflammation in ageing, cardiovascular disease, 
and frailty. Nature Reviews Cardiology, 15, 505-522. 
FLAK, J. N., MYERS, B., SOLOMON, M. B., MCKLVEEN, J. M., KRAUSE, E. G. & HERMAN, J. P. 2014. Role of 
paraventricular nucleus-projecting norepinephrine/epinephrine neurons in acute and chronic 
stress. Eur J Neurosci, 39, 1903-11. 
FLAK, J. N., OSTRANDER, M. M., TASKER, J. G. & HERMAN, J. P. 2009. Chronic stress-induced 
neurotransmitter plasticity in the PVN. J Comp Neurol, 517, 156-65. 
FLOOD, S., PARRI, R., WILLIAMS, A., DUANCE, V. & MASON, D. 2007. Modulation of interleukin-6 and 
matrix metalloproteinase 2 expression in human fibroblast-like synoviocytes by functional 
ionotropic glutamate receptors. Arthritis Rheum, 56, 2523-34. 
FRANCESCHI, C. & CAMPISI, J. 2014. Chronic inflammation (inflammaging) and its potential contribution 
to age-associated diseases. J Gerontol A Biol Sci Med Sci, 69 Suppl 1, S4-9. 
FRANCESCHI, C., CAPRI, M., MONTI, D., GIUNTA, S., OLIVIERI, F., SEVINI, F., PANOURGIA, M. P., INVIDIA, 
L., CELANI, L., SCURTI, M., CEVENINI, E., CASTELLANI, G. C. & SALVIOLI, S. 2007a. Inflammaging 
and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in 
humans. Mech Ageing  Devel, 128, 92-105. 
FRANCESCHI, C., CAPRI, M., MONTI, D., GIUNTA, S., OLIVIERI, F., SEVINI, F., PANOURGIA, M. P., INVIDIA, 
L., CELANI, L., SCURTI, M., CEVENINI, E., CASTELLANI, G. C. & SALVIOLI, S. 2007b. Inflammaging 
and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in 
humans. Mechanisms of Ageing and Development, 128, 92-105. 
FRASER, S., GREEN, C., BODE, H. & GILULA, N. 1987. Selective disruption of gap junctional communication 
interferes with a patterning process in hydra. 237, 49-55. 
290 
 
FRIEBEL, K., SCHONHERR, R., KINNE, R. W. & KUNISCH, E. 2014. Functional role of the KCa3.1 potassium 
channel in synovial fibroblasts from rheumatoid arthritis patients. J Cell Physiol. 
FRIEBEL, K., SCHÖNHERR, R., KINNE, R. W. & KUNISCH, E. 2015. Functional role of the KCa3.1 potassium 
channel in synovial fibroblasts from rheumatoid arthritis patients. 230, 1677-1688. 
FU, C. H., YANG, C. C. & KUO, T. B. 2006. Age-related changes in cerebral hemodynamics and their 
correlations with cardiac autonomic functions. Neurol Res, 28, 871-6. 
GARCIA-ELIAS, A., LORENZO, I. M., VICENTE, R. & VALVERDE, M. A. 2008. IP3 Receptor Binds to and 
Sensitizes TRPV4 Channel to Osmotic Stimuli via a Calmodulin-binding Site. 283, 31284-31288. 
GAVRILOV, L. A. & GAVRILOVA, N. S. 2002. Evolutionary Theories of Aging and Longevity. The Scientific 
World JOURNAL, 2, 339-356. 
GEORGIEV, D., YOSHIHARA, T., KAWABATA, R., MATSUBARA, T., TSUBOMOTO, M., MINABE, Y., LEWIS, D. 
A. & HASHIMOTO, T. 2016. Cortical Gene Expression After a Conditional Knockout of 67 kDa 
Glutamic Acid Decarboxylase in Parvalbumin Neurons. Schizophrenia Bulletin, 42, 992-1002. 
GERALDES, V., GONÇALVES-ROSA, N., LIU, B., PATON, J. F. R. & ROCHA, I. 2014. Chronic depression of 
hypothalamic paraventricular neuronal activity produces sustained hypotension in hypertensive 
rats. 99, 89-100. 
GIEPMANS, B. 2004. Gap junctions and connexin-interacting proteins. 62, 233-245. 
GOLDRING, M. B. & GOLDRING, S. R. 2007. Osteoarthritis. Journal of Cellular Physiology, 213, 626-634. 
GOODENOUGH, D. A. & PAUL, D. L. 2009. Gap Junctions. 1, a002576-a002576. 
GREENWOOD, M. P., GREENWOOD, M., ROMANOVA, E. V., MECAWI, A. S., PATERSON, A., SARENAC, O., 
JAPUNDŽIĆ-ŽIGON, N., ANTUNES-RODRIGUES, J., PATON, J. F. R., SWEEDLER, J. V. & MURPHY, D. 
2018. The effects of aging on biosynthetic processes in the rat hypothalamic osmoregulatory 
neuroendocrine system. Neurobiology of Aging, 65, 178-191. 
GRIDER, M. H., BELCEA, C. Q., COVINGTON, B. P. & SHARMA, S. 2019. Neuroanatomy, Nodes of Ranvier. 
StatPearls. Treasure Island (FL). 
GRIDER, M. H. & GLAUBENSKLEE, C. S. 2019. Physiology, Action Potential. StatPearls. Treasure Island (FL). 
GRUBB, B. D. 2004. Activation of sensory neurons in the arthritic joint. Novartis Found Symp, 260, 28-36; 
discussion 36-48, 100-4, 277-9. 
GRUNDER, S., GEISSLER, H. S., BASSLER, E. L. & RUPPERSBERG, J. P. 2000. A new member of acid-sensing 
ion channels from pituitary gland. Neuroreport, 11, 1607-11. 
GUI, Y. X., WAN, Y., XIAO, Q., WANG, Y., WANG, G. & CHEN, S. D. 2011. Verification of expressions of Kir2 
as potential peripheral biomarkers in lymphocytes from patients with Parkinson's disease. 
Neurosci Lett, 505, 104-8. 
GUILAK, F., LEDDY, H. A. & LIEDTKE, W. 2010. Transient receptor potential vanilloid 4: The sixth sense of 
the musculoskeletal system? Annals of the New York Academy of Sciences, 1192, 404-409. 
HAMADA, T., SAKAI, T., HIRAIWA, H., NAKASHIMA, M., ONO, Y., MITSUYAMA, H. & ISHIGURO, N. 2013. 
Surface markers and gene expression to characterize the differentiation of monolayer expanded 
human articular chondrocytes. Nagoya J Med Sci, 75, 101-11. 
HANUKOGLU, I. 2017. ASIC and ENaC type sodium channels: conformational states and the structures of 
the ion selectivity filters. The FEBS Journal, 284, 525-545. 
HAQUE, A., ENGEL, J., TEICHMANN, S. A. & LÖNNBERG, T. 2017. A practical guide to single-cell RNA-
sequencing for biomedical research and clinical applications. Genome Medicine, 9. 
HARDY, R. S., HÜLSO, C., LIU, Y., GASPARINI, S. J., FONG-YEE, C., TU, J., STONER, S., STEWART, P. M., RAZA, 
K., COOPER, M. S., SEIBEL, M. J. & ZHOU, H. 2013. Characterisation of fibroblast-like synoviocytes 
from a murine model of joint inflammation. Arthritis Research & Therapy, 15, R24. 
HDUD, I. M., EL-SHAFEI, A. A., LOUGHNA, P., BARRETT-JOLLEY, R. & MOBASHERI, A. 2012. Expression of 
transient receptor potential vanilloid (TRPV) channels in different passages of articular 
chondrocytes. International Journal of Molecular Sciences, 13, 4433-4445. 
291 
 
HE, W., LIU, W., CHEW, C. S., BAKER, S. S., BAKER, R. D., FORTE, J. G. & ZHU, L. 2011. Acid secretion-
associated translocation of KCNJ15 in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol, 
301, G591-600. 
HEINZE, C., SENIUK, A., SOKOLOV, M. V., HUEBNER, A. K., KLEMENTOWICZ, A. E., SZIJÁRTÓ, I. A., 
SCHLEIFENBAUM, J., VITZTHUM, H., GOLLASCH, M., EHMKE, H., SCHROEDER, B. C. & HÜBNER, C. 
A. 2014. Disruption of vascular Ca2+-activated chloride currents lowers blood pressure. 124, 675-
686. 
HERNANDEZ, C. M. & RICHARDS, J. R. 2019. Physiology, Sodium Channels. StatPearls. Treasure Island (FL). 
HILL, R. A., LI, A. M. & GRUTZENDLER, J. 2018. Lifelong cortical myelin plasticity and age-related 
degeneration in the live mammalian brain. Nature Neuroscience, 21, 683-695. 
HOSHIKAWA, M., KATO, A., HOJO, H., SHIBATA, Y., KUMAMOTO, N., WATANABE, M. & UGAWA, S. 2017. 
Distribution of ASIC4 transcripts in the adult wild-type mouse brain. Neuroscience Letters. 
HOSOYA, Y., SUGIURA, Y., OKADO, N., LOEWY, A. & KOHNO, K. 1991. Descending input from the 
hypothalamic paraventricular nucleus to sympathetic preganglionic neurons in the rat. 
Experimental Brain Research, 85, 10-20. 
HOTTA, H. & UCHIDA, S. 2010. Aging of the autonomic nervous system and possible improvements in 
autonomic activity using somatic afferent stimulation. Geriatr Gerontol Int, 10 Suppl 1, S127-36. 
HU, X., LARAGIONE, T., SUN, L., KOSHY, S., JONES, K. R., ISMAILOV, II, YOTNDA, P., HORRIGAN, F. T., GULKO, 
P. S. & BEETON, C. 2012a. KCa1.1 potassium channels regulate key proinflammatory and invasive 
properties of fibroblast-like synoviocytes in rheumatoid arthritis. Journal of biological chemistry, 
287, 4014-22. 
HU, X., LARAGIONE, T., SUN, L., KOSHY, S., JONES, K. R., ISMAILOV, I. I., YOTNDA, P., HORRIGAN, F. T., 
GULKO, P. S. & BEETON, C. 2012b. KCa1.1 Potassium Channels Regulate Key Proinflammatory and 
Invasive Properties of Fibroblast-like Synoviocytes in Rheumatoid Arthritis. 287, 4014-4022. 
HUBER, R., HUMMERT, C., GAUSMANN, U., POHLERS, D., KOCZAN, D., GUTHKE, R. & KINNE, R. W. 2008. 
Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression 
profiles in the rheumatoid arthritis synovial membrane. Arthritis Res Ther, 10, R98. 
HUI, A. Y., MCCARTY, W. J., MASUDA, K., FIRESTEIN, G. S. & SAH, R. L. 2012. A systems biology approach 
to synovial joint lubrication in health, injury, and disease. Wiley Interdiscip Rev Syst Biol Med, 4, 
15-37. 
HWANG, B., LEE, J. H. & BANG, D. 2018. Single-cell RNA sequencing technologies and bioinformatics 
pipelines. Experimental & Molecular Medicine, 50. 
IMBRICI, P., LIANTONIO, A., CAMERINO, G. M., DE BELLIS, M., CAMERINO, C., MELE, A., GIUSTINO, A., 
PIERNO, S., DE LUCA, A., TRICARICO, D., DESAPHY, J. F. & CONTE, D. 2016. Therapeutic Approaches 
to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol, 7, 121. 
IORGA, A. & HOROWITZ, B. Z. 2019. Phenytoin Toxicity. StatPearls. Treasure Island (FL). 
IWANAGA, T., SHIKICHI, M., KITAMURA, H., YANASE, H. & NOZAWA-INOUE, K. 2000. Morphology and 
functional roles of synoviocytes in the joint. Arch Histol Cytol, 63, 17-31. 
JANSEN, A. S. P., WESSENDORF, M. W. & LOEWY, A. D. 1995. Transneuronal Labeling of Cns Neuropeptide 
and Monoamine Neurons after Pseudorabies Virus Injections into the Stellate Ganglion. Brain 
Research, 683, 1-24. 
JAVIER CAMACHO, J., CHÁVEZ-LÓPEZ, M., ZÚÑIGA-GARCÍA, V., PÉREZ-CARREÓN, J., AVALOS-FUENTES, A. 
& ESCOBAR, Y. 2016. Eag1 channels as potential early-stage biomarkers of hepatocellular 
carcinoma. Biologics: Targets and Therapy, Volume 10, 139-148. 
JAYASURIYA, C. T., HU, N., LI, J., LEMME, N., TEREK, R., EHRLICH, M. G. & CHEN, Q. 2018. Molecular 
characterization of mesenchymal stem cells in human osteoarthritis cartilage reveals contribution 
to the OA phenotype. Sci Rep, 8, 7044. 
292 
 
JENSEN, A. B., JOERGENSEN, H. B., DAM, V. S., KAMAEV, D., BOEDTKJER, D., FÜCHTBAUER, E.-M., 
AALKJAER, C. & MATCHKOV, V. V. 2018. Variable Contribution of TMEM16A to Tone in Murine 
Arterial Vasculature. Basic & Clinical Pharmacology & Toxicology. 
JENTSCH, T. J. & GUNTHER, W. 1997. Chloride channels: an emerging molecular picture. Bioessays, 19, 
117-26. 
JENTSCH, T. J., STEIN, V., WEINREICH, F. & ZDEBIK, A. A. 2002. Molecular Structure and Physiological 
Function of Chloride Channels. Physiological Reviews, 82, 503-568. 
JI, M. J. & HONG, J. H. 2019. An overview of carbonic anhydrases and membrane channels of synoviocytes 
in inflamed joints. J Enzyme Inhib Med Chem, 34, 1615-1622. 
JIANG, Y., PICO, A., CADENE, M., CHAIT, B. T. & MACKINNON, R. 2001. Structure of the RCK domain from 
the E. coli K+ channel and demonstration of its presence in the human BK channel. Neuron, 29, 
593-601. 
JOMBART, T., DEVILLARD, S. & BALLOUX, F. 2010. Discriminant analysis of principal components: a new 
method for the analysis of genetically structured populations. BMC Genet, 11, 94. 
JULIUS, S. 1993. Sympathetic Hyperactivity and Coronary Risk in Hypertension. Hypertension, 21, 886-893. 
JYLHA, M., PAAVILAINEN, P., LEHTIMAKI, T., GOEBELER, S., KARHUNEN, P. J., HERVONEN, A. & HURME, M. 
2007. Interleukin-1 receptor antagonist, interleukin-6, and C-reactive protein as predictors of 
mortality in nonagenarians: the vitality 90+ study. J Gerontol A Biol Sci Med Sci, 62, 1016-21. 
KAJIWARA, Y., WANG, E., WANG, M., SIN, W. C., BRENNAND, K. J., SCHADT, E., NAUS, C. C., BUXBAUM, J. 
& ZHANG, B. 2018. GJA1 (connexin43) is a key regulator of Alzheimer's disease pathogenesis. Acta 
Neuropathol Commun, 6, 144. 
KANE, G. C., LAM, C. F., O'COCHLAIN, F., HODGSON, D. M., REYES, S., LIU, X. K., MIKI, T., SEINO, S., KATUSIC, 
Z. S. & TERZIC, A. 2006. Gene knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal 
susceptibility to endotoxemia. FASEB J, 20, 2271-80. 
KANG, Y. M., HE, R. L., YANG, L. M., QIN, D. N., GUGGILAM, A., ELKS, C., YAN, N., GUO, Z. & FRANCIS, J. 
2009. Brain tumour necrosis factor-alpha modulates neurotransmitters in hypothalamic 
paraventricular nucleus in heart failure. Cardiovasc Res, 83, 737-46. 
KAPLAN, J., GERBER, S., BONNEAU, D., ROZET, J. M., DELRIEU, O., BRIARD, M. L., DOLLFUS, H., GHAZI, I., 
DUFIER, J. L., FRÉZAL, J. & MUNNICH, A. 1992. A gene for usher syndrome type I (USH1A) maps to 
chromosome 14q. 14, 979-987. 
KARIMI, A. & MILEWICZ, D. M. 2016. Structure of the Elastin-Contractile Units in the Thoracic Aorta and 
How Genes That Cause Thoracic Aortic Aneurysms and Dissections Disrupt This Structure. 
Canadian Journal of Cardiology, 32, 26-34. 
KARSDAL, M. A. 2016. Collagens - Introduction. 
KIM, D., LANGMEAD, B. & SALZBERG, S. L. 2015. HISAT: a fast spliced aligner with low memory 
requirements. Nature Methods, 12, 357-360. 
KIM, G.-T., CHO, Y.-W., TAK, H.-M., LEE, J.-S., KIM, E.-J., HAN, J. & KANG, D. 2012. Age-related changes in 
two-pore domain acid-sensitive K+ channel expression in rat dorsal root ganglion neurons. 39, 43-
48. 
KIM, J. B. 2014. Channelopathies. Korean J Pediatr, 57, 1-18. 
KIRKWOOD, T. B. L. 1977. Evolution of ageing. Nature, 270, 301-304. 
KIRKWOOD, T. B. L. & HOLLIDAY, R. 1979. The Evolution of Ageing and Longevity. 205, 531-546. 
KONDO, C., CLARK, R. B., KIM, T. Y., BELKE, D., BANDERALI, U., SZERENCSEI, R. T., JALLOUL, A. H., 
SCHNETKAMP, P. P. M., SPITZER, K. W. & GILES, W. R. 2018. ATP triggers a robust intracellular 
[Ca(2+) ]-mediated signalling pathway in human synovial fibroblasts. Exp Physiol, 103, 1101-1122. 
KOTIPOYINA, H. R. & WARRINGTON, S. J. 2019. Tetrodotoxin Toxicity. StatPearls. Treasure Island (FL). 
KRAMER, A., GREEN, J., POLLARD, J., JR. & TUGENDREICH, S. 2014. Causal analysis approaches in Ingenuity 
Pathway Analysis. Bioinformatics, 30, 523-30. 
293 
 
KUMAHASHI, N., NAITOU, K., NISHI, H., OAE, K., WATANABE, Y., KUWATA, S., OCHI, M., IKEDA, M. & 
UCHIO, Y. 2011. Correlation of changes in pain intensity with synovial fluid adenosine 
triphosphate levels after treatment of patients with osteoarthritis of the knee with high-
molecular-weight hyaluronic acid. The Knee, 18, 160-164. 
KUO, C. J., LAMONTAGNE, K. R., GARCIA-CARDEÑA, G., ACKLEY, B. D., KALMAN, D., PARK, S., 
CHRISTOFFERSON, R., KAMIHARA, J., DING, Y.-H., LO, K.-M., GILLIES, S., FOLKMAN, J., MULLIGAN, 
R. C. & JAVAHERIAN, K. 2001. Oligomerization-Dependent Regulation of Motility and 
Morphogenesis by the Collagen Xviii Nc1/Endostatin Domain. 152, 1233-1246. 
KURIYAMA, H., KITAMURA, K., ITOH, T. & INOUE, R. 1998. Physiological features of visceral smooth muscle 
cells, with special reference to receptors and ion channels. Physiol Rev, 78, 811-920. 
KWOK, A., RAULF, N. & HABIB, N. 2019. Developing small activating RNA as a therapeutic: current 
challenges and promises. Ther Deliv, 10, 151-164. 
LAINA, A., STELLOS, K. & STAMATELOPOULOS, K. 2018. Vascular ageing: Underlying mechanisms and 
clinical implications. Experimental Gerontology, 109, 16-30. 
LAMBERT, C., DUBUC, J.-E., MONTELL, E., VERGÉS, J., MUNAUT, C., NOËL, A. & HENROTIN, Y. 2014. Gene 
Expression Pattern of Cells From Inflamed and Normal Areas of Osteoarthritis Synovial 
Membrane. Arthritis & Rheumatology, 66, 960-968. 
LANG, F. & HOFFMANN, E. K. 2013. CrossTalk proposal: Cell volume changes are an essential step in the 
cell death machinery. J Physiol, 591, 6119-21. 
LATORRE, R. & BRAUCHI, S. 2006. Large conductance Ca2+-activated K+ (BK) channel: activation by Ca2+ 
and voltage. Biol Res, 39, 385-401. 
LEE, J. C. & CHOE, S. Y. 2014. Age-related changes in the distribution of transient receptor potential 
vanilloid 4 channel (TRPV4) in the central nervous system of rats. J Mol Histol, 45, 497-505. 
LEE, S. W., SONG, Y. S., LEE, S. Y., YOON, Y. G., LEE, S. H., PARK, B. S., YUN, I., CHOI, H., KIM, K., CHUNG, W. 
T. & YOO, Y. H. 2011. Downregulation of Protein Kinase CK2 Activity Facilitates Tumor Necrosis 
Factor-α-Mediated Chondrocyte Death through Apoptosis and Autophagy. PLoS ONE, 6, e19163. 
LESAGE, F. & LAZDUNSKI, M. 2000. Molecular and functional properties of two-pore-domain potassium 
channels. American Journal of Physiology-Renal Physiology, 279, F793-F801. 
LEVINE, J. D. & ALESSANDRI-HABER, N. 2007. TRP channels: Targets for the relief of pain. Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease, 1772, 989-1003. 
LEWIS, R., ASPLIN, K. E., BRUCE, G., DART, C., MOBASHERI, A. & BARRETT-JOLLEY, R. 2011a. The Role of 
the Membrane Potential in Chondrocyte Volume Regulation. Journal of Cellular Physiology, 226, 
2979-2986. 
LEWIS, R. & BARRETT-JOLLEY, R. 2015. Changes in Membrane Receptors and Ion Channels as Potential 
Biomarkers for Osteoarthritis. Front Physiol, 6, 357. 
LEWIS, R., FEETHAM, C. H. & BARRETT-JOLLEY, R. 2011b. Cell Volume Regulation in Chondrocytes. Cellular 
Physiology and Biochemistry, 28, 1111-1122. 
LEWIS, R., MILLS, A. & BARRETT-JOLLEY, R. 2010. Models Of Paraventricular Nucleus (PVN) Sympathetic 
Neurone Modulation by Glucose and Hypoglycaemia. Biophysical Journal - BIOPHYS J, 98. 
LI, Y., WEI, X., ZHOU, J. & WEI, L. 2013. The Age-Related Changes in Cartilage and Osteoarthritis. BioMed 
Research International, 2013, 1-12. 
LI, Y., ZHAO, Z., CAI, J., GU, B., LV, Y. & ZHAO, L. 2017. The Frequency-Dependent Aerobic Exercise Effects 
of Hypothalamic GABAergic Expression and Cardiovascular Functions in Aged Rats. Frontiers in 
Aging Neuroscience, 9. 
LI, Y. F., CORNISH, K. G. & PATEL, K. P. 2003. Alteration of NMDA NR1 receptors within the paraventricular 
nucleus of hypothalamus in rats with heart failure. Circulation Research, 93, 990-997. 
LI, Y. F., JACKSON, K. L., STERN, J. E., RABELER, B. & PATEL, K. P. 2006a. Interaction between glutamate and 
GABA systems in the integration of sympathetic outflow by the paraventricular nucleus of the 
294 
 
hypothalamus. American Journal of Physiology-Heart and Circulatory Physiology, 291, H2847-
H2856. 
LI, Y. F. & PATEL, K. P. Paraventricular nucleus of the hypothalamus and elevated sympathetic activity in 
heart failure: the altered inhibitory mechanisms. Apr 20-24 2002 New Orleans, Louisiana. 17-26. 
LI, Y. F. & PATEL, K. P. 2003. Paraventricular nucleus of the hypothalamus and elevated sympathetic 
activity in heart failure: the altered inhibitory mechanisms. Acta Physio Scand, 177, 17-26. 
LI, Y. F., WANG, W., MAYHAN, W. G. & PATEL, K. P. 2006b. Angiotensin-mediated increase in renal 
sympathetic nerve discharge within the PVN: role of nitric oxide. American Journal of Physiology-
Regulatory Integrative and Comparative Physiology, 290, R1035-R1043. 
LIPPIAT, J. D., STANDEN, N. B., HARROW, I. D., PHILLIPS, S. C. & DAVIES, N. W. 2003. Properties of BK(Ca) 
channels formed by bicistronic expression of hSloalpha and beta1-4 subunits in HEK293 cells. The 
Journal of membrane biology, 192, 141-8. 
LOEWY, A. 1991. Forebrain nuclei involved in autonomic control. Progress in brain research, 87, 253. 
LOEWY, A. D. & MCKELLAR, S. 1980. The neuroanatomical basis of central cardiovascular control. 
Fed.Proc., 39, 2495-2503. 
LONG, S. B., CAMPBELL, E. B. & MACKINNON, R. 2005a. Crystal structure of a mammalian voltage-
dependent Shaker family K+ channel. Science, 309, 897-903. 
LONG, S. B., CAMPBELL, E. B. & MACKINNON, R. 2005b. Voltage sensor of Kv1.2: structural basis of 
electromechanical coupling. Science, 309, 903-8. 
LOVICK, T. A. & COOTE, J. H. 1988. Effects of volume loading on paraventriculo-spinal neurones in the rat. 
J Auton Nerv Syst, 25, 135-40. 
LOVICK, T. A. & COOTE, J. H. 1989. Circulating atrial natriuretic factor activates vagal afferent inputs to 
paraventriculo-spinal neurones in the rat. J Auton Nerv Syst, 26, 129-34. 
LOVICK, T. A., MALPAS, S. & MAHONY, M. T. 1993. Renal vasodilatation in response to acute volume load 
is attenuated following lesions of parvocellular neurones in the paraventricular nucleus in rats. 
Journal of the Autonomic Nervous System, 43, 247-256. 
LYTTON, J. 2007. Na+/Ca2+ exchangers: three mammalian gene families control Ca2+ transport. Biochem 
J, 406, 365-82. 
MA, S., MURPHY, T. W. & LU, C. 2017. Microfluidics for genome-wide studies involving next generation 
sequencing. Biomicrofluidics, 11, 021501. 
MACDONALD, M. L. E., VAN ECK, M., HILDEBRAND, R. B., WONG, B. W. C., BISSADA, N., RUDDLE, P., 
KONTUSH, A., HUSSEIN, H., POULADI, M. A., CHAPMAN, M. J., FIEVET, C., VAN BERKEL, T. J. C., 
STAELS, B., MCMANUS, B. M. & HAYDEN, M. R. 2009. Despite Antiatherogenic Metabolic 
Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis. 29, 341-
347. 
MACKINNON, R., HEGINBOTHAM, L. & ABRAMSON, T. 1990. Mapping the receptor site for charybdotoxin, 
a pore-blocking potassium channel inhibitor. Neuron, 5, 767-71. 
MACKINNON, R. & MILLER, C. 1989. Mutant potassium channels with altered binding of charybdotoxin, a 
pore-blocking peptide inhibitor. Science, 245, 1382-5. 
MADEJ, W., VAN CAAM, A., BLANEY DAVIDSON, E. N., HANNINK, G., BUMA, P. & VAN DER KRAAN, P. M. 
2016. Ageing is associated with reduction of mechanically-induced activation of Smad2/3P 
signaling in articular cartilage. 24, 146-157. 
MAEZAWA, I., JENKINS, D. P., JIN, B. E. & WULFF, H. 2012. Microglial KCa3.1 Channels as a Potential 
Therapeutic Target for Alzheimer’s Disease. International Journal of Alzheimer's Disease, 2012, 1-
8. 
MAKITA, N., BENNETT, P. B., JR. & GEORGE, A. L., JR. 1994. Voltage-gated Na+ channel beta 1 subunit 
mRNA expressed in adult human skeletal muscle, heart, and brain is encoded by a single gene. J 
Biol Chem, 269, 7571-8. 
295 
 
MANSOUR, F. A., HASSAN, M. O., KHAN, A. A. & ALBARWANI, S. 2016. Aging Down Regulates L-Type 
Voltage-gated Calcium Channels in Resistance Coronary Arteries. Faseb Journal, 30. 
MARTIN, D. S. & HAYWOOD, J. R. 1993. Hemodynamic responses to paraventricular nucleus disinhibition 
with bicuculline in conscious rats. American Journal of Physiology- Heart and Circulatory 
Physiology, 265, H1727-H1733. 
MARTIN, D. S., SEGURA, T. & HAYWOOD, J. R. 1991. Cardiovascular responses to bicuculline in the 
paraventricular nucleus of the rat. Hypertension, 18, 48-55. 
MARTINEZ, A. H. & MOHIUDDIN, S. S. 2019. Biochemistry, Chloride Channels. StatPearls. Treasure Island 
(FL). 
MARTINSEN, A., DESSY, C. & MOREL, N. 2014. Regulation of calcium channels in smooth muscle: New 
insights into the role of myosin light chain kinase. 8, 402-413. 
MCCUSKER, S. M., CURRAN, M. D., DYNAN, K. B., MCCULLAGH, C. D., URQUHART, D. D., MIDDLETON, D., 
PATTERSON, C. C., MCILROY, S. P. & PETER PASSMORE, A. 2001. Association between 
polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of 
Alzheimer's disease and vascular dementia: a case-control study. 357, 436-439. 
MCMANUS, O. B., HELMS, L. M., PALLANCK, L., GANETZKY, B., SWANSON, R. & LEONARD, R. J. 1995. 
Functional role of the beta subunit of high conductance calcium-activated potassium channels. 
Neuron, 14, 645-50. 
MCNERLAN, S. E., REA, I. M. & ALEXANDER, H. D. 2002. A whole blood method for measurement of 
intracellular TNF-alpha, IFN-gamma and IL-2 expression in stimulated CD3+ lymphocytes: 
differences between young and elderly subjects. Exp Gerontol, 37, 227-34. 
MCNULTY, M., SPIERS, P., MCGOVERN, E. & FEELY, J. 2005. Aging is associated with increased matrix 
metalloproteinase-2 activity in the human aorta. 18, 504-509. 
MEDVEDEV, Z. A. 1990. AN ATTEMPT AT A RATIONAL CLASSIFICATION OF THEORIES OF AGEING. Biological 
Reviews, 65, 375-398. 
MEERA, P., WALLNER, M., SONG, M. & TORO, L. 1997. Large conductance voltage- and calcium-dependent 
K+ channel, a distinct member of voltage-dependent ion channels with seven N-terminal 
transmembrane segments (S0-S6), an extracellular N terminus, and an intracellular (S9-S10) C 
terminus. 94, 14066-14071. 
MELTZER, H., MAROM, E., ALYAGOR, I., MAYSELESS, O., BERKUN, V., SEGAL-GILBOA, N., UNGER, T., 
LUGINBUHL, D. & SCHULDINER, O. 2019. Tissue-specific (ts)CRISPR as an efficient strategy for in 
vivo screening in Drosophila. Nature Communications, 10. 
MENDONCA, M. M., SANTANA, J. S., DA CRUZ, K. R., IANZER, D., GHEDINI, P. C., NALIVAIKO, E., FONTES, 
M. A. P., FERREIRA, R. N., PEDRINO, G. R., COLUGNATI, D. B. & XAVIER, C. H. 2018. Involvement of 
GABAergic and Adrenergic Neurotransmissions on Paraventricular Nucleus of Hypothalamus in 
the Control of Cardiac Function. Front Physiol, 9, 670. 
MEŞE, G., RICHARD, G. & WHITE, T. W. 2007. Gap Junctions: Basic Structure and Function. Journal of 
Investigative Dermatology, 127, 2516-2524. 
MISRA, V., LEE, H., SINGH, A., HUANG, K., THIMMULAPPA, R. K., MITZNER, W., BISWAL, S. & TANKERSLEY, 
C. G. 2007. Global expression profiles from C57BL/6J and DBA/2J mouse lungs to determine aging-
related genes. 31, 429-440. 
MOBASHERI, A., LEWIS, R., FERREIRA-MENDES, A., RUFINO, A., DART, C. & BARRETT-JOLLEY, R. 2012. 
Potassium channels in articular chondrocytes. Channels, 6, 416-425. 
MOCZYDLOWSKI, E., LUCCHESI, K. & RAVINDRAN, A. 1988. An emerging pharmacology of peptide toxins 
targeted against potassium channels. J Membr Biol, 105, 95-111. 
MONK, B. A. & GEORGE, S. J. 2015. The Effect of Ageing on Vascular Smooth Muscle Cell Behaviour--A 
Mini-Review. Gerontology, 61, 416-26. 
296 
 
MORTAZ, E., ADCOCK, I. M., SHAFEI, H., MASJEDI, M. R. & FOLKERTS, G. 2012. Role of P2X7 Receptors in 
Release of IL-1β: A Possible Mediator of Pulmonary Inflammation. Tanaffos, 11, 6-11. 
MORTH, J. P., PEDERSEN, B. P., TOUSTRUP-JENSEN, M. S., SORENSEN, T. L., PETERSEN, J., ANDERSEN, J. P., 
VILSEN, B. & NISSEN, P. 2007. Crystal structure of the sodium-potassium pump. Nature, 450, 1043-
9. 
MOSKALEV, A., ALIPER, A., SMIT-MCBRIDE, Z., BUZDIN, A. & ZHAVORONKOV, A. 2014. Genetics and 
epigenetics of aging and longevity. 13, 1063-1077. 
MUELLER, O., LIGHTFOOT, S., SCHROEDER, A. <RNA Integrity Number (RIN) - Standardization of RNA 
Quality Control.pdf>. 
MUN, M. J., KIM, J. H., CHOI, J. Y. & JANG, W. C. 2016. Genetic polymorphisms of interleukin genes and 
the risk of Alzheimer's disease: An update meta-analysis. Meta Gene, 8, 1-10. 
NASRABADY, S. E., RIZVI, B., GOLDMAN, J. E. & BRICKMAN, A. M. 2018. White matter changes in 
Alzheimer’s disease: a focus on myelin and oligodendrocytes. Acta Neuropathologica 
Communications, 6. 
NGUYEN, T. P. & TAYLOR, R. S. 2019. Guillain Barre Syndrome. StatPearls. Treasure Island (FL). 
NICHOLS, C. G., SINGH, G. K. & GRANGE, D. K. 2013. KATP Channels and Cardiovascular Disease: Suddenly 
a Syndrome. 112, 1059-1072. 
NIISSALO, S., LI, T. F., SANTAVIRTA, S., TAKAGI, M., HIETANEN, J. & KONTTINEN, Y. T. 2002. Dense 
innervation in pseudocapsular tissue compared to aneural interface tissue in loose totally 
replaced hips. J Rheumatol, 29, 796-803. 
NILSSON, L., SZYMANOWSKI, A., SWAHN, E. & JONASSON, L. 2013. Soluble TNF receptors are associated 
with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One, 8, 
e55477. 
NOSS, E. H. & BRENNER, M. B. 2008. The role and therapeutic implications of fibroblast-like synoviocytes 
in inflammation and cartilage erosion in rheumatoid arthritis. Immunological Reviews, 223, 252-
270. 
NOVAKOVIC, S. D., EGLEN, R. M. & HUNTER, J. C. 2001. Regulation of Na+ channel distribution in the 
nervous system. 24, 473-478. 
NUNN, N., WOMACK, M., DART, C. & BARRETT-JOLLEY, R. 2011. Function and pharmacology of spinally-
projecting sympathetic pre-autonomic neurones in the paraventricular nucleus of the 
hypothalamus. Current neuropharmacology, 9, 262-77. 
O'LEARY, N. A., WRIGHT, M. W., BRISTER, J. R., CIUFO, S., HADDAD, D., MCVEIGH, R., RAJPUT, B., 
ROBBERTSE, B., SMITH-WHITE, B., AKO-ADJEI, D., ASTASHYN, A., BADRETDIN, A., BAO, Y., 
BLINKOVA, O., BROVER, V., CHETVERNIN, V., CHOI, J., COX, E., ERMOLAEVA, O., FARRELL, C. M., 
GOLDFARB, T., GUPTA, T., HAFT, D., HATCHER, E., HLAVINA, W., JOARDAR, V. S., KODALI, V. K., LI, 
W., MAGLOTT, D., MASTERSON, P., MCGARVEY, K. M., MURPHY, M. R., O'NEILL, K., PUJAR, S., 
RANGWALA, S. H., RAUSCH, D., RIDDICK, L. D., SCHOCH, C., SHKEDA, A., STORZ, S. S., SUN, H., 
THIBAUD-NISSEN, F., TOLSTOY, I., TULLY, R. E., VATSAN, A. R., WALLIN, C., WEBB, D., WU, W., 
LANDRUM, M. J., KIMCHI, A., TATUSOVA, T., DICUCCIO, M., KITTS, P., MURPHY, T. D. & PRUITT, K. 
D. 2016. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, 
and functional annotation. Nucleic Acids Research, 44, D733-D745. 
O'MAHONY, L., HOLLAND, J., JACKSON, J., FEIGHERY, C., HENNESSY, T. P. & MEALY, K. 1998. Quantitative 
intracellular cytokine measurement: age-related changes in proinflammatory cytokine 
production. Clin Exp Immunol, 113, 213-9. 
O'MALLEY, H. A. & ISOM, L. L. 2015. Sodium channel beta subunits: emerging targets in channelopathies. 
Annu Rev Physiol, 77, 481-504. 
OEGEMA, R., MCGILLIVRAY, G., LEVENTER, R., LE MOING, A. G., BAHI‐BUISSON, N., BARNICOAT, A., 
MANDELSTAM, S., FRANCIS, D., FRANCIS, F., MANCINI, G. M. S., SAVELBERG, S., HAAFTEN, G., 
297 
 
MANKAD, K. & LEQUIN, M. H. 2019. EML1‐ associated brain overgrowth syndrome with ribbon‐
like heterotopia. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 
OKAMOTO, K., IWASAKI, N., DOI, K., NOIRI, E., IWAMOTO, Y., UCHIGATA, Y., FUJITA, T. & TOKUNAGA, K. 
2012. Inhibition of glucose-stimulated insulin secretion by KCNJ15, a newly identified 
susceptibility gene for type 2 diabetes. Diabetes, 61, 1734-41. 
OKAMOTO, K., IWASAKI, N., NISHIMURA, C., DOI, K., NOIRI, E., NAKAMURA, S., TAKIZAWA, M., OGATA, 
M., FUJIMAKI, R., GRARUP, N., PISINGER, C., BORCH-JOHNSEN, K., LAURITZEN, T., SANDBAEK, A., 
HANSEN, T., YASUDA, K., OSAWA, H., NANJO, K., KADOWAKI, T., KASUGA, M., PEDERSEN, O., 
FUJITA, T., KAMATANI, N., IWAMOTO, Y. & TOKUNAGA, K. 2010. Identification of KCNJ15 as a 
Susceptibility Gene in Asian Patients with Type 2 Diabetes Mellitus. 86, 54-64. 
ORLOV, S. N., GUSAKOVA, S. V., SMAGLII, L. V., KOLTSOVA, S. V. & SIDORENKO, S. V. 2017. Vasoconstriction 
triggered by hydrogen sulfide: Evidence for Na(+),K(+),2Cl(-)cotransport and L-type Ca(2+) 
channel-mediated pathway. Biochem Biophys Rep, 12, 220-227. 
ORLOV, S. N., MODEL, M. A. & GRYGORCZYK, R. 2013. CrossTalk opposing view: The triggering and 
progression of the cell death machinery can occur without cell volume perturbations. J Physiol, 
591, 6123-5. 
PAL, R., SINGH, S. N., CHATTERJEE, A. & SAHA, M. 2014. Age-related changes in cardiovascular system, 
autonomic functions, and levels of BDNF of healthy active males: role of yogic practice. Age 
(Dordr), 36, 9683. 
PARASHAR, R., AMIR, M., PAKHARE, A., RATHI, P. & CHAUDHARY, L. 2016. Age Related Changes in 
Autonomic Functions. J Clin Diagn Res, 10, CC11-5. 
PATEL, K. P., ZHANG, K., KENNEY, M. J., WEISS, M. & MAYHAN, W. G. 2000. Neuronal expression of Fos 
protein in the hypothalamus of rats with heart failure. Brain Research, 865, 27-34. 
PATTHY, L., TREXLER, M., VÁLI, Z., BÁNYAI, L. & VÁRADI, A. 1984. Kringles: modules specialized for protein 
binding. 171, 131-136. 
PEARL, J. 2009. Causal inference in statistics: An overview. Statistics Surveys, 3, 96-146. 
PECANHA, F. M., WIGGERS, G. A., BRIONES, A. M., PEREZ-GIRON, J. V., MIGUEL, M., GARCIA-REDONDO, A. 
B., VASSALLO, D. V., ALONSO, M. J. & SALAICES, M. 2010. The role of cyclooxygenase (COX)-2 
derived prostanoids on vasoconstrictor responses to phenylephrine is increased by exposure to 
low mercury concentration. J Physiol Pharmacol, 61, 29-36. 
PEDERSEN, B. K. 2006a. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular 
disease control. Essays in Biochemistry, Vol 42, 42, 105-117. 
PEDERSEN, B. K. 2006b. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular 
disease control. Essays Biochem, 42, 105-17. 
PERTEA, M., PERTEA, G. M., ANTONESCU, C. M., CHANG, T.-C., MENDELL, J. T. & SALZBERG, S. L. 2015. 
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nature 
Biotechnology, 33, 290-295. 
PETERS, A. 2002. The effects of normal aging on myelin and nerve fibers: a review. J Neurocytol, 31, 581-
93. 
PETERS, N. S., SEVERS, N. J., ROTHERY, S. M., LINCOLN, C., YACOUB, M. H. & GREEN, C. R. 1994. 
Spatiotemporal relation between gap junctions and fascia adherens junctions during postnatal 
development of human ventricular myocardium. 90, 713-725. 
PETHŐ, Z., TANNER, M. R., TAJHYA, R. B., HUQ, R., LARAGIONE, T., PANYI, G., GULKO, P. S. & BEETON, C. 
2016. Different expression of β subunits of the KCa1.1 channel by invasive and non-invasive 
human fibroblast-like synoviocytes. 18. 
PI, Y., GOLDENTHAL, M. J. & MARIN-GARCIA, J. 2007. Mitochondrial channelopathies in aging. J Mol Med 
(Berl), 85, 937-51. 
PINTO, E. 2007. Blood pressure and ageing. Postgraduate Medical Journal, 83, 109-114. 
298 
 
PLANELLS-CASES, R. & JENTSCH, T. J. 2009. Chloride channelopathies. Biochim Biophys Acta, 1792, 173-
89. 
PRETZEL, D., POHLERS, D., WEINERT, S. & KINNE, R. W. 2009. In vitro model for the analysis of synovial 
fibroblast-mediated degradation of intact cartilage. Arthritis Res Ther, 11, R25. 
PRUITT, K. D., BROWN, G. R., HIATT, S. M., THIBAUD-NISSEN, F., ASTASHYN, A., ERMOLAEVA, O., FARRELL, 
C. M., HART, J., LANDRUM, M. J., MCGARVEY, K. M., MURPHY, M. R., O’LEARY, N. A., PUJAR, S., 
RAJPUT, B., RANGWALA, S. H., RIDDICK, L. D., SHKEDA, A., SUN, H., TAMEZ, P., TULLY, R. E., 
WALLIN, C., WEBB, D., WEBER, J., WU, W., DICUCCIO, M., KITTS, P., MAGLOTT, D. R., MURPHY, T. 
D. & OSTELL, J. M. 2014. RefSeq: an update on mammalian reference sequences. 42, D756-D763. 
PRUITT, K. D., TATUSOVA, T. & MAGLOTT, D. R. 2007. NCBI reference sequences (RefSeq): a curated non-
redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Research, 35, 
D61-D65. 
QIN, N., D'ANDREA, M. R., LUBIN, M. L., SHAFAEE, N., CODD, E. E. & CORREA, A. M. 2003. Molecular cloning 
and functional expression of the human sodium channel beta1B subunit, a novel splicing variant 
of the beta1 subunit. Eur J Biochem, 270, 4762-70. 
QIU, Y., HUANG, L., FU, J., HAN, C., FANG, J., LIAO, P., CHEN, Z., MO, Y., SUN, P., LIAO, D., YANG, L., WANG, 
J., ZHANG, Q., LIU, J., LIU, F., LIU, T., HUANG, W., YANG, H. & JIANG, R. 2020. A TREK Channel 
Family Activator with Well-Defined Structure-Activation Relationship for Pain and Neurogenic 
Inflammation. J Med Chem. 
RAMA, A., MATSUSHITA, T., CHAROLIDI, N., ROTHERY, S., DUPONT, E. & SEVERS, N. J. 2006. Up-regulation 
of connexin43 correlates with increased synthetic activity and enhanced contractile 
differentiation in TGF-β-treated human aortic smooth muscle cells. 85, 375-386. 
RAMSEY, I. S., DELLING, M. & CLAPHAM, D. E. 2006. AN INTRODUCTION TO TRP CHANNELS. Annual Review 
of Physiology, 68, 619-647. 
RAO, V., KAJA, S., AND GENTILE, S. 2016. Ion channels in Aging and Age-related Diseases. 
REA, I. M., GIBSON, D. S., MCGILLIGAN, V., MCNERLAN, S. E., ALEXANDER, H. D. & ROSS, O. A. 2018. Age 
and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Front Immunol, 9, 586. 
REDDY, M. M. & KAR, S. S. 2019. Unconditional probability of dying and age-specific mortality rate because 
of major non-communicable diseases in India: Time trends from 2001 to 2013. Journal of 
postgraduate medicine, 65, 11-17. 
RIBEIRO-RODRIGUES, T. M., MARTINS-MARQUES, T., MOREL, S., KWAK, B. R. & GIRAO, H. 2017. Role of 
connexin 43 in different forms of intercellular communication - gap junctions, extracellular 
vesicles and tunnelling nanotubes. J Cell Sci, 130, 3619-3630. 
RICHARDS, M. W., LAW, E. W. P., RENNALLS, L. P., BUSACCA, S., O'REGAN, L., FRY, A. M., FENNELL, D. A. & 
BAYLISS, R. 2014. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic 
EML4-ALK by disruption of an atypical  -propeller domain. Proceedings of the National Academy 
of Sciences, 111, 5195-5200. 
RIDKER, P. M., RIFAI, N., PFEFFER, M., SACKS, F., LEPAGE, S. & BRAUNWALD, E. 2000. Elevation of tumor 
necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. 
Circulation, 101, 2149-53. 
RIVERA-APONTE, D. E., MÉNDEZ-GONZÁLEZ, M. P., RIVERA-PAGÁN, A. F., KUCHERYAVYKH, Y. V., 
KUCHERYAVYKH, L. Y., SKATCHKOV, S. N. & EATON, M. J. 2015. Hyperglycemia reduces functional 
expression of astrocytic Kir4.1 channels and glial glutamate uptake. Neuroscience, 310, 216-223. 
ROBERTSON, D. W. & STEINBERG, M. I. 1990. Potassium channel modulators: scientific applications and 
therapeutic promise. J Med Chem, 33, 1529-41. 
ROSASCO, M. G. & GORDON, S. E. 2017. TRP Channels: What Do They Look Like? In: ND & EMIR, T. L. R. 
(eds.) Neurobiology of TRP Channels. Boca Raton (FL). 
299 
 
ROSSI, N. F. & MALISZEWSKA-SCISLO, M. 2008. Role of paraventricular nucleus vasopressin V1A receptors 
in the response to endothelin 1 activation of the subfornical organ in the rat. J Physiol Pharmacol, 
59 Suppl 8, 47-59. 
RUDIJANTO, A. 2007. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. 
Acta Med Indones, 39, 86-93. 
RUPARELIA, N., CHAI, J. T., FISHER, E. A. & CHOUDHURY, R. P. 2017. Inflammatory processes in 
cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol, 14, 133-144. 
SANDER, S. E., LEMM, C., LANGE, N., HAMANN, M. & RICHTER, A. 2012. Retigabine, a K(V)7 (KCNQ) 
potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats. 
Neuropharmacology, 62, 1052-61. 
SANDOVICI, I., HAMMERLE, C. M., COOPER, W. N., SMITH, N. H., TARRY-ADKINS, J. L., DUNMORE, B. J., 
BAUER, J., ANDREWS, S. R., YEO, G. S. H., OZANNE, S. E. & CONSTÂNCIA, M. 2016. Ageing is 
associated with molecular signatures of inflammation and type 2 diabetes in rat pancreatic islets. 
59, 502-511. 
SANTI, C. M. 2006. Opposite Regulation of Slick and Slack K+ Channels by Neuromodulators. Journal of 
Neuroscience, 26, 5059-5068. 
SASAKI, S., ISHIBASHI, K. & MARUMO, F. 1998. Aquaporin-2 and -3: representatives of two subgroups of 
the aquaporin family colocalized in the kidney collecting duct. Annu Rev Physiol, 60, 199-220. 
SAWCHENKO, P. E. & SWANSON, L. W. 1982. Immunohistochemical identification of neurons in the 
paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in 
the rat. Journal of Comparative Neurology, 205, 260-272. 
SCANZELLO, C. R. & GOLDRING, S. R. 2012. The role of synovitis in osteoarthritis pathogenesis. Bone, 51, 
249-57. 
SCHELLER, J., CHALARIS, A., SCHMIDT-ARRAS, D. & ROSE-JOHN, S. 2011. The pro- and anti-inflammatory 
properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research, 1813, 878-888. 
SCHOLZ, A. 2002. Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br 
J Anaesth, 89, 52-61. 
SCHREIBER, M. 1998. Slo3, a Novel pH-sensitive K+ Channel from Mammalian Spermatocytes. 273, 3509-
3516. 
SCUDIERI, P., CACI, E., VENTURINI, A., SONDO, E., PIANIGIANI, G., MARCHETTI, C., RAVAZZOLO, R., PAGANI, 
F. & GALIETTA, L. J. V. 2015. Ion channel and lipid scramblase activity associated with expression 
of TMEM16F/ANO6 isoforms. Journal of Physiology-London, 593, 3829-3848. 
SELLAM, J. & BERENBAUM, F. 2010. The role of synovitis in pathophysiology and clinical symptoms of 
osteoarthritis. Nat Rev Rheumatol, 6, 625-35. 
SESTI, F. 2016. Oxidation of K+Channels in Aging and Neurodegeneration. 7, 130. 
SHAMIM, D. & LASKOWSKI, M. 2017. Inhibition of Inflammation Mediated Through the Tumor Necrosis 
Factor alpha Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease. J Cent 
Nerv Syst Dis, 9, 1179573517722512. 
SHIH, C. D., AU, L. C. & CHAN, J. Y. 2003. Differential role of leptin receptors at the hypothalamic 
paraventricular nucleus in tonic regulation of food intake and cardiovascular functions. J Biomed 
Sci, 10, 367-78. 
SHOCK, N. W. 1964. Ageing: The Biology of Senescence. Journal of Gerontology, 19, 521-522. 
SHORTER, E., SANNICANDRO, A. J., POULET, B. & GOLJANEK-WHYSALL, K. 2019. Skeletal Muscle Wasting 
and Its Relationship With Osteoarthritis: a Mini-Review of Mechanisms and Current Interventions. 
Current Rheumatology Reports, 21. 
SIMMONS, D. M. & SWANSON, L. W. 2008. High-resolution paraventricular nucleus serial section model 
constructed within a traditional rat brain atlas. 438, 85-89. 
300 
 
SIMMS, B. A. & ZAMPONI, G. W. 2014. Neuronal voltage-gated calcium channels: structure, function, and 
dysfunction. Neuron, 82, 24-45. 
SIMON, L. V., HASHMI, M. F. & FARRELL, M. W. 2019. Hyperkalemia. StatPearls. Treasure Island (FL). 
SIMS, J. E. & SMITH, D. E. 2010. The IL-1 family: regulators of immunity. Nat Rev Immunol, 10, 89-102. 
SONG, M. Y. & YUAN, J. X. 2010. Introduction to TRP channels: structure, function, and regulation. Adv 
Exp Med Biol, 661, 99-108. 
STÄNDKER, L., SCHRADER, M., KANSE, S. M., JÜRGENS, M., FORSSMANN, W.-G. & PREISSNER, K. T. 1997. 
Isolation and characterization of the circulating form of human endostatin. 420, 129-133. 
STATLAND, J., PHILLIPS, L. & TRIVEDI, J. R. 2014. Muscle channelopathies. Neurol Clin, 32, 801-15, x. 
STEVENS, A. L., WISHNOK, J. S., CHAI, D. H., GRODZINSKY, A. J. & TANNENBAUM, S. R. 2008. A sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis-liquid chromatography tandem mass 
spectrometry analysis of bovine cartilage tissue response to mechanical compression injury and 
the inflammatory cytokines tumor necrosis factor alpha and interleukin-1beta. Arthritis Rheum, 
58, 489-500. 
STEVENS, A. L., WISHNOK, J. S., WHITE, F. M., GRODZINSKY, A. J. & TANNENBAUM, S. R. 2009. Mechanical 
injury and cytokines cause loss of cartilage integrity and upregulate proteins associated with 
catabolism, immunity, inflammation, and repair. Mol Cell Proteomics, 8, 1475-89. 
STEVENSON, K. & UVERSKY, V. N. 2019. Single-cell RNA-Seq: a next generation sequencing tool for a high-
resolution view of the individual cell. J Biomol Struct Dyn, 1-6. 
STEWART, J., MANMATHAN, G. & WILKINSON, P. 2017. Primary prevention of cardiovascular disease: A 
review of contemporary guidance and literature. JRSM Cardiovascular Disease, 6, 
204800401668721. 
STOCKER, M. & KERSCHENSTEINER, D. 1998. Cloning and Tissue Distribution of Two New Potassium 
Channel α-Subunits from Rat Brain. 248, 927-934. 
STOJILKOVIC, S. S., TABAK, J. & BERTRAM, R. 2010. Ion channels and signaling in the pituitary gland. Endocr 
Rev, 31, 845-915. 
SUGITA, S., MIZUTANI, E., HOZAKI, M., NAKAMURA, M. & MATSUMOTO, T. 2019. Photoelasticity-based 
evaluation of cellular contractile force for phenotypic discrimination of vascular smooth muscle 
cells. Scientific Reports, 9. 
SUTTON, S., CLUTTERBUCK, A., HARRIS, P., GENT, T., FREEMAN, S., FOSTER, N., BARRETT-JOLLEY, R. & 
MOBASHERI, A. 2009. The contribution of the synovium, synovial derived inflammatory cytokines 
and neuropeptides to the pathogenesis of osteoarthritis. Vet J, 179, 10-24. 
SWANSON, L. W. & SAWCHENKO, P. E. 1983. Hypothalamic Integration - Organization of the 
Paraventricular and Supraoptic Nuclei. Annual Review of Neuroscience, 6, 269-324. 
SWANSON, L. W., SAWCHENKO, P. E., WIEGAND, S. J. & PRICE, J. L. 1980. Separate Neurons in the 
Paraventricular Nucleus Project to the Median-Eminence and to the Medulla or Spinal-Cord. Brain 
Research, 198, 190-195. 
SWARTZ, K. J. 2007. Tarantula toxins interacting with voltage sensors in potassium channels. Toxicon, 49, 
213-30. 
SWARTZ, K. J. & MACKINNON, R. 1997. Hanatoxin Modifies the Gating of a Voltage-Dependent K+ Channel 
through Multiple Binding Sites. Neuron, 18, 665-673. 
TANG, C.-Y. & CHEN, T.-Y. 2011. Physiology and Pathophysiology of CLC-1: Mechanisms of a Chloride 
Channel Disease, Myotonia. 2011, 1-10. 
TANNER, M. R., HU, X., HUQ, R., TAJHYA, R. B., SUN, L., KHAN, F. S., LARAGIONE, T., HORRIGAN, F. T., 
GULKO, P. S. & BEETON, C. 2015a. KCa1.1 Inhibition Attenuates Fibroblast-like Synoviocyte 
Invasiveness and Ameliorates Disease in Rat Models of Rheumatoid Arthritis. Arthritis & 
Rheumatology, 67, 96-106. 
301 
 
TANNER, M. R., HU, X., HUQ, R., TAJHYA, R. B., SUN, L., KHAN, F. S., LARAGIONE, T., HORRIGAN, F. T., 
GULKO, P. S. & BEETON, C. 2015b. KCa1.1 Inhibition Attenuates Fibroblast-like Synoviocyte 
Invasiveness and Ameliorates Disease in Rat Models of Rheumatoid Arthritis. Arthritis Rheumatol, 
67, 96-106. 
TEICHER, B. A. 2019. CD248: A therapeutic target in cancer and fibrotic diseases. Oncotarget, 10, 993-
1009. 
TERRAR, D. A. 1993. Structure and function of calcium channels and the actions of anaesthetics. Br J 
Anaesth, 71, 39-46. 
TIAN, C., ZHU, R., ZHU, L., QIU, T., CAO, Z. & KANG, T. 2014. Potassium channels: structures, diseases, and 
modulators. Chem Biol Drug Des, 83, 1-26. 
TORP, K. D. & SIMON, L. V. 2019. Lidocaine Toxicity. StatPearls. Treasure Island (FL). 
TORRES, V. E., CAI, Y., CHEN, X., WU, G. Q., GENG, L., CLEGHORN, K. A., JOHNSON, C. M. & SOMLO, S. 2001. 
Vascular expression of polycystin-2. J Am Soc Nephrol, 12, 1-9. 
TRAPNELL, C., WILLIAMS, B. A., PERTEA, G., MORTAZAVI, A., KWAN, G., VAN BAREN, M. J., SALZBERG, S. 
L., WOLD, B. J. & PACHTER, L. 2010. Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation. Nature Biotechnology, 
28, 511-515. 
TROMPET, S., DE CRAEN, A. J. M., SLAGBOOM, P., SHEPHERD, J., BLAUW, G. J., MURPHY, M. B., BOLLEN, 
E. L. E. M., BUCKLEY, B. M., FORD, I., GAW, A., MACFARLANE, P. W., PACKARD, C. J., STOTT, D. J., 
JUKEMA, J. W. & WESTENDORP, R. G. J. 2008. Genetic variation in the interleukin-1 -converting 
enzyme associates with cognitive function. The PROSPER study. Brain, 131, 1069-1077. 
TURGUTALP, K., BARDAK, S., HELVACı, I., İŞGÜZAR, G., PAYAS, E., DEMIR, S. & KıYKıM, A. 2016. Community-
acquired hyperkalemia in elderly patients: risk factors and clinical outcomes. 38, 1405-1412. 
UEBELE, V. N., LAGRUTTA, A., WADE, T., FIGUEROA, D. J., LIU, Y., MCKENNA, E., AUSTIN, C. P., BENNETT, 
P. B. & SWANSON, R. 2000. Cloning and functional expression of two families of beta-subunits of 
the large conductance calcium-activated K+ channel. J Biol Chem, 275, 23211-8. 
ULBRICHT, W. 2005. Sodium Channel Inactivation: Molecular Determinants and Modulation. 85, 1271-
1301. 
UNGVARI, Z., TARANTINI, S., DONATO, A. J., GALVAN, V. & CSISZAR, A. 2018. Mechanisms of Vascular 
Aging. Circulation Research, 123, 849-867. 
VAISHALI, M. P. & SATYA, P. G. 2016. Studies on Chloride Channels and their Modulators. Current Topics 
in Medicinal Chemistry, 16, 1862-1876. 
VAN GULICK, L., SABY, C., MORJANI, H. & BELJEBBAR, A. 2019. Age-related changes in molecular 
organization of type I collagen in tendon as probed by polarized SHG and Raman 
microspectroscopy. Scientific Reports, 9. 
VAN MAANEN, M. A., STOOF, S. P., VAN DER ZANDEN, E. P., DE JONGE, W. J., JANSSEN, R. A., FISCHER, D. 
F., VANDEGHINSTE, N., BRYS, R., VERVOORDELDONK, M. J. & TAK, P. P. 2009. The alpha7 nicotinic 
acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid 
arthritis patients: a possible role for a key neurotransmitter in synovial inflammation. Arthritis 
Rheum, 60, 1272-81. 
VARANI, K., DE MATTEI, M., VINCENZI, F., TOSI, A., GESSI, S., MERIGHI, S., PELLATI, A., MASIERI, F., 
ONGARO, A. & BOREA, P. A. 2008. Pharmacological characterization of P2X1 and P2X3 purinergic 
receptors in bovine chondrocytes. Osteoarthritis Cartilage, 16, 1421-9. 
VARGAS-ALARCON, G., ALVAREZ-LEON, E., FRAGOSO, J.-M., VARGAS, A., MARTINEZ, A., VALLEJO, M. & 
MARTINEZ-LAVIN, M. 2012. A SCN9A gene-encoded dorsal root ganglia sodium channel 
polymorphism associated with severe fibromyalgia. BMC Musculoskeletal Disorders, 13, 23. 
VASILAKI, A., VAN DER MEULEN, J. H., LARKIN, L., HARRISON, D. C., PEARSON, T., VAN REMMEN, H., 
RICHARDSON, A., BROOKS, S. V., JACKSON, M. J. & MCARDLE, A. 2010. The age-related failure of 
302 
 
adaptive responses to contractile activity in skeletal muscle is mimicked in young mice by deletion 
of Cu,Zn superoxide dismutase. 9, 979-990. 
VERGULT, S., DHEEDENE, A., MEURS, A., FAES, F., ISIDOR, B., JANSSENS, S., GAUTIER, A., LE CAIGNEC, C. & 
MENTEN, B. 2015. Genomic aberrations of the CACNA2D1 gene in three patients with epilepsy 
and intellectual disability. 23, 628-632. 
VLADIS, N. A., FISCHER, K. E., DIGALAKI, E., MARCU, D.-C., BIMPOS, M. N., GREER, P., AYRES, A., LI, Q. & 
BUSCH, K. E. 2019. Gap junctions in theC. elegansnervous system regulate ageing and lifespan. 
VON BANCHET, G. S., RICHTER, J., HUCKEL, M., ROSE, C., BRAUER, R. & SCHAIBLE, H. G. 2007. Fibroblast-
like synovial cells from normal and inflamed knee joints differently affect the expression of pain-
related receptors in sensory neurones: a co-culture study. Arthritis Res Ther, 9, R6. 
WALDBURGER, J. M., BOYLE, D. L., PAVLOV, V. A., TRACEY, K. J. & FIRESTEIN, G. S. 2008. Acetylcholine 
regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor. Arthritis Rheum, 
58, 3439-49. 
WALSTON, J. D. 2012. Sarcopenia in older adults. Current Opinion in Rheumatology, 24, 623-627. 
WANG, H. & WOOLF, C. J. 2005. Pain TRPs. Neuron, 46, 9-12. 
WANG, J., OU, S. W. & WANG, Y. J. 2017. Distribution and function of voltage-gated sodium channels in 
the nervous system. Channels (Austin), 11, 534-554. 
WANG, S., HU, L. F., YANG, Y., DING, J. H. & HU, G. 2005. Studies of ATP-sensitive potassium channels on 
6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating 
Parkinson's disease? Neuropharmacology, 48, 984-92. 
WANG, T. 2015. TNF-alpha G308A polymorphism and the susceptibility to Alzheimer's disease: an updated 
meta-analysis. Arch Med Res, 46, 24-30 e1. 
WATANABE, M., ICHINOSE, S. & SUNAMORI, M. 2004. Age-related changes in gap junctional protein of 
the rat heart. Exp Clin Cardiol, 9, 130-2. 
WEI, A., JEGLA, T. & SALKOFF, L. 1996. Eight potassium channel families revealed by the C. elegans genome 
project. Neuropharmacology, 35, 805-29. 
WEI, X. & RICHARDS, J. R. 2019. Physiology, Cardiac Repolarization Dispersion and Reserve. StatPearls. 
Treasure Island (FL). 
WEINERT, B. T. & TIMIRAS, P. S. 2003. Invited Review: Theories of aging. Journal of Applied Physiology, 95, 
1706-1716. 
WEINGARTH, M., PROKOFYEV, A., VAN DER CRUIJSEN, E. A., NAND, D., BONVIN, A. M., PONGS, O. & 
BALDUS, M. 2013. Structural determinants of specific lipid binding to potassium channels. J Am 
Chem Soc, 135, 3983-8. 
WESTENDORP, R. G., LANGERMANS, J. A., HUIZINGA, T. W., VERWEIJ, C. L. & STURK, A. 1997. Genetic 
influence on cytokine production in meningococcal disease. Lancet, 349, 1912-3. 
WIBBERLEY, A., STAUNTON, C. A., FEETHAM, C. H., VERENINOV, A. A. & BARRETT-JOLLEY, R. 2015. An In 
Vitro Model of Skeletal Muscle Volume Regulation. PLOS ONE, 10, e0127889. 
WILDERS, R. 2012. Cardiac ion channelopathies and the sudden infant death syndrome. ISRN Cardiol, 
2012, 846171. 
WILLIAMS, A. 2014. Proteomic studies of an explant 
model of equine articular cartilage in response to proinflammatory and anti-inflammatory stimuli. PhD 
Thesis University of Nottingham. 
WILLIAMS, A., SMITH, J. R., ALLAWAY, D., HARRIS, P., LIDDELL, S. & MOBASHERI, A. 2011. Strategies for 
optimising proteomic studies of the cartilage secretome: establishing the time course for protein 
release and evaluating responses of explant cultures to il-1 beta, tnf-alpha and carprofen. 
Osteoarthritis and Cartilage, 19, S209-S209. 
303 
 
WILLIAMS, M. E., FELDMAN, D. H., MCCUE, A. F., BRENNER, R., VELICELEBI, G., ELLIS, S. B. & HARPOLD, M. 
M. 1992. Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel 
human neuronal calcium channel subtype. Neuron, 8, 71-84. 
WRIGHT, S. H. 2004. Generation of resting membrane potential. Adv Physiol Educ, 28, 139-42. 
WU, C., YANG, K., LIU, Q., WAKUI, M., JIN, G. Z., ZHEN, X. & WU, J. 2010. Tetrahydroberberine blocks ATP-
sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra 
pars compacta. Neuropharmacology, 59, 567-72. 
WULFF, H., CASTLE, N. A. & PARDO, L. A. 2009. Voltage-gated potassium channels as therapeutic targets. 
8, 982-1001. 
XU, H., RAMSEY, I. S., KOTECHA, S. A., MORAN, M. M., CHONG, J. A., LAWSON, D., GE, P., LILLY, J., SILOS-
SANTIAGO, I., XIE, Y., DISTEFANO, P. S., CURTIS, R. & CLAPHAM, D. E. 2002. TRPV3 is a calcium-
permeable temperature-sensitive cation channel. Nature, 418, 181-186. 
YANG, C. T., ZENG, X. H., XIA, X. M. & LINGLE, C. J. 2009. Interactions between beta subunits of the KCNMB 
family and Slo3: beta4 selectively modulates Slo3 expression and function. PLoS One, 4, e6135. 
YANG, H., ZHANG, G. & CUI, J. 2015. BK channels: multiple sensors, one activation gate. 6. 
YOUNG, M. D., WAKEFIELD, M. J., SMYTH, G. K. & OSHLACK, A. 2010. Gene ontology analysis for RNA-seq: 
accounting for selection bias. Genome Biol, 11, R14. 
YU, F. H. & CATTERALL, W. A. 2003. Overview of the voltage-gated sodium channel family. Genome Biol, 
4, 207. 
YU, F. H., YAROV-YAROVOY, V., GUTMAN, G. A. & CATTERALL, W. A. 2005. Overview of molecular 
relationships in the voltage-gated ion channel superfamily. Pharmacol Rev, 57, 387-95. 
ZAMPONI, G. W. 2016. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. 
Nat Rev Drug Discov, 15, 19-34. 
ZAMPONI, G. W. 2017. A Crash Course in Calcium Channels. ACS Chem Neurosci, 8, 2583-2585. 
ZAMPONI, G. W., STRIESSNIG, J., KOSCHAK, A. & DOLPHIN, A. C. 2015. The Physiology, Pathology, and 
Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. 
Pharmacol Rev, 67, 821-70. 
ZHANG, J. M. & AN, J. 2007. Cytokines, inflammation, and pain. Int Anesthesiol Clin, 45, 27-37. 
ZHANG, K., MAYHAN, W. G. & PATEL, K. P. 1997. Nitric oxide within the paraventricular nucleus mediates 
changes in renal sympathetic nerve activity. American Journal of Physiology-Regulatory 
Integrative and Comparative Physiology, 273, R864-R872. 
ZHANG, K., ZUCKER, I. H. & PATEL, K. P. 1998. Altered number of diaphorase (NOS) positive neurons in the 
hypothalamus of rats with heart failure. Brain Research, 786, 219-225. 
ZHANG, P., WU, X., LI, G., HE, Q., DAI, H., AI, C. & SHI, J. 2017. Tumor necrosis factor-alpha gene 
polymorphisms and susceptibility to ischemic heart disease: A systematic review and meta-
analysis. Medicine (Baltimore), 96, e6569. 
ZHENG, C., ZHOU, X. W. & WANG, J. Z. 2016. The dual roles of cytokines in Alzheimer's disease: update on 
interleukins, TNF-alpha, TGF-beta and IFN-gamma. Transl Neurodegener, 5, 7. 
ZHOU, R. P., WU, X. S., WANG, Z. S., XIE, Y. Y., GE, J. F. & CHEN, F. H. 2016. Novel Insights into Acid-Sensing 
Ion Channels: Implications for Degenerative Diseases. Aging Dis, 7, 491-501. 
ZHU, R., SUN, Z., LI, C., RAMAKRISHNA, S., CHIU, K. & HE, L. 2019a. Electrical stimulation affects neural 
stem cell fate and function in vitro. Exp Neurol, 319, 112963. 
ZHU, Y., QU, J., HE, L., ZHANG, F., ZHOU, Z., YANG, S. & ZHOU, Y. 2019b. Calcium in Vascular Smooth Muscle 
Cell Elasticity and Adhesion: Novel Insights Into the Mechanism of Action. Frontiers in Physiology, 
10. 
ZIEGENHAIN, C., VIETH, B., PAREKH, S., REINIUS, B., GUILLAUMET-ADKINS, A., SMETS, M., LEONHARDT, H., 
HEYN, H., HELLMANN, I. & ENARD, W. 2017. Comparative Analysis of Single-Cell RNA Sequencing 




fphys-11-00226 March 21, 2020 Time: 9:6 # 1
ORIGINAL RESEARCH




University of Waterloo, Canada
Reviewed by:
Christine Beeton,
Baylor College of Medicine,
United States
Robert Brenner,
The University of Texas Health






This article was submitted to
Membrane Physiology
and Membrane Biophysics,
a section of the journal
Frontiers in Physiology
Received: 03 September 2019
Accepted: 27 February 2020
Published: 24 March 2020
Citation:
Haidar O, O’Neill N, Staunton CA,
Bavan S, O’Brien F, Zouggari S,
Sharif U, Mobasheri A, Kumagai K
and Barrett-Jolley R (2020)
Pro-inflammatory Cytokines Drive
Deregulation of Potassium Channel
Expression in Primary Synovial
Fibroblasts. Front. Physiol. 11:226.
doi: 10.3389/fphys.2020.00226
Pro-inflammatory Cytokines Drive
Deregulation of Potassium Channel
Expression in Primary Synovial
Fibroblasts
Omar Haidar1, Nathanael O’Neill1, Caroline A. Staunton1, Selvan Bavan1, Fiona O’Brien1,
Sarah Zouggari1, Umar Sharif1, Ali Mobasheri2,3,4,5, Kosuke Kumagai1,6 and
Richard Barrett-Jolley1,5*
1 Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, 2 Research Unit of Medical
Imaging, Physics and Technology, University of Oulu, Oulu, Finland, 3 Department of Regenerative Medicine, State Research
Institute Centre for Innovative Medicine, Vilnius, Lithuania, 4 Department of Orthopedics and Department of Rheumatology &
Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, 5 Versus Arthritis Centre for Sport, Exercise and Osteoarthritis
Research, Queen’s Medical Centre, Nottingham, United Kingdom, 6 Department of Orthopaedic Surgery, Shiga University of
Medical Science, Shiga, Japan
The synovium secretes synovial fluid, but is also richly innervated with nociceptors and
acts as a gateway between avascular joint tissues and the circulatory system. Resident
fibroblast-like synoviocytes’ (FLS) calcium-activated potassium channels (KCa) change
in activity in arthritis models and this correlates with FLS activation.
Objective: To investigate this activation in an in vitro model of inflammatory arthritis;
72 h treatment with cytokines TNFα and IL1β.
Methods: FLS cells were isolated from rat synovial membranes. We analyzed global
changes in FLS mRNA by RNA-sequencing, then focused on FLS ion channel genes
and the corresponding FLS electrophysiological phenotype and finally modeling data
with ingenuity pathway analysis (IPA) and MATLAB.
Results: IPA showed significant activation of inflammatory, osteoarthritic and calcium
signaling canonical pathways by cytokines, and we identified ∼200 channel gene
transcripts. The large KCa (BK) channel consists of the pore forming Kcnma1 together
with β-subunits. Following cytokine treatment, a significant increase in Kcnma1 RNA
abundance was detected by qPCR and changes in several ion channels were detected
by RNA-sequencing, including a loss of BK channel β-subunit expression Kcnmb1/2
and an increase in Kcnmb3. In electrophysiological experiments, there was a decrease in
over-all current density at 20 mV without change in chord conductance at this potential.
Conclusion: TNFα and IL1β treatment of FLS in vitro recapitulated several common
features of inflammatory arthritis at the transcriptomic level, including increase in
Kcnma1 and Kcnmb3 gene expression.
Keywords: TNFα, IL1β, inflammation, synovial fibroblast, ion channel
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INTRODUCTION
Rheumatoid arthritis (RA) and osteoarthritis (OA) are
degenerative diseases that target articular joint structures
resulting in pain, loss of function and frequent disability.
Whilst RA is an established inflammatory condition, the
contribution of inflammatory processes to OA was less
well known until recently. Mediators of inflammation (i.e.,
including pro-inflammatory cytokines) contribute to the
development of synovitis, which is known to drive disease
progression in RA. In contrast, it is thought that in OA,
synovitis can be caused by the release of cartilage fragments
and meniscal damage that in turn, activate synovial lining
cells (Fernandez-Madrid et al., 1995; Roemer et al., 2013;
Mathiessen and Conaghan, 2017). How inflammation
drives joint destruction is not fully known. One feature of
synovitis, however, is the presence of major pro-inflammatory
cytokines, such as interleukin-1β (IL-1β), tumor necrosis
factor alpha (TNFα), and interleukin 6 (IL-6), resulting in
suppression of collagen and proteoglycan synthesis, increased
inflammatory signaling, and protease expression and activation
(Martel-Pelletier et al., 1999).
Management of arthritis has significantly improved in recent
years’, however, remission is rarely achieved, and many patients
remain unresponsive to conventional and/or biologic treatments.
In addition, current therapies and treatments are associated
with notable side effects that can pose great challenges for
long-term treatment, especially in patients with cardiovascular
co-morbidities. For example, some drugs can increase the
risk of cardiovascular disease or significantly impair immune
responses, rendering patients more susceptible to infections and
cancer (Kahlenberg and Fox, 2011). Therefore, new therapeutic
options and novel targets are needed that lead to pronounced
improvement without inducing unwanted side effects and thus
avoiding the need for joint replacement.
The synovium is the major barrier between the joint and
the systemic circulation and plays a role in maintaining the
health of articular cartilage (Sutton et al., 2009; Berenbaum,
2013). The synovium lubricates the articular surfaces and
provides nutrients for chondrocytes within the avascular
cartilage; it has been suggested that catabolic enzymes such
as matrix metalloproteinase (MMPs) are produced by synovial
cells and diffuse into the cartilage. The intimal lining layer
of the synovium produces lubricious synovial fluid and is
composed of two cell types in relatively equal proportions:
Type A or macrophage-like synovial cells and Type B or
fibroblasts like synoviocytes (FLS). FLS cells contribute to
the structural integrity of the joints by controlling the
composition of the synovial fluid and extracellular matrix (ECM)
of the joint. The synovial environment changes physically,
chemically, and physiologically with injury or the onset
of disease and is thought to be a mediator in arthritis
pain (Grubb, 2004; Sellam and Berenbaum, 2010; Kumahashi
et al., 2011). FLS cells have been implicated in arthritis
as they exhibit a transformed phenotype with increased
invasiveness and production of various pro-inflammatory
mediators that perpetrate inflammation and proteases that
contribute to cartilage destruction (Noss and Brenner, 2008;
Bartok and Firestein, 2010). Understanding the biology and
regulation of FLS cells provides insight into the pathogenesis of
inflammatory arthritis. FLS cells could potentially be targeted
pharmacologically to produce increased volumes of synovial
fluid as an alternative to intra-articular hyaluronan or synthetic
fluid injection therapies. They are also a plausible analgesic
target because they may interact with sensory neurons and
have been described as “amplifiers” of neuropeptide mediated
inflammation and pain.
To deepen our understanding of the synovium in the context
of synovial joint health and disease, the electrophysiological
profile of FLS cells needs to be characterized, along with the
ion channels that are present. Ion channels are an essential
component of any cell membrane that controls ion movement
in and out of the cell and play an important role in a
multitude of cell regulating processes, typically by modulating
the membrane potential. Electrophysiological techniques have
been used to characterize the biophysical properties of a number
of different FLS preparations, including mouse, rabbit, bovine
and human (Large et al., 2010; Friebel et al., 2014; Clark et al.,
2017). The best available whole-cell mathematical model of
the FLS is heavily dominated by a Ca2+-activated potassium
conductance, with small added components of inward rectifiers,
background and leak. A recent study by Kondo et al. (2018)
demonstrated that human FLS express high levels of Ca2+-
activated potassium channels and these ion channels were also
identified in both RA-derived and rodent model FLS studies.
Typically, Ca2+-activated channels couple with Ca2+ entry
channels such as transient receptor potential (TRP) channels;
they are both activated by the Ca2+ ions that enter and
maintain the membrane potential hyperpolarized to “draw
in” further Ca2+. In FLS, Ca2+-activated potassium channels
appear to drive invasiveness of synoviocytes and progression of
arthritis in both human and rodent RA models (Petho et al.,
2016; Tanner et al., 2019), by increasing production of both
inflammatory mediators and catabolic enzymes (Hu et al., 2012;
Friebel et al., 2014; Tanner et al., 2015). This is a paradoxical
effect for a potassium conductance, that would be predicted
to hyperpolarize cells and reduce migration, proliferation and
activity in general.
The synovium is an obvious target for the development of
novel interventions in both RA and OA. The role of synovitis,
the low-grade inflammation of the synovial lining of the joint, in
OA progression is gradually emerging. Therefore, in this work we
investigate the pathophysiology of cytokine induced synovitis in
cultured synovial cells.
We investigate whether the TNFα and IL1β cytokine in vitro
model of inflammation leads to a significant change of the BK
ion channel and quantify the mechanism of this change. We use a
combination of next generation RNA sequencing (NGS), qPCR,
and patch-clamp electrophysiology to uncover several changes
in potassium channel gene expression together with changes
in cellular phenotype which involves a phenotypic switch in
response to inflammation.
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MATERIALS AND METHODS
Further methodological details are included in the
Supplementary Methods section (see Supplementary File S2).
Animals
Synovial cells were prepared from tissue from rats euthanized by
Home Office Approved methods for unassociated reasons in line
with the ARRIVE Guidelines. All rats were untreated/wild-type
male adult Wistar.
Preparation of FLS Cells
Synovial fibroblasts were isolated from rat knee joints as
described previously. Briefly, patella and menisci with attached
synovial membranes were isolated and placed in 12-well plates
in low glucose DMEM (Thermo Fischer, United Kingdom) with
20% fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml
streptomycin and 2.5 µg/ml amphotericin B (Thermo Fischer,
United Kingdom) at 37◦C in a 5% CO2 incubator. For the
first 7 days medium was replaced daily whilst out-growing FLS
emerged from the tissues. At 7 days residual tissue was discarded
and cells cultured as normal; when confluent, cells were detached
from the flask surface by 1% Trypsin-EDTA solution. The
suspension was centrifuged (340 × g, 5 min) and the resulting
pellet was resuspended in culture medium (as above).
Immunohistochemistry
In brief, cell suspension at a density of 2.5 × 104 cell/ml
was transferred to multiwall plates and fixed with 2%
paraformaldehyde in PBS at room temperature. CD248 (an
FLS marker) immunohistochemistry was performed using
rabbit anti-CD248 primary antibody (Ab, 1:100 dilution;
Abcam, Cambridge) and FITC-conjugated donkey Anti-
rabbit IgG secondary antibody (Ab, 1:500 dilution; Jackson
ImmunoResearch Laboratories). Non-specific binding was
blocked as previously described (Mobasheri et al., 2005). After
24 h at 4◦C, cells were washed three times for 5 min with 0.05%
SSC-20 and 0.005% Triton-X100. Slides were finally dipped
into distilled water, air dried, and mounted with mounting
media (Vectashield with DAPI). Cells were visualized with
confocal microscopy.
Real−Time PCR
RNA extraction was carried out using the RNeasy Plus
Micro kit, together with gDNA eliminator and MinElute
spin columns (Qiagen, United Kingdom). cDNA synthesis
(mRNA) was performed using the RT2 First Strand kit (Qiagen,
Netherlands) according to the manufacturer’s protocol. qPCR
analysis was performed using the Stratagene MX3000P RT-PCR
System (Stratagene, La Jolla, CA, United States) in a 25−µL
reaction mixture. Expression relative to housekeeper Rplp1 was
calculated as 1Ct.
RNA “Next Generation Sequencing”
(NGS)
Figure 1 summarizes our NGS workflow. In brief, cells were
treated with 10 ng/ml of both TNF-α + IL1β (TNF-α from
Thermo Fischer, United Kingdom and IL1β from R&D systems)
for 72 h. RNA extraction was carried out using the RNeasy
Plus Micro kit (Qiagen, United Kingdom) according to the
manufacturers protocol. Any RNA samples with concentrations
of less than 5 µg/ml and/or purity (260/280 and 260/230) less
than 1.8 were excluded. RNA samples were sent to GATC-
Biotech, Germany for sequencing. Samples were read as paired-
end with a sequencing depth of 30 M and a read length of
50 bp. Further details are included in Supplementary Methods
(see Supplementary File S2). Further bioinformatics were
performed with R, for example the DAPCA package or our
local installation of the Galaxy server suite (Afgan et al., 2018).
Specific packages are mentioned in the text, Supplementary
Methods (see Supplementary File S2) and Figure 1. Full data are
available on the EBI array express database with accession number:
E-MTAB-7798.
Electrophysiology
Electrophysiology was performed as described previously (Lewis
et al., 2013) but using isolated FLS. Intracellular solution was
115 mM gluconic acid/potassium salt, 26 mM KCl, 1 mM
MgCl2 (BDH, VWR International Ltd.), 5 mM Ethylene glycol
tetraacetic acid (EGTA), 10 mM HEPES, pH 7.2. Extracellular
(bath) solution was 140 mM NaCl, 5 mM KCl, 2 mM CaCl2
(Fluka Analytical cat#: 21114), 1 mM MgCl2, 10 mM HEPES,
and 5 mM Glucose, osmolality approximately 300 mOsm, pH
7.4. Junction potential −14.4 mV (Lewis et al., 2013). Thick-
walled patch-pipettes were pulled from borosilicate glass capillary
tubes (outer diameter 1.5 mm, inner diameter 0.86 mm; Intracel,
United Kingdom) and gave a resistance of ∼8 M when filled.
Whole cell patch-clamp electrophysiology was performed on
FLS cells using a Cairn Optopatch amplifier (Cairn Research,
United Kingdom). To compare voltage-gated currents, we
performed whole-cell patch clamp experiments with voltage steps
starting from a holding potential of −80 mV for 2 s. Recordings
were filtered at 1 kHz, digitized at 3 kHz and recorded on
a computer using WinWCP 5.3.4 software (John Dempster,
Strathclyde University, United Kingdom). All experiments were
performed at room temperature (18–22◦C), and the results are
expressed as the mean± SEM.
Analysis was performed using WinWCP 5.3.4 software (John
Dempster, Strathclyde University, United Kingdom). Boltzmann
curve fits were computed in MATLAB through non-linear least
squares optimization.
RESULTS
Enriched Pathways in FLS Cells After
Cytokine Treatment
RNA-seq detected 33251 transcripts and the full data are
available on the EBI array express database with accession
number: E-MTAB-7798. The top (highest FPKM) expressed
10 genes were similar between control and cytokine treated
cells (Supplementary Tables S1, S2). Our first bioinformatic
analysis tested the reproducibility of the 72 h, 10 ng/ml
TNFα + IL1β treatment. We used discriminant analyses of
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FIGURE 1 | Experimental pipeline and verification. (A) Schematic of the next generation sequencing (NGS) pipeline. RNA was extracted from synovial tissue from
eight animals, were split into control and test groups and the test samples were treated with 10 ng IL1β and TNFα as described in the section “Materials and
Methods.” These eight samples sequenced with Illumina and raw data files were uploaded using a FTP client to a bioinformatics platform for analysis. Within the
bioinformatics platform, reads were aligned/mapped with Hisat2 program using the reference genome Rat Jul. 2014 (RGSC 6.0/rn6) (rn6). The resulting BAM files
were used to measure phred quality score for all samples. Also, BAM files along with an annotation file (Rat GFF3) to assemble mapped reads and quantify gene
expression. Such assembly and quantification took place with StringTie and CuffDiff package/tool that generated gene abundance estimates and differentially
expressed genes, respectively. After that, using several servers and a local custom-script in MATLAB software allowed us to filter the transcriptome for all known ion
channel genes for further analysis (for example, see Tables 1, 2). (B) Expression of CD248 in FLS cells. Immunofluorescence FLS cells showing the FLS marker
CD248. DAPI was used for nuclear counterstaining (see Supplementary Methods in Supplementary File S2 for details).
principal components (DAPC) with in the DAPC package
to show good separation of the two populations (Figure 2);
the genes primarily discriminating the treatment and control
populations are largely those well established to be important
for joint function, including several collagens and a matrix
metallopeptidase (MMP2). Ingenuity pathway (IPA) analysis
(Qiagen, United Kingdom) was then used to identify the
upstream regulators of the global differential expression pattern.
This analysis predicted the top two regulators to be TNFα and
IL1β (p-values 3e-17 and 6e-13, respectively), this is unsurprising
since this was indeed the treatment regimen.
Figure 3 shows the canonical calcium signally pathway
(p < 0.5e-7), which was enriched following cytokine treatment.
In addition, the rheumatoid (p < 5e-13) and OA (p < 1e-
9) pathways and cellular movement and proliferation canonical
pathways (predicted activation, p < 1e-13 in both cases) were
also enriched following cytokine treatment (data not shown).
In all cases, TNFα was determined to be the top causal agent,
but four ion channels were also significant causal regulators
(adjusted p < 0.05) of the transcript-wide treatment changes;
Clcn5, Trpv4, Trpv1, Kcnn4.
Next Generation RNA Sequencing
Analysis of Ion Channel Gene Expression
Initial RNA-seq experiments were intended to give a
transcriptome wide, unbiased, assessment of ion channel
changes in cytokine treated FLS. We identified 190 channel
genes, including porins, connexins and ion-channel isoform
genes (including α- to ε-subunits), but excluded interacting
proteins, other regulatory proteins and the so-called potassium
tetramerization domain proteins. The top 50 genes, in terms
of FPKM are given for control and cytokine treated datasets in
Supplementary Tables S3, S4, respectively.
Next Generation RNA Sequencing Ion
Channel Differential Expression
One of the key ion channels involved with regulation of FLS is
the large calcium activated potassium channel (BK, Kcnmx) and
it is notable that there was a reduction in expression of β-subunit
Kcnmb1/2 and appearance of Kcnmb3 after cytokine treatment.
We further analyzed this family transcript by transcript for the
13 known (already annotated) splice variants of these channels;
Kcnma1, Kcnmb1, Kcnmb2, Kcnmb3, Kcnmb4 (Figure 4C). The
most abundantly expressed of all these transcripts is Kcnma1
(ENSRNOT00000077671) with rather lower expression of any of
the β-subunits and no detection of the one annotated Kcnmb4
variant. Following cytokine treatment expression of all of the
detectable Kcnma1 splice variants was higher, but there was a
lower abundance of Kcnmb4.
In total, 20 ion channel genes, undetectable in control
conditions became detectable or ‘appeared’ after cytokine
treatment (Supplementary Table S5), of which, the top expressed
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FIGURE 2 | Discriminant analyses of global IL-1β TNFα treatment effects. (A) Shows the kernel density plots of the discriminant component co-ordinates for the
control and IL-1β/TNFα treatment groups; co-ordinates on the x-axis and density on the y-axis; Individual co-ordinate center points are illustrated by the vertical line
and circle. There is clear separation between control and cytokine treated FLS samples. (B) A graphical confusion matrix showing the actual group membership
(y-axis) and predicted cluster membership (on the y-axis). All groups are correctly clustered with greater than 0.9 probability. (C) The top 15 contributors to the linear
discriminator function: Fn-1, fibronectin 1; Col1a1, collagen type I alpha 1 chain; Col3a1, collagen type III alpha 1 chain; Lcn2, lipocalin 2; PAI, serpine1; Grem1,
gremlin 1; Mmp2, matrix metallopeptidase 2; Thbs2, thrombospondin 2; Cxcl12, C-X-C motif chemokine ligand 12; Mgp, matrix Gla protein; C3, complement C3;
Col1a2, collagen type I alpha 2 chain; Sod2, superoxide dismutase 2; Lrp1, LDL receptor related protein 1; Col1a2, collagen type I alpha 2.
of these was Trpc3. Conversely, seven ion channel genes became
undetectable or “disappeared” following cytokine treatment
(Supplementary Table S6). Following cytokine treatment, we
found an additional 15 genes to be down by −1.5 (log2) or
more and 21 genes 1.5 (log2) greater than control (Tables 1, 2,
respectively). We used tissue from four animals for the NGS
study each animal tissue split into test and control groups; the
“n” presented in the legends refers to the number of biological
replicates (= animals).
qPCR Verification of RNA Changes
To add further support to the unbiased RNA-seq ion
channel analysis we performed qPCR on sets of control
and IL1β/TNFα treated FLS with panels of Ca2+-potassium
channels (Kcnma1, Kcnn1, Kcnn2, Kcnn3) and other ion
channel genes (Figure 4B). We did not have primers for all
the potassium channel genes identified by next generation
sequencing. Three potassium genes were differentially expressed;
two voltage-gated potassium channels Kcna6 and Kcnc2-
significantly decreased (p < 0.05, n = 4,4), whereas the
large calcium potassium channel Kcnma1 was upregulated
(p < 0.05, n = 4,4).
Electrophysiology
Neither RNA nor protein expression studies can confirm
changes in functional ion channel expression or, functional
changes resulting from post-translational changes, Furthermore,
several different potassium channel isoforms were identified,
of which some upregulated and some downregulated.
Therefore, to investigate the effect of cytokine treatment on the
electrophysiological fingerprint, we conducted functional assays
of ion channel expression with patch-clamp electrophysiology.
The primary changes observed in the more limited qRT-PCR
data would predict over all loss of voltage-gated potassium
ion channel activity and increase in the less voltage-dependent
calcium activated potassium channels.
Resting Membrane Potential
Following cytokine treatment, the resting membrane
potential of FLS decreased (depolarized) from −48.6 ± 1.7
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FIGURE 3 | Enriched calcium regulation pathway. Genes mapped to the calcium signaling canonical pathway by IPA. Red, increased expression; green, decreased
expression (for interpretation of the references to color in the figure legend, please refer to the online version of this article).
to−38.6± 2.8 mV, junction potential corrected (data not shown,
p ≤ 0.05, unpaired t-test).
Current Voltage Currents
As seen in Figure 5A, some cells exhibited clear transient
and sustained components whereas others exhibited only the
sustained component of the current. We therefore analyzed
the transient and sustained components of the current
separately in all cases.
We found no overall change in the maximum amplitude
of the transient current (Figure 5B), but the sustained current
(Figure 5C) density, measured at +20 mV was decreased
(12.5 ± 2.3 pA/pF to 3.8 ± 0.8 pA/pF, n = 24,20, p < 0.05).
There was no change in chord conductance measured at this
potential (271 ± 45 pS/pF to 120 ± 20 pS/pF, n = 24,20). To
characterize the nature of the conductance apparently inhibited
by cytokine treatment we calculated the difference current for
cytokine treatment (i.e., cytokine-treated current; Figure 5D).
This revealed a strongly voltage-gated current with mid-point for
activation 40± 1.2 mV and slope 17.6± 1.2 mV, n = 25.
Pharmacological Modulation of Currents
Despite the increase of KCNMA1 RNA in both qPCR and
RNA-Seq our electrophysiological data show a reduced current
density. To investigate if the maximum possible BK current is
altered in cytokine treatment, we repeated our standard voltage
protocol (above) in the presence of 1 µM of the BK channel
opener NS1619 and found a significant increase in current
density in the presence of NS1619 in control cells (Figures 6A,C,
p ≤ 0.05, n = 9,6), we did not see an equivalent increase in
the cytokine treated cells (Figures 6B,D). We then repeated this
experiment with 1 µM of the BK channel inhibitor paxilline.
Untreated cell current density was significantly smaller in the
presence of paxilline, but not significantly reduced in treated
cells (Figures 6E,F).
DISCUSSION
In this study, we used an in vitro model of synovial cell
inflammation to investigate the pathophysiology of cytokine
induced synovitis. We have demonstrated that IL1β and
TNFα treatment of FLS cells resulted in profound changes
in arthritic, inflammatory, and Ca2+ regulatory pathways
similar to that reported in RA models. We found differential
expression of several ion channels with transcriptomics and our
electrophysiological experiments show a reduction of whole-cell
current density.
The Pathophysiological Validity of the
72 h IL1β and TNFα Model
Treatment of joint tissue with TNFα and IL1β cytokines
is an established in vitro model of inflammatory arthritis
with tissue typically exposed to between 10 ng/ml of TNFα
and IL1β for between 2 and 7 days. In the present study,
we use the lower end of the concentration range, 10 ng
and treat for 72 h (De Ceuninck et al., 2004; Stevens
et al., 2008, 2009; Pretzel et al., 2009; Williams et al., 2011;
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FIGURE 4 | The correlation between control and NGS expression data. (A) We found a strong correlation between control and treated (72 h of IL1β + TNFα) channel
expression data. Each point represents the intersection of four control and four test values. In (B), the correlation between qPCR (11Cts) and NGS ratio (FPKM
values) are shown. Data suggest that there only a weak linear correlation between qPCR and NGS. P-value = 0.3. R = 0.29. n = 14 (eight animals for NGS and six
animals for PCR). Genes that were upregulated in both datasets are indicated in red. (C) Summary of NGS expression of all known (rat) splice variants of Kcnma1
and associated Kcnmb subunits.
Williams, 2014). This regime is hypothesized to activate
inflammatory pathways, but there will be no cytokine remaining
by the time of the electrophysiological experiments that
could cause confounding direct effects. We treated FLS cells
with the pro-inflammatory cytokines IL1β and TNFα in
order to understand the cellular changes that occur when
these FLS are subjected to higher-than-normal levels of these
cytokines in vivo, for example, in arthritis. This model has
distinct advantages of 3Rs, consistency, reproducibility and
allowing the investigation of distinct pathways in isolation
but since it is an acute model it may lack some chronic
features of in vivo models. Our transcriptome analysis
demonstrated that pathways were activated in common
with arthritis movement of cells, proliferation and both
RA and OA. In an in vitro model of RA, Tanner et al.
(2019) also showed up regulation of Kcnma1 (message and
protein) analogous to that observed with our 72 h cytokine
treatment. Furthermore, more recent data suggests a correlation
between FLS invasiveness and expression of the β-subunit
(KCNMB3) in human samples of FLS from RA patients
(Petho et al., 2016). Taken together with the changes in
Ca2+ signaling, we show that our in vitro model captures
several features of the inflammatory joint phenotype and
that FLS have been “activated” as observed in animal models
of arthritis.
Causal analysis is a relatively new mathematical technique that
allows one to move from probability of agreement or simple
correlation toward probability of causation in networks. The
IPA implementation of this identified both IL1β and TNFα as
master-regulators of the changes we observe and considering
our experimental design included time matched controls, this
strongly supports a suitable dosage and incubation time. Whilst
both IL1β and TNFα were identified by IPA as “master
regulators,” TNFα transcriptome-wide causation was stronger
than that of IL1β. Interestingly, FLS cells harvested from RA
patients exhibit a marked transient elevation of intracellular Ca2+
on exposure to TNFα (Yoo et al., 2006) raising the possibility
that this could be the initial trigger for the resulting pathway
changes. However, it should be noted that such a transient lasts
less than a minute and in our study cells were challenged with
cytokines 72 h prior to experiments. Furthermore, cells were
replaced in cytokine-free medium for electrophysiology, so there
would be no cytokine physically present at that time. Also, the
previously reported TNFα induced Ca2+ signal was only clear in
FLS from RA; it was largely absent in FLS from OA patients and
not investigated in FLS from healthy controls (Yoo et al., 2006).
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TABLE 1 | FLS channel gene RNA expression lower after cytokine (10 ng/ml TNFα
and IL1β) treatment.
Gene Official name Log2 (95% CI)
Kcnj15 Potassium inward rectified channel
subfamily j member 15
−5.51 (−9.57 to −2.48)
Ano2 Anoctamin 2 −2.59 (−5.5 to 0)
Kcnb1 Potassium voltage-gated channel subfamily
b member 1
−2.44 (−1.85 to −1)
Kcnv2 Potassium voltage-gated channel modifier
subfamily v member 2
−2.4 (−4.85 to 0)
Kcnip1 Potassium voltage-gated channel
interacting protein 1
−2.36 (−3.88 to −0.88)
Kcnmb1 Potassium calcium-activated channel
subfamily m regulatory beta subunit 1
−1.98 (−3.28 to 0.69)
Kcns1 Potassium voltage-gated channel modifier
subfamily s member 1
−1.88 (−6.84 to −0.42)
Kcnj8 Potassium inward rectifier j member 8
(Kir6.1)
−1.79 (−4.71 to 2.17)
Kcnd3 Potassium voltage-gated channel subfamily
d member 3
−1.78 (−2.63 to 0.29)
Nalcn Sodium leak channel, non-selective −1.77 (−3.43 to −0.85)
Clca2 Chloride channel accessory 2 −1.76 (−6.72 to 0.65)
Kcne3 Potassium voltage-gated channel subfamily
e regulatory subunit 3
−1.67 (−1.84 to −0.15)
Asic1 Acid sensing ion channel subunit 1 −1.64 (−6.44 to 0)
Clcn4 Chloride voltage-gated channel 4 −1.61 (−2.61 to −0.95)
Trpm8 Trpm8 channel associated factor 1 −1.61 (−2.09 to −0.99)
Qualification cytokine log2 (geometric mean) < −1.5 of control (= approximately
33%), n = 4 control and 4 cytokine treated samples (from four animals).
Previous Studies of Differential
Expression of Membrane Ion Channels in
Synovium
Until very recently, little was known of the FLS ion channel
compliment (the “channelome”) compared to that of the another
central joint cell, the chondrocyte (Barrett-Jolley et al., 2010). One
of the best-studied families of ion channels in FLS, however, is the
Ca2+-activated potassium channel family. The high conductance
member of this family, termed BK (KCa1.1 or KCNMA1) and the
“intermediate” conductance member (“IK,” or KCa3.1) are both
expressed and have roles in invasive migration, proliferation,
cytokine, and MMP release (Hu et al., 2012; Friebel et al.,
2014). Interestingly, inhibitors of BK decrease the signs of joint
degeneration in the pristane-induced arthritis model. These
channels are therefore potential drug targets to protect against
joint degeneration as well as being putative biomarkers. Whilst
the BK channel β- subunit (KCNMB1) was slightly increased in
transcript abundance in the Lambert et al., 2014 data (similar seen
by Huber et al., 2008), both of the two BK α-subunit (KNMA1)
probes on the chip exhibit small decreases in expression. It should
be noted that the expression of BK channel β- subunits confers
modulation of ion channel activity, in many cases decreasing
its sensitivity to, for example, Ca2+ ions (Lippiat et al., 2003;
Mobasheri et al., 2012).
A recent study by Kondo et al. (2018) demonstrated that
human FLS express high levels of both intermediate (KCa3.1)
and large (BK/KCa1.1/KCNMA1) Ca2+-activated potassium
TABLE 2 | FLS channel gene RNA expression increased after cytokine (10 ng/ml
TNFα and IL1β) treatment.
Gene ID Official name Log2 (95% CI)
Kcnc1 Potassium voltage-gated channel subfamily c
member 1
4.32 (0.68 to 5.93)
Kcnc3 Potassium voltage-gated channel subfamily c
member 3
3.46 (0.76 to 5.94)
Trpc3 Transient receptor potential cation channel
subfamily c member 3
3.06 (3.73 to 6.5)
Catsper3 Cation channel sperm associated 3 2.83 (0.14 to 5.75)
Kcng3 Potassium voltage-gated channel modifier
subfamily g member 3
2.81 (2.77 to 6.65)
Tmc7 Transmembrane channel like 7 2.77 (1.99 to 5.53)
Gjc3 Gap junction protein gamma 3 2.75 (0.03 to 4.35)
Scnn1g Sodium channel epithelial 1 gamma subunit 2.56 (2.77 to 5.45)
Asic2 Acid sensing ion channel subunit 2 2.52 (0.66 to 4.65)
Kcnmb3 Potassium calcium-activated channel subfamily
m regulatory beta subunit 3
2.34 (0 to 4.73)
Cracr2a Calcium release activated channel regulator 2a 2.32 (0.01 to 1.96)
Kcnn3 Potassium calcium-activated channel subfamily
n member 3
2.07 (0.57 to 4.09)
Tmc4 Transmembrane channel like 4 1.94 (0.27 to 2.47)
Asic4 Acid sensing ion channel subunit family
member 4
1.75 (0.52 to 2.76)
Kcnj11 Potassium inward rectifier j member 11 (Kir6.2) 1.74 (0 to 6.56)
Trpv6 Transient receptor potential cation channel
subfamily v member 6
1.7 (0.01 to 5.43)
Hvcn1 Hydrogen voltage gated channel 1 1.69 (0.98 to 2.84)
Trpv1 Transient receptor potential cation channel
subfamily v member 1
1.61 (0.98 to 2.07)
Kcnk7 Potassium two pore domain channel subfamily
k member 7
1.6 (−1.85 to 1.03)
Cacna1d Calcium voltage-gated channel subunit alpha1
d
1.57 (0.32 to 2.09)
Asic5 Acid sensing ion channel subunit family
member 5
1.55 (0 to 5.78)
Qualification cytokine log2 (geometric mean) > 1.5 of control (= approximately
300%), n = 4 control and 4 cytokine treated samples (from four animals).
channels. The other most highly expressed ion channels identified
by Kondo et al. (2018) were KCNK2, ANO6, ANO10, and
KCNK6. KCNK2/6 are members of the two-pore-domain
potassium channel family and are particularly thought of as
molecular sensors, whereas the ANO (anoctamin) channels are
members of the large chloride channel family. This family is
relatively understudied compared to potassium channels, but
ANO6 (TMEM16F) is, interestingly, thought to be a Ca2+-
activated chloride channel as well as a lipid “scramblase”
(Scudieri et al., 2015), therefore, likely to be activated in parallel
to Ca2+-activated potassium channels.
Changes in Ion Channel Currents in the
Present Study
The phenotype of FLS current recorded by whole-cell patch
clamp was quite variable in terms of the presence of transient
and sustained components of current, as seen in Figure 5. We
found no significant changes in the transient phase of current
and therefore, we focused on the sustained component of voltage
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FIGURE 5 | Whole-cell voltage-gated currents from control and cytokine treated FLS. (A) Top panels show the voltage step protocols and the evoked currents are
shown below for control (left) and IL1β + TNFα (right) conditions. Note that FLS exhibit both transient and sustained currents. These phases of current were then
analyzed separately as indicated. (B) Current–voltage curves (left) from the transient currents recorded in a number or experiments such as that illustrated in (A).
There was no significant difference between control and treated transient current density. Data points are shown as mean ± SEM (n = 18 for control and n = 11 for
IL1β + TNFα). (C) Current–voltage curves from the sustained currents recorded in a number or experiments such as that illustrated in (A). The red line in the
current–voltage curve is the difference current for control-cytokine treated. (D) Difference conductance–voltage curve for the cytokine difference current shown in
(C). The line is fit with a Boltzmann, see text.
activated currents that would be expected to include BK activity if
it was present. Although we found a significant increase in RNA
expression of the BK α-subunit gene, Kcnma1, following cytokine
treatment (by qPCR), there was a decrease in over-all current
density of the sustained current. To characterize the voltage-
gated characteristics of the current lost after cytokine treatment
we subtracted IV curves following cytokine treatment from the
control IV curves and transformed this to a conductance-voltage
curve. Since this curve fully saturated, we were able to fit it
with a Boltzmann curve and derive the midpoint for activation;
+40 mV. This is rather positive to most voltage-gated potassium
channels, the most “positive” of which (Kcnbx/Kcncx) have
activation mid-points in the +10 to +20 mV range (Coetzee
et al., 1999). This cytokine sensitive conductance could be an
ensemble average of a number of different ion channel changes,
including increase of some and decrease of others. It could also
be a BK current under conditions of low intracellular Ca2+ (Cui
et al., 1997, 2009; Coetzee et al., 1999; Contreras et al., 2012),
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FIGURE 6 | Effects of BK channel drugs on FLS whole-cell currents. (A) Representative examples of untreated (control) cells before (left) and in the presence of
1 µM of the BK channel opener NS1619 (left). Voltage protocols as shown in Figure 5. (B) Representative raw example current families of cytokine (10 ng/ml
IL1β + TNFα) treated cells in the absence (left) and presence (right) of 1 µM NS1619. (C) Current–voltage curves from a number of control FLS cells such as that
shown in (A). Current is significantly greater in the presence of NS1619, p < 0.05, n = 9 and 6. (D) Current–voltage curves for a number of treated FLS cells such as
that shown in (B). These two curves are not significantly different from each other n = 6 and 6. (E) Current–voltage curves from a number of control FLS cells treated
with and without paxilline; there is a significant decrease in paxilline current p < 0.05 n = 13,5), but (F) there was no significant different of current density in the
presence of the BK inhibitor paxilline following cytokine treatment (n = 6, 12). (G) Numerical simulation of data from Clark et al. (2017) model. To quantify the degree
of change of BK channel modulation apparently taking place with this treatment we used the model of verbatim with the exception that we varied the inherent BK
channel Ca2+ sensitivity parameter Kd. In this simulation, the independent variable Kd is plotted on the x-axis and the predicted BK current midpoint (V1/2) is plotted
on the y-axis. In blue, we have added hypothetical midpoints of 40 mV and 80 mV representing a hypothetical shift in 40 mV by cytokine treatment. The complete
MATLAB code for this simulation is included in the Supplementary File S1.
but, since the true local concentration of intracellular Ca2+ is
unknown, this is difficult to assess. V1/2 for the BK channel in
the virtual absence of Ca2+ can be much higher, for example
200–300 mV (Bao and Cox, 2005; Orio and Latorre, 2005; Wang
and Brenner, 2006). The value of this parameter also depends on
the nature of the co-expressed β-subunit (Coetzee et al., 1999;
Contreras et al., 2012). V1/2 is typically shifted to the left in
the presence of beta subunits (Brenner, 2014). In our transcript
data (Figure 4C), we show a range of BK transcripts including
the Lrrcx subunits, but none, on their own, show significant
alteration by treatment. Note that with experimentally elevated
intracellular Ca2+ concentration these would likely lie well to the
left of where they lay in our experiments. In our experiments
we included 5 mM EGTA, which allows for the Ca2+-activation
of BK channels so long as they are physically close to the Ca2+
source (Fakler and Adelman, 2008). Functional coupling between
BK and the Ca2+ source appears a common phenomenon (Fakler
and Adelman, 2008); we also showed this with a coupling between
TRPV4 channels and KCa channels previously in neurones
(Feetham et al., 2015) and it has also been shown in smooth
muscle cells too (Nilius and Droogmans, 2001). Increasing, or
attempting to “clamp” intracellular Ca2+ before investigating
BK channels would be tempting, but this could cause greater
constitutive activation of BK and mask a physiological coupling.
Our electrophysiological experiments also demonstrated
significantly more depolarized resting membrane potentials in
cytokine treated cells. This could result from loss of constitutive
potassium or chloride conductances, but equally it could result
from the elevation of the non-specific or Na+ selective or ion
channels such as Trpc3 or Asic2, etc. (Table 2).
The BK pharmacological activator (NS1619) and inhibitor
(paxilline) both had the expected effects (increase and decrease
of current density, respectively) in the untreated FLS but neither
had a significant effect. This is surprising in the light of the
Tanner et al. (2015) data showing that paxilline ameliorate
development joint degeneration in a model of RA and the
continued effectiveness of paxilline in FLS from RA patients
(Petho et al., 2016). One possible explanation could be differences
in transcript expression between strains as has been observed
with ion channels previously (Kunert-Keil et al., 2006). Our
RNA data showed a clear shift from RNA-expression of β1 (and
β2) subunits to β3 and sensitivity to voltage, calcium and some
drugs is well-known to be conveyed by co-expression of the
β subunits (McManus et al., 1995; Uebele et al., 2000; Yang
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et al., 2009). However, neither paxilline nor NS1619 themselves
are thought to be influenced by the β-subunit; paxilline acts
as a closed channel blocker (Zhou and Lingle, 2014) whereas
NS1619 opens the BK channel by binding to the KCNMA1
S6/RCK linker and is effective in some splice variants, but not
others (Soom et al., 2008; Gessner et al., 2012). In humans
there are 93 known s[lice variants of KCNMA1, but there
are only four in rats listed on ENSEMBL (Zerbino et al.,
2018). Figure 4 shows the relative transcript expression for
Kcnma1. The most abundant transcript (ENSRNOT00000077671
Kcnma1-203) is present in both conditions. None of the Kcnma1
transcripts decrease with cytokine so it seems unlikely (but
not impossible) that pharmacological changes result directly
from splice variant switching. Note that the one known
transcript that was not detected is the truncated transcript
Kcnma1-204 (ENSRNOT00000091318). The lack of effect of
NS1619 and paxilline after cytokine treatment could be also
be secondary to changes in β-subunits or intracellular Ca2+
in microdomains or some unknown reason leaving insufficient
residual functional BK activity to be noticeably modulated. The
simple (K+ channel focused) FLS electrophysiological model
of Clark allows us to use numerical simulation to estimate
the change in BK channel Ca2+ that would be required to
shift a BK conductance voltage curve by about +40 mV and
largely leave the cells virtually free of measurable BK current
(Figure 6G). We find that retaining all the parameters of Clark
et al. (2017) except the Ca2+ Kd itself, such data would be the
equivalent to increasing Kd from 0.46 µM to approximately
1.05 µM. The upstream pathway (beyond the activation of
the cytokine pathway including NFκB, etc.) for these changes
is difficult to identify from our data, especially since there
are relatively few ion channel interaction data in the IPA
databases. It is notable, however, that there were significant
changes in the calcium signaling pathway (Figure 3) and
so it is possible that change in calcium activated potassium
channel expression follows this, by way of compensatory
expression. The lack of apparent effect of paxilline could also
be technical. For example, there was considerable variability
between cells and we compared population means rather than
pairing each cell with and without paxilline increasing the risk
of a type II error.
Role of Ion Channels in Pro-inflammatory
Cytokine Production and Secretion
Ion channels are involved not just in the response to
cytokines, but can also contribute to their production. For
example, ionotropic NMDA and kainite glutamate receptors
contribute to synovial inflammation by increasing expression
of the inflammatory cytokine IL-6 (Flood et al., 2007) and
nicotinic acetylcholine receptor activation reduces the synovial
production of IL-6, IL-8, TNFα, and several other cytokines
(Waldburger et al., 2008; van Maanen et al., 2009). P2X7
is an established conduit for release of mediators such as
IL1β (Mortaz et al., 2012). We saw little P2X7 RNA, but
there is evidence that in chondrocytes P2X1, may sub serve
the same function (Varani et al., 2008) and we detected
RNA for this channel only after cytokine treatment. In a
previous report, inhibition of the small Ca2+ activated potassium
ion channel decreased the production of cytokines IL-6, IL-
8, and MCP1 in response to TGF-1β, but they did not
examine secretion of IL1β or TNFα (Friebel et al., 2014).
In other-words activation of Ca2+ potassium ion channels is
essentially a secretion trigger. This result is somewhat counter
intuitive since one would expect activation of a potassium
channel to hyperpolarize and decrease secretion. One possible
explanation is that activation of Ca2+ potassium ion channels
draws in additional Ca2+ by increasing the driving force for
Ca2+ entry.
Ca2+ entry α (Vm− EqCa2+)
Where negative values are equivalent to inward driving force
for Ca2+, Vm is the membrane potential and EqCa2+ is the
equilibrium potential for Ca2+.
CONCLUSION
To our knowledge, this is the first report using a combined NGS
and patch-clamp electrophysiological approach to understanding
the control of potassium channels in inflammation in joint
tissues. We found an increased RNA expression of the BK
potassium gene Kcnma1, but the constitutive activity of the
channel was not increased. The decreased sensitivity to voltage
activation and to drugs could be explained by a switch the RNA
expression of β-subunits KcnmB1, 2, and 3.
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